Hartford Hospital Research Program

2008/09 Annual Report

Welcome
A Message From The Vice President For Research
The past two years have presented serious economic challenges across many sectors of our society including medical research. During this period some grant makers and funders were forced to cut back or suspend their programs in the interest of a brighter economic forecast. At the same time, these years were characterized by unprecedented opportunity. For example, the American Recovery and Reinvestment Act of 2009 ear marked billions of dollars to support advancements in biomedical and behavioral research, research infrastructure, faculty recruitment and academics with the primary aim of creating and preserving U.S. jobs in these and related sectors. In the midst of these challenges and opportunities Hartford Hospital investigators have continued to press onward, obtaining $11.7 million in funding for research studies during fiscal year 2009, an amount that represents a 22.8% increase in external funding over last year. In 2009, research was identified as a key value of our organization, and consequently Academic Excellence was added as a pillar on the Hospitals Balanced Scorecard. This addition acknowledges the world-class work being carried out by our investigators and highlights the hospitals culture of innovation in which physicians perform research because they are genuinely committed to asking important scientific questions that will change the practice of medicine here and nationally. The Research Program is proud to recognize the achievements of Hartford Hospital investigators in this 2008-2009 Biennial Report. We are committed to supporting them as they continue to meet the challenges and opportunities that the coming decade will bring to health care and medical research. In closing, I would also like to take the opportunity to thank the dedicated staff of Research Administration for their excellent support of Research at Hartford Hospital, and a special note of thanks to Dr. Tara McLaughlin, for her excellent work in preparing our Biennial Report. Sincerely, Laurine Bow, PhD Vice President for Research

Contents
1 3 4 5 6 7 10 12 13 18 35 43 47 50 53 64 65 69 89 91 98 106 107 115 Research program summary Financial summary External funding Internal funding Committees Research administration Clinical research center Preclinical research facility Genomas Cardiology Center for anti-infective research Medicine Neurology Nursing Oncology Orthopedics Pathology Psychiatry Radiology Surgery Traumatology & emergency medicine Urology Womens health Other departments & collaborations

Research Program Summary

At the close of 2009, over 600 active research projects were on going Hartford Hospital Hartford Hospital investigators initiated over 350 new studies in FY 08 and 09 and produced over 870 scientific publications, abstracts and presentations during this period

Hartford Hospital: Committed to Research Excellence..

Translational Research $1.4 Million SBIR Grant: Dr. Gualberto Ruao, and the Genomas

Research Program Initiatives During This Period Include:

New Research Program website (www.hartfordhealth.org/
research)

team were awarded a $1.4 million, 3 year NIH SBIR grant to develop MRI+DNA- guided biomarker system for mental illness, bringing the total amount of NIMH funding secured by Genomas in collaboration with the Institute of Living to nearly $4 Million.

CEHDL trial preliminary results applied in community setting:

Results from the 5 year, NIH funded Center for Eliminating Health Disparities in Latinos (CEHDL) peer-counseling trial suggest that peer counseling is effective for diabetes management in Latino patients. The knowledge gained was applied in a community-based setting by PI Jyoti Chhabra, PhD and researchers at the University of Connecticut and the Hispanic Health Council through support group forums that took place in the Hospitals Brownstone clinics.

Research Rundown newsletter distributed electronically to

over 500 recipients including Hartford Hospital investigators, medical staff and external researchers

Research Week 2009 featured research symposium, speakers,

poster display and information

Research Program also Supported Several Special Awards:

Pressure Ulcer Prevention Database awarded CQIA Silver
Innovation Prize

Federal Recovery Act Funding

Dr. Paul Thompson was awarded $865,207 Challenge Grant from the National Institutes of Health for a two-year project CoEnzyme Q10 in Statin Myopathy. Dr. Godfrey Pearlson was awarded Recovery Act Funding to expand studies of high-risk drinking in college students, represents $771,000 in direct costs awarded through a Challenge Grant from the National Institutes of Health/NIAAA for two-year project Genetic Architecture of Alcohol Misuse Candidate Endophenotypes.

Falls Prevention Program awarded 2009 CQIA Innovation

Silver Award

Stroke Center awarded American Stroke Associations

Get With The Guidelines Stroke (GWTGStroke) Silver Performance Achievement Award

2008/09
New Investigator Initiated Clinical Trial Support.
Dr. Paul Tulikangas awarded grant from Astellas Pharma Inc: The new $214,238 study will evaluate use of vaginal pessaries in the treatment of overactive bladder symptoms in women with pelvic organ prolapse.

Other New Funding

Dr. Godfrey Pearlson: BARCS (Brain and Alcohol Research with College Students) study awarded $1.5 million NIAAA genetics grant to continue to study drinking and brain function in college students and to identify markers for vulnerability to dysfunctional drinking and alcohol toxicity. Evidence Based Practice Center: The EPC received awards through the University of Connecticut for over $600,000 for AHRQ-sponsored projects on the use of antiepileptics and human growth hormone. Beth Parker PhD and Cardiology Department Research Team: Awarded Biomedical Research Grant through State of Connecticut Tobacco Settlement Funds to study impact of smoking cessation on vascular function in chronic smokers- Represents a total of $267,187 in new funding.

Hartford Hospital selected by Lance Armstrong Foundation to develop breast cancer survivorship program:
Hartford Hospital was awarded one of only eight national community grants to develop a unique resource program for breast cancer survivors, was the only site in New England to be selected for this three-year grant representing $150,000. The evaluation component will involve Research Program Senior Scientists.

2.

External

Research Funding Received

The external funds received are derived from the September accounting statement. All calculations are based on the fiscal cycle of October 1 - September 30.

2008
Psychiatry Cardiology Oncology CAIRD* Experimental Research Medicine Neurology/Neurosurgery Emergency Medicine/ Traumatology Orthopedics Radiology $3,856,000 $1,423,000 $808,000 $1,691,000 $310,000 $197,000 $309,000 $15,000 $77,000 $74,000

2009
$4,038,000 $2,782,000 $1,608,000 $1,418,000 $413,000 $311,000 $147,000 $141,000 $119,000 $60,000 Pharmacy/EPC** Womens Health Gastroenterology Surgery Anesthesia Miscellaneous Support (Research Admin)

2008
$129,000 $29,000 $5,000 $69,000

2009
$45,000 $37,000 $30,000 $24,000 $3,000 $527,000

$538,000

TOTAL

$9,530,000

$11,703,000

$11,703,000

$9,530,000

1998

'00

'02

'04

'06

'08

2009

* Center for Anti-Infective Research and Development ** Evidence-based Practice Center

External Awards
Federal, Foundation and State figures represent annual awards. All other figures represent new initial total awards.

Industry: Investigator Initiated

2008
CAIRD Cardiology Emergency Medicine/ Traumatology Oncology* Pharmacy/EPC Psychiatry Surgery Total:
* represents funds received

Federal
Cardiology Emergency Medicine/ Traumatology Medicine Neurology Neurosurgery Oncology Pharmacy/EPC Psychiatry Radiology Total:

2008
$1,529,570 $35,220 $232,801 $83,195 $12,600 $543,355 $4,322,960 $141,075

2009
$1,481,097 $35,220 $384,551 $89,905 $20,047 $117,570 $685,361 $4,415,887 $72,387

2009
$1,012,219 $115,116

$207,758 $149,500 $18,500 $184,640 $214,875

$404,785 $100,000 $13,306

$775,273

$1,645,426

$6,900,776

$7,302,025

Foundation
Medicine Neurology Oncology Pharmacy Psychiatry Radiology Total: $19,225 $550 $23,341 $47,756 $5,184 $40,000 $1,500

Industry: Clinical Trials

CAIRD Cardiology Emergency Medicine/ Traumatology Medicine Neurology Oncology Orthopedics Pre-clinical Psychiatry Radiology Surgery Womens Health Pathology Total: $822,428 $1,264,493 $63,516 $205,371 $22,500 $504,829 $82,000 $233,648 $19,000 $143,982 $109,850 $44,163 $188,388 $1,749,326

$70,000

$144,238 $54,835 $509,588

$89,775

$117,781

State
Cardiology Oncology Psychiatry Total: $25,000 $5,000 $267,186 $25,000 $1,500

$329,930 $30,000 $12,250 $22,750

$30,000

$293,686

$3,515,780

$3,041,305

4.

Internal Awards
Medical Staff Supported Awards
The following projects received awards generously co-sponsored by the Medical Staff and the Hartford Hospital Research Endowment Fund:
Alberghini, Tod, Transplant: Clinical significance of solid-phase assay (flow cytometric and Luminex) detection of pre-transplant HLA antibody as measured by graft survival in renal transplant recipients: A retrospective analysis. $9,954 Anglade, Moise, MD, Cardiology: Use of N-Acetylcysteine for prevention of postoperative atrial fibrillation: A meta-analysis. $5,450 Azemi, Talket, MD, Cardiology: Diagnostic and prognostic significance of ischemic electrocardiographic changes during vasodilator stress myocardial perfusion imaging. $9,507 Blondin, Nick, Neurology: A stroke of luck: Can cerebral hemisphere predict thrombolysis and good outcome in an acute ischemic stroke? $2,250 Clyne, Christopher, MD, Cardiology: Identifying atrial ablation lines through two-dimensional delayed enhancement MR imaging. $6,360 Collins, Sarah, MD, Urogynecology: Perioperative exercise tolerance and pain control in women undergoing robotic vs. traditional abdominal sacral colpopexy. $8,428 Corbera, Silvia, PhD, Psychiatry: Application of Event-Related Potentials (ERPs) to evaluate the effects of coaching on cognitive rehabilitation in schizophrenia. $300 Eagye, Kathy, MPH, Center for Anti-infective Research and Development: Health outcomes investigation of infection in colorectal surgical procedures. $14,854 Feeney, James, MD Traumatology and Emergency Medicine: Retrospective review of pre-hospital HMG Co- A reductase inhibitor use in hemorrhagic shock due to ruptured AAA. $450 Lundbye, Justin, MD, Cardiology: Elevated plasma cytokines are a marker for unstable coronary syndrome: The Hartford Chest Pain Study. $10,777 Lyle, Brian, MD, Cardiology: Follow up of patients with coronary artery disease who have undergone rapid aspirin desensitization prior to percutaneous coronary intervention. $5,826 Mace, Melanie, PsyD, Psychology Testing: A survey of regional referring providers use of and perceived utility of neuropsychological services. $750 Norberg, Melissa, PhD, Psychiatry: D-Cycloserine augmented CBT for prior treatment non-responders with OCD. $9,531 Patel, Minita, MD, Urogynecology: The use of SennaS for prevention of postoperative constipation in urogynecologic surgery: A randomized, placebocontrolled, double blinded trial. $9,758 Silverman, David, MD, Cardiology: Freedom from atrial fibrillation following radio-frequency ablation depends upon integrity of atrial function. $9,975 Silverman, David, MD, Cardiology: Systolic strain abnormalities to predict hospital readmission in patients with heart failure and normal ejection fraction. $3,680 Sood, Nitesh, MD, Cardiology: Heart rate variability and brain natriuretic peptide. $5,760 Gross, Ronald,MD (Spinella, Phillip, MD,) Traumatology and Emergency Medicine: Relationship between age of RBCs transfused and mortality in critically ill trauma patients. $9,861 Suozzi, James, MD, Traumatology and Emergency Medicine: Comparison of the Airtraq optical laryngoscope to direct laryngoscopy by paramedics: A randomized, controlled, clinical trial. $8,969 Thumar, Jaykumar, MD, Oncology: CD 133 expression and clinical outcome in patients with rectal cancer. $12,462 Turner, Beth, PhD, Psychiatry: Simulated driving: Effects of road conditions. $9,811

Open Competition Awards

The following projects received funding through the Open Competition program in fiscal years 2008 and 2009: DAgostino, Darrin, DO, Medicine: DNA-guided Warfarin management. $62,475 Fischer, Edward, PhD, Cardiology: Community and patient attitudes towards seeking medical help: Development and standardization of a comprehensive attitude measure. $21,146 Goethe, John, MD, Psychiatry: Research infrastructure for the Depression and Bipolar Disorders Center. $49,760 Kuti, Joseph, PharmD, Center for Anti-infective Research and Development: The effect of hyperbaric oxygen therapy on the penetration of Linezolid into subcutaneous tissue of diabetics with lower extremity wounds. $74,847 Parker, Beth, PhD Cardiology: Sex differences in the mechanisms underlying endothelial function. $78,685 Stevens, Michael, PhD, Psychiatry: Linux cluster infrastructure enhancement. $74,513 Vergara, Cunegundo, MD, Medicine: Creation of an ambulatory database to measure access to primary preventive care services. $61,000 Wilber, Charles, MED. Psychiatry: Cognitive training in elderly with normal aging and mild cognitive impairments. $82,487

The Research Program extends its appreciation to the Medical Staff for its continued support of research at Hartford Hospital.
In addition to the projects listed above, Research Endowment and Medical Staff funds supported statistical analysis and database development through Small Grants, as indicated throughout this report.

Committees
Research Committee
The responsibilities of the Research Committee are fourfold. The Committee reviews the scientific merit of research projects and awards internal research funding. It also investigates any allegations of research misconduct and evaluates potential conflicts of interest.

The Research Committee, Institutional Review Board and Institutional Animal Care and Use Committee each fulfill specific roles and responsibilities that are crucial to the conduct of research at Hartford Hospital.

Institutional Review Board

The Institutional Review board is charged with the ethical oversight of research projects involving human research subjects at Hartford Hospital. It conducts risk/benefits analyses of potential research studies and monitors ongoing studies for safety.

Members
Laurine Bow, PhD, Chair James Bowers, JD Karyl Burns, PhD Erika Cappelutti, MD William Crombleholme, MD Ellen Dornelas, PhD John Goethe, MD Joseph Kuti, PharmD Jeffrey Mather, MS Pavlos Papasavas, MD Godfrey Pearlson, MD Ilene Staff, PhD Cunegundo Vergara, MD Detlef Wencker, MD C. Michael White, PharmD Les Wolfson, MD Cathy Yavinsky, RN

Members
Robert D. Siegel, MD, Chair David OSullivan, PhD, Vice Chair Christopher Clyne, MD Cherie Bilbie, MS Alexandra Flowers, MD Margarita Garcia Yvette Gauthier John Goethe, MD Debra Hein, CNM Gary Heller, MD, PhD Rev. James Ibekwe, PhD Kevin Keating, MD Jacqueline Lyon, MD Leslie Lothstein, MD Joseph Nesta, MD James Rancourt, PharmD Richard M. Shulman, PhD

THANK YOU!

The Research Program would like to thank those individuals who completed their committee tenure during this report period.

Institutional Animal Care & Use Committee

The Institutional Animal Care and Use Committee is charged with the ethical oversight of research projects involving animal research subjects.

Research Committee:
Jaber Aslanzadeh, MD Gary Heller, MD, PhD Kevin Keating, MD Jeffrey Kluger, MD Joanne Roy, RN, PhD

IRB:
George Perdrizet, MD, PhD (Vice Chair) Benjamin Goldfarb Jenifer Ash Tiffany R. Hubbard Joanne Roy, PhD

6.

Research Administration

Supports and facilitates the growth of research at Hartford Hospital Provides administrative oversight for all research activities at Hartford Hospital Centralized infrastructure includes Grants Administration, Human Research Protections, Database Design and Development and Proposal Design and Statistical Analysis. The Clinical Research Center and the Preclinical Research Facility support research activities under the auspices of Research Administration. Research Administration carries out its mission under the leadership of Laurine Bow, PhD, Vice President for Research.

Human Research Protections Program (HRPP)

Offers a combined total experience of 20 years in conducting
research studies and 32 years in Research Administration.

Provides oversight for the protection of human research subjects in

accordance with international principles of Good Clinical Practice, U.S. Federal Regulations, and Hospital policies.

Provides public assurance that the rights, safety and well-being of

research subjects are protected and that all research data obtained are credible.

Grants and Contracts

Insures that grants and contracts are prepared according
to the appropriate regulations and policies and that accounting procedures for research studies are followed correctly. Provides financial oversight on research projects Assists with contract negotiations for clinical trials and other research activities Provides administrative guidance for all external grant submissions Assists with budget preparation and accounting procedures Informs hospital research community of regulatory changes that impact the research finances and contracts Processed 62 grant applications to federal, foundation and state sources representing over $48,000,000 during fiscal year 2008 and 2009

Provides outreach and education on applying research regulations to

the research community.

Provides administrative support to the Institutional Review Board and

Institutional Animal Care and Use Committee.

Monitors ongoing research studies for compliance with all applicable

regulations and policies.

Processed 109 full IRB reviews of new research projects and 125
expedited reviews of new research projects during FY 2008 and 2009.

Working toward achieving full accreditation status by the Association

for the Accreditation of Human Research Protection Programs (AAHRPP) by the close of 2010.

HRPP Staff:
Cherie Bilbie, MS, CCRP, Director, HRPP 545 - 0088 Dottie Bearse, IRB Coordinator, 545 - 5647 Corey Glider, IRB Administrator, 545 - 4410 Susan Hughes, IRB Administrator, 545 - 4413 Pamela Johnson, IRB Administrator, 545 - 0141
Grants Administration. Left: (from left): Linda Thompson, Tammy Weirs, Christine Harvey, Anita Fowler HRPP Group. below: (from left): Dottie Bearse, Pamela Johnson, Cherie Bilbie, Susan Hughes, Corey Glider

Grants Administration Staff:

Tammy Weirs, Manager, Grants and Contracts, 545 - 4412 Anita Fowler, Grants Administrator, 545 - 2093 Christine Harvey, Administrative Associate to VP of Research, 545 - 5620 Linda Thompson, Administrative Associate, 545 - 5611

Database Design and Development Group

Creates databases, registries and specialized data collection instruments for numerous hospital departments including: Brownstone Clinics Diabetes Life Care Surgery (Bariatrics, Nephrectomy) Cardiology/ Cath lab Tissue typing and Transplant registries

Provides technical support to investigators processing research projects through the departments electronic submission system Assists with queries of hospitals administrative database in support of numerous grant applications Experienced with a range of platforms including:

Oncology (Prostate cancer registry, Cancer Connect, TCC/Moffitt

database) Responsible for Quality Management reporting such as: NDNQI National Benchmark reporting HCAHPS - Responsiveness initiative Adverse event drug triggers Central line insertion Transformation of the ICU Rapid Response Team Data Analysis Eastern Rehabilitation Health Network Quality Survey

Microsoft Access SQL Server Web Development Teleform Design ADT/Lab/HL7 Interfacing

Database Design and Development Group Staff:

Jeff Mather, MS, Director, Data Management, 545 - 3560 Gil Fortunato, MBA, Systems Analyst, 545 - 3194 Juan Gonzalez, Systems Analyst, 545 - 4474 Da-dong Li, PhD, Research Technician, 545 - 4211 Joseph Tortora, Systems Analyst, 545 - 3446 Steve Wilcox, Systems Analyst, 545 - 6056 Data Management Technical Support 545 - 5621

Collaborates on award-winning Quality Improvement and benchmarking initiatives: Falls Prevention Pressure Ulcer Prevention Get With The Guidelines National Stroke Benchmarking

Database Design and Development Group (from left): Gil Fortunato, Steven Wilcox, Jeff Mather, Joseph Tortora, Juan Gonzalez (not pictured Da-Dong Li)

8.

Research Administration

Proposal Design and Statistical Analysis

Provides assistance with the scientific design of research studies and
with statistical and data analysis Supports the development of external grant applications Has conducted public health research and program evaluation for many internal departments and external entities. Has published numerous peer-reviewed manuscripts and presents research at a variety of scientific meetings Jyoti Chhabra, PhD:

Site-Principal Investigator on the 5-year, NIH-funded Center for

Eliminating Health Disparities (CEHDL) clinical trial on diabetes peer-counseling Provides methodological review for research projects involving the Brownstone Outpatient clinics and Nutrition Services Member of the Education subcommittee of the How Hartford Hospital Works (H3W) initiative David OSullivan, PhD:

Ilene Staff, PhD: Research Program Liaison and member, Research Committee Provides methodological review and consultation for: Emergency Medicine/Trauma Oncology/Radiation Oncology Urology Neurology/Stroke Center Surgery Anesthesiology Infectious Disease/CAIRD Pulmonology Hematology Rheumatology Gynecologic Oncology (Breast) Orthopedic Surgery Integrative Medicine

Proposal Design and Statistical Analysis Staff:

Jyoti Chhabra PhD, 545 - 1004 Tara McLaughlin PhD, 545 - 5065 David OSullivan PhD, 545 - 4544 Ilene Staff PhD, 545 - 0178

Vice Chairperson for the Hartford Hospital Institutional

Review Board Provides methodological review and consultation for: Cardiology Dentistry Endocrinology Gastroenterology Nursing Opthamology Toxicology Womens Health Tara McLaughlin, PhD: Primarily responsible for grant-writing for all research areas Provides methodological review and consultation for: Preclinical research studies Psychiatry Pastoral/Palliative Care Community Projects with City of Hartford Compiles monthly newsletter, Research Rundown

Proposal Design and Statistical Analysis Group (from left): David OSullivan,Tara McLaughlin, Ilene Staff, Jyoti Chhabra

Clinical Research Center

he Clinical Research Center (CRC) is an invaluable resource for clinicians interested in conducting research initiatives at Hartford Hospital. The CRC provides administrative and research coordinator support for research activities of the institutions medical staff. Support is provided for both investigator- initiated studies as well as industry funded trials sponsored by pharmaceutical and medical device companies. While the CRC staff supports many experienced investigators they are also able to assist new investigators. As part of Research Administration, the CRC interacts with a multidisciplinary staff with expertise in areas of clinical research design, grant-writing, contract negotiation and budget review, IRB document preparation, database design and data analysis.

Services:
Services provided by the CRC include: Marketing of services to potential study sponsors and referrals to our physician investigators Marketing of trial opportunities to potential subjects Study initiation and regulatory maintenance Contract and budget preparation, regulatory documentation preparation and maintenance including IRB submission and continuing review Coordinator study support Patient screening, enrollment, randomization Coordination of all study procedures (i.e., study visits, study drug administration, study-related interventions per study protocol) Availability for all sponsor monitoring visits and audits Data management Completion of case report forms, query resolution Reporting adverse events and other regulatory requirements to the IRB Data entry

Phase I IV Study Center:

The Study Center is located on the 6th floor of the Education and Resource Center building and is available to investigators by reservation to support Phase I IV studies requiring overnight accommodations. The Center has a suite of 24 private sleep rooms with bathroom and shower facilities for each group of 4 rooms. Each room includes a bed with bedding, dresser, closet and desk as well as a wallmounted television. The Center also has a shared lounge area with television, DVD player, couches and chairs. The kitchen facility includes a large refrigerator, microwaves, toaster ovens and storage cabinet areas. An area for clinical assessments is available with an exam table, scale, blood pressure monitor and medical supplies. A specimen processing laboratory includes a centrifuge, refrigerator/freezer, sink and phlebotomy chair. The facility is alarmed and can be used to monitor patients and ensure subject compliance. Trained medical personnel with clinical trial experience are available to staff the Study Center. Additional staffing and supplies are available to meet the needs of individual studies

Locations:
The administrative office of the CRC is located in Research Administration on the 2nd floor of the ERC Building. Additionally, satellite offices are located throughout the hospital including offices in the Stroke Center and the Division of Cardiology. An outpatient clinical trials office is located in the medical building to facilitate studies being conducted by our private physician groups.

10.

Clinical Research Center

CRC Staff:
The CRC has supported the clinical research activity of hospital investigators since 1993. The staff has grown to include 19 research professionals committed to providing excellence in clinical research. A Director and Study Center Coordinator provide management of the operational and financial areas of the department. A Research Pharmacy Technician is part of the CRC staff and assumes accountability for all investigational drug use at the institution. The CRC study coordination staff includes 14 Clinical Research Associates with clinical research certification through the Society of Clinical Research Associates (SOCRA) or the Association of Clinical Research Professionals (ACRP). Two of the coordinators also have experience in basic science research. The CRC is also staffed by two Clinical Research Assistants who support the study coordinators and provide other assistance with research tasks as needed.

New Clinical Trial Initiatives:

The CRC continues to support clinical research in Cardiology (Divisions of Preventive Cardiology, Arrhythmia Services, Interventional Cardiology and Heart Failure and Transplantation), Neurology, Gastroenterology, Orthopedic Surgery, Infectious Disease, Pulmonary Medicine, Trauma/Emergency Medicine, Interventional and General Radiology and Urogynecology. We were pleased to provide study coordination services to several additional hospital divisions this past year.

Neurosurgery:
The Neurosurgery Department has enlisted the coordinator support of the CRC to conduct several clinical trials. The trials will study the use of investigational interventions for patients requiring neurosurgical procedures.

Colorectal Surgery:
The CRC staff is coordinating an investigator initiated study being conducted by Kristina Johnson, MD, Connecticut Surgical Group. Dr. Johnsons study will evaluate the use of a medication in laparoscopic colectomy patients and its effect on hospital length of stay.

PreClinical Research Facility

innovative research and training supported by the facility has resulted in many significant developments for the hospital, such as open-heart surgery, heart and liver transplants, and intra-coronary drug delivery via balloon catheters. The facility performs preclinical contract work including Good Laboratory Practices (GLP) and non-GLP studies. Three surgical suites are available for testing, training or research. The facility is licensed by the United States Department of Agriculture (USDA) and Accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC).

artford Hospitals preclinical research facility was established in 1952, and has provided support for numerous surgical specialties. The

Current Collaborators:
FarmingtonPharma Corporation Maquet (formerly Datascope) Matrix Bioanalytical Laboratories

Facility Capabilities:
In Vivo Medical Device Testing In Vivo Biocompatibility Testing Surgical Research and Development Surgical Training Courses GLP and non-GLP studies Quality Assurance Program

12.

Genomas
Gualberto Ruao, MD, PhD
Director of Genetics Research, Hartford Hospital President, Genomas Genomas (www.genomas.com) is the biotechnology anchor of the Hartford Hospital Genetics Research Center (GRC) and was inaugurated in 2004 by Gualberto Ruao, MD, PhD. Dr. Ruao, who holds MD and PhD degrees from Yale, and a baccalaureate from Johns Hopkins, has been an advocate of personalized medicine for 15 years, and is one of the leading medical experts in the field. Genomas is located on the Hartford Hospital campus in downtown Hartford and occupies 4,000 sq. ft. of state-of-the-art laboratory and office space in the first floor of the Florence T. Crane building at 67 Jefferson St Genomas is a biomedical company advancing DNA-Guided medicine with products for personalized prescription of drugs used in the treatment of mental illness, diabetes, and cardiovascular disease (CVD). Their products eliminate trialand-error prescription with DNA-Guided medicine and enable physicians to treat with unprecedented precision, avoiding significant drug side effects, improving efficacy and enhancing patient compliance. Core applications are drug treatments of mood and thought disorders in mental illness and of cardiometabolic risk in diabetes and CVD. The products are developed in partnership with three leading Connecticut medical institutions, Hartford Hospital, The Institute of Living and the Hospital of Central Connecticut and with the University of Puerto Rico Medical Sciences. As of November 2009, the GRC and Genomas have published 32 peer-reviewed scientific articles and established an intellectual property portfolio of 8 patents pending as US applications. The research is being advanced in partnership with the National Institutes of Health which have awarded GRC and Genomas $4.8 M in grants as of November 2009 for PhyzioType System research and development. The company has won 3 Phase II SBIR awards subsequent to respective Phase I awards from NIH for PhyzioType product development. Clinical research and molecular diagnostics service are conducted at the Physiogenomics Laboratory and Laboratory of Personalized Health, respectively.

PhysioGenomics Laboratory (PGL)

PhysioGenomics Laboratory (PGL) Resources. PGL has installed the whole-genome Human-I BeadChip genotyping technology from Illumina, Inc. This technology merges parallel processing through nanoscale high resolution scanning. The genotyping analysis has the capacity of 8 million SNPs per day and is a proven technology. Genomas was one of the first biomedical companies with this capability fully deployed internally. For its genotyping approach, PGL has access to an expanding SNP database of 1,000,000 high-confidence, mapped, and annotated SNP markers which merges parallel processing through fiber optics and nanoscale high resolution scanning. To increase throughput and quality PGL has added a Tecan Robot to provide pre-and post PCR automation of the Illumina genotyping protocol and an Autoloader to automate loading and scanning of the Illumina Bead Chips and Sentrix Arrays. PGL has two robotic systems in operation. A Qiagen BioRobot EZ1 is used to automate DNA extraction from blood or other samples, and a Perkin Elmer Janus liquid handling system is used to automate repetitive liquid handling tasks throughout the process.

PGL Technology
Physiogenomics Technology is a proprietary platform integrating genotypic and phenotypic measures to correlate gene variability with physiological variability (Fig. 1). Genomas has established a DNA repository and clinical registry of 6,000 patients in mental illness, diabetes and cardiovascular disease. The clinical data from these extensive cohorts is integrated systematically into the PhyzioClinica Database (Fig. 2). Physiogenomics Technology is a medical application of sensitivity analysis and systems engineering. Sensitivity analysis is the study of the relationship between input and output from a system as determined by each system

Andreas Windemuth, PhD Chief Technology Officer Genomas Inc. Mohan Kocherla MS, MS-MIS Research Scientist and Manager of Laboratory Operations Genomas Inc.

Gualberto Ruao, MD, PhD President and CEO, Genomas Inc. Director of Genetics Research, Hartford Hospital David Villagra BS Research Associate Genomas Inc.

component. Physiogenomics Technology utilizes the genes as the components of the system. The gene variability, measured by single nucleotide polymorphisms (SNPs), is correlated to physiological responses of a population, the output. Physiogenomics Technology determines how the SNP frequency varies among individuals similarly responding to the input over the entire range of the response distribution. The mechanisms of drug resistance and of common, clinically intensive side effects involve multiple physiological pathways suitable for Physiogenomics analysis. Genomas has branded their medical management products as PhyzioType Systems. Genomas analyzes the genome to derive the optimal candidate genes for which SNPs are included in each PhyzioType System. This approach is carried out by means of PhyzioGenomic Arrays derived from selected cardio-metabolic and neuro-endocrine genes, from selected pharmacokinetic and pharmacodynamic genes, and from genome-wide representation as well as genomic controls. Physiogenomics utilizes nanotechnology-based platforms and biomedical systems engineering to integrate genomic variations with clinically validated predictions of drug response.

Fig. 1 Physiogenomics Principles

Fig. 2 Resources of the PhysioGenomics Laboratory

PhyzioType Systems
PhyzioType Systems for drug management have 3 components (Fig. 3): an ensemble of inherited, stable DNA markers from various genes, a bioclinical algorithm validated in clinical studies to ascertain the medical significance of a patients DNA marker configuration and a reporting portal enabling physicians to select the best drug based on each patients individuals efficacy response and risk of developing side effects. Each PhyzioType Systems is designed to have the following properties: Clinically Actionable Information. Personalized information regarding an individuals drug response for major drugs in a therapeutic class to provide treatment guidance to physicians Objective Results. Statistically predictive analysis which will allow the physician to objectively recommend an initial treatment course Noninvasive Tests. Performance using a sample of the patients peripheral blood Quality Control. All tests processed at Genomas Laboratory

Fig. 3 Components of the PhyzioType Systems

of Personalized Health to provide consistent quality and ensure timely turnaround.

Laboratory of Personalized Health LPH

LPH Resources. Operational since 2005 as a Division of Genomas, LPH is a high-complexity molecular diagnostic reference laboratory licensed by the Connecticut Department of Public Health (license #CL-0644) and certified by the Centers for Medicare and Medicaid Services (ID #07D1036625) under CLIA (Clinical Laboratory Improvement Amendments). On March 2009, LPH underwent its third biannual inspection, and successfully met all criteria for continued operation. LPH has installed the Luminex 100 analyzer using xMAP technology (Luminex Corp., Austin, TX). LPH provides clinical DNA typing for the

14.

Genomas

HILOmet PhyzioType System for antidepressant and anxiolytic management to psychiatrists who refer patients for evaluation of innate drug metabolism capacity. The molecular diagnostic analysis is performed under contract to Clinical Laboratory Partners (a Hartford Hospital subsidiary) for distribution throughout Connecticut.

The balance, 43% in the psychiatric population and 64% in the control, were carriers of non wild-type alleles for 0-1 genes. Differences in carrier prevalence in HILOmet PhyzioType combinatorial genotypes between the psychiatric and control populations are substantial and highly significant (Fig. 4). There is a much higher prevalence of carriers of non wildtype alleles in 2 or 3 genes among the referred psychiatric patients than there is in the control population (p=1.2x10-5). Analysis of the genotype data results for each patient revealed that 36% of the control population had 2 or 3 genes with variant alleles resulting in deficient or null metabolism. Of those, 34% were deficient in 2 genes and 2% were deficient in 3 genes. 52% of the control population had only one null or deficient gene while 12% were wild-type for all 3 genes in question. In comparison, 57% of the psychiatric population possessed deficient or null alleles on more than 1 gene. 47% had variant alleles in 2 genes and 10% had variant alleles in 3 genes. Only 6% were wild-type for all 3 genes and the remaining 36% had a deficient or null allele in 1 gene. A significant cumulative metabolic deficiency was observed in the psychiatric population for HILOmet PhyzioType combinatorial genotypes. The high prevalence of carriers with deficient and null alleles suggests that HILOmet PhyzioType combinatorial genotyping may play a role in the management of psychiatric patients at tertiary care institutions. The definition of a novel drug sensitivity syndrome is warranted in carriers of multiple null and deficient alleles in the HILOmet PhyzioType. Genomas researchers had already presented one patient in this series as a detailed case study. Independently segregating alleles have the property of sporadic, non-familial, concurrence in an individual depending on chance. Such individuals are multiply deficient in HILOmet PhyzioType metabolic routes, placing them at risk for adverse reactions with several antidepressants and anxiolytics. That 57% of referred psychiatric patients may be severely compromised in drug metabolism capacity ascertained for 2 or 3 genes in the HILOmet PhyzioType System should serve as a public health imperative for DNA-Guided medicine in high risk patients. Combinatorial HILOmet PhyzioType genotyping could be useful for patients with histories of drug resistance and intolerance reactions to multiple psychotropics. Genotypeguided prescription of psychotropics may prevent druginduced morbidity in many psychiatric care settings, including

LPH Technology: Psychiatry

The HILOmet PhyzioType product consists of 3 tests for genotyping each of the 3 key CYP450 (Cytochrome P450) genes: CYP2D6, CYP2C9, and CYP2C19. These genes are critical for the metabolism of several psychiatric and cardiovascular drugs. Altogether, the HILOmet tests genotype a total of 34 functional variants of these 3 drug metabolism genes. The 3 genes and 34 variants interpreted as a combinatorial ensemble constitute the HILOmet PhyzioType System. The HILOmet product has already been employed to benchmark drug metabolism reserve for 600 patients referred to LPH. Genomas researchers have compared the types and carrier prevalences of combinatorial HILOmet PhyzioType genotypes in Major Depressive Disorder (MDD) patients to a control group of nonpsychiatrically ill, medical outpatients. They conducted a case control study using 73 psychiatric outpatients diagnosed with depression and referred to The Institute of Living, for treatment resistance or intolerable side effects to psychotropic drugs. The controls were 120 cardiovascular patients from Hartford Hospital being treated for dyslipidemia but otherwise healthy and not psychiatrically ill. Within the psychiatric population, 57% of individuals were carriers of non wild-type alleles for 2-3 genes, compared to 36% in the control population (p<0.0001).
IOL Psych Referrals HH Cardiology

** 57%

** 43%

** 36% ** 64%

Deficiencies:

0 or 1 gene

2 or 3 genes

Fig.4 Combinational HILOmet PhyzioType Deficiencies in control versus psychiatric populations

treatment resistant and drug intolerant patients, as well as children and adolescents. As the field of personalized healthcare advances to clinical practice, Genomas researchers foresee DNA-guided medicine being used to prevent adverse drug reactions, particularly in high-risk populations referred to tertiary hospitals.

LPH Technology: Cardiologyw

Pharmacogenetic studies from the past decade have revealed that common polymorphisms in 2 genes, cytochrome P450 2C9 (CYP2C9) and Vitamin K epoxide reductase complex subunit 1 (VKORC1), greatly affect warfarin dose through different mechanisms. Genome wide scans have confirmed these findings. The most frequent polymorphisms of CYP2C9 include *2 and *3 which are associated with decreases in 2C9 enzyme activity to about 70% and 5% of the normal level, respectively. The FDA revised the Coumadin (warfarin) label in August 2007 including discussion of these gene variants to personalize initial dose and subsequent management. The result is excess warfarin accumulation, elevated INR (>4.0) and possible hemorrhagic complications. Warfarin exerts an anticoagulant effect through its inhibition of the Vitamin K epoxide reductase multiprotein complex

(VKOR), part of which is subunit 1, encoded by VKORC1. VKOR is responsible for converting vitamin K epoxide to vitamin K hydroquinone which is an essential co factor required for the carboxylation of clotting factors II, VII, IX and X. A common polymorphism of the VKORC1 promoter sequence (-1639 G>A) results in decreased Vitamin K epoxide reductase enzyme activity as shown by in vitro promoter luciferase activity assays. As an illustration, the population wide impact of combinatorial genotyping for VKORC1 and CYP2C9 on effective warfarin dose is predicted for a cohort of outpatients at the Hartford Hospital Preventive Cardiology clinic. The decreases were calculated using published algorithms that employ age, gender, weight, height, CYP2C9 genotype, and VKORC1 genotype. Fig.5 presents the frequency of individual combinatorial genotypes for CYP2C9 and VKORC1 found in that population (horizontal axis) and the predicted decrease in effective warfarin dose associated with each combinatorial genotype (vertical axis). Warfarin therapeutic risk increases with the number of deficient alleles.

New Projects
Seip, Richard, PhD
DNA as a Predictor of Effective Warfarin Levels. Hartford Hospital Research Endowment Funds, $62,475.

Fig.5

Active Projects
Seip, Richard, PhD
Relationship of Muscle Injury to Muscle Hypertrophy. Hartford Hospital Research Endowment Funds, $35,488.

Publications
de Leon J, Arranz MJ, Ruao G. Products for pharmacogenetic testing in psychiatry: A review of features and clinical realities. Clinics in Laboratory Medicine, 28: 599-617, 2008. de Leon J, Correa JC, Ruao G, Windemuth A, Arranz MJ, Diaz FJ. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophrenia Research, 98: 40-46, 2008.

Cumulative percentage of the population

16.

Genomas

Diaz FJ, Meary A, Arranz MJ, Ruao G, Windemuth A, de Leon J. Acetyl-coenzyme A carboxylase gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophrenia Research, 115: 136140, 2009. LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip RL, Duconge J, Ruao G. Integrating genomic based information into clinical Warfarin (Coumadin) management: An illustrative case report. Connecticut Medicine, 72 (7): 399-403, 2008. Liu J, Pearlson G, Windemuth A, Ruao G, Perrone-Bizzozero NI, Calhoun V. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Human Brain Mapping, 30: 241-255, 2009. Ruao G, Bernene J, Windemuth W, Bower B, Wencker D, Seip RL, Kocherla M, Holford TR, Petit W, Hanks S. Physiogenomic comparison of edema and BMI in patients receiving Rosiglitazone or Pioglitazone. Clinica Chimica Acta, 400: 48-55, 2009. Ruao G, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Villagra D, Renta J, Holford TR, Santiago-Borrero PJ. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics, 10 (4): 565-577, 2009. Ruao G, Thompson PD, Villagra D, Bower B, Kocherla M, Yazdanpanah G, Seip RL, Windemuth A, White CM, Duconge J, Holford TR, Wu AHB. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing. Personalized Medicine, 5 (3): 225-232, 2008. Ruao G, Villagra D, Rahim US, Windemuth A, Kocherla M, Bower B, Szarek BL, Goethe JW. Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital. Personalized Medicine, 5 (6): 579-587, 2008. Ruao G. DNA collage and personalized medicine. Connecticut Medicine, 72 (6): 322-cover, 2008. Ruao G. Bringing DNA-guided medicine to the Hispanic population. Puerto Rico Health Sciences Journal, 28 (3): 266-267, cover, 2009.

Seip RL, Volek JS, Windemuth A, Kocherla M, Fernandez ML, Kraemer WJ, Ruao G. Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat. Nutrition and Metabolism, 5: (1):4 [Epub ahead of print], 2008. Windemuth A, Calhoun V, Pearlson G, Kocherla M, Jaganathan K, Ruao G. Physiogenomic analysis of localized fMRI brain activity in schizophrenia. Annals of Biomedical Engineering, 36 (6): 877-88, 2008.

Cardiology
Paul D. Thompson, MD
Alan Ahlberg, MA Jeremy Barbagallo, MA Jill Cloutier RN Christopher Clyne, MD Eric Crespo, MD. Giselle Cyr, RN Marcin Dada, MD Ellen Dornelas, PhD Edward Fischer, PhD Brenda Foxen, RN Daniel Fram, MD Dalia Giedrimiene, MD, Ph.D Danette Guertin, APRN Deborah Katten, RN Francis Kiernan, MD Jeffery Kluger, MD Gary Heller, MD Jeffrey Hirst, MD Justin Lundbye, MD Raymond McKay, MD Roger Mennett, MS Joseph Mitchel, DO Deborah Murphy, RN Beth A. Parker. PhD Charles Primiano, MD Donna M. Polk, MD Joseph Radojevic, MD Aleksandra Ras, BS David Silverman, MD Marilyn Siwy, RN Cara Statz, PhD Detlef Wencker, MD Charles White, PharmD Steven Zweibel, MD Research is a major emphasis for all faculty in the Division of Cardiology because it contributes directly to improving patient care and medical education. The Division of Cardiology and the Henry Low Heart Center are directed by Paul D. Thompson, MD. The Center has active research programs in heart failure, preventive cardiology, nuclear cardiology, electrophysiology and cardiac catheterization. In the last two years, the Division of Cardiology has published more than 120 empirical articles in peer reviewed publications and been awarded more than $1.8M in federally funded research projects, more than $2M in external and industry funding and $135,000 in Hartford Hospital endowment funding.

Preventive Cardiology
This division has several ongoing clinical trials focused on developing new approaches to treating cholesterol thereby reducing cardiovascular disease risk, evaluating the effect of the statin cholesterol drugs on muscle strength and aerobic performance, evaluating the effect of statins on brain function, examining the effects of exercise training on brain function, and utilizing smoking cessation and stress management to improve cardiac outcomes for patients with implantable cardioverter defibrillators. In 2009, Dr. Thompson was one of a very selective number of researchers to be awarded a challenge grant from the National Institute of Health. Along with co-investigators, Drs. Polk and Parker, he will examine the effects of Coenzyme Q10 (ubiquinol) supplementation on severity of skeletal muscle myopathy in patients with statin-associated myalgia. Dr. Thompson also is the principal investigator of a multi-site, federally funded clinical trial determining the incidence of statin-induced myalgia and the effects of statins on skeletal muscle strength and aerobic exercise performance. Additionally, the Department of Preventive Cardiology is working with Dr. Gualberto Ruano of Genomas and Dr. Eric Hoffman of Washington Childrens National Medical Center on two other NIH funded clinical trials investigating genetic differences underlying statinassociated muscle symptoms and the muscle strength response to resistance training, respectively. Two preventive cardiology fellows, Drs. Shishir Mathur and Afrooz Ardestani, have initiated studies which involve the participation of local runners. Dr. Mathur studied runners

18.

Cardiology

participating in the Hartford Marathon in October to determine whether marathon running is associated with improvements in genetic markers of aging as well as functional properties of high-density lipoprotein (HDL) cholesterol. Dr. Ardestani is examining markers of muscle damage before and after the Manchester Road Race in runners both taking and not taking statins to determine whether chronic statin use affects the muscle response to intense aerobic exercise. Both studies have utilized the participation of local running organizations and may yield valuable information about the benefits of exercise as well as the effects of cholesterollowering drugs on the muscle response to exercise. Preventive Cardiology is also home to multiple industry funded trials of cholesterol lowering medications. These studies, lead by Dr. Donna Polk are focused on new classes of cholesterol lowering drug aimed at raising HDL as well as drugs targeting the inflammatory process of athereosclerosis to try to further reduce the risk of heart disease. Additionally we are involved in several studies designed to evaluate the best treatment of diabetics after a heart attack to improve outcomes in this high risk group. Dr Polk and Dr. Parker are also involved in evaluating the role of the non invasive test carotid intimal medial thickness (cIMT) in the behavior of individuals with hyperlipidemia In 2008, exercise physiologist Dr. Beth Parker joined the Department of Preventive Cardiology and has been funded by the CT Department of Public Health to determine the effects of smoking cessation on vascular function in chronic smokers. Dr. Parker is also the principal investigator of a research study that examines whether the vascular response to stress varies with age and sex in healthy humans. Both studies use noninvasive imaging techniques such as brachial artery reactivity and arterial stiffness and follow the theme as to how simple interventions can improve cardiovascular health. Drs. Parker, Polk and Thompson are also collaborating with Dr. Godfrey Pearlson in the Olin Neuropsychology Research Center to conduct studies on the effects of statin therapy on brain neuronal activation using functional magnetic

resonance imaging. Emerging evidence suggests that statin therapy may influence the brain as well as blood lipids, and determining brain activation of individuals on and off statins allows researchers a direct look at the functional consequences of statin therapy. The collaborative research team of Drs. Parker, Thompson and Pearlson also completed a preliminary study on exercise training and the hippocampus, again using magnetic resonance imaging, to determine whether hippocampal structure changed after a 10 week program of aerobic exercise training. Preventive cardiology also has an active behavioral cardiology research program under the direction of psychologist, Ellen Dornelas, Ph.D. Working together with Matthew Burg, Ph.D. and Rachel Lampert, MD, from Yale University and collaboratively with Dr. Kluger from the Department of Electrophysiology and Arrhythmia Services, Hartford Hospital is enrolling patients with implantable cardioverter defibrillators (ICDs) in a study funded by the National Heart Lung and Blood Institute that will test whether stress management effectively reduces risk of shock from ICD due to emotional stress. Additionally, Dr. Edward Fischer and Dr. Dornelas are co-principal investigators on a study examining community attitudes about seeking help from medical professionals. The research program in preventive cardiology is home to national recognized researchers in the fields of lipid management, cardiac function of elite athletes, exercise physiology, smoking cessation and behavioral cardiology. Studies conducted in preventive cardiology are interdisciplinary, collaborative and innovative, focused on improving cardiovascular and behavioral health in various patient populations.

Heart Failure and Transplant Center (HFTC)

This Center is home to cutting edge research performed at our newly designed, NIH funded translational research Center of the HFTC. This research center offers new insight and development of novel therapy and diagnosis of advanced heart failure. To better understand the relentless progression of heart failure, the translational research center studies the role of death receptor signaling pathways in heart muscle, skeletal muscle and serum as a marker for disease progression and as a tool to provide new therapies for advanced heart failure. Therapies involve new pharmaceutical, VAD and electro-

physiologic device therapy. The HFTC is also participating in six multi-national heart failure trials and two ventricular assist device (VAD) trials. These trials, headed by Dr. Detlef Wencker, are critical for many patients in end-stage cardiomyopathy that could offer potentially life saving support with most advanced therapies and technologies

Nuclear Cardiology
This division has a very active research program involving both SPECT and PET imaging techniques. Research into SPECT imaging techniques include a large database to evaluate outcomes for patients undergoing nuclear cardiology studies. The SPECT imaging techniques also involve new pharmaceuticals for stress including regadenoson and adenoscan. In addition, a program to evaluate new technologies developed to improve image quality and reduce patient time and radiation exposure is an important aspect of the research effort. PET perfusion imaging has become a very important part of nuclear cardiology. The Nuclear Cardiology Laboratory is conducting research into new radiotracers which holds potential to improve identification in patients with coronary artery disease. These tracers will identify at risk patients for ventricular cardiac arrest and may help direct patients towards ICD placement.

Hartford Hospital is home to many federally and industry funded clinical trials focused on improving treatment for complex electrical cardiac disorders. These include the VESTPREDICTS Trial led by Dr. Zweibel, an NIH sponsored trial that examine whether a wearable defibrillator will save lives and improve cardiac outcomes months after an heart attack. Dr. Zweibel is also collaborating on the APPROPRIATE Trial a study that will evaluate two different sensors (minute ventilation and accelerometer) in patients receiving a dualchamber pacemaker for the indication of chronotropic incompetence. Additionally, the PROVIDE Trial, under the leadership of Dr. Zweibel, will test different sets of ICD programming parameters to minimize shock therapy without increasing the risk of syncope or untreated ventricular tachycardia. Cardiac Electrophysiology is also one of 140 centers worldwide investigating the possible benefit of early implantation of cardiac resynchronization devices for reduction of heart failure hospitalization and total mortality in the MADIT-CRT trial. Dr. Christopher Clyne is principal investigator on the first multi-center NIH-sponsored study to investigate the effect of primary atrial fibrillation ablation versus drug therapy on total mortality and outcome. Also under Dr. Clynes direction is the Hartford Area Resuscitation Research Trial (HARRT), a project which will advance basic life support and AED operation into the West Hartford Public High Schools. Dr. Eric Crespo is the site principal investigator on the Direct His Bundle Pacing to Implement Cardiac Resynchronization Therapy (DIRECT) Study, which is a multi-center clinical trial investigating a novel pacing technique (Direct His Bundle Pacing) as an alternative to conventional cardiac resynchronization therapy in patients with advanced heart failure.

Cardiovascular Pharmacy Research Group

Hartford Hospital is fortunate to have a longstanding relationship with the University of Connecticut School of Pharmacy. Dr. Jeffrey Kluger has been working collaboratively with the Cardiovascular Pharmacy Research and the Pharmacy Outcomes group under the leadership of Drs. Mike White and Craig Coleman, respectively. This effort has resulted in the UCONN/HH Evidence Based Practice Center obtaining funding through the Federal Agency AHRQ. The contract evaluating comparative effectiveness of ACEI and ARB in patients with preserved cardiac function was completed. The group now has a contract to investigate the role of thrombolytic devices in coronary disease. The CV Pharmacy research is now enrolling patients in AFIST IV evaluating the role of Vitamin C in modifying inflammatory markers after cardiac surgery. In collaboration with Dr. Craig Coleman and Dr. Jeffrey Kluger there are multiple observational studies ongoing in the area of antiarrhythmic drug therapy including the role of adjuvant magnesium for atrial fibrillation. Other outcome studies have focused on our implantable defibrillator and syncope populations.

Echocardiography
Current research projects in Echocardiography are under the direction of Dr. David Silverman and focus on examination diastolic dyssynchrony as a marker for diastolic heart failure (with Sanjeev Bahvnani, MD, Detlef Wencker MD and Sayeed Zaeem, MD) evaluation of the prognostic value of systolic strain in a series of patients with diastolic heart failure, analysis of appropriateness of echo ordering, and an examination of the prognostic value of plasma cytokine levels in patients presenting to the emergency room with chest pain. In collaboration with Dr Isaac Silverman in Neurology and Dr Jeffrey Kluger in Cardiology, we are building a program to examine utilization of echocardiography for several common diagnoses including stroke and syncope. This year the echocardiography laboratory reported its accumulated experience with echocardiographic imaging to guide prognosis following percutaneous device closure of patent foramen ovale.

Cardiac Electrophysiology and Arrhythmia Services

20.

Cardiology

Publications
Ahlberg AW, Baghdasarian SB, Athar H, Thompsen JP, Katten DM, Noble GL, Mamkin I, Shah AR, Leka IA, Heller GV. Symptomlimited exercise combined with dipyridamole stress: prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT imaging. J Nucl Cardiol. 2008 Jan-Feb;15(1):42-56.

Cardiac Catheterization Research Program

The research program of the cardiac catheterization laboratory led by Dr. Francis Kiernan and Raymond McKay, MD currently focuses on the development and testing of new interventional and cardiac imaging techniques, on the assessment of adjunctive interventional pharmacology, and on the maintenance and analysis of a comprehensive research database to tract clinical outcomes in all interventional patients. Previous research accomplishments by members of the catheterization laboratory have included the development of balloon aortic and mitral valvuloplasty, catheter-based local drug delivery, radiofrequency coronary angioplasty, and intra-cardiac ultrasound. Major contributions have also been made in the past by the catheterization laboratory physicians in the assessment of drug-coated stents, primary percutanaeous intervention for acute myocardial infarction, directional coronary atherectomy, catheter-based femoral arteriotomy closure, catheter-based thrombectomy, multiple new intracoronary stents, intracoronary brachytherapy, and left ventricular assist devices. In addition, catheterization physicians have served as principal investigators for over 30 multi-center, national trials over the last five years.

Akhtar S, Assaad S, Amin M, Holt NF, Barash PG, Silverman DG. Preoperative beta-blocker use: impact of national guidelines on clinical practice. J Clin Anesth. 2008 Mar;20(2):122-8. Angelopoulos TJ, Miles MP, Lowndes J, Sivo SA, Seip RL, Pescatello LS, Zoeller RF, Visich PS, Gordon PM, Moyna NM, Thompson PD. Apolipoprotein E genotype and sex influence C-reactive protein levels regardless of exercise training status. Metabolism. 2008 Sep;57(9):1204-10. Angelopoulos TJ, Sivo SA, Kyriazis GA, Caplan JD, Zoeller RF, Lowndes J, Seip RL, Thompson PD. Doage and baseline LDL cholesterol levels determine the effect of regular exercise on plasma lipoproteincholesterol and apolipoprotein B levels? Eur J Appl Physiol. 2007 Nov;101(5):621-8. Anglade MW, Kluger J, White C,M, Aberle J, Coleman C. Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study. Curr Med Res Opin. 2007 Nov;23(11)2849-55. Augeri AL, Tsongalis GJ, Van Heest JL, Maresh CM, Thompson PD, Pescatello LS. The endothelial nitric oxide synthase-786 T>C polymorphism and the exercise-induced blood pressure and nitric oxide responses among men with elevated blood pressure. Atherosclerosis. 2009 Jun;204(2):e28-34. Epub 2008 Dec 16. Awad AA, Haddadin AS, Tantawy H, Badr TM, Stout RG, Silverman DG, Shelley KH. The relationship between the photoplethysmographic waveform and systemic vascular resistance. J Clin Monit Comput. 2007 Dec;21(6):365-72. Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, Moriarty PM. Effectiveness and tolerability of everyother-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008 Mar;42(3):341-6. Baggish A, Thompson PD. Thick hearts, high stakes, great uncertainties: Screening athletes for hypertrophic cardiomyopathy. Heart. 2008 Oct 31. [Epub ahead of print] Baghdasarian SB, Heller GV. Patient preparation for nuclear imaging: when should anti- schemic medications be withheld? J Nucl Cardiol. 2007 Nov-Dec;14(6):775-81. Baghdasarian SB, Noble GL, Ahlberg AW, Katten D, Heller, GV.

Cardiac Intensive Care Unit

The CICU has multiple research projects underway under the leadership of Justin Lundbye, MD. These include the Hypothermia Database Project a comprehensive database collection project. Drs. Lundbye, Silverman, Rabdiya and Ahmed are also working on the Cytokine Project a study designed to predict cardiovascular outcomes using cytokine inflammatory markers. Drs. Lundbye and McKay are also overseeing the Proton Pump Inhibitor (PPI) and Plavix Projects and have analyzed outcome data from more than 3000 patients treated at Hartford Hospital. Dr Lundbye is working on two prospective research trials, one looking at new CHF therapies and one looking at medications in patients with coronary artery disease to prevent future events. Multiple industry funded trials are also underway to examine new therapeutic approaches tested in hospitalized, critically ill cardiac patients.

Risk stratification with attenuation corrected stress Tc-99m sestamibi SPECT myocardial perfusion imaging in the absence of ECG-gating due to arrhythmias. J Nucl Cardiol 2009;16:533-9. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA, Merli GJ, OGara PT, Thompson PD, Underberg JA. ACCF/ AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/ American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2009 Sep 29;54(14):1336-63.

WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. Boden WE, ORourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Gau G, Weintraub WS; COURAGE Trial Co-Principal Investigators and Study Coordinators. The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol. 2007 Jan 15;99(2):208-12. Bower B, Klimek J, Yeston N, Ruano G. DNA-guided decision support. Hosp Health Netw. 2007 Nov;81(11):10. Coleman C, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens. 2008 Apr;26(4)622-9. Coleman C, Kuger J, Bhavnani S, Clyne C, Yarlagadda R, Guertin D, White CM. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction. Heart Rhythm. 2008 Apr;5(4):507-10. Coleman C, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Med Res Opin. 2008 May;24(5): 1359-62. Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger J; Dofetilide and Intravenous Magnesium Evaluation (DIME) Investigators. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Europace. 2009 Jul;11(7):892-5. Epub 2009 Apr 6. Cosio-Lima LM, Seip R, Thompson PD, Lagasse MA, Hodges TH. Intertester reliability of brachial artery flow-mediated vasodilation using upper and lower arm occlusion in healthy subjects. Vasc Health Risk Manag. 2008;4(3):731-4. Crespo E, Oliveira G, Honeycutt E, Becker R, Berger P, Moliterno D, Anstrom K, Abrams C, Kleiman N, Moll S, Rice L, Rodgers J, Steinhubl S, Tapson V, Granger C, Ohman E. Evaluation and management of suspected Heparin-induced thrombocytopenia in hospitalized patients: The complications after thrombocytopenia caused by heparin (CATCH) registry. Am Heart J. 2009;157(4):651-7.

Baker WL, Anglade MW, Baker EL, White CM, Kluger J, Coleman CI. Use of N- cetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis. Eur J Cardiothorac Surg. 2009 Mar;35(3):521`-7. Epub 2009 Jan 14. Review. Baker WL,Gutierrez-Williams G, White CM, Kluger J, Coleman C. Effect of cinnamon on glucose control and lipid parameters. Diabetes Care. 2008 Jan;31(1):41-3. Baker WL, Kluger J, White CM, Dale KM, Silver BB, Coleman CI. Effect of magnesium L-lactate on blood pressure in patients with an implantable cardioverter defibrillator. Ann Pharmacother. 2009 Apr;43(4):569-76. Epub 2009 Mar 31. Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel AA, Coleman CI. Dopamine agonists in the treatment of early Parkinsons disease: a meta-analysis. Parkinsonism Relat Disord. 2009 May; 15(4):287-94. Epub 2008 Sep 6. Bateman TM, Heller GV, McGhie AI, Courter SA, Golub RA, Case JA, Cullom SJ. Multicenter investigation comparing a highly efficient half-time stress-only attenuation correction approach against standard rest-stress Tc-99m SPECT imaging. J Nucl Cardiol 2009;16:726-35. Bhavnani SP, Coleman Cl, White CM, Clyne CA, Yarlagadda R, Guertin D, Kluger J. Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. Europace. 2008 Jul;10(7):854-9 Boden WE, ORourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk

22.

Dada MR, Hirst JA, Kiernan FJ, Smally AJ, Lundbye JB, Thompson PD, McKay RG. Use of prehospital electrocardiograms for the treatment of patients with ST-segment elevation myocardial infarction. Conn Med 2009;73(2):69-72. de Leon J, Correa JC, Ruao G, Windemuth A, Arranz MJ, Diaz FJ. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res. 2008 Jan;98(1-3):40-6. Denktas AE, Athar H, Henry TD, Larson DM, Simons M, Chan RS, Niles NW, Thiele H, Schuler G, Ahn C, Sdringola S, Anderson HV, McKay RG, Smalling RW. Reduced- dose fibrinolytic acceleration of ST-segment elevation myocardial infarction treatment coupled with urgent percutaneous coronary intervention compared to primary percutaneous coronary intervention alone results of the AMICO (Alliance for Myocardial Infarction Care Optimization) Registry. JACC Cardiovasc Interv 2008;1(5):504-10. Devaney JM, Tosi LL, Fritz DT, Gordish-Dressman HA, Jiang S, Orkunoglu-Suer FE, Gordon AH, Harmon BT,Thompson PD, Clarkson PM, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF,Brandoli C, Hoffman EP, Rogers MB. Differences in fat and muscle mass associated with a functional human Polymorphism in a post-transcriptional BMP2 gene regulatory element. J Cell Biochem. 2009 Aug 15;107(6):1073-82. Dey D, Suzuki Y, Suzuki S, Ohba M, Slomka PJ, Polk D, Shaw LJ, Berman DS. Automated quantitation of pericardiac fat from noncontrast CT. Invest Radiol. 2008 Feb;43(2):145-53. Dornelas, E.A. (2008). Psychotherapy for Cardiac Patients: Behavioral Cardiology in Practice. Washington, DC: American Psychological Association Press. Fernandez AB, Ahmed S, Duncan B, Firshein S, Kluger J. Cardiac tamponade: a rare complication of idiopathic hypereosinophilic syndrome. .J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):188-91. Fernndez AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest. 2008 Oct;134(4):824-30. Fernandez AB, Keyes MJ, Pencina M, DAgostino R, ODonnell CJ, Thompson PD. Relation of corneal arcus to cardiovascular disease (from the Framingham Heart Study data set). Am J Cardiol. 2009 Jan 1;103(1):64-6. Epub 2008 Oct 4. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008 Jun 15;101(12):1747-8.

Gesquiere MJ, Awad AA, Silverman DG, Stout RG, Jablonka DH, Silverman TJ, Shelley KH. Impact of withdrawal of 450 ml of blood on respiration-induced oscillations of the ear plethysmographic waveform. J Clin Monit Comput. 2007 Oct;21(5):277-82. Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS, Heller GV, McCollough CH, McNitt-Gray MF, Mettler FA, Mieres JH, Morin RL, Yester MV. Ionizing radiation in cardiac imaging. Circulation. 2009;119:1056-1965. Giedrimas A, Giedrimiene D, Guertin D, White CM, Clyne CA, Kluger J. A comparison of outcomes for patients receiving implantable cardioverter defibrillators for primary vs secondaryprevention. Conn Med. 2008 Jun-Jul;72(6):329-33. Gold M, Val-Mejias J, Leman RB, Tummala R, Goyal S, Kluger J, Kroll M, Oza A. Optimization of superior vena cava coil position and usage for transvenous defibrillation. Heart Rhythm. 2008 Mar;5(3):394-9. Gonzales JU, Parker BA, Ridout SJ, Smithmyer SL, Proctor DN. Femoral shear rate response to knee extensor exercise: an age and sex comparison. Biorheology. 2009;46(2):145-54 Green CD, Thompson PD, Johnston PG, El-Tanani MK. Interaction between transcription factor, basal transcription factor 3, and the NH2-terminal domain of human estrogen receptor alpha. Mol Cancer Res. 2007 Nov;5(11):1191-200. Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinick EH, Churchwell KB, Cooke CD, Corbett JR, Cullom SJ, Dahlberg ST, Druz RS, Ficaro EP, Galt JR, Garg RK, Germano G, Heller GV, Henzlova MJ, Hyun MC, Johnson LL, Mann A, McCallister BD Jr, Quaife RA, Ruddy TD, Sundaram SN, Taillefer R, Ward RP, Mahmarian JJ; American Society of Nuclear Cardiology. Myocardial perfusion and function: single photon emission computed tomography. J Nucl Cardiol. 2007 Nov-Dec;14(6):e39-60. Review. Heller GV, Katanick SL, Sloper T, Garcia M. Accreditation for Cardiovascular Imaging. JACC: Cardio Imaging 2008;1:390-7. Hernandez AB, Ahmed S, Duncan B, Firshein S, Kluger J. Cardiac tamponade: a rare complication of idiopathic hypereosinophilic syndrome. J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):188-91. Hubal MJ, Chen TC, Thompson PD, Clarkson PM. Inflammatory gene changes associated with the repeated-bout effect. Am J Physiol Regul Integr Comp Physiol. 2008 May;294(5):R1628-37. Irwin ML, Cadmus L, Alvarez-Reeves M, ONeil M, Mierzejewski E, Latka R, Yu H, Dipietro L, Jones B, Knobf MT, Chung GG, Mayne ST. Recruiting and retaining breast cancer survivors into a randomized controlled exercise trial: the Yale Exercise and Survivorship Study. Cancer. 2008 Oct 1;113(7):1716.

Jablonka DH, Awad AA, Stout RG, Silverman DG, Shelley KH. Comparing the effect f arginine vasopressin on ear and finger photoplethysmography. J Clin Anesth. 2008 Mar;20(2):90-3. Jolicoeur E, Ohman E, Honeycutt E, Becker R, Crespo E, Oliveira G, Moliterno D, Anstrom J, Granger C. Contribution of bleeding and thromboembolic events to in- hospital mortality among patients with thrombocytopenia treated with Heparin. American J Cardiol. 2009;104(2):292-297. Kapetanopoulos A, Ahlberg AW, Taub CC, Katten DM, Heller GV. Regional wall- motion abnormalities on post-stress electrocardiographic-gated technetium-99m sestamibi single-photon emission computed tomography imaging predict cardiac events. J Nucl Cardiol. 2007 Nov-Dec;14(6):810-7 . Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, OFallon KS, Gadarla M, Thompson PD. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis. 2008 Sep;200(1):121-5. Kostek MA, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller RF, Price TB, Seip RL,Thompson PD, Devaney JM, Gordish-Dressman H, Hoffman EP, Pescatello LS. Myostatin and follistatin poly-morphisms interact with muscle phenotypes and ethnicity. Med Sci Sports Exerc. 2009 May;41(5):1063-71. LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, Duconge J, Ruao G. Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Conn Med. 2008 Aug;72(7):399-403. Erratum in: Conn Med. 2008 Oct;72(9):572. Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, Heller GV. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2008 Nov-Dec;15(6):745-53. Lertsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman C. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008 Feb;135(2):405-11. Liu J, Pearlson G, Windemuth A, Ruano G, Perrone-Bizzozero NI, Calhoun V. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum Brain Mapp. 2007 Dec 10. Mamkin I, Elkoustaf RA, Zhang Q, Mather JF, Kiernan FJ, McKay RG. Drug-eluting stent implantation results in effective treatment of small coronary artery disease (DESIRE Small CAD). Conn Med. 2007;71(9):517-22.

Mamkin I, Mather JF, Kiernan FJ, McKay RG. More studies are needed on gender-based outcomes in percutaneous coronary intervention with drug-eluting stents. Am J Cardiol. 2007;100(3):560-1. Mamkin I, Vaksman M, Kiernan FJ, McKay RG, Boden WE. Letter to Editor regarding Weekend onset of acute myocardial infarction does not have a negative impact on outcome in Japan. Circ J 2008;72:864. Maron BJ, Haas TS, Doerer JJ, Thompson PD, Hodges JS. Comparison of U.S. and Italian experiences with sudden cardiac deaths in young competitive athletes and implications for preparticipation screening strategies. Am J Cardiol. 2009 Jul 15;104(2):276-80. Epub 2009 May 18. McBride BF, White CM, Kalus JS, Guertin DC, Clyne CA, Baker WL, Kluger J. The impact of carvedilol on the defibrillation threshold. Heart Lung. 2008 Jan-Feb;37(1):67- 1. McKay RG, Dada MR, Mather JF, Mennet RR, Murphy DJ, Maloney KW, Hirst JA, Kiernan FJ. Comparison of outcomes and safety of facilitated versus primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2009;103(3):316-21. McKay RG, Murphy DJ, Cloutier J, Mather JF, Mennett RA, Dada MR, Shah AR, Kiernan FJ. Long-term efficacy and safety of sirolimuseluting vs bare-metal stents. Conn Med. 2008;72(8):453-63. Mieres JH, Shaw LJ, Hendel RC, Heller GV. The WOMEN Study: What is the optimal method for ischemia evaluation in women? A multi-center, prospective randomized study to establish the optimal method for detection of coronary artery disease (CAD) risk in women at an intermediate-high pretest likelihood of CAD: study design. J Nucl Cardiol 2009;16:105-12. Moore TA, Sorokin AV, Hirst C, Thornton-Thompson S, Thompson PD. The accuracy of aneroid sphygmomanometers in the ambulatory setting. Prev Cardiol. 2008 Spring;11(2):90-4. Noble GL, Ahlberg AW, Kokkirala AR, Cullom SJ, Bateman TM, Cyr GM, Katten DM, Tadeo GD, Case JA, OSullivan DM, Heller GV. Validation of attenuation correction using transmission truncation compensation with a small field of view dedicated cardiac SPECT camera system. J Nucl Cardiol 2009;16:222-232. Oliveira G, Crespo E, Becker R; Honeycutt E, Abrams S, Anstrom K, Berger P, Davidson-Ray L, Eisenstein E, Kleiman N, Moliterno D, Moll S, Rice L, Rodgers J, Steinhubl S, Tapson V, Ohman E, Granger C. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008;168(1):94-102.

24.

Oncken, C., Dornelas, E., Greene, J., Sankey, H., Glasmann, A., Feinn, R.. Krnazler, H.R. (2008). Nicotine gum for pregnant smokers: A randomized controlled trial. Obstetrics & Gynecology, 112, 859-867. Orkunoglu-Suer FE, Gordish-Dressman H, Clarkson PM, Thompson PD, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Harmon B, Seip RL, Hoffman EP, Devaney JM. INSIG2 gene poly-Morphism is associated with increased subcutaneous fat in women and poor response to resistance training in men. BMC Med Genet. 2008 Dec 23;9:117. Parker B, Proctor D. Commentary on Viewpoint: Exercise and cardiovascular risk reduction: time to update the rationale for exercise? Considering the role of sex in modulating direct effects of exercise on the vasculature. J Appl Physiol 2008 August;105(2):778 Parker BA, Smithmyer SL, Pelberg JA, Mishkin AD, Herr MD, Proctor DN. Sex differences in leg vasodilation during graded knee extensor exercise in young adults. J Appl Physiol 2007 November;103(5):1583-91. Parker BA, Smithmyer SL, Pelberg JA, Mishkin AD, Proctor DN. Sex-specific influence of aging on exercising leg blood flow. J Appl Physiol 2008 March;104(3):655-64. Parker BA, Smithmyer SL, Proctor DN. Hormone therapy is associated with preserved smooth muscle structure and dilation in the arterial vasculature of the leg in older women. Maturitas 2008 January 20;59(1):46-54. Parker BA, Smithmyer SL, Ridout SJ, Ray CA, Proctor DN. Age and microvascular responses to knee extensor exercise in women. Eur J Appl Physiol 2008 June;103(3):343 -51. Parker BA, Trehearn TL, Meendering JR. Pick Your Poiseuille: Normalizing the Shear Stimulus In Studies of Flow-Mediated Dilation. J Appl Physiol 2008 November 13. Patten CA, Decker PA, Dornelas EA, Barbagallo J, Rock E, Offord K, Hurt R, Pingree S. (2008). Changes in readiness to quit and selfefficacy among adolescents receiving a brief office intervention for smoking cessation. Psychology, Health and Medicine, 13, 326-336. Pescatello LS, Blanchard BE, Van Heest JL, Maresh CM, GordishDressman H, Thompson PD. The metabolic syndrome and the immediate antihypertensive effects of aerobic exercise: a randomized control design. BMC Cardiovasc Disord. 2008 Jun 10;8:12. Pistilli EE, Devaney JM, Gordish-Dressman H, Bradbury MK, Seip RL, Thompson PD, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Gordon PM, Hoffman EP. Interleukin-15 and interleukin-15R alpha SNPs and associations with muscle, bone, and predictors of the metabolic syndrome. Cytokine 2008 Jul;43(1):45-53.

Poirier P, Alpert MA, Fleisher LA, Thompson PD, Sugerman HJ, Burke LE, Marceau P, Franklin BA. American Heart Association Obesity Committee of Council on Nutrition, Physical Activity and Metabolism, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiopulmonary Perioperative and Critical Care, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovas. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation. 2009 Jul 7;120(1)86-95. Epub 2009 Jun 15. Richards KA, Lleuser LP, Kluger J. Fortuitous therapeutic effect of Taser shock for a patient in atrial fibrillation. Ann Emerg Med. 2008 Dec;52(6):686-8. epub 2008 June 2. Ruao G. DNA collage and personalized medicine. Conn Med. 2008 Jun-Jul;72(6):322. Ruao G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL, Kocherla M, Holford TR, Hanks S. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta. 2008, Oct. 26. Ruao G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL, Kocherla M, Holford TR, Hanks S. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta. 2008 Oct 26. Ruffin RT Jr, Kluger J, Baker WL, Wills SM, White CM, Coleman C. Association between perioperative NSAID use and postcardiothoracic Esurgery atrail fibrillation, blood transfusions, and cardiovascular outcomes: a nested cohort study from the AF Suppression Trials (AFIST) I, II and III. Curr Med Res Opin. 2008 Apr;24(4):1131-6. Seip RL, Volek JS, Windemuth A, Kocherla M, Fernandez ML, Kraemer WJ, Ruao G. Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat. Nutr Metab (Lond). 2008 Feb 6;5:4. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007 Nov;9(5):389-96. Shafi N. Malek A, Silverman DI. Management of hypertension in Takayasu arteritis during pregnancy. J Clin Hypertension, 2009, 11:383-5. Shafi N, McKay RG, Kiernan FJ, Silverman IE, Ahlquist M, Silverman I. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent Foramen Ovale Closure Devices. Int J Cardiol July 2009, epublication ahead of print.

Shah SA, Clyne CA, Henyan N, Migeed M, Yarlagadda R, Silver BB, Kluger J, White CM. Impact of magnesium sulfate on serum magnesium concentrations and intracellular electrolyte concentrations among patients undergoing radio frequency catheter ablation. Conn Med. 2008 May;72(5):261-5. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, ORourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008 Mar 11;117(10):1283-91. Shaw LJ, Berman DS, Blumenthal RS, Budoff MJ, Faber TL, Goraya T, Halliburton SS, Hecht H, Kiat H, Koenig W, Malik S, Merhige M, Nasir K, Min JK, OKeefe J, Polk DM, Raggi P, Rosenblatt JA, Schwartz RG, Taylor AJ, Thomas GS, Wijns W. Clinical imaging for prevention: directed strategies for improved detection of presymptomatic patients with undetected atherosclerosis--Part I: Clinical imaging for prevention. J Nucl Cardiol. 2008 JanFeb;15(1):e6-19. Review. Shaw LJ, Hendel RC, Heller GV, Borges-Neto S, Cerqueira M, Berman DS. Prognostic estimation of coronary artery disease risk with resting perfusion abnormalities and stress ischemia on myocardial perfusion SPECT. J Nucl Cardiol 2008;15:762-73. Sheridan S, Crespo, E. Is the routine use of global coronary heart disease risk scores associated with clinical benefits or harms? A systematic review of the literature. BMC Health Services Research 2008, 8:60. Siddiqi SA, Thompson PD. How do you treat patients with myalgia who take statins? Curr Atheroscler Rep. 2009 Jan;11(1):9-14. Singh B, Bateman TM, Case JA, Heller GV. Attenuation artifact, attenuation correction, and the future of myocardial perfusion SPECT. J Nucl Cardiol 2007;14:153-64. Soman P, Lahiri A, Mieres JH, Calnon DA, Wolinsky D, Beller GA, Sias T, Burnham K, Conway L, McCullough PA, Daher E, Walsh MN, Wight J, Heller GV, Udelson JE. Etiology and pathophysiology of new-onset heart failure: Evaluation by myocardial perfusion imaging. J Nucl Cardiol 2009;16:82-91. Sood M, Coleman Cl, Kluger J, White CM, Padala A, Baker WL. The association among blood transfusions, white blood cell count, and the frequency of post-cardiothoracic surgery atrial fibrillation: A nested cohort study from the Atrial Fibrillation Suppression Trials I, II, and III. J Cardiothorac Vasc Anesth. 2008 Aug 28.

Sorokin AV, Araujo CG, Zweibel S, Thompson PD. Atrial fibrillation in endurance trained athletes. Br J Sports Med. 2009 Aug 11. Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007 Oct;194(2):293-9. Review. Talati R, Reinhart KM, White CM, Phung OJ, Sedrakyan A, Kluger J, Coleman CI, Outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery: a meta-analysis. Ann Pharmacother. 2009 Jul;43(7):1181-8. Epub 2009 Jun 16. Tercius AJ, Kluger J, Coleman C, White CM. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation of flutter. Pacing Clin Elcetrophysiol, 2007 Nov;30(11):1331-5. Thompson PD, Venero CV. A history of medical reports on the Boston Marathon: 112 years and still running. Med Sci Sports Exerc. 2009 Jun;41(6):1341-8. Thompson PD. Pre-participation screening of competitive athletes: seeking simple solutions to a complex problem. Circulation. 2009 Mar 3;119(8):1072-4. Epub 2009 Feb 16. Venero CV, Heller GV, Bateman TM, McGhie AI, Ahlberg AW, Katten D, Courter SA, Golub RJ, Case JA, Cullom SJ. A Multicenter evaluation of a new post-processing method with depth-dependent collimator resolution applied to full-time and half-time acquisitions without and with simultaneously acquired attenuation correction. J Nucl Cardiol 2009;16;714-25 Venero CV, Thompson PD, Fernandez AB. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate. Am J Med. 2008 Oct;121(10):e3-4. Venero CV, Thompson PD. Managing statin myopathy. Endocrinol Metab Clin North Am. 2009 Mar;38(1):121-36. Venero CV, Venero JV, Seip RL, Thompson PD. Effectiveness of thrice weekly ezetimibe. Am J Cardiol. 2008 Nov 1;102(9):1205-6. Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE; Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care. 2007 Nov;30(11):2892-8. Walsh S, Kelsey BK, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller RF, Seip RL, Bilbie S, Thompson PD, Hoffman EP, Price TB, Devaney JM, Pescatello LS. The CNTF 1357 G>A polymorphism and the muscle strength response to resistance training. J Appl Physiol. 2009 Jul 23 [Epub ahead of print]

26.

vWard RP, Al-Mallah MH, Grossman GB, Hansen CL, Hendel RC, Kerwin TC, McCallister BD Jr, Mehta R, Polk DM, Tilkemeier PL, Vashist A, Williams KA, Wolinsky DG, Ficaro EP; American Society of Nuclear Cardiology. American Society of Nuclear Cardiology review of the ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI). J Nucl Cardiol. 2007 Nov-Dec;14(6):e26-38. Windemuth A, Calhoun VD, Pearlson GD, Kocherla M, Jagannathan K, Ruao G. Physiogenomic analysis of localized FMRI brain activity in schizophrenia. Ann Biomed Eng. 2008 Jun;36(6):877-88. Young LH, Wackers F J, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk, N, Ratner RE, Inzucchi SE. Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients with Type 2 Diabetes. JAMA 2009;301(15):1547-1555. Zoeller RF, Ryan ED, Gordish-Dressman H, Price TB, Seip RL, Angelopoulos TJ, Moyna NM, Gordon PM, Thompson PD, Hoffman EP. Allometric scaling of isometric biceps strength in adult females and the effect of body mass index. Eur J Appl Physiol. 2008 Nov;104(4):701-10.

Guler AL, Chien P, Ahlberg A, Faheem O, Katten D, Heller GV. Attenuation Corrected SPECT Myocardial Perfusion Imaging Provides Highly Effective Risk Stratification for Future Cardiac Events. JACC: 2009;53:A287. Hendel RC, Mieres JH, Heller GV, Bairey-Merz CN, Boden WE, Shaw LJ. Prevalence of False Positive Exercise Electrocardiograms in Women? Results from the What is the Optimal Method for Ischemia Evaluation in Women (WOMEN) Trial. JACC: 2009;53:A287. Lustgarten D, Neal S, Crespo E, Lobel R, Spector P, VanBuren P. Direct His Bundle Pacing Results in Significant QRS Narrowing in Patients Referred for Cardiac Resynchronization Therapy (CRT). Abstract presented at the Heart Rhythm Society Scientific Session in May 2009. Padala A, Shah AR, Ahlberg A, Kokkirala AR, Katten D, Heller GV. Value of Transient Ischemic Dilatation for Risk Stratification of Patients Undergoing Gated Rubidium-82 Positron Emission Tomography Imaging. JACC: 2009;53:A288. Parker, BA, Thompson, PD, Ruopp, KC, Meda, SA, Grimaldi, AS, Pearlson, GD (2009). Direct Effects Of Exercise Training On The Hippocampus In Humans. American College of Sports Medicine 2009 Annual Meeting, Seattle, WA. Med Sci Sports Exerc. 41(5) Supplement 1:8. Shephal K Doshi, MD, Jesus E. Val-Mejias, MD, Michael Pittaro, MD, Russell Reeves, MD, John Payne, MD, Richard Henthorn, MD, Mauricio Hong, MD, Steven Zweibel, MD, Mark Kroll, PhD, Robert Graumann, MS, Ashish L Oza, MS. Do similar T-Shock and Rescue Shock Waveforms, When Altered, Affect ULV based DFT Estimations? Heart Rhythm Society Meeting, May 2009. Sood N, Coleman C, Padala A, Kluger J, Guertin D, Clyne C. Association Between ICD Lead Diameter and ICD Lead Failure. Presented at Heart Rhythm Society National Meeting, Denver, Colorado, May 15th, 2008, published in HRS Supplement, May, 2008. Yekta A, Ruffin R, Ahlberg A, Katten D, Heller GV. Outcomes Analysis of Stress-Only Gated Myocardial Perfusion Imaging with Attenuation Correction in Patients with Suspected Coronary Artery Disease. JACC: 2009;53:A296.

Abstracts
Barmpouletos D, Stavens G, Ahlberg A, OSullivan DM, Katten DM, Heller GV. Risk Stratification of Diabetic Patients with Single Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT-MPI): Does duration of Disease and Type of Therapy Matter? JACC: 2009;53:A291. Bhavnani S, Coleman C, Guertin D, White CM, Yarlagadda R, Clyne C, Kluger J. Clinical predictors of early mortality among patients receiving implantable cardioverter-defibrillators. Europace Journal 2009, 11(Supplement 2), Abstract 507. Chawla D, Sood N, Guertin D, Zweibel S, Coleman C, Kluger J, Clyne C. Predictors of Pacemaker Dependence and Pacemaker Dependence as a Predictor of Mortality in Patients Implanted with Implantable Cardioverter Defibrillator. Heart Rhythm Society Meeting, May 2009. Ching G, Li D, McKay R, Mather J, Lundbye J. Proton Pump Inhibitors Increase Major Adverse Cardiac Events Among Post Percutaneous Coronary Intervention Patients on Clopidogrel. Circulation, 2009; 120:S936-S937 Faheem O, Mohyuddin Y, Iqtidar AF, Guler AL, Chawla D, Ahlberg A, Heller, GV. Diabetics with Positive SPECT Myocardial Perfusion Imaging Referred for Catheterization: Gender Bias? JACC: 2009;53:A297

New Projects
Federal
Dornelas, Ellen, PhD
Reducing Vulnerability to ICD Shock Treated Ventricular Arrhythmias. NHLBI/ Yale University, $412,725. Reducing Vulnerability to ICD Shock Treated Ventricular Arrhythmias (Substudy). NHLBI/ Yale University, $46,916.

Kluger, Jeffrey, MD
Task Order 2, Project 1. Comparative Effectiveness of Medical Therapies for Stable Ischemic Heart Disease. ACE_ARB CER/AHRQ/ University of Connecticut, $134,119.

with Rate Adaptive Pacing Driven by Minute Ventilation or Accelerometer. Boston Scientific Corp., $77,500.

Lundbye, Justin, MD
A Multicenter, Randomized, Double-Blind, Parallel Group, PlaceboControlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure. Novartis Pharmaceutical Corp, $37,479.

Thompson, Paul, MD
Co Enzyme Q10 in Statin Myopathy. NIH/NCCAM, $865,207. DNA Diagnostic System for Statin Safety and Efficacy. NIH/ Genomas, $74,812.

Wencker, Detlef, MD
Studies on Skeletal and Cardiac Muscle Apoptosis in Advanced Cardiac Failure. NIH, $562,115.

McKay, Raymond, MD
IntraCoronary Treatment with Integrilin to Improve Angiographic Outcomes (IC Titan Timi-47). The Brigham and Womens Hospital, $74,163.

White, Charles, PharmD

Human Growth Hormone in Cystic Fibrosis. UCONN/AHRQ, $3,106.

Polk, Donna, MD
A Phase III, Double-Blind, Randomized Placebo-Controlled Study, to Evaluate the Effects of RO4607381 on Cardiovascular Risk in Stable CHD Patients, with a Documented Recent Acute Coronary Syndrome. Hoffman-LaRoche, $221,980. A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease (CG 104). Parexel International, $169,543.

Foundation
White, Charles, PharmD
The Impact of Ascorbic Acid Therapy on Inflammatory Mediators in Cardiothoracic Surgery Patients: The Atrial Fibrillation Suppression Trial IV (AFIST IV) Pilot Study. The Gustavus and Louise Pfeiffer Research Foundation, $72,282.

State
Parker, Beth, PhD
Does Smoking Cessation restore Vascular Function in Chronic Smokers? CT Department of Public Health, $267,187.

Wencker, Detlef, MD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects with Acute Heart Failure Syndrome and Renal Impairment Who are Hospitalized. Averion International Corp., $103,575. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess The Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficiency. Biogen Idec, $79,400. Recover II Trial: A Prospective Randomized Trial Investigating the Use of the Impella RECOVER LP 2.5 System in Patients with Acute Myocardial Infarction Induced Hemodynamic Instability. ABIOMED, Inc., $56,500. The Effect of Eplerenone Versus Placebo on Cardiovascular Mortality and Heart Failure Hospitalization in Subjects with NYHA Class II Chronic Systolic Heart Failure (EMPHASIS-HF). Pfizer, $60,450.

Industry
Clyne, Christopher, MD
FREEDOM: A Frequent Optimization Study Using the QuickOpt Method. St. Jude Medical, $50,360.

Heller, Gary, PhD, MD

A Phase 2, Open-Label, Multicenter Study for the Development of One-Day Rest/Stress Cardiac Positron Emission Tomography (PET) Perfusion Imaging Protocols of BMS 747158. Lantheus Medical Imaging, $19,646. An Open-Label, Multicenter, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects with Heart Failure who will Experience an Adverse Cardiac Event during 24 Months Follow-up. GE Healthcare, $13,839.

Kiernan, Francis, MD
A Clinical Evaluation of the Medtronic Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm. Medtronic Vascular, $149,000.

Zweibel, Steven, MD
PROVIDE: Programming Implantable Cardioverter Defibrillators in Patients with Primary Prevention Indication to Prolong Time to First Shock. St. Jude Medical, Scientific Studies Organization, $63,000. The Vest Prevention of Early Sudden Death Trial (VEST) PREDiction of ICD Therapies Study (PREDICTS). NIH/NHLBI/ University of California, San Francisco, $325,438.

Kluger, Jeffrey, MD
APPROPRIATE Assessment of Proper Physiologic Response

28.

Industry (Investigator Initiated)

Coleman, Craig, PharmD
A Clinicians Perspective on Rating the Strength of Evidence in a Systematic Review. Pfizer, $45,000. A Clinicians Perspective on the Use of Meta-Regression in Systematic Review: Caveats and Cautions. Pfizer, $45,000. A Healthcare Decision Makers Guide to Reviewing and Using Meta-Analyses: A White Paper of the Health Outcomes, Policy, and Economics (HOPE) Collaborative Group. Pfizer, Inc., $25,000. Cost-Effectiveness of Aggrenox in Reduction of Graft Failures Among Dialysis Patients: A Markov Model. Boehringer Ingelheim, $26,616. Evaluating the Impact of Study-Level Factors on Anticoagulation Control in US-Based Clinical Trials: A Meta-Analysis. BoehringerIngelheim, $44,500. Meta-Analysis of Dopamine Agonists, Catechol-o-methyltransferase Inhibitors and Monoamine Oxidase Type B Inhibitors for the Treatment of Advanced Parkinsons Disease. BIPI, $15,000. Oral Hypoglycemic Medications and Their Impact on New-Onset Diabetes Mellitus Incidence: A Mixed Treatment Comparison MetaAnalysis of Randomized Controlled Trials. Takeda Pharmaceuticals, $58,500.

McKay, Raymond, MD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P - TIMI 50). Schering Plough, $545,625.

Polk, Donna, MD
A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). GlaxoSmithKline, $274,075.

Wencker, Detlef, MD
A Phase II/III, Multicenter, Randomized, Double Blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects with Acute Heart Failure. Corthea, Inc., $71,260. Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF). Scios, Inc., $76,938. PROTECT II: A Prospective, Multi-center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System versus Intra Aortic Balloon Pump (IABP) in Patients Undergoing Non Emergent High Risk PCI. ABIOMED, Inc., $85,000.

Departmental
Mathur, Shishir, MD
Effects of Acute and Chronic Physical Activity on Genetic Damage and Lipoproteins. $19,500.

Industry (Multi-center)
Heller, Gary, PhD, MD
A Phase 3b, Multicenter, Randomized, Double-Blind, PlaceboControlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson. Astellas Pharma Global Development, Inc., $90,242. A Single-Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial of LMI1195 in Healthy Subjects (Study Number: LMI1195-101). Lantheus Medical Imaging, $153,200.

McKay, Raymond, MD
A Pilot Study to Assess the Histological Effects and Biomechanical Strength of a Novel, Knotless Suturing Technique. $22,363.

Parker, Beth, PhD

The Effect of Statins on Cognitive Function in Individuals with Statin-Associated Cognitive Complaints. $2,000.

Thompson, Paul, MD
Assessments of Muscle Outcomes in Clinical Patients with Statin Myalgia. $12,000.

Kiernan, Francis, MD
Protocol P07-6330: A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing The Cypher Elite to The Cypher Bx VELOCITY Sirolimus-Eluting Stent Systems. Cordis Corporation, $85,000.

Hartford Hospital Research Endowment Funds

Azemi, Talhat, MD
Diagnostic and Prognostic Significance of Ischemic Electrocardiographic Changes During Vasodilator Stress Myocardial Perfusion Imaging. Small Grant, $9,507.

Lundbye, Justin, MD
Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome. Bristol-Myers Squibb Company, $130,606.

Clyne, Christopher, MD
Identifying Atrial Ablation Lines through Two-Dimensional Delayed Enhancement MR Imaging. Small Grant, $6,300; St. Jude Medical, Scientific Studies Organization $5,000.

Heller, Gary, PhD, MD

The Prognostic Role of Myocardial Perfusion Imaging in Elderly Patients Undergoing Stress Test? A Meta-Analysis. Statistical analysis supported through Hartford Hospital Small Grant.

Fischer, Edward, PhD

Community and Patient Attitudes Towards Seeking Medical Help: Development and Standardization of a Comprehensive Attitude Measure. Open Competition, $21,146.

Humayun, Naeem, MD
Does Cardiac Resynchronization Therapy (CRT) Increase Susceptibility to Malignant Arrhythmias?

Iqtidar, Ali, MD
Predictors of Rapid Aortic Dilatation in Adult Patients with a Bicuspid Aortic Valve. Statistical analysis supported through Hartford Hospital Small Grant.

Lundbye, Justin, MD
Elevated Plasma Cytokines are a Marker for Unstable Coronary Syndrome: The Hartford Chest Pain Study. Small Grant, $10,777.

Parker, Beth, PhD

Sex Differences in the Mechanisms Underlying Endothelial Function. Open Competition, $78,685.

Kluger, Jeffrey, MD
Simple Bedside Method of Monitoring QTc in Patients with Pacemaker Receiving QTc Prolonging Drugs.

Silverman -Cardiology, David, MD

Freedom from Atrial Fibrillation Following Radio-Frequency Ablation Depends Upon Integrity of Atrial Function. Small Grant, $9,975. Systolic Strain Abnormalities to Predict Hospital Readmission In Patients with Heart Failure and Normal Ejection Fraction. Small Grant, $3,680.

Lundbye, Justin, MD
A Quality Improvement Project on Congestive Heart Failure Readmission. Cardiac Intensive Care Unit Clinical Outcomes- A Quality Improvement Project. Clinical Outcomes Blanket Protocol for Induction of Hypothermia in Patients with Cardiac Arrest.

Sood, Nitesh, MD
Heart Rate Variability and Brain Natriuretic Peptide. Small Grant, $5,760.

Mendes, Beverly, APRN

Phenomena of Inner Strength in Women Recovering Post Myocardial Infarction Coronary Stent: A Grounded Theory Study.

Unfunded
Anglade, Moise, MD
Use of N-Acetylcysteine for Prevention of Postoperative Atrial Fibrillation: A Meta-Analysis.

Morales, Donna Chelle, MD

Ethnic Differences in Depression Amongst Female Cardiac Rehabilitation Patients.

Polk, Donna, MD
The Effects of Carotid IMT Scans on Intent and Actual Likelihood to Change Health Behaviors.

Book, Gregory, BS
Automatic Extraction of Heart Valve Models from 64 Slice CT Data Using Active Appearance Models.

Rabdiya, Vimal, MD
Is Left Ventricular Diastolic Dysfunction an Arrhythmogenic Marker in Patients with Implantable Cardioverter-Defibrillator and Relatively Preserved Left Ventricular Systolic Function?

Chaudhri, Priya, PhD

The Effects of Sleep Disturbance on Adherence to Cardiac Rehabilitation.

Richards, Kyle, MD
Cardiac PET FDG and MR Imaging in Patients with Sarcoidosis: A Retrospective Study for Clinical Outcomes.

Chemmarappally, Shiny, RN
Infusion Center Treatment Effect on Quality of Life in Congestive Heart Failure Patients.

Silverman, David, MD
Do Repeat Echocardiograms Alter Clinical Outcomes? A Prospective Study. Statistical analysis supported through Hartford Hospital Small Grant. Dyssynchrony Determines Prognosis in Diastolic Heart Failure. Evaluation of Load Independent Diastolic Function Using Velocity Vector Imaging- A Novel Technique.

Coleman, Craig, PharmD

Context-Based Learning by Pharmacy Students during their Clinical Rotations: The Role of Situated Learning in Experiential Education. Examining the Barriers to Updating Systematic Review Research: A Survey of Authors of Published Systematic Reviews in the Medical Literature.

30.

Predictors of Success after Percutaneous Patent Foramen Ovale Closure for Stroke Prevention. Validation of Velocity Vector Imaging for Assessment of Diastolic Function.

Coleman, Craig, PharmD

Can HMG-CoA Reductase Inhibitors Decrease Atrial Fibrillation Following Cardiothoracic Surgery? A Retrospective Cohort Evaluation. Drug Assistance Program to Reduce Disparities in Health. Meta-Analyses of the Impact of Appropriate Antibiotic Therapy on Mortality in Patients with Ventilator-Associated Pneumonia and Blood Stream Infections. AstraZeneca, $20,625. Meta-Analysis of Therapies for Treatment of Early- and Late-Stage Parkinsons Disease. Boehringer-Ingelheim Pharmaceuticals, $17,500. The Impact of Oral Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias and Patient Perceived Quality of Life Among Patients with Implantable Cardioverter-Defibrillators: The Adjuvant Magnesium (AdMag) Trial Cost-Utility Analysis. Hartford Hospital Research Endowment Funds, $9,952.

Wencker, Detlef, MD
Effect of Neurohormonal Agents on Ejection Fraction of Chronic Heart Failure Patients. INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).

Zafian, Ruth, APRN

An Exploratory, Descriptive Pilot Study to Examine the Quality of Hand-offs Reports at Hartford Hospital Using the ISBAR Technique.

Active Projects
Ahmed, Shafeeq, MD
Is Cardiac Memory Blocked by Calcium Channel Blockers and Amiodarone?

Donahue, Stephen, BS
CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines?). Millennium Pharm. & Schering Plough Pharm., $20,000.

Bilbie, Stephen, MS
Upper Arm Muscle Injury, Soreness, and Strength Changes Associated with Two Bouts of Resistance Exercise. Hartford Hospital Research Endowment Funds, $10,000.

Dornelas, Ellen, PhD

A 12 Week, Double-Blind, Placebo-Controlled, Multicenter Study with a 40 Week Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 MG BID for Smoking Cessation in Subjects with Cardiovascular Disease. Pfizer, $160,327. Nicotine Replacement Treatment for Pregnant Smokers. NIH/ University of Connecticut, $527,683. Study of treatment for Antepartum Depression in expecting Mothers (SAD-Moms). Hartford Hospital Research Endowment Funds, $73,000.

Clyne, Christopher, MD
Impact of Corticosteroids on Immediate Postoperative Recurrence of Atrial Tachyarrhythmias after Radiofrequency Catheter Ablation of Atrial Fibrillation. Interventional Electrophysiology Outcomes Protocol. Multicenter Automatic Defibrillator Implantation Cardiac Resynchronization Therapy (MADIT-CRT). University of Rochester/ Guidant Corporation, $133,793. OPTION CRT/Atx (Cardiac Resynchronization Therapy & Atrial Therapy). BIOTRONIK, Inc., $59,698. Statistical analysis supported through Hartford Hospital Small Grant. Response of Cardiac Resynchronization Therapy Optimization with V-V Timing in Heart Failure Patients (RESPONSE HF). St. Jude Medical, $34,247. The Impact of Intravenous Magnesium on Atrial Vulnerability in Patients Receiving Radiofrequency Catheter Ablation for Atrial Fibrillation. Hartford Hospital Research Endowment Funds, $40,894. Use of Gated Blood Pool Imaging to Predict Improvement with Bi-Ventricular Pacing - A Pilot Study. Hartford Hospital Research Endowment Funds, $9,295.

Heller, Gary, MD, PhD

A Prospective Comparison of Gated, Rest/Stress Rubidium-82 Positron Emission Computed Tomography (PET) vs. Gated, Rest/ Stress Technetium 99-M SPECT: A Pilot Study. Bracco Diagnostics, Inc., $285,802. An Open-Label Multi-Center, Phase 3 Study Evaluating the Prognostic Usefulness of I123-mIBG Scintigraphy for Identifying Subjects with Heart Failure who will Experience an Adverse Cardiac Event? ( Protocol PC MBG311 CPR). GE Healthcare (Amersham), $157,500. Assessment of Myocardial Perfusion and Left Ventricular Function from Stress and Rest Tc-99m Sestamibi Gated SPECT Imaging for the Prediction of Future Cardiac Events in Patient with Known or Suspected Coronary Artery Disease. Hartford Hospital Research Endowment Funds, $44,280.

Attenuation Correction with the CardioMD Camera: Validation by Comparison with Attenuation Correction with the Vertex Cardio 60 Camera. Nuclear Medicine Division - Philips Med. System, $100,632. Clinical Utility of Attenuation Correction of Pharmacologic Stress Tc-99 Sestamibi SPECT Myocardial Perfusion Imaging in Patients with Known or Suspected Coronary Artery Disease. Detection of Ischemia in Asymptomatic Diabetics (DiaD). Yale University School of Medicine, $289,843. Development of a Normal Database and Criteria for Abnormality for b Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid (Iodofiltic Acid I 123) for Quantitative Imaging (Protocol MIP-BP22). Molecular Insight Pharmaceuticals, $50,094. Evaluation of Astonish Processing Phase II. Philips Nuclear Medicine (Cleveland), Inc., $139,583. Impact of Stress Modality Upon Diagnosis and Risk Stratification in Patients with Left Bundle Branch Block (LBBB). Nuclear Cardiology Imaging Clinical Outcomes Blanket Protocol. Statistical analysis supported through Hartford Hospital Small Grant. Nuclear Imaging Database Research Project. Bristol Meyers Squibb Imaging, Inc., $95,000. Open-Label, Phase 2 Study of the Safety and Efficacy of -Methylp-[123I]-Iodophenyl-Pentadecanoic Acid (Iodofiltic Acid I 123) for Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (SPECT) in Adults with Symptoms Consistent with Acute Coronary Syndrome (ACS). Molecular Insight Pharmaceuticals, $56,445. Progression of Coronary Artery Disease in Diabetic and NonDiabetic Individuals as Measured by Serial Gated Myocardial Perfusion Imaging. Hartford Hospital Research Endowment Funds, $10,074. Stress technetium-99m Sestamibi Gated SPECT Imaging in the Detection of Coronary Artery Disease in Patients with Dilated Cardiomyopathy. Hartford Hospital Research Endowment Funds, $50,000. Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in CAD: (SPARC). Brigham & Womens Hospital, $50,375. The Prognostic Value of Left Ventricular Ejection Fraction From Cardiac PET Myocardial Perfusion Imaging in Patients with Known or Suspected Coronary Artery Disease. BRACCO, $78,738. The Role of Cardiac PET Perfusion Imaging in the Diagnosis of Coronary Disease in Patients with Diabetes Mellitus. Hartford Hospital Research Endowment Funds, $48,394.

of the Zomaxx Drug Eluting Coronary Stent System as Compared to the TAXUS Express Paclitaxel-Eluting Stent in de novo Coronary Artery Lesion. Abbott Vascular, $300,956. ARRIVE - Taxus Peri-Approval Registry: A Multi-Center Safety Surveillance Program. Boston Scientific Corporation, $114,410. CSP-424 Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE). Department of Veterans Affairs, $378,000. Humanitarian Use Device - JOSTENT Coronary Stent Graft. Protocol P00-6302 A Multicenter, Randomized, Double Blind Study of the SIROLIMUS-Coated BX Velocity Balloon Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions. Cordis, Inc., $102,000.

Kluger, Jeffrey, MD
MASTER: Microwave T Wave Alternans Testing for Risk Stratification of Post MI Patients. Medtronic, $120,023. The Adjuvant Magnesium Trial (AdMag): Assessment of the Impact of Oral Magnesium on ICD Firing and Quality of Life. Donaghue Foundation, $162,175. The Use of Magnesium to Improve Hemodynamics, Cholesterol and Glucose Control: A Substudy of AdMag. Hartford Hospital Research Endowment Funds, $47,000.

LaGasse, Marie
Exercise Training and Endothelial Vasomotor Function in Patients with Coronary Artery Disease. Hartford Hospital Research Endowment Funds, $52,575.

Lundbye, Justin, MD
Follow up of Patients with Coronary Artery Disease who have Undergone Rapid Aspirin Desensitization Before or After Percutaneous Coronary Intervention. Hartford Hospital Research Endowment Funds, $5,826.

McKay, Raymond, MD
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention/TRITON-TIMI 38. Quintiles, Inc., $143,022. A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared to Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) - PLATO. AstraZeneca Pharmaceuticals, $182,265. A Single-Center Registry to Investigate the Long-Term Safety and Efficacy of the Sirolimus-Eluting CYPHER Intracoronary Stent. Cordis, $140,410. Clinical Outcomes Blanket Protocol of Get-with-the-guidelines Heart Failure (GWTG-HF) database.

Kiernan, Francis, MD
A Randomized, Controlled Trial to Evaluate the Safety and Efficacy

32.

Cardiology

Novel Suture-based Arteriotomy Closure Device Feasibility Study. Departmental, $105. Percutaneous Coronary Intervention Clinical Outcomes Blanket Protocol. Statistical analysis supported through Hartford Hospital Small Grant. The Role of Glycemic Control During Cardiac Catheterization Procedures and Cardiac Events.

Reduction of LDL Cholesterol in Subjects with Hypercholesterolemia Refractory to Current Conventional Treatment. B. Braun Medical, Inc., $91,875. A Randomized, Placebo Controlled, Parallel Group, Double-Blind Study of the Efficacy and Safety of Rimonabant in Abdominally Obese Subjects with Multiple Cardiovascular and Metabolic Risk Factors and with LDL-Cholesterol at NCEP ATP III Treatment Goal (Protocol Number L-0137). Sanofi-Aventis US, ICON Clinical Research, $77,967. B. Braun Medical Inc. Patient Registry for the H.E.L.P. System. Correlation of Cytochrome P450 and Drug Transport Gene Polymorphisms in Statin-Induced Myopathies. Hartford Hospital Research Endowment Funds, $23,680. Determining the Reliability and Reproducibility of Brachial Artery Reactivity. Hartford Hospital Research Endowment Funds, $13,125. Does Exercise Training Alter Hippocampal Size and Function in Humans: A Preliminary Study. Hartford Hospital Research Endowment Funds, $56,317. Effects of Low and High Dose Atorvastatin On Exercise-Induced Muscle Injury. Merck & Co., Inc., $408,227. Functional SNPs associated with Human Muscle Size and Strength ( FAMUSS). NIAMS/Childrens National Medical Center, $447,280. Gene Expression Profiling and the Repeated Bout Effect: A Pilot StudyHF-ACTION: Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing: Ancillary Study - Investigation of the Role of Genetic Variation in the Clinical Expression of Heart Failure. NHLBI, $685,000. Lipid Treatment Assessment Project 2 (L-TAP 2) Protocol #NRA5090005. Pfizer, $6,250.

Polk, Donna, MD
A Preliminary Study of Statin-Associated Cognitive Impairment. Hartford Hospital Research Endowment Funds, $34,588.

Rock, Josh, DO
Pulmonary Venous Catheter Ablation and its Effect on P-Wave Dispersion in Patients with Atrial Fibrillatoin. The Effects of Statin Therapy on the Development of Early Recurrent Atrial Fibrillation after Catheter-Based Pulmonary Vein Ablation.

Ruao, Gualberto, MD, PhD

Genetic Modulation of Lipid Metabolic Response to Aerobic Exercise. Hartford Hospital Research Endowment Funds, $50,000.

Seip, Richard, PhD

Relationship of Muscle Injury to Muscle Hypertrophy. Hartford Hospital Research Endowment Funds, $35,488.

Sood, Nitesh, MD
Effect of Heart Rate on Ventricular Dyssynchrony.

Thompson, Paul, MD
(JUPITER) A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (Crestor\200) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein (JUPITER) (Protocol No. 4522US/0011). PPD Development, LP, $102,250. A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate and Compare the Efficacy and Safety of Ezetimibe Added On to Atorvastatin 40 mg Versus Up Titration to Atorvastatin 80 mg in Hypercholesterolemic Patients at High Risk for Coronary Heart. Merck & Co., Inc., $26,500. A Randomized Multicenter Crossover FUTURA Trial to Compare the Performance of the Plasmat Futura Heparin Induced Extracorporeal LDL Precipitation (H.E.L.P.) Apheresis System to the Approved Plasmat Secura H.E.L.P. Apheresis System in the

Molecular Changes in Human Muscle with Unloading/Reloading. Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group Evaluation of the Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (QD), Compared with Atorvastatin Alone, on the Occurrence of Major Cardiovascular Events in Subjects with Coronary Heart Disease or Risk Equivalents. Pharmanet, $347,000. Skeletal Muscle Gene Expression in Patients with Statin-Induced Myalgia. Donaghue Medical Research Foundation, $239,996. The Effect of Statins on Skeletal Muscle Function. NIH, $3,007,870.

White, Charles, PharmD

Electrocardiographic (ECG) Evaluation of Transmural Dispersion of Repolarization and QT Prolongation in Patients Receiving Amiodarone or Pure Blockers of the Rapid Component of the Delayed Rectifier Potassium Channel (Sotalol or Dofetilide). The Impact of Short-Term High Intensity Statin Therapy Versus Low Intensity Statin Therapy on Inflammatory Mediators in Cardiothoracic Surgery Patients: The Atrial Fibrillation Suppression Trial IV (AFIST IV) Pilot Study. Gustavus and Louise Pfeifer Research Foundation, $74,583.

34.

Center for

Anti-Infective Research & Development

David Nicolau, PharmD, FCCP, FIDSA, Director Charles Nightingale, PhD, Co-Director Joseph L. Kuti, PharmD, Associate Director Kathryn J. Eagye, MPH, Associate Director Mary Banevicius, BS, Research Supervisor Pamela Tessier, MS, Research Supervisor Christina Sutherland, BS, Research Assistant Debora Santini, BS, Research Assistant Lindsay Tuttle, BS, Research Assistant Henry Christensen, BS, Research Assistant Jennifer Hull, BS, Research Assistant Aryun Kim, PharmD, Postdoctoral Fellow Anthony Nicasio, PharmD, Postdoctoral Fellow Jared Crandon, PharmD, Postdoctoral Fellow Catherine Bulik, PhD, Postdoctoral Fellow Rebecca Keel, PhD, Postdoctoral Fellow Dora Wiskirchen, PhD, Postdoctoral Fellow Pashalina Konto, MD, Visiting Scholar, Papanikolaou Hospital, Thessaloniki, Greece Li Peng, Visiting Scholar, PUMC Hospital, Beijing, China Pornpan Koomanachai, MD, Visiting Scholar, Siriraj Hospital, Mahidol Univ.,Thailand Within the institution, the CAIRD continues to focus its efforts on discovering the most clinically, as well as costeffective method of administering anti-infectives, efforts which began nearly 30 years ago via the founding insights of Drs. Richard Quintiliani and Charles Nightingale. The Center for Anti-Infective Research and Development at Hartford Hospital has a national and international reputation for being on the leading edge of Infectious Disease research and its clinical application. Throughout the course of the year, members of the Center have given numerous presentations involving both clinical practice and research related topics at various local, national and international meetings.

New Projects
Industry
Kuti, Joseph, PharmD
Bronchopulmonary Pharmacokinetics of Micafungin in Healthy Adult Volunteers. Astellas Pharma US, Inc., $148,862. A Phase 4, Open Label Study to Assess the Bronchopulmonary Pharmacokinetics of Anidulafungin and Voriconazole following Intravenous Administration in Healthy Subjects. Pfizer, Inc., $259,259.

The Center for Anti-Infective Research and Development (CAIRD) is recognized both nationally and internationally for its efforts surrounding the development and commercialization of anti-infective therapies. Over the past decade efforts have been undertaken to expand the preclinical study capabilities of CAIRD to further enhance our services to companies involved in the drug development of novel compounds. The CAIRD has enhanced its provision of analytical services for both investigator-sponsored studies and industry-sponsored investigations throughout the United States. Additionally, over the last five years the Center has managed and published on its global efforts to assist the prescriber with the optimal selection of antimicrobial therapies based on local epidemiology, resistance and the utilization of available dosing strategies. New global collaborative efforts will allow similar studies to be conducted for the foreseeable future.

Nicolau, David, PharmD

Evaluation of AstraZeneca Novel Antimicrobials against Streptococcus Pneumoniae and Staphylococcus Aureus in Murine Pneumonia Models. Astra-Zeneca, Inc., $75,766. Evaluation of Novel AstraZeneca Anti-Infectives against Staphylococcus aureus in a Murine Thigh Model. Astra-Zeneca, Inc., $102,766. Evaluation of Iclaprim against Staphylococcus aureus in a Murine Thigh Model. Arpida, Inc., $78,725. Evaluation of the Bactericidal Activity of High-Dose Doripenem Human Simulated Exposures Against Pseudomonas Aeruginosa in a Neutropenic Murine Thigh Infection Model. Johnson & Johnson PRD, $157,050.

Industry (Developmental)
Nicolau, David, PharmD
In Vivo Evaluation of CXA-101 Tazobactam Versus PiperacillinTazobactam using Human Simulated Exposures Against Phenotypically Diverse Gram-Negative Organisms. Calixa Therapeutics, Inc., $154,188. Evaluation of Lead Therapeutics Novel Antimicrobials Against Staphylococcus Aureus in a Murine Pneumonia Model. LEAD Therapeutics, Inc., $34,200.

Patients with Chronic Wound Infections by In Vivo Microdialysis. Wyeth, $122,927. Pharmacodynamic Profiling of Intravenous Antibiotics Against Prevalent US Derived Gram-Negative Organisms. Ortho McNeil Janssen, $71,000. A Hospital Specific Program to Assess Anti-Infective Minimum Inhibitory Concentrations (MICs) and Pharmacodynamic Target Attainment against Methicillin-Resistant Staphylococcus aureus Strains. Pfizer, Inc., $16,625. Evaluation of AlphaRx Novel Antimicrobials Against Staphylococcus Aureus in a Murine Pneumonia Model. AlphaRx, Inc., Ontario, Canada, $26,883.

Industry (Investigator Initiated)

Kuti, Joseph, PharmD
In Vitro Pharmacodynamics of Pulmonary Exposures of Tigecycline Alone and in Combination with Rifampin or Meropenem Against Klebsiella spp. Producing the KPC-2 Carbapenemase. Wyeth Pharmaceuticals, $87,000. An in Vitro Pharmacodynamic Model of a Human Simulated High Dose, Prolonged Infusion Meropenem Regimen Against Klebsiella spp. Producing the KPC-2 Carbapenemase. AstraZeneca Pharmaceuticals, $77, 250. Daptomycin MICs against Vancomycin-Susceptible Staphylococcus aureus with Higher Vancomycin MICs: A Comparison of Three Testing Methods. Cubist Pharmaceuticals, $59,250.

Hartford Hospital Research Endowment Funds

Kuti, Joseph, PharmD The Effect of Hyperbaric Oxygen Therapy on the Penetration
of Linezolid into Subcutaneous Tissue of Diabetics with Lower Extremity Wounds. Open Competition, $74,847.

Eagye, Kathy, MPH

Health Outcomes Investigation of Infection in Colorectal Surgical Procedures. Small Grant, $14,854.

Unfunded
Nicolau, David, PharmD
Subcutaneous and Intravenous Tissue Levels of Cefazolin During Abdominoplasty: A Pilot Study.

Nicolau, David, PharmD

Comparison of Simulated Human Exposures of Telavancin and Vancomycin against Staphylococcus aureus with Increasing Vancomycin MICs in a Murine Pneumonia Model. Astellas Pharma, $130,615. Pharmacodynamic Evaluation of CB-182804 Against Acinetobacter Baumannii and Pseudomonas aeruginosa in a Murine Pneumonia Model. Cubist, $128,019. Assessment of Doripenem Stability within Two Infusion Devices: A Focus on Use in the Home Infusion Arena. Ortho McNeil Jasssen, $52,413. Ertapenem Utilization and Resistance Emergence Among Collateral Antimicrobials (EURECA). Merck & Co., Inc., $259,688. Tissue Penetration and Pharmacokinetics of Linezolid in Diabetic Patients with Chronic Wound Infections by In Vivo Microdialysis. Pfizer,Inc., $117,900. Evaluation of CEN-101 as Adjunctive Therapy for Staphylococcus aureus Pneumonia in a Murine Model. Centegen Inc., $50,719. In Vitro Evaluation of CXA-101 Potency Against Selected Isolates of Pseudomonas Aeruginosa. Calixa Inc., $19,688 Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic

Active Projects
Kuti, Joseph, PharmD
Clinical Outcomes and Costs Associated with a Ventilator Associated Pneumonia Clinical Pathway in Intensive Care Units. Cost-effectiveness of telavancin versus vancomycin in the treatment of complicated gram-positive skin and skin structure infections. Theravance, Inc., $102,375. Pharmacoeconomics of Antifungals in the Treatment of Invasive Aspergillosis with a Focus on the Polyenes. Enzon Pharmaceuticals, $118,250

Nicasio, Anthony, PharmD

The Impact of Automated Testing on the Clinical Outcomes and Economics of Infections Due to Extended Spectrum Beta-lactamase Producing Enterobacteriaceae. Small Grant, $9,390.

Nicolau, David, PharmD

Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals Systemic Antibacterials in the Rat Thigh Infection Model. Vertex Pharmaceuticals, Inc. $29,814.

36.

Blanket Protocol: Efficacy Evaluation of Affinium Pharmaceuticals Novel Systemic Antibacterials in the Murine Model of Staphylococcus Aureus Intra-Abdominal Sepsis. Affinium Pharmaceuticals, $34,045. Bioanalytical Validation and Sample Analysis of Aztreonam in Human Plasma by HPLC for the Telavancin Clinical Program. Theravance, $28,000. Blanket Protocol: Efficacy Evaluation of Affinium Pharmaceuticals Novel Systemic Antibacterials in the Murine Staphylococcus Aureus Thigh Infection Model. Affinium Pharmaceuticals, $40,030. Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals Novel Systemic Antibacterials in the Mouse S. aureus Thigh Infection Model. Vertex Pharmaceuticals, $85,095. Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals Novel Systemic Antibacterials in the Murine (Mouse) Model of IntraAbdominal Sepsis. Vertex Pharmaceuticals, Inc., $16,706. Blanket Protocol: Efficacy of Vertex Pharmaceuticals Novel Systemic Antibacterials in the Murine (Rat) Model of Pneumococcal IntraAbdominal Sepsis. Vertex Pharmaceuticals, Inc., $38,889. Bronchopulmonary Pharmacokinetic and Pharmacodynamic Profiles of Leofloxacin 750mg in Adults Undergoing Treatment of Acute Exacerbaction of Chronic Bronchitis. Orth-McNeil Pharmaceuticals, $211,341. Clinical and Economic Implication of Antibiotic Prophylaxis Failure in Elective Colorectal Surgery. Merck & Co., Inc., $57,505. Clinical Pharmacodynamics of Beta-lactam Antibiotics in Patients with Pseudomonas Aeruginosa Infections. Determination of Gatifloxacin Concentrations in Biological Matrixes. Armed Forces Radiobiology Research Institute, $6,300. Determination of Piperacillin and Tazobactam in Biological Matrixes. Wyeth Pharmaceuticals, $35,000. Efficacy Evaluation of Affinium Pharmaceuticals Novel Systemic Antibacterials in the Murine Staphylococcus Aureus Pneumonia Model. Affinium Pharmaceuticals, $86,288 Evaluation of Ceftobiprole Against Staphylococcus aureus in a Murine Pneumonia Model Blanket Protocol. Johnson & Johnson Pharmaceuticals, $110,494. Evaluation of Destiny Pharmas Novel Antimicrobials Against Staphylococcus Aureus in a Murine Thigh Model. Destiny Pharmaceuticals, $59,635. Evaluation of Novexecel Inc. Novel Antimicrobials Against Staphylococcus aureus in a Murine Thigh Model Blanket Protocol. Novexel, Inc., $125,231. Evaluation of Novexel Inc. Novel Antimicrobials against Staphylococcus aureus in a Murine Pneumonia Model. Novexel, Inc., $111,010.

Evaluation of Polymedix Inc. Novel Antimicrobials Against Staphylococcus aureus in a Murine Thigh Model - Blanket Protocol. PolyMedix, Inc., $92,542. Evaluation of the Bactericidal Activity of Doripenem Human Simulated Exposures Against Pseudomonas aeruginosa in a Neutropenic Mouse Thigh Model. Johnson & Johnson

Pharmaceutical R&D, $169,040.

Evaluation of the Impact of Inadequate Empirical Therapy Against Pathogens Causing Complicated Skin & Soft Tissue Infections. Wyeth Pharmaceuticals, $81,413. Evaluation of the Pharmacodynamic Profile of Novel Vertex Pharmaceuticals Compounds in Murine Models of Infection (Blanket Protocol). Vertex Pharmaceuticals, Inc., $52,186. HPLC Analysis of Daptomycin in Human Serum. Cubist Pharmaceuticals, $35,000. Identificeftazidime Susceptible Pseudomonas aeruginosa Among Clinical Isolates from Hartford Hospital. AstraZeneca Pharmaceuticals, $11,250. Murine (Rat) Staphylococcus aureus intra-abdominal sepsis model: efficacy of affinium pharmaceuticals novel systemic antibacterials. Affinium Pharmaceuticals, $18,625. Murine (Rat) Thigh Infection Model: Efficacy Evaluation of Affinium Pharmaceuticals Systemic Antibacterials. Affinium Pharmaceuticals, $19,569. OPTAMA: Evaluating in vivo Potency Against Important GramNegative Rods over the Period of 2002 to 2006. AstraZeneca Pharmaceuticals, $46,250. Pharmacodynamic Comparison of the Carbapenems against Extended-Spectrum Beta-Lactamases from the MYSTIC Surveillance Program. AstraZeneca, $51,875. Pharmacodynamic comparison of tigecycline versus other intravenous antimicrobials in the treatment of serious nosocomial infections #3074A1-102039. Wyeth Pharmaceuticals, $195,625. Pharmacodynamic Evaluation of Tigecycline Against Phenotypically Diverse S. sureus and E. coli in a Murine Thigh Model. Wyeth Pharmaceuticals, $235,823. Pharmacodynamic Evaluation of Tigecycline Against Staphylococcus Aureus and Acinetobacter Baumannii in a Murine Pneumonia Model. Wyeth Pharmaceuticals, $218,328. Pharmacodynamic Modeling of Antimicrobials in the Treatment of Hospital Acquired Pneumonia: Comparison with 2003 OPTAMA Report and Agreement with ATS/IDSA Guidelines for the Management of Hospital Acquired Pneumonia. AstraZeneca Pharmaceuticals, $40,625.

Pharmacokinetics of Daptomycin in Patients Receiving Continuous Veno-Venous Hemodiafiltration (CVVHDF). Cubist Pharmaceuticals, $99,599. Provision and Reporting of Susceptibility Testing for Hospital Based Anti-Infectives. AstraZeneca Pharmaceuticals, $399,375. Risk Factors for Infection with Meropenem High-level Resistant Pseudomonas Aeruginosa and Impact on Mortality and Hospital Costs. AstraZeneca Pharmaceuticals, $62,188. Tigecycline Concentration Determinations. Wyeth Pharmaceuticals, $35,000. Tissue Penetration and Pharmacokinetics of Daptomycin in Healthy and Diabetic Volunteers by In Vivo Microdialysis. Cubist Pharmaceuticals, $119,285. Trends in MIC Distributions of Several Antibiotics Against Pseudomonas aeruginosa over a 5-Year Period at a Large Urban Teaching Hospital. Wyeth Pharmaceuticals, $56,250. Urea Determination in Human Plasma and Bronchial Alveolar Lavage Fluid by a Colorimetric Method for the Telavancin Clinical Program. Theravance, $10,000. projects continued

Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of Tigecycline against phenotypically diverse Staphylococcus aureus in a murine thigh model. Antimicrobial Agents & Chemotherapy 2009;53(3):1165-1169. Crandon JL, Bulik CC, Nicolau DP. In Vivo Efficacy of 1- and 2-Gram human simulated prolonged infusions of Doripenem against Pseudomonas aeruginosa. Antimicrobial Agents & Chemotherapy 2009;53(10):4352-4356. Crandon JL, Kim A, Nicolau DP. Comparison of Tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. Journal of Antimicrobial Chemotherapy 2009;64:837839. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of the 2002-2006 OPTAMA programs for the US Hospitals: Focus on gramnegative resistance. Annals of Pharmacotherapy 2009;43(2):220-227. Crandon JL, Kuti JL, Nicolau DP. Antimicrobial efficacy review. Pharmacy Practice News. 2009;(9):29-32 ; Infectious Disease Special Edition. 2009. McMahon Publishing Group. Dandache P, Nicolau DP, Sakoulas G. Tigecycline for the treatment of multidrug-resistant Klebsiella pneumoniae meningitis. Infectious Diseases in Clinical Practice 2009;17:66-68. Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Surgical site infections: Does inadequate antibiotic therapy affect patient outcomes? Surgical Infections 2009;10(4):323-331. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with infection with Meropenem high-level resistant Pseudomonas aeruginosa. Infection Control and Hospital Epidemiology 2009;309(8):746-752. Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia. Seminars in Respiratory and Critical Care Medicine 2009;30:116-124. Eagye KJ, Nicolau DP. Incidence of infection and impact on hospital length of stay and costs in patients undergoing elective colorectal surgery. American Journal of Surgery 2009;198:359-367. Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP. Pharmacodynamic target attainment of oral -lactams for the empiric treatment of acute otitis media in children. Pediatric Drugs 2008;10(5):329-335. Gerding DN, Friedenberg FK, Nicolau DP. Clostridium Difficile infection: Guidance on optimal diagnosis and treatment. Continuing Medical Education Supplement, Advancing Knowledge in Healthcare, Inc., 2009;1-8.

Publications
Beneri CA, Nicolau DP, Seiden HS, Rubin LG. Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a Daptomycin-containing regimen. Infection and Drug Resistance 2008;1:9-11. Bulik CC, Kuti JL, Nicolau DP. Clostridium difficile infection not just a burden anymore. Connecticut Medicine 2009;73(3):407-411. Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTriran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Swenson LL, Tang Q, Tesier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. Novel dual targeting Aminobenzimidazole Urea Inhibitors of DNA Gyrase & Topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure and SAR. Journal of Medicinal Chemistry 2008;51(17):5243-5263. Courter J, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for-lactams via extended infusions in the pediatric population. Pediatric Blood & Cancer 2009;53:379-385. Crandon J, Nicolau DP. Oritavancin, a potential weapon in the battle against serious gram-positive pathogens. Future Microbiology 2008;3:251-263.

38.

Kiffer CRV, Kuti JL, Nicolau DP. Optimization of therapy using pharmacodynamic principles: The case for prolonged infusion -lactam antibiotic therapy. Brazilian Journal of Infectious Diseases 2008;12(Suppl. 2):22-28. Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic profiling of Doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrobial Agents & Chemotherapy 2008;52(7):2497-2502. Kim A, Sakoulas G, Kuti JL, Nicolau DP. Prevalence of Methicillinresistant Staphylococcus aureus (MRSA) strains with Vancomycin MIC 2 g/mL in New York City area hospitals and implications on pharmacodynamic target attainment. Infectious Diseases in Clinical Practice 2009;7(2):95-98. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. Penetration of Daptomycin into soft tissues in diabetic versus healthy volunteers by in vivo microdialysis. Antimicrobial Agents & Chemotherapy 2008;52(11):3941-3946. Kim SW, Kuti JL, Nicolau DP. Review on inhaled antimicrobial therapies for respiratory infections. Current Infectious Disease Reports 2008;10:29-36. Kioumis IP, Kuti JL, Nicolau DP. Antibiotic therapy: General considerations. Pharmacologic management of the orthopedic trauma patient. In Browner BB, Jupiter JB, Levine AM, Trafton PG, Krettek C, eds. Skeletal Trauma: Basic Science, Management, and Reconstruction, Volume I: General Principles, Spine, Pelvis. 4th ed, Philadelphia, PA: Saunders Elsevier 2009:258-264. Kontou P, Kuti JL, Nicolau DP. Ceftobiprole: The first anti-MRSA Cephalosporin. Formulary 2008;43:66-79. Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society Criteria to Predict Severe Community Acquired Pneumonia Caused by Streptococcus pneumoniae. American Journal of Emergency Medicine 2009;27:968974. Koomanachai P, Crandon JL, Kuti JL, Nicolau DP. Comparison of the cumulative fraction of response for 19 antibiotic regimens against nosocomial pathogens in Europe between 2002 and 2006. International Journal of Antimicrobial Agents 2009;33(4):348-353. Koomanachai P, Kim A, Nicolau DP. Pharmacodynamic evaluation of Tigecycline against Acinetobacter Baumannii in a murine pneumonia model. Journal of Antimicrobial Chemotherapy 2009;63(5):982-987. Kuti JL, Dowzicky M, Nicolau DP. A pharmacodynamic model to assess Tigecycline predicted efficacy for hospital-acquired pneumonia. Journal of Chemotherapy 2008;20(1): 69-76.

Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance of Tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and soft tissue infections. Surgical Infections 2008;9(1):57-66. Kuti JL, Kiffer CRV, Mendes CMF, Nicolau DP. Pharmacodynamic comparison of Linezolid, Teicoplanin, and Vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococci collected from hospitals in Brazil. Clinical Microbiology & Infection 2008:14:116-123. Kuti JL, Nicasio AM, Sutherland CA, Nicolau DP. Elevated Vancomycin minimum inhibitory concentrations among Methicillinresistant Staphylococcus aureus isolated from patients with ventilator associated pneumonia at a Connecticut hospital. Connecticut Medicine 2009;73(6):337-340. Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empiric antibiotic therapy for ventilator-associated pneumonia in your ICU: Guidelines for implementing the guidelines. Seminars in Respiratory and Critical Care Medicine 2009;30:102-115. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Costeffectiveness of Telavancin versus Vancomycin for the treatment of complicated skin and skin structure infections. Pharmacotherapy 2008;28(12):1471-1482. Laohavaleeson S, Lolans, Quinn JP, Kuti JL, Nicolau DP. Identification of the MexXY-OprM Efflux System in Pseudomonas aeruginosa with discordant Cefepime / Ceftazidime dusceptibility profiles. Infection and Drug Resistance 2008;1:51-55. Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of Ceftobiprole in experimental pneumonia model caused by phenotypically diverse Staphylococcus aureus. Antimicrobial Agents & Chemotherapy 2008;52(7):2389-2394. Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP. Population pharmacokinetics of extended infusion high dosed-Cefepime in adult critically-ill patients with ventilator associated pneumonia. Antimicrobial Agents & Chemotherapy 2009;53(4):1476-1481. Nicasio Am, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of Tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae. Antimicrobial Agents & Chemotherapy 2009;53(7):2756-2761. Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of automated screening and confirmation of extended spectrum -lactamase producing Enterobacteriaceae on antibiotic prescribing. Journal of Medical Microbiology 2008;57:1147-1151.

Nicasio AM, Kuti JL, Nicolau DP. Pharmacotherapy of complicated urinary tract and intra-abdominal infections with Doripenem. Clinical Medicine: Therapeutics 2009;1:787-799. Nicasio AM, Kuti JL, Nicolau DP. The current state of multipledrug resistant gram-negative bacilli in North America: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2008;28(2):235-249. Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Shore E, Russomanno J, Kuti JL. Bronchopulmonary disposition of Micafungin in healthy adult volunteers. Antimicrobial Agents & Chemotherapy 2009;53(3):1218-1220. Nicolau DP. Bugs vs. drugs: What is the pharmacists challenge? American Journal of Health-System Pharmacy 2008;65(1) Suppl 2:S2-S3. Nicolau DP. Carbapenems: A potent class of antibiotics. Expert Opinion on Pharmacotherapy 2008;9(1):23-37. Nicolau DP. Containing costs and containing bugs: Are they mutually exclusive? Journal of Managed Care Pharmacy 2009;15(Suppl)2:S12-S17. Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: The role of Tigecycline. Expert Opinion on Pharmacotherapy 2009;10(7):1213-1222. Nicolau DP. Pharmacodynamic optimization of -lactams in the patient care setting. Critical Care 2008;12(Suppl 4):S1-5. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of Meropenem. Clinical Infectious Diseases 2008;47(Suppl 1):S3240. Nicolau DP. Spotlight on Clostridium difficile infection: An educational resource for pharmacists. Pharmacy Times 2009;2:91-100. Nicolau DP. What is the 360-degree approach to defining success for VAP? Journal of Managed Care Pharmacy 2009;15(Suppl)5:S3-S4. Pichichero ME, Doern GV, Kuti JL, Nicolau DP. Probability of achieving requisite pharmacodynamic exposure for oral -lactam regimens against Hemophilus influenzae in children. Pediatric Drugs 2008;10(6):391-397. Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel G, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL. Identifying exposure targets for the treatment of Staphylococcal Pneumonia with Ceftobiprole. Antimicrobial Agents & Chemotherapy 2009;53(8):3294-3301.

Stein GE, Schooley S, Tyrrell KL, Citron DM, Nicolau DP, Goldstein EJ. Serum bactericidal activities of Moxifloxacin and Levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008;14(1):8-12.

Abstracts
Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of single doses (250, 500, 750, 1000 milligrams) of Levofloxacin against Fluoroquinolone-resistant strains of Escherichia coli. International Journal of Antimicrobial Agents 2008;32:320-325. Bulik CC, Christensen H, Li P, Nicolau DP, Kuti JL. An In Vitro Pharmacodynamic Model of a Human Simulated High Dose, Prolonged Infusion Meropenem Regimen against Klebsiella spp. producing the KPC Carbapenemase. (Abstract No. 231). 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL, April 2009. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Pharmacodynamics (PD) of Human Simulated, High Dose, Prolonged Infusion Meropenem (MEM) Against Pseudomonas aeruginosa (PSA) and Carbapenemase Producing Klebsiella pneumoniae (KPC). (Abstract No. A1-019). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Bulik CC, Fauntleroy KA, Jenkins SG, Nicolau DP, Kuti JL. Comparison of Meropenem (MEM) MICs for Carbapenemase Producing Klebsiella pneumoniae (KPC) by E-Test, Broth Microdilution (BMD), and VITEK 2 Methods. (Abstract No. D-721). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Bulik CC, Nicolau DP. In Vivo Efficacy of 1g Human Simulated Prolonged Infusion DOR (DOR) against Carbapenemase Producing Klebsiella pneumoniae (KPC). (Abstract No. A1014). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing Bactericidal Exposure For -lactams Using Extended Infusions in the Pediatric Population. (Abstract No. 332). 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL, April 2009. Crandon J, Kuti JL, Jones R, Nicolau DP. Pharmacodynamic Target Attainment Rates for 9 Antibiotics against Escherichia coli, Klebsiella spp., and Pseudomonas aeruginosa isolates in USA Hospitals. (Abstract No. 44). American College of Clinical Pharmacy, 2008 Spring Research and Practice Forum, Phoenix, AZ, April 5 - 9, 2008.

40.

Center for

Anti-Infective Research & Development

Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope J, Russomanno J, Shore E, Nicolau DP, Kuti JL. Bronchopulmonary Disposition of Intravenous (IV) Voriconazole (VRC) and Anidulafungin (ANI) Given in Combination to Healthy Adults. (Abstract No. A1-423). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of Tigecycline Against Phenotypically Diverse Staphylococcus aureus in a Murine Thigh Model. (Abstract No. A-987). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical Pharmacodynamics (PD) of Cefepime (FEM) in Patients Infected with Pseudomonas aeruginosa (PSA). (Abstract No. A1-011). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Crandon JL, Bulik CC, Nicolau DP. In Vivo Efficacy of 1 and 2g Human Simulated Prolonged Infusion Doripenem Against Pseudomonas aeruginosa. (Abstract No. A1-013). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Crandon JL, Kim A, Nicolau DP. Tigecycline Penetration into the Epithelial Lining Fluid of Infected and Uninfected Murine Lungs. (Abstract No. 228). 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL, April 2009. Crandon JL, Kuti JL, Nicolau DP. Comparison of Simulated Human Exposures of Telavancin (TLV) and Vancomycin (VAN) against Methicillin Resistant Staphylococcus aureus (MRSA) with Ranging Vancomycin MICs in a Murine Pneumonia Model. (Abstract No. A11292). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Eagye KJ, Kuti JL, Nicolau DP. Prior Carbapenem Use Not Associated with Infection with Meropenem High-Level Resistant Pseudomonas aeruginosa (MRP). (Abstract No. K-3492). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008.

Eagye KJ, Nicolau DP. Change in Anti-pseudomonal Carbapenem Susceptibility (ACS) in 25 Hospitals Is Not Associated with the Use of Ertapenem (ERT). (Abstract No. K-2061). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Eagye KJ, Sutherland CA, Christensen H, Kuti JL, Nicolau DP. Prevalence of Pseudomonas aeruginosa (PSA) with Reduced Susceptibility to Piperacillin-Tazobactam (TZP) at 39 Hospitals. (Abstract No. C2-201). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008. Kim A, Banevicius MA, Nicolau DP. In Vivo Efficacy of Doripenem Human Simulated Exposures against Pseudomonas aeruginosa. (Abstract No. 109E). American College of Clinical Pharmacy, 2007 Annual Meeting, Denver, CO, October 14-17, 2007. Kim A, Nicolau DP, Kuti JL. Hospital Costs and Outcomes of Patients Discharged with a Diagnosis of Pulmonary Aspergillosis in the United States. (Abstract No. 189). American College of Clinical Pharmacy, 2007 Annual Meeting, Denver, CO, October 14-17, 2007. Kim A, Sakoulas G, Kuti JL, Nicolau DP. Pharmacodynamic Analysis of Vancomycin versus Linezolid against Methicillin-Resistant Staphylococcus aureus Strains in New York (Abstract No. RP18). American Society of Hospital Pharmacists, 42nd Annual Midyear Clinical Meeting, Las Vegas, Nevada, December 2-6, 2007. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers by In Vivo Microdialysis. (Abstract No. A-1884). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008. KimA, Koomanachai P, Nicolau DP. Pharmacodynamic Evaluation of Tigecycline against Acinetobacter Baumannii in a Murine Pneumonia Model. (Abstract No. A-041). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008.

Kontou P, Kuti JL, Nicolau DP. Validation of the 2007 Infectious Diseases Society of America/American Thoracic Society (IDSA/ ATS) Criteria in Predicting Severe Community Acquired Pneumonia (CAP) Caused by Streptococcus pneumoniae (SP). (Abstract No. L-677). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008. Koomanachai P, Crandon JL, Banevicius MA, Li P, Nicolau DP. Pharmacodynamic Evaluation of Tigecycline against Staphylococcus aureus in a Murine Pneumonia Model. (Abstract No. A1-552). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Kuti JL, Nicasio A, Shore E, Palter M, Pepe J, Nicolau DP. Outcomes of an Empiric Antibiotic Algorithm (EAA) for Ventilator Associated Pneumonia (VAP) that Considers Local MIC Distributions and Pharmacodynamics (Abstract No. 1026). 45th Annual Meeting of Infectious Diseases Society of America, San Diego, CA, October 4-7, 2007. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of Telavancin versus Vancomycin for the Treatment of Complicated Skin and Skin Structure Infections. (Abstract No. 185E). American College of Clinical Pharmacy, 2007 Annual Meeting, Denver, CO, October 14-17, 2007. Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP. Population Pharmacokinetics of Extended Infusion High Dosed-Cefepime in Adult Critically-Ill Patients with Ventilator Associated Pneumonia. (Abstract No. A-1880). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008. Nicasio AM, Crandon JL, Nicolau DP. Pharmacodynamic Profile of Tigecycline Against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Model. (Abstract No. A-040). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008. Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Hospital Costs Associated with a Pharmacodynamic Based Clinical Pathway for Empiric Antibiotic Choice in Patients Infected with Ventilator Associated Pneumonia. (Abstract No. 227). 2009 ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, FL, April 2009.

Nicasio AM, Eagye KJ, Shore E, Palter M, Pepe J, Nicolau DP, Kuti JL. A Pharmacodynamic (PD) Based Clinical Pathway (CP) for Empiric Antibiotic Choice in Patients with Ventilator Associated Pneumonia (VAP). (Abstract No. K-490). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008. Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Shore E, Russomanno J, Kuti JL. Bronchopulmonary Pharmacokinetics (PK) of Micafungin (MICA) in Healthy Adult Volunteers. (Abstract No. A-010). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008. Stein GE, Smith C, Kepros J, Ji A, Nicolau DP, Dybas L, Saunders JP. Tigecycline Skin Penetration and Activity against MethicillinResistant Strains of Staphylococcus aureus (MRSA). (Abstract No. A1-554). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009. Tessier PR, Love W, Hayter I, Rhys- Williams W, Nicolau DP. A Novel XF Antibacterial, DPD-207, against Staphylococcus aureus (SA) in a Murine Thigh Infection Model. (Abstract No. F13969). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008.

42.

Medicine
New Projects
Federal
King, Mary, MD, Gerontology
FOCUS Cognitive Ancillary Study. NHLBI/University of Maryland, $18,144. and Pseudomonas aeruginosa. Gilead Sciences (Multicenter), $32,575.

Wettstein, Markus, MD, Endocrinology

A Multi-center, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Safety and Tolerability of 24 weeks Treatment with Vildagliptin (50 mg gd or 100 mg qd) versus Sitagliptin (25 mg qd) in Patients with Type 2 Diabetes and Severe Renal Insufficiency. Novartis (MultiCenter), $24,721.

Foundation
Kates, Richard, MD, Medicine
Preventive IVIG Therapy for Congenital Heart Block (PITCH). Alliance for Lupus Research/ New York Univ School of Med, $10,100.

Hartford Hospital Research Endowment Funds

Seip, Richard, PhD, Medicine
DNA as a Predictor of Effective Warfarin Levels. Open Competition, $62,475.

Knauft, R. Frederic, MD, Pulmonology

Cystic Fibrosis Foundation Therapeutics: Clinical Research Facilitation Award. Cystic Fibrosis Foundation/ University of Connecticut Health center, $9,125.

Vergara, Cunegundo, MD, Ambulatory Care

Creation of an Ambulatory Database to Measure Access to Primary Preventive Care Services. Open Competition, $61,000.

Industry
Cappa, Joseph, MD, Gastroenterology
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versos Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) E3810-G000-303. Eisai/Quintiles, $64,140. A Randomized Double-Blind Parallel Study off Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease E3810-G000-301. Eisai/ Quintiles, $64,140. A Multi-Center, Investigator-blinded, Randomized, 12-Month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4g Asacol Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis. Proctor and Gamble Pharmaceuticals (Multicenter), $27,400. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients with Moderate to Severe Ulcerative Colitis. Prometheus (Multicenter), $111,663.

Departmental
DAgostino, Darrin DO, MPH, Ambulatory Care
The Effects of Massage on Bronchodilation in Asthmatics Enrolled in the ACE Program. $29,340.

Reagan, Louise, APRN, Medicine

The Effect of a Peer Delivered Motivational Message on Intention to Exercise for Hispanic Persons with Type 2 Diabetes (T2DM): An Experimental Pilot Study. $454.

Unfunded
Brown, Seth, Medicine
Endoscopic Repair of Frontal Sinus Cerebrospinal Fluid Leaks.

Karabin-Mah, Tessa, RD, Nutrition Services

Food Frequency in Cystic Fibrosis.

King, Mary, MD, Gerontology

Do Properly Functioning Bed Alarms Reduce the Number of Hospital Falls?

Israel, Jonathan, MD, Medicine

Prospective Observational Study on Predictors of Early On-Treatment Response and Sustained Virological Response in a Cohort of Treatment Naive HCVInfected Patients Treated with Pegylated Interferons. Roche Laboratories, Inc., $24,970.

Pope, Samuel, MD, Pulmonology

Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression.

Knauft, R. Frederic, MD, Pulmonology

A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis

Ranga, Kasturi, MD, Medicine

Does Hydration Status Impact Outcomes at the End of the First Year Post Renal Transplantation? Analytic support provided through Hartford Hospital Small Grant. Effects of Rapid Steroid Taper on Patient and Graft Survival Following Transplant. HLA Identical Renal Transplant: Single Center Outcome Study. Incidental Kidney Biopsies, Neither Indicated nor Protocol: Any Lessons to Learn? Prevalence of Malignancy in Renal Transplant Recipients: A Single Center Experience. Utility Of Renal Isotopic Scans In Predicting Delayed Graft Function Post Renal Transplant. Analytic support provided through Hartford Hospital Small Grant.

Prevention of Hemodialysis Catheter Related Bloodstream Infection. Hartford Hospital Research Endowment Funds, $48,000.

Czarnecki, Gregory, DO, Medicine

Internal Medicine Clinical Assessment Program.

King, Mary, MD, Gerontology

Examining the Use of the Safety Screen to Predict Risk of Hospital Falls. Statistical analysis supported through Hartford Hospital Small Grant.

Knauft R. Frederic, MD, Pulmonology

Evaluation of Multiple Bioassays in Serum and Pleural Fluid to Estimate the Probability of Cancer in Patients Presenting with Undiagnosed Pleural Effusion. Fujirebio Diagnostic, Inc., $72,000. NOVARTIS TBM100C2302 - A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess Safety of Tobramycin Inhalation Powder Compared to TOBI in Cystic Fibrosis Subjects. Novartis Pharmaceuticals, $47,845. Participation in the Cystic Fibrosis Patient Registry.

Reagan, Louise, APRN, Medicine

A Narrative Analysis Pilot Study: Hispanic Patients Perspective of Managing their Chronic Illness.

Vergara, Cunegundo, MD, Ambulatory Care

Misperceptions and Barriers to Seeking Dermatologic Care in Minority Populations. The Effect of an Educational Intervention for Older Adults Osteoarthritis Pain: A Pilot Study.

Meyer, Ariel, DO, Medicine

Evaluation of Systems Based Practice Changes on Patient Care Near Misses on the Medical Teaching Service at the University of Connecticut.

Paquette, Anthony, MPH, Medicine

Active Projects
Albino, Susan, BS, Pulmonology
NICO Non-Invasive Cardiac Output/Respiratory Profile Monitor with Software for Spontaneous Breathing. Respironics, Inc., $7,000. Clinical Evaluation of the Respironics Capnostat 5 CO2 Sensor. Respironics, Inc., $4,500. Clinical Evaluation of a Non-Invasive Cardiac Output (NICO2) and Respiratory Profile Monitor.

Case Review: Successful Multi-Organ Donation from a Donor with Idiopathic Thrombocytopenia Purpura.

Post, Jarrod, MD, Dialysis

Hemodynamic Responses to Dialysate Sodium Individualization in Hemodialysis. Satellite Research Foundation LLC/Yale University, $27,751.

Quintiliani Jr. Richard, MD, Infectious Diseases

Linezolid in the Treatment of Subjects with Complicated Skin and Soft Tissue Infections Proven to Be Due to Methicillin-Resistant Staphylococcus Aureus. Covance Inc., $63,556. Clonal Outbreak of Clostridium Difficile-Associated Disease with High Morbidity and Mortality. Hartford Hospital Research Endowment Funds, $58,500.

Cappa, Joseph, MD Gastroenterology

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg B.I.D. Given Orally for 4 Weeks in Female Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). Novartis Pharmaceuticals, $12,300. A Double-Blind, Randomized, 6-week, Parallel-Group Clinical Trial to Assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis. Proctor and Gamble Pharmaceuticals, $58,700.

Ranga, Kasturi, MD, Medicine

Thymoglobulin: Now or Later? Evaluation of long-term outcomes amongst living donor kidney transplant recipients from donors older than 50 years: Are they comparable to recipients of kidneys from donors less than 50 years of age? Statistical analysis supported through Hartford Hospital Small Grant. Assessment of Changes in Renal Function in Living Kidney Donors PostNephrectomy in the First Year After Donation.

Chhabra, Jyoti, PhD, Research Administration

Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic and Health Outcomes Among Latinos. NIH subcontract through the University of Connecticut, $1,081,928.

Cooper, Brian, MD, Infectious Diseases

A Randomized Trial of Hypertonic Saline/Heparin Flush Solution in the

Robbins, Karen, RN, Dialysis

Reiki: What are its Effects for Patients During Hemodialysis? Hartford Hospital

44.

Research Endowment Funds, $9,963.

Diabetes? Preliminary Results: DIALBEST Trial. Obesity. 2008: Abstract Presentation/Publication Number: 681-P. Chhabra J, Vega-Lpez S, DAgostino D, Fernandez M, SeguraPrez M, Damio G, Prez-Escamilla R. Relationship of dietary micronutrient intake with fasting plasma glucose and HbA1c: DIALBEST Trial Preliminary Results. FASEB J. 2009. 23; 4: 550.3. Colby J, Wang F, Chhabra J, Prez-Escamilla R. Predictors of medication non-adherence in an urban community with healthcare disparities. Presented at Eastern States Conference for Pharmacy Residents and Preceptors, American Society for Health-system Pharmacists Foundation Research Abstracts, Hershey Lodge, Hershey, PA, April 29 to May 1, 2009. Czarnecki, G. The diabetic patient. In Busconi B, Stevenson JH, eds. Sports Medicine Consult. New York, NT; Lippincott, Williams and Wilken. 2009. Czarnecki, G. The mature patient. In Busconi B, Stevenson JH, eds. Sports Medicine Consult. New York, NT; Lippincott, Williams and Wilken. 2009. Ghuman N, Patel V, de Palma J, Datla A, Nataraj S, Ranga K. De novo minimal change disease (MCD) following kidney transplantation. American Journal of Kidney Diseases, 2008, 51 (4): B49. Kannan S, Bansal R, Nataraj S, Sathyan S, Ricci A, Ranga K. Need for diagnostic criteria for antibody mediated rejection (AMR) in pancreas after kidney transplantation. American Journal of Kidney Diseases, 2008, 51(4): B56. Knauft W, Chhabra J, McCullough L. Gender differences in the time of presentation to the emergency department and outcome in patients with acute ischemic stroke. Stroke. 2009; 40(2): Abstract # 2315. Kopecky R, Wang F, Vega-Lpez S, DAgostino D, Chhabra J, PrezEscamilla R. Evaluation of medication appropriateness in Latinos enrolled in the DIALBEST Trial. Presented at the 27th Annual Eastern States Conference for Pharmacy Residents and Preceptors. Hershey, PA May 2008. Nataraj S, Vellanki V, Dada A, Balarezo F, Ranga K. De novo focal segmental glomerulosclerosis following renal transplant in a patient with autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases, 2008, 51(4): B73. Ojo P, Ranga KV, Brown M, Hull D, Charpentier KP. Transplantation of a unilateral fused kidney with inferior ectopia: revascularization utilizing donor aorta and vena cava. Connecticut Medicine. 72(10):585-8, 2008 Nov-Dec. Prez-Escamilla R, Damio G, De Jess J, Bow L, Chhabra J, and Bull N. (2008). The Connecticut Center of Excellence for Eliminating

Rosson, Robert, MD, Gastroenterology

A Multi-Center, Longitudinal Study of Drug- and CAM-Induced Liver Injury (Version 2.2). NIDDK/UCONN, $10,000. Incidence of Positive Screening Gastric Biopsies for Helicobacter Pylori in Clinic Patients at Hartford Hospital: Comparison with Chinese Patients at Shandung University Hospital.

Shore, Eric, MD, Pulmonology

Roche Integrin Antagonist Follow-up for Undetected PML. Roche, $600.

Spada, Michael, MD, Ambulatory Care

A Comparison of Symptoms of Acute Coronary Syndrome and Length of Time to Seeking Treatment Based on Gender and Race.

Sundararajan, Lavanya, MD, Ambulatory Care

A Pilot Study for Increasing Osteoporosis Awareness in Internal Medicine Residency Clinics.

Vergara, Cunegundo, Ambulatory Care

Hypertension Compliance and the Factors that Affect the Health Status and Behaviors of Hispanics in the Ambulatory Care Setting. Using Preoperative Electrocardiograms as a Predictive Marker for Perioperative Adverse Outcomes in Hispanic Patients Undergoing Elective Non-cardiac Surgery. Statistical analysis supported through Hartford Hospital Small Grant.

Publications, Presentations and Abstracts

Calle C, Vega-Lpez S, Puglisi M, Chhabra J, Prez-Escamilla R, Volek J, and Fernandez M. Effects of a peer-counseled intervention on diet and risk factors for cardiovascular disease in Hispanics diagnosed with type 2 diabetes. Results from the DIALBEST trial. FASEB J. 2009. 23; 4: 910.3. Calle M, Vega-Lpez S, Prez-Escamilla R, Chhabra J, DAgostino D, Damio G, and Fernandez M. Dietary habits and cardiovascular disease risk factors in Hispanics with type 2 diabetes mellitus enrolled in the DIALBEST trial. Preliminary results. FASEB J. 2008 22:1084.11. Chhabra J, Vega-Lpez S, Calle M, Putnik P, Fernandez M, DAgostino D, Damio G, and Prez-Escamilla R. Relationship between energy intake and weight in Latino adults with type 2 diabetes, preliminary results: DIALBEST Trial. FASEB J. 2008 22:875.4. Chhabra J, Vega-Lpez S, DAgostino D, and Prez-Escamilla R. Does calcium intake relate to weight/BMI in Latinos with type 2

Health Disparities among Latinos (CEHDL). Journal of Higher Education, Outreach and Engagement, 12(3):167-177. Prez-Escamilla R, Vega-Lpez S, Damio G, Segura-Prez S, Fernandez M, Calle M, Samuel G, Chhabra J, DAgostino D. Short and long term impact of diabetes peer counseling on HbA1c among Latinos: DIALBEST Trial preliminary results. FASEB J. 2009. 23; 4: 336.8. Perez-Escamilla R, Vega-Lopez S, Segura-Perez S, Damio G, Fernandez M, Calle M, Samuel G, Chhabra J, and DAgostino D. Impact of diabetes peer counseling on glycosylated hemoglobin among Latinos enrolled in the DIALBEST Trial: Preliminary results. FASEB J. 2008 22:677.19. Putnik P, Calle M, Fernandez M, Damio G, Segura-Prez S, VegaLpez S, Chhabra J, and Perez-Escamilla R. Influence of acculturation on food label use and nutrient intakes among Latinos participating in the DIALBEST trial: Preliminary results. FASEB J. 2008 22:681.5. Samuel G, Fernandez M, Chhabra J, Vega-Lpez S, Segura-Prez S, Damio G, Calle M, DAgostino D, Prez-Escamilla R. Determinants of fasting plasma glucose and HbA1c among Latinos with type 2 diabetes: DIALBEST trial preliminary results. FASEB J. 2009. 23; 4: 736.7. Sathyan S, Khan F, Ranga K. A case of recurrent immunotactoid glomerulopathy in an allograft treated with Rituximab. Transplantation Proceedings, 2009, 41 (9): 3953-3955. Sathyan S, Khawaja Z, de Palma J, Brown M, Lally A, Hull D, Ranga K. Co-Existing peritubular capillary basement membrane lamination and podocyte effacement on EM in kidney transplant on CNI-free regimen. American Journal of Kidney Diseases, 2008, 51(4): B86. Sathyan S, Nataraj S, Dada M, Ranga K. Clinical improvement in nephrogenic systemic fibrosis following renal transplantation: Should NSF Points be considered in allocation? American Journal of Kidney Diseases, 2008, 51 (4): B86. Tausif Z, Fabio A, Ranga KV. Deafness, preauricular pits, and renal failure. American Journal of Kidney Diseases, 2008 (51): xliv-xlvi. Vega-Lpez S, Calle M, Fernandez M, Chhabra J, DAgostino D, Samuel G, Segura- Prez S, Damio G, and Prez-Escamilla R. Threemonth effect of diabetes peer counseling on plasma lipids of Latinos enrolled in the DIALBEST trial: Preliminary findings. FASEB J. 2008 22:44.8. Vega-Lpez S, Chhabra J, DAgostino D, Calle M, Samuel G, SeguraPrez S, Fernandez M, Damio G, Prez-Escamilla R. Associations

between fast food and fried food intake and metabolic risk factors in Latinos with type 2 diabetes: Preliminary results from the DIALBEST study. FASEB J. 2009. 23; 4: 550.1. Vega-Lpez S, Chhabra J, DAgostino D, and Prez-Escamilla R. Socioeconomic and lifestyle determinants of increased body weight in a subgroup of Latinos with diabetes enrolled in the DIALBEST peer counseling trial: Preliminary findings. Obesity. 2008: Abstract Presentation/Publication Number: 309-P. Vergara C, Richards K, Faucher J. Using preoperative electrocardiograms as a predictive marker for perioperative adverse outcomes in Hispanic patients undergoing elective non-cardiac Surgery. New England SGIM Meeting, March 13, 2009. Boston, MA. Vergara C. Creating an ambulatory preventive care database. 4th Annual CEDHL Conference: Social Determinants of Health. University of Connecticut, Storrs. Rome Ballroom. May 19, 2009. Zar T, Aglieco F, Ranga KV. Quiz page April 2008: deafness, preauricular pits, and renal failure. BOR syndrome or Melnick-Fraser syndrome. American Journal of Kidney Diseases. 51(4):A44-6, 2008 Apr.

46.

Neurology
The Departments of Neurology at Hartford Hospital and the University of Connecticut continue to receive NIH grants, foundation grants, drug studies and internal grant support exceeding one-million dollars. Active participation of faculty in the department strengthens its educational and clinical activities. Dr. Leslie Wolfson: Dr. Wolfson is the Principal Investigator (PI) on Brain Changes and Risk Factors Causing Impaired Mobility (RO1AG022092), an NIA funded 4-year longitudinal study to define vascular disease risk factors leading to ischemic white matter lesions that compromise mobility, cognitive and urinary function. In conjunction with collaborator Dr. Godfrey Pearlson (Director of the Olin Center at the Institute of Living), the study includes magnetic resonance imaging performed at the Olin Center. Baseline results have demonstrated that damage to specific white matter structures is associated with slowed thinking, impaired mobility and urinary function and that that there is a stereotyped distribution/ evolution to the development of white matter lesions making the total lesion volume an index of the severity of these impairments. The total white matter lesion volume accounts for ~10% of the variability of each of the three functions and is relatively easy to measure making it a valuable measure for geriatricians. We have begun to collect two year follow-up data and have already determined that ambulatory blood pressure predicts change in white matter lesion volume as well as changes in mobility. Thus blood pressure control may mitigate deterioration. A renewal application is planned for March 2010, the focus of which will be to determine whether blood pressure control leads to decreased white matter lesion accrual and better functional outcomes. Dr. Louise McCullough: Dr. McCullough is the Research Director of the Stroke Center. She was awarded two NIH RO1 grants studying ischemic mechanisms of cell death at UCHC. both to better understand our own patient population and as a resource to support students and residents as they pursue research projects. Results from these projects are currently in press in the Journal of Stroke and Cerebrovascular Diseases (under the authorship of Dr. Blondin), and in the Journal of Womens Health (under the authorship of Dr. Knauft). Two papers are in preparation under the authorship of Dr. Neer Zeevi. Three abstracts have also been prepared over the past year, two were presented at the American Geriatric Society and one is scheduled for presentation at the International Stroke Meeting (February 2010). We continue to encourage residents and fellows to utilize this database to obtain retrospective data for future studies. The Stroke Center has continued its strong involvement in acute and secondary stroke prevention trials. Dr. Isaac Silverman is the PI on the IMS-3 trial, an NINDS-sponsored Phase-3 randomized clinical trial (RCT) investigating IV t-PA + endovascular approaches (e.g., MERCI, Penumbra, EKOS ultrasound, or IA t-PA) versus IV t-PA alone in the treatment of acute ischemic stroke. This trial includes patients with NIHSS >10 points who are randomized within the first 40 minutes after starting IV t-PA infusion. Three patients have been enrolled to date. Dr. Joao Gomes will be the PI on the planned ICTUS trial. This NINDS-sponsored Phase-3 RCT will investigate the use of an endovascular cooling device (<3 hours +/- IV t-PA) versus no cooling device in the treatment of acute ischemic stroke. We were amongst the enrollment leaders nationally in the earlier Phase-2 RCT, ICTUS-L. A new study is planned focusing on transient ischemic attack (TIA). Under the leadership of PI Dr. Isaac Silverman, the NINDS-funded POINT study will investigate the use of clopidogrel + ASA vs. ASA alone for acute TIA. Intracerebral hemorrhage (ICH) continues to be a focus of multiple active and planned research studies. Dr. Gomes is the PI on the DFO study, a NINDS-sponsored trial that involves studying Desferoxamine (an iron chelating agent) in

Stroke Center
Over the past year we have continued to utilize the Stroke Center database at Hartford Hospital for research endeavors,

a safety (Phase-1) evaluation for patients with ICH (<18 hours onset; 3-day IV infusion). Four patients have been enrolled thus far and we are one of only 4 study centers nationally to participate in this trial. The STICH-II trial continues under the leadership of Dr. Inam Kureshi. This trial involves the surgical evacuation of highly-selected patients with lobar ICH. The planned MISTIE study will involve Drs. Kureshi and Schwartz and will investigate the use of minimally-invasive endoscopic neurosurgery to remove hematoma in deep cerebral locations. The planned CLEAR 3 - IVH study, which will involve PI Dr. Kureshi, is an NINDS-sponsored Phase-3 RCT investigating infusion of t-PA via EVD as a treatment of predominantly intraventricular hemorrhage. We participated in the earlier CLEAR-IVH trial also. Given that several acute ICH trials will be running concurrently, a randomization grid for the ongoing studies will be generated by Martha Ahlquist, LPN, Clinical Trials Coordinator, to guide our physicians in trial selection. Secondary stroke prevention continues to be an active research area. The ongoing IRIS study (Dr. Silverman, PI) is an NINDS-sponsored RCT of pioglitazone versus placebo in patients with insulin resistance and recent (<6 months ago) ischemic stroke. All stroke inpatients at HH are screened for potential enrollment. The SAPPHIRE Registry (Dr. Michael Hallisey, PI) is an endovascular angioplasty / stenting trial for carotid stenosis in high-risk patients (e.g., prior radiation therapy or prior carotid endarterectomy, or high cardiovascular risk for open endarterectomy). The recently concluded CLOSURE 1 trial (Dr. Silverman, PI) was an RCT investigating the use of PFO transcatheter closure with the CardioSEAL device (vs antithrombotic agents alone) for secondary stroke prevention in patients with embolic stroke and PFO on TEE. Fourteen patients were enrolled and preliminary trials results will be available in Spring, 2010.

Research Inc. (2007-2008). He has also received research grants from Eisai Medical Research Inc. for $30,000 in 20072008 and from ACADIA Pharmaceutical for $62,000 in 20082009.

New Projects
Federal
Gomes, Joo, MD
Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage. NINDS/ Beth Israel Deaconess Medical Center, $48,000.

Foundation
McCullough, Louise, MD
Perception of Risk of First Time and Recurrent Ischemic Stroke in Women. North East Cerebrovascular Consortium/UCHC, $550.

Industry
Hassan, Mohamed, MD
A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinsons Disease (The Rubens Study). Solvay Pharmaceuticals, $48,425.

Silverman, Isaac, MD
Merci Registry Protocol. Concentric Medical, Inc. (Multicenter), $22,500.

Hartford Hospital Research Endowment Funds

Lee, Nora, MD
A Stroke of Luck: Can Cerebral Hemisphere Predict Thrombolysis and Good Outcome in an Acute Ischemic Stroke? Small Grant, $2,250.

Other Faculty Research

Dr. Mohamed Hassan is the PI on clinical trials studying novel pharmaceutical agents with the potential to modulate disease progression in early stage Parkinsons Disease and to improve fluctuations and dyskinesia in advanced Parkinsons disease through non-dopaminergic mechanisims (e.g., by manipulation of serotonin). He is the Site PI on A Multi-Center, Open Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa-Treated Parkinsons Disease Patients with Motor Fluctuations sponsored by Eisai Medical

Active Projects
Bilchik, Tanya, MD
A Multicenter Study Evaluating the Efficacy & Safety of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or more Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase. Allergan, $551,297. A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for

48.

Trexima (sumatriptan 85mg/naproxen sodium 500 mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migra. Glaxo Smith Kline, $41,594. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose, Efficacy & Safety Outpatient Study of Staccato Prochlorperazine for Inhalation in Patients with Migraine Headaches. Alexza Pharmaceuticals, Inc., $41,400. A Study of Combination Product (Sumitriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Eletriptan (Study 1 of 2). Glaxo Smith Kline Pharmaceuticals, $40,000.

PRoFESS: Prevention Regimen For Effectively Avoiding Second Strokes: A double-blind, active and placebo controlled study of Aggrenox vs. Clopidogrel, with and without Micardis. BoehringerIngelheim, $149,994. Siblings With Ischemic Stroke (SWISS). NIH / NINDS, $34,320.

Spiegel, Gary, MD
Evaluation of the Penumbra Stroke System in the Revascularization of Patients with Acute Ischemic Stroke Secondary to Intracranial Large Vessel Occlusive Disease. Penumbra, Inc., $22,500.

Staff, Ilene, PhD

Evaluation of Outcomes of Patients with Stroke Across the Continuum. Departmental, $24,600.

Gomes, Joo, MD
NeuroThera Effectiveness and Safety Trial - 2 (NEST-2): A Double Blind, Randomized, Controlled, Parallel Group, Multicenter, Pivotal Study to Assess the Safety and Effectiveness of the Treatment of Acute Ischemic Stroke with the NeuroThera Laser System within 24 hours from stroke onset. Parexel International, $16,130. Phase I Study of Intravenous Thrombolysis plus Hypothermia for Acute Treatment of Ischemic Stroke. NINDS/University of California, $25,000.

Wolfson, Leslie, MD
Brain Changes and Risk Factors Causing Impaired Mobility. Federal/ University of Connecticut, $185,805.

Publications
Kaplan RF, Cohen RA, Moscufo N, Guttmann C, Chasman J, Buttaro M, Hall CH, Wolfson L. Demographic and biological influences on cognitive reserve. J Clin Exp Neuropsychol, 31:1-9, 2009. Kuchel GA, Moscufo N, Guttmann C, Zeevi N, Wakefield D, Schmidt J, DuBeau CE, Wolfson L. Localization of brain white hyperintensities and urinary incontinence in community dwelling older persons. J Gerontol Med Sci, 64A:902-909, 2009. Moscufo N, Guttmann CRG, Meier D, Csapo I, Hildenbrand PG, Schmidt JA, Wolfson L. Brain regional lesion burden and impaired mobility in the elderly. Neurobiol Aging, May 8, 2009. White WB, Salzman P, Schwid SR for the Parkinsons Rasagiline: Efficacy and Safety in the Treatment of Off Parkinson Study Group, Mohamed N. Hassan, Principal Site Investigator, UCHC. Hypertension, 2008; 52:1-7.

Hassan, Mohamed, MD
A Multi-center, Open label Extension Study to Evaluate the Longterm Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons Disease Patients with Motor Fluctuations. Eisai Medical Research Inc., $16,781. A Multi-Center, Randomized, Double-Blind Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, & Tolerability of E2007 in Levodopa Treated Parkinsons Disease Patients with Motor Fluctuations. Quintiles, Inc., $84,435.

Lee, Nora, MD
Variability in stroke outcomes across the population.

Silverman, Isaac, MD
Insulin Resistance Intervention After Stroke (IRIS) Trial. NIH/Yale University Medical Center, $328,591. Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients with Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale (CLOSURE I Trial). NMT Medical, Inc., $120,000.

Nurses

Participating in Research
On Thursday, October 8, 2009, The Connecticut Nursing Research Alliance and the Institute for Healthcare Education held its 13th Annual Conference, Raising the Voice of Nursing in Quality and Patient Safety at Hartford Hospital. Over 300 nurses, faculty and nursing students attended from across Connecticut and neighboring states. Barbara Mackoff EdD, Visiting Professor at the Adelphi University School of Nursing, presented the keynote address titled Nurse Manager Engagement: the Power of Positive Deviance. Dr. Mackoffs qualitative research, funded by the Robert Wood Johnson Foundation, identifies characteristics of successful, engaged nurse managers and reveals the cultural elements needed to grow engaged nurse managers. Her forthcoming book on her research is due in early 2010. Dr. Mackoff is a consulting psychologist, a leadership educator and a core faculty member of The Nurse Management Fellowship Program of The American Association of Nurse Executives. The plenary address, Quality and Safety Education for Nursing: Update on the National Initiative was presented by Dori Taylor Sullivan PhD, RN, NE-BC, CNL, CPHQ. Dr. Sullivan is the Associate Dean for Academic Affairs at the Duke University School of Nursing. In addition to the keynote and plenary speakers, conference participants were given the opportunity to choose from a variety of oral abstract presentations and four skill-building sessions. These sessions included The Process of Evidence Based Practice: From Formulating the Question to Writing the Abstract by Barbara Aronson APRN, PhD, CNE, Associate Professor, Southern Connecticut State University; Searching the Research Literature: Pub Med by Lisa Carter MSLIS, Clinical Librarian for Nursing, Hartford Hospital; From Pondering to Publication: Nurse-Author Panel moderated by Karen Robbins MS, RN, CNN Nurse Educator, Dialysis, Hartford Hospital; and Choosing a Research Design: Finding the Right Approach to Answer Your Research Questions by Cynthia Adams, EdD, Director of Nursing, Capitol Community College. Several prizes were awarded in order to recognize excellence in nursing research and evidence based practice. The Excellence in Nursing Research Award was presented to Bonnie Edelen PhD, RN from Capitol Community College for her study Measuring and Enhancing Clinical DecisionMaking Ability Among Students in an Associate Degree Nursing Program. Dr. Edelens study offers strategies that nurse educators can use to maximize and promote optimal student learning across a variety of clinical practice environments. The Excellence in Evidence-Based Practice Award went to Susan Thibeault MS, APRN, CRNA, EMTP of LIFESTAR at Hartford Hospital for her work in improving patient outcomes by enhancing infection control practices. Additionally Poster Awards were given to three recipients whose posters were judged by conference attendees to be of highest quality. First place went to Lynn Deasy RN, MPH, Danette Alexander RN, MSN, NEA-BC, Carolyn Bauer RNC, Kristen McClure RN, Susan Smith RN, Kim Murphy RN, and Laura Collins RN of Hartford Hospital for their poster Partnering with Patients and their Families. Second place went to Deborah Gingras MS, RN, CNS and Michelle Connor ASN, BA, RN of Hartford Hospital for Use of Aromatherapy with Patients Undergoing Induction of Labor. Third place went to Jacquelyn Calamari MSN, MS, RN, CEN of Middlesex Hospital for Medication Errors in the Context of an Acute Care Setting. Several attendees received raffle prizes including research books generously donated by Jeane Kalanta of Elsevier Medical Publishing. The food service, provided by Wayne Oden and his staff from Hartford Hospitals Food & Nutrition Services, was superb. Special thanks are extended to the Hartford Hospital Research Department for an Education Grant that supported this conference.

CT Nursing Research Alliance Conference Planning Team

Hartford Hospital: Nancy Bafundo RN, MS, BC, Dawn Beland RN, MSN, Cynthia Belonick APRN, BC, Lisa Carter MSLIS, Cathy Chance RN, BS, Karen Cudworth RN, MSN, Deborah Gingras, MS, RN, CNS, Ginger Goddu RN, MSN, Andrea Hagstrom RN, MSN, CNOR, Eileen Hermann RN,MHS, Beverly Mendes APRN, PhD, Amy Schrder RNC, MSN, Linda Spivack RN, MSN

50.

Linda Berger-Spivack, RN, MSN, VP Patient Care Services, Hartford Hospital (at left) and Amy Schrder RNC, MSN, Chair CT Nursing Research Alliance welcome conference attendees.

Bristol Hospital: Shannon Grad RN, MSN and Fran Leach RN, MSN Capitol Community College: Cynthia Adams RN, EdD Central Connecticut State University: Meg Levvis MSN, PhD Eastern Connecticut Health Network: Linda Quirici RN, MSN, CCRN, APRN, BC Midstate Medical Center: Joanne Roy RN, PhD and Kathy Barta RN, MS, MSN, CCRN Quinnipiac University: Mary Ann Cordeau PhD, RN Saint Joseph College: Joyce Fontana RN, PhD Southern Connecticut State University: Barbara Aronson RN, PhD, CNE University of Connecticut: Jennifer Telford PhD, APRN University of Hartford: Anne Marie Buonocore PhD, RNC Windham Hospital: Anne Schmidt RN, MSN, APRN-BC

Dr. Barbara Mackoff delivers keynote address on Nurse Manager Engagement.

New Projects
The following list of projects highlights the role that nurses play in research at Hartford Hospital. Many of these projects are also listed in this report under other departments.
Dr. Dori Taylor Sullivan shares an update from the Quality and Safety Education for Nursing National Initiative

State
Servodidio, Camille, RN, MPH, Oncology
Will Housing a Research Nurse on site in a Private Practice Increase Recruitment and Enrollment into Cancer Clinical Trials? CCOT through Yale University, $25,000.

Departmental
Reagan, Louise APRN, Medicine
The Effect of a Peer Delivered Motivational Message on Intention to Exercise for Hispanic Persons with Type 2 Diabetes (T2DM): An
Gail Nelson MS, RN, NEA-BC, Director of Professional Development and Performance Improvement, Hartford Hospital (at left) presents the Excellence in Evidence-Based Practice Award to Susan Thibeault MS, APRN, CRNA, EMTP of LIFESTAR, Hartford Hospital

Experimental Pilot Study. Departmental, $454.

Unfunded
Chemmarappally, Shiny, RN, Cardiology
Infusion Center Treatment Effect on Quality of Life in Congestive Heart Failure Patients.

Gingras, Deborah, RN, Womens Health

Use of Aromatherapy with Patients Undergoing Induction of Labor.
Nancy Bafundo RN, MS, BC, Nurse Educator, Hartford Hospital (at left) presents the Excellence in Nursing Research Award to Dr. Bonnie Edelen of Capitol Community College.

Kessler, Jeanne, RN, Medicine

Risk Assessment for Skin Breakdown in a Geriatric Psychiatric InPatient Population - A Pilot Study.

Ratcliffe, Tammy, RN, BSN, Nursing

Central Line Infection Prevention (or Reduction) Implementation of and Evidence-Based Central Line Dressing Change Policy and Education in the ICU setting: A pilot Study.

Gonci, Mary-Ellen, APRN, Womens Health

Oral Health and its Implications During Pregnancy.

Lloyd, Jennifer, RN, Nursing

Nurses Experience in Caring for Patients with Substance Abuse.

Roy, Joanne, RN, PhD, Nursing

Hospital Nurses Lived Experience of Power.

McDaniel, Aimee, RN, Nursing

Evaluation of Dialysis/Transplant Nurses Knowledge and Selfefficacy Regarding Advance Directives.

Reagan, Louise, APRN, Medicine

A Narrative Analysis Pilot Study: Hispanic Patients Perspective of Managing their Chronic Illness.

Murphy, Mary, RN, Nursing

Pilot-Testing of a Tool Titled: Confidence Assessment in the Management of Simulated Patient Cardiac Arrest Situations.

Shanaman, Jennifer, MS, Nursing

Comparison of Team Behavior Assessment Between Different Surgical Specialty Staff Groups in a Large Teaching Hospitals Operating Room Department.

Nelson, Gail, RN, MSN, Nursing

National Database of Nursing Quality Indicators.

Robbins, Karen, RN, MSN, Medicine Thibeault, Susan, APRN, Emergency Medicine
Reasons for Cancellation of LIFE STAR Transport by Requester. Reiki: What are its Effects for Patients During Hemodialysis? Hartford Hospital Small Grant, $9,963.

Mendes, Beverly, APRN, Cardiology

Phenomena of Inner Strength in Women Recovering Post Myocardial Infarction Coronary Stent: A Grounded Theory.

Roy, Joanne, RN, PhD, Nursing

Evidence Based Practice Fellowship Program: Prospective and Systematic Evaluation of an Organizational-level Evidence Based Practice Initiative.

Zafian, Ruth, APRN, Cardiology

An Exploratory, Descriptive Pilot Study to Examine the Quality of Hand-offs Reports at Hartford Hospital Using the ISBAR Technique.

Satherlie-Deasy, Lynn, RN, Womens Health

Food Insecurity, Meal Skipping, Nutrient Intakes and Pregnancy Outcomes Among Low-Income Latinas.

Active Projects
Blair, Ellen, APRN, Psychiatry
Inpatient Psychiatric Unit Medications and Falls Outcomes.

Waszynski, Christine, APRN, Nursing

Assessment of the Prevalence of Delirium in Three Unique Populations of Hospitalized Persons. Pauline A. Toner Fund UCONN School of Nursing, $1,500. Perspectives of Clinicians and Social Service Personnel on the Needs of Older Adults With HIV/AIDS. University of Connecticut, $750. Nursing Assessment, Management and Treatment of Delirium in Hospitalized Older Adults: Identifying Related Outcomes. Nursing Geriatric Resource Nurse Program Evaluation.

Brown, Susanne, RN, MSN

Womens HealthDoes Simulation Training Improve Nursing and Residents Clinical Performance?

Duclos-Miller, Patricia, MSN, Nursing

Transition from Student to Graduate Nurse.

Yavinsky, Cathy, RN, MSN, Nursing

The Effect of a Specialized RN Intervention Designed to Maximize Patient-Provider Relationships on Adherence to Anti-depressant Medication. Donaghue Medical Research Foundation, $48,350.

Frakes, Michael, APRN, Emergency Medicine

Effectiveness of a Read-and-Respond Checklist in Assuring Safety Behavior Compliance at a Rotor Wing Air Medical Program. A Comparison of Pre-hospital Trauma Analgesia By Air and Ground EMS Providers. Evaluation of Helicopter Air Medical Transport Utilization by Prospective Application of Consensus Criteria. Effect of Line Oriented Flight Training On Team Behaviors and Beliefs at a Helicopter Air Medical Program. Evaluation of a Modified Sign-Out Procedure on Hospital Documentation of Medications Administered by Critical Care Transport Teams.

Young, Sara, MSN, Womens Health

Breastfeeding Education and Support Trial for Obese Women: Early Dyad Dynamics (BESTOW:EDD). University of Connecticut, $16,796. Breastfeeding Education and Support Trial for Obese Women (BESTOW). Donaghue Medical Research Foundation through the University of Connecticut, $20,590.

Andrew L. Salner, MD
Director, Helen & Harry Gray Cancer Center

Donna Handley
VP, Cancer Services

Oncology
Cancer Clinical Research Office
Camille Servodidio, RN, MPH, CRNO, OCN Coordinator Robert Siegel, MD, Medical Director, Cancer Clinical Research
The Cancer Clinical Research Office (CCRO) is an active participant in a variety of national cooperative group research studies and several industry-supported trials. In 2007, Hartford Hospital was selected as one of 16 community hospitals to participate in the NCI Community Cancer Centers Program Pilot (NCCCP). One of the charges of the NCCCP is to expand clinical trials and reduce disparities. The NCCCP pilot created a network of community hospitals that shared best practices and pooled strategies to recruit patients and endorse particular trials. Abstracts highlighting accomplishments were presented at both national meetings of the American Society of Clinical Oncologists and the Oncology Nurses Society. Through Hartford Hospitals continuing affiliation with Dana Farber Partners/Cancer Care, the CCRO has had the opportunity to open several additional cancer clinical trials. The CCRO participates in multiple National Cancer Institute (NCI) trials sponsored by the Cancer and Leukemia Group B (CALGB), the Gynecologic Oncology Group (GOG), and the National Surgical Adjuvant Breast and Bowel Project (NSABP) as well as several pharmaceutical/industry trials. The NSABP has recently opened several new breast cancer treatment trials, active at Hartford Hospital under the leadership of Dr. Patricia DeFusco, principal investigator and the coordination of Susan Zahorodni, RN. NSABP B-40 involves chemotherapy before surgery for women with palpable breast masses with half of the women receiving bevacizumab, a drug which blocks a tumors blood supply, after surgery. NSABP B-42 involves post-menopausal ER+/PR+ women diagnosed with invasive breast cancer to determine if five years of additional Letrozole will improve survival. The PACCT-1 trial will assign treatment regimens based on pathology specimens of women with ER+/PR+ node negative breast cancer. The CCRO has continued to recruit gynecologic oncology patients into GOG trials under the leadership of principal investigators Dr. Stacy Nerenstone and Dr. Amy Brown. Karen Cuddy, RN has joined the team this year as the GOG trial coordinator. GOG continues to sponsor cutting edge chemotherapy trials for gynecologic cancers. GOG # 212 provides women who have recently received chemotherapy for ovarian cancer an opportunity for additional chemotherapy (standard of care Taxol vs. Xyotax, a drug which can be delivered over a shorter period of time) and compares them to women who receive standard of care physician observation prior to tumor recurrence. GOG # 213 is a treatment trial for women diagnosed with platinum-sensitive, recurrent ovarian, peritoneal primary or fallopian tube cancer. Women who are surgical candidates are randomized to cytodreductive surgery or none. If they are not surgical candidates they may be randomized to chemotherapy treatments of carboplatin and paclitaxel alone or in combination with bevacizumab.

Hartford Hospital participates in several Dana Farber and CALGB trials under the leadership of Dr. Robert Siegel, principal investigator and the coordination of Kathleen VanGelder, RN. CALGB 40101 compares Cytoxan and Adriamcyin chemotherapy versus Taxol in women with node negative breast cancer and CALGB 70301 is a companion study focusing on quality of life and employment. CALGB 50501 is a phase II trial of bortezomib vs. lenalidomide for relapsed /refractory mantle cell lymphoma. Dana Farber 06116 involves patients diagnosed with metastatic transitional cell carcinoma in which patients receive docetaxel with or without Zactima, a drug that inhibits blood vessel growth in cancers. The ASSURE trial compares sorafenib versus Sunitinib vesus a placebo for unfavorable renal carcinoma. The CCRO is involved in several pharmaceutical /industry trials under the leadership of Dr. Todd Alekshun, principal investigator and the coordination of Karen Burnham, RN, BSN, OCN. SNDX- 275-0301 is a Phase II randomized double blind study of exemestane with and without SNDX-275, a pill, in post-menopausal women diagnosed with local recurrent or metastatic ER+ breast cancer progressing on treatment with a non-steroidal aromatase inhibitor. The Sanofi-Aventis ECF6546 (VENICE) is a phase II randomized double blind trial comparing Aflibercept to placebo for metastatic androgen-independent prostate cancer. Finally, the best treatment for cancer is to either prevent it or detect it early. Since 1995, the CCRO has been involved in the Connecticut Breast & Cervical Cancer Early Detection Program (CBCCEDP), a state sponsored outreach program that provides clinical breast examinations, mammograms and cervical cancer screening to the underserved and underinsured women of the greater Hartford area. A total of 82 cancers have been detected since the inception of the program. These outreach efforts are funded by the Centers for Disease Control and Prevention (CDC) and organized by the State of Connecticut Department of Public Health. Dr. Merwood Jones serves as medical director, Nora Brugueras is the case manager, and Damaris Perez is the outreach educator. The CCRO continues in its ninth year of the CDC funded WISEWOMAN grant, which offers glucose and cholesterol screening, nutrition counseling, cooking and exercise demonstrations for women over 40 years old. The CBCCEDP has partnered with the American Heart Association to offer CBCCEDP participants under age 39 the opportunity to receive free cholesterol screenings and cardiovascular

educational materials. The AVON Foundation Breast Care Fund grant supports community outreach and breast cancer education for underserved and underinsured women. These are intriguing times in cancer research and treatment. The CCRO remains committed to our patients and families through education, screening, and participation in clinical trials.

CHESS Program
Sherri Storms, BSN, RN-BC, Cancer Program Project Coordinator
CHESS (Comprehensive Health Enhancement Support System) is an internet-based information and support system for patients with breast and prostate cancer who often have difficulty finding good information, who may be hesitant or unable to attend support groups, and who often feel pressured to make difficult decisions with little information. The CHESS program helps patients and their families become more actively involved in their treatment and recovery, making high quality information and social support easily accessible and helping patients make choices and decisions based on their individual needs. In partnership with the University of Wisconsin, Hartford Hospital has offered CHESS to its patients for more than 12 years, reaching over 1400 women with breast cancer and 400 men with prostate cancer. Thanks to our generous donors, we own 40 laptop computers available for loan to patients, who also receive training on how to use them. In addition to serving Hartford Hospital patients, we collaborate with Windham Hospital to offer CHESS to patients in the Eastern part of the state. This year we completed enrollment of 95 men into an innovative NCI-sponsored study, Human and Computer Mentors for Prostate Cancer Patients which aims to test the effectiveness of a Human Cancer Mentor vs. CHESS vs. a combination of CHESS and the Human Cancer Mentor on improving quality of life for men with prostate cancer. While the primary outcome measure is patient quality of life, secondary outcomes include patient preparedness for interactions with clinicians and mentors, self-efficacy, health care use, decision satisfaction, and considerations of treatment alternatives. This study will help us learn how a human cancer mentor might affect a prostate cancer patients quality of life and we expect that it will provide valuable information about ways that the Internet and other communication tools may be

54.

used to improve the quality of life for all cancer patients. We are also collaborating with the University of ConnecticutStorrs Departments of Psychology and Family Studies on two Quality of Life studies, Adjustment to Breast Cancer and Lifestyle Change Intervention for Recently Diagnosed Breast Cancer Survivors: Pilot Study. The first study focuses on newly diagnosed breast cancer patients. Currently 55 patients have been recruited into the study, the goals of which are: (1) to examine differences in treatment decision-making between African-American, Hispanic and Caucasian women with breast cancer at two time points post-surgery; (2) to examine whether specific socio-cultural and psychosocial factors are associated with treatment decision-making among African-American and Hispanic women with breast cancer; and (3) to examine whether certain coping strategies commonly employed by African-American and Hispanic women with breast cancer are associated with treatment decision-making. This study will provide valuable information how socio-cultural and psychosocial factors impact treatment decision-making and health disparities among minority breast cancer patients and will inform the development of interventions in this area. Our participation underscores our ongoing commitment to providing the very best in care to all of our cancer patients. Lifestyle Change Intervention for Recently Diagnosed Breast Cancer Survivors is a pilot study of health behavior change among breast cancer survivors completing their primary treatment. The study evaluates the effectiveness of mail-based lifestyle interventions in helping breast cancer survivors make and maintain important changes in diet and exercise, factors that are important for survivorship among breast cancer patients completing their primary treatment. Thus far we have recruited 22 patients from Hartford Hospital into the pilot study and we expect that the results will provide a springboard for Hartford Hospital and the University of Connecticut to collaborate on a larger Lifestyle Change Intervention Study.

reported statewide. All Connecticut hospitals and labs are required by Connecticut State statute to report all diagnoses of cancer to the Connecticut State Tumor Registry at the Department of Health, the oldest and most widely used central registry in the nation. The information housed in Hartford Hospitals Cancer Registry provides valuable data on patient demographics and cancer incidence, information that has been used to support presentations, research, certificates of need and grant applications in addition to identifying areas for improvement in patient care.

New Projects
Federal
Baker, William-Jeffrey, MD
CALGB 50303: A Phase III Study of R-CHOP V. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas. Cancer And Leukemia Group B, $53,400. CALGB 50501: A Phase II Trial of Bortezomib + Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma. Cancer And Leukemia Group B, $10,000.

Brown, Amy, MD
A Phase II Evaluation of AMG 706 in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. GOG, $8,361. GOG 205: A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva. GOG, $16,500. GOG 126R: A Phase II Evaluation of Abraxane in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. GOG, $3,300. GOG 136: Acquisition of Human Gynecologic Specimens and Serum to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer. GOG/HOCCT, $33,000. GOG 213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. GOG, $27,720. GOG 224: A Randomized Controlled Phase II Evaluation of (MEGACE) Megestrol in Different Dose and Sequence in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) from a Referred Cohort of a Typical Endometrial Hyperplasia (AEH) or EIN. GOG, $9,350.

The Cancer Registry at Hartford Hospital

Debra Jacques, MSM, CTR, Manager, Cancer Registry
The Cancer Registry at Hartford Hospital was established in 1928 and contains over 85,000 cancer cases. It submits over 2,500 new cancer cases to the Connecticut Tumor Registry each year, accounting for approximately 15% of all cancers

GOG 229F: A Phase II Evaluation of VEGF-Trap (Aflibercept, NSC #724770, IND #BB100137, NCI Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma. GOG, $5,280. GOG 239: A Phase II Trial of AZD6244 In Women with Recurrent Low-Grade Serous Carcinoma of the Ovary. GOG, $6,160. GOG 87M: A Phase II Evaluation of Trabectedin (Yondelis, R279741, IND #75,111) In The Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas. GOG, $3,300. GOG 0232C: A Phase II Evaluation of Paclitaxel (Taxol,NSL #673089) Carboplatin (Paraplatin, NSL #241240) and BSI-201 (NSC #7466045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinomas. GOG/HOCCT, $2,860. GOG 0235: A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy. GOG, $19,800. GOG-0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus. GOG, $11,000.

CALGB 10404: A Randomized Phase II Study of Three Fludarabine / Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia. CALGB, $10,000. CALGB 30607: A Randomized, Phase III, Double-Blind PlaceboControlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer. CALGB, $8,000. CALGB 30704: A Randomized Phase II Study To Assess The Efficacy Of Pemetrexed Or Sunitinib (NSC #736511, IND #74019) Or Pemetrexed Plus Sunitinib In The Second-Line Treatment Of Advanced Non-Small Cell Lung Cancer. CALGB, $10,000. CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. CALGB, $25,800. CALGB 9665: The Leukemia Tissue Bank (companion to CALGB 10404). CALGB, $2,000. CALGB90203: Randomized Phase III Study Of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer. CALGB, $17,500. DF07-199: A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer. Dana Farber Cancer Institute, $26,000. DF05-043: Randomized Controlled Study of Docetaxel plus 6-month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for patients with High-Risk Localized or Locally Advanced Prostate Cancer. Dana-Farber, $27,000. DF06-116: A Randomized Phase II Study of Docetaxel +/- Zactima (ZD6474) in Metastatic Transitional Cell Carcinoma. Dana Farber, $25,000. DFCI07-214: A Phase II Study of Bevacizumab in Combination with Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer. Dana Farber, $16,800. E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers. ECOG via CTSU, $12,510.

DeFusco, Patricia, MD
B-44-I: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab. NSABP (Genetech), $160,600.

Nerenstone, Stacy, MD
A Phase II Evaluation of Gemcitabine (Gemzar, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma. GOG, $4,290. GOG 170M: A Phase II Evaluation of Dasatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. GOG/HOCCT, $2,860. GOG-0249: A Phase III Trial Of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy In Patients With High Risk, Early Stage Endometrial Carcinoma. GOG, $25,300.

Siegel, Robert, MD
A Phase III Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients with Chronic Lymphocytic Leukemia. CALGB, $1,818.

56.

ECOG E2805 ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma. ECOG via CTSU, $8,000. ECOG 1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer. ECOG via CTSU, $25,500. ECOG E1A06: An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy. ECOG Via CTSU, $11,250. COG E2804: The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma. ECOG via CTSU, $10,000.

C10953/2036/ON/US: A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Armodafinil Treatment (150 mg/day) for Patients with Fatigue Associated with Taxane Chemotherapy. CEPHALON, INC., $80,081. GTx, Inc. Protocol Number: G200502 Double-Blind, PlaceboControlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (cachexia) in Patients with Cancer. GTx Inc., $56,520. Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry. Alexion Pharmaceuticals Inc., $19,625. Pfizer A6181094: A Phase 3 Study of SU011248 in Combination with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-line Advanced Disease Setting in Patients Having Breast Cancer. North American Shared Services, $185,381. Pfizer A7471028: A Randomized Phase II Trial of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy Regimen. Pfizer Inc./ North American Shared Services, $180,686.

Sorosky, Joel, MD
GOG-0237: Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cell (AGC). GOG, $6,600.

Industry (Investigator Initiated)

Salner, Andrew, MD
Total Cancer Care: A Partnership with High Risk and/or Diagnosed Cancer Patients For Life. H. Lee Moffitt Cancer Center & Research Institute, Inc., $2,942,143.

Foundation
Salner, Andrew, MD
Assessing Quality of Life in Young Adult Cancer Survivors. Lance Armstrong Foundation/UCONN Storrs, $30,000. Breast Cancer Survivorship: A Patient Navigator Program. Lance Armstrong Foundation, $47,756. Lifestyle Change Intervention for Recently Diagnosed Breast Cancer Survivors: Pilot Study. UCONN Research Foundation, $2,000.

Industry (Multicenter)
Baker, William-Jeffrey, MD
A Worldwide, Observational Registry collecting Longitudinal Data on the management of Chronic Myelogenous Leukemia (CML) patients (The WORLD CML Registry) in routine practice. Novartis, $38,375.

Siegel, Robert, MD
A Prospective, Non-Interventional Multicenter Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients. Novartis, $69,000. EFC10203: A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/ m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with Advanced Pancreatic Cancer Previously Treated with a Gemcitabine Based-Regimen. Sanofi-aventis, $79,350. EFC6546, A Multicenter, Randomized, Double blind Study Comparing the efficacy and Safety of Aflibercept Versus Placebo administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer. Sanofi Aventis, $155,788.

DeFusco, Patricia, MD
NSABP Protocol B 41: A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response. NSABP Foundation Inc., $32,813.

Industry
Siegel, Robert, MD
ACORN/Onyx NU07B1: A Double Blind, Randomized Phase IIb Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. ACORN, $43,815.

Protocol PGT307: Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Nave Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol >25 pg/mL. Cell Therapeutics, $72,983.

Active Projects
Baker, William-Jeffrey, MD
A Phase II Study Of Fludarabine + Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) Consolidation in Untreated Patients with B-Cell Chronic Lymphocytic Leukemia. CALGB / Dana-Farber, $8,400.

State
Salner, Andrew, MD
Development of Culturally Appropriate Educational Approaches to Enhance Clinical Trial Participation Among Underserved Populations in the Greater Hartford Area. Connecticut Clinical Oncology Trials Network/Yale University, $25,000.

Brown, Amy, MD
GOG # 210: A Molecular Staging Study of Endometrial Carcinoma. GOG/ Tufts New England Medical Center, $11,616. GOG 209: Randomized Phase III Trial of Doxorubicin / Cisplatin / Paclitaxel and G-CSF Versus Carboplatin / Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer. GOG, $6,313. GOG 219: A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine (IND #46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervival Carcinoma Limited to the Pelvis. GOG, $6,601. GOG 215: A Phase II Randomized Study of the Effect of Zoledronic Acid (Zometa) versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries. GOG, $3,960. GOG0170K (0170): A Phase II Evaluation of Mifepristone in the Treatment of Recurrent or Persistent Ovarian or Primary Peritoneal Cancer. GOG, $6,313.00 The Utility of Coronal CT Reformatting in Predicting Extent of Disease in Ovarian Cancer and Pelvic Mass Patients.

Servodidio, Camille, RN, MPH

Will Housing a Research Nurse on site in a Private Practice Increase Recruitment and Enrollment into Cancer Clinical Trials? Connecticut Clinical Oncology Trials Network/Yale University, $25,000.

Departmental
Salner, Andrew, MD
Chart Review- Treatment of Base of Tongue Cancer. $200. Analytic support provided through Hartford Hospital Small Grant. Evaluation of Community Based Prostate Cancer Screening Program. $23,910.

Hartford Hospital Research Endowment Funds

Thumar, Jaykumar, MD
CD133 Expression and Clinical Outcome in Patients with Rectal Cancer. Small Grant, $12,462.

Buckley, Judith, MD
Partial Breast Radiation Therapy-A Paradigm Shift. Standardized Uptake Value in PET as a Predictor of Survival in Esophageal Cancer.

Unfunded
Brown, Amy, MD
A Retrospective Comparison of Clinical Outcomes Between Laparotomy and Robotic Hysterectomy for Endometrial Cancer.

DeFusco, Patricia, MD
NSABP B-34: A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy. NSABP, $15,000.00 A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin with 5-FU Plus LV for the Treatment of Patients with Stages II and III Carcinoma of the Colon (C-07 NSABP). NSABP Protocol - P-2 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer MIN21-CON. NSABP, $75,000. NSABP B-33: A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3 NO-1 MO

Buckley, Judith, MD
Prevalence and Significance of Perineural Invasion as a Feature of Invasive Breast Cancer.

Salner, Andrew, MD
Outcomes and Survival Rates of Adenoid Cystic Carcinoma in 62 Patients: A Hospital Registry Based Study. Survivors of Cancer in Adolescents and Young Adults (YES Project).

58.

Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy. NSABP, $1,000. A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma In Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy. NSABP, $21,000. A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Flouroracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), With or Without Celocoxib, in Patients with Node-Negative Breast Cancer. NSABP, $16,000 NSABP B-38 A phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel / Doxorubicin / Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin / Cyclophosphamide Followed by DD Paclitaxel (DD AC>P). NSABP, $19,000. A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5FU), Leucovorin, And Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab To The Same Regimen Without Bevacizumab For The Treatment Of Patients With Resected Stages II And III Carcinoma of the Colon. NSABP, $19,000. A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I or II Breast Cancer. NSABP/RTOG, $20,900. NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer. NSABP, $23,100. A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathological Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC (Adriamycin - Cytoxan) -with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens. NSABP, $10,450. NSABP-B-31. A Randomized Trial Comparing The Safety And Efficacy of Adriamycin And Cyclophosphamide Followed By Taxol (AC-T) To That Of Adriamycin And Cyclophosphamide Followed By Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2. A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin) Cyclophosphamide (AC) to Preoperative AC

Followed by Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed by Postoperative Docetaxel in Patients with Operable Carcinoma of the Breast. A Trial to Evaluate the Worth of Tumor Biomarkers Obtained by FNA or Core Biopsy in Predicting Response to Preoperative Chemotherapy and Long-Term Outcome in Patients with Operable Breast Cancer Who are Participating in NSABP Protocol B-27. A Trial to Evaluate the Worth of Serum ErbB-2 Extracellular Domain and Serum ErbB-2 Antibodies in Predicting Response to Preoperative Chemotherapy and Long-Term Outcome in Patients with Operable Breast Cancer Who are Participating in NSABP Protocol B-27. NSABP B-30: A Three Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Axillary Lymph Nodes. A Clinical Trial to Evaluate the Worth of Tamoxifen in Conjunction with Lumpectomy and Breast Irradiation for the Treatment of Noninvasive Intraductal Carcinoma (DCIS) of the Breast (B-24). A Clinical Trial to Determine the Worth of Tamoxifen and the Worth of Breast Radiation in the Management of Patients with Node-negative, Clinically Occult, Invasive Breast Cancer Treated by Lumpectomy (B-21). Breast Conservation Rates in Breast Cancer Surgery: Comparison Based On Ethnicity, Race, and Insurance Status. A Randomized Trial Evaluating the Worth of Paclitaxel (Taxol) Following Doxorubicin (Adriamycin)/Cyclophosphamide in Breast Cancer Patients with Positive Axillary Nodes (B-28) . A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) with 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients with Stages II and III Carcinoma of the Colon (C-06). Angiogenesis in Breast Cancer: A Retrospective Analysis of Patients with Stage III or IV Disease Before and After Neoadjuvant Chemotherapy.

Flowers, Alexandra, MD
Pilot Study of Combination Temozolamide and 6-Thioguanine Chemotherapy for Patients with Recurrent Malignant Gliomas. NOVARTIS EPO906: An Open-Label, Multi-Center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer. Novartis Pharmaceuticals, $180,339.

Leopold, Kenneth, MD
RTOG 0232, A Phase III Study Comparing Combined External Beam Radiation And Transperineal Interstitial Permanent Brachytherapy

With Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma. RTOG, $20,700. RTOG 0214, A Phase III Comparison Of Prophylactic Cranial Irradiation Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer. RTOG, $18,200.

Salner, Andrew, MD
Prognostic Value of HER2 Status in High Risk Node Negative Breast Cancer. Departmental, $3,200. Clinical and Quality of Life Outcomes Following Diagnosis of Prostate Adenocarcinoma. Departmental, $27,000; matching funds generously provided by the Medical Staff. Centers of Excellence in Cancer Communication: Component and Couple Analysis of Cancer Communication (CHESS Program). NCI/ University of Wisconsin, $101,362. Center of Excellence in Cancer Communications - Mentor Integration Project (CHESS Program). NCI/University of Wisconsin, $101,362. Web-Based Support for Informal Caregivers in Cancer (CHESS - Comprehensive Health Enhancement Support System). The University of Wisconsin/NIH, $127,244. Human and Computer Mentors for Prostate Cancer Patients - CHESS Program. NCI/University of Wisconsin, $111,559 NCI NCCP Pilot Program. NCI/SAIC-Fredericks, $1,457,633. Reaching Urban African American Men with Prostate Cancer Screening Information. CDC/National Cancer Prevention & Control Program, $258,670. The Effects of Training and Follow-up Patients Contact on Utilization of the Internet-Based Information and Support Program CHESS (Comprehensive Health Enhancement Support System). Hartford Hospital Research Endowment Funds, $10,000. City of Hartford Comprehensive Cancer Prevention and Control Plan. City of Hartford-Health & Human Services Dept., $25,000. Environment, Gene, and Testicular Cancer Risk (Hartford Hospital). Environment, Gene, and Testicular Cancer Risk (Windham Hospital). Meningioma: Risk Factors and Quality of Life (Windham Hospital). Meningioma: Risk Factors and Quality of Life (Hartford Hospital). Psychosocial Needs Assessment of Colorectal Cancer Patients and Partners in the First Year After Diagnosis (Qualitative Research Phase). Self-Determined Length and Patterns of Usage for the Internet-Based Information and Support Program CHESS (Comprehensive Health Enhancement Support System) Living with Breast Cancer. Psychosocial Needs of Colorectal Cancer Patients and Partners in the First Year After Diagnosis

Nerenstone, Stacy, MD
GOG #182: A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma. GOG, $1,500. GOG #199: Prospective Study of Risk-Reducing SalpingoOophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer. GOG, $20,000. GOG 212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Ct-2103 (Ind #70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy. GOG, $49,500. GOG 218: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (RhuMab VEGF, NSC #704865, IND#7921) Followed by Placebo, versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated Suboptimal Advanced Stage Epithelial Ovarian and Peritoneal Cancer. GOG/The Hospital of Central Connecticut at New Britain, $49,368. Phase III Randomized Trial of 12 Months vs 3 Months of Paclitaxel in Patients with Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxelbased Chemotherapy (GOG 178) . Randomized Clinical Trial for the Treatment of Women with Selected Stage IC and II (A,B,C) and Selected Stage IA and IB Ovarian Cancer (GOG95). A Randomized Phase III Trial of IV Carboplatin (AUC6) and Paclitaxel 175 mg/m2 Q 21 days x 3 courses Plus Low Dose Paclitaxel 40 mg/m2/wk versus IV Carboplatin (AUC6) and Paclitaxel 175/mg/m2 Q 21 days x 3 courses Plus Observation in Patients with Early Stage Ovarian Carcinoma (GOG 175).

Rotondaro, Roxanne, MPH

Pilot Study on Mobile Mammography: Estimating Eligibility and Participation in a Senior Housing Setting.

60.

Siegel, Robert, MD
Retrospective Analysis of Breast Cancers Negative for Estrogen Receptor, Progesterone Receptor and HER-2/neu (Basal Like Cancers). Departmental, $1,600. Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Lung Cancer (CALGB 79803/E5597) CALGB, $1,500. CALGB #99811 - A Phase II Study of Neo-Adjuvant Paclitaxel, Estramustine and Carboplatin (TEC) Plus Androgen Ablation Prior to Radiation Therapy in Patients with Poor Prognosis Localized Prostate Cancer. Dana Farber / Partners Cancer Care, $8,000. Cyclophosphamide and Doxorubicin (CA x 4 cycles) versus Paclitaxel (4 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study (CALGB 40101). CALGB / Dana Farber Cancer Institute, $8,000. Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (IBCSG 24002 SOFT). CTSU/IBCSG , $8,000. CALGB 80101: Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma. Dana Farber Cancer Institute, $4,000. A Randomized, Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer (CALGB). NCIC/CALGB, $6,000. ECOG PACCT-1: Program For The Assessment Of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: The TAILORx Trial. ECOG, $21,000. ECOG E2603: A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma. ECOG via CTSU, $15,400. NCCTG N0147: A Randomized Phase III Trial Of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection For Patients With Stage III Colon Cancer CALGB via Dana-Farber, $20,000. CALGB 70301: A Clinical Trial to Determine The Quality of Life, Employment and Informal Care Cost d, Placebo-controlled, Phase III Study of AE941 in Addition to Combined Modality Treatment Chemotherapy/ Radiotherapy) for Locally Advanced Unresectable Non-Small-Cell Lung Cancer (AE-941). NCI/Cancer Treatment Evaluation Program, $40,750. Phase III Trial of Novel Epothilone Plus Capecitabine versus

Capecitabine alone in Patients with Advanced Breast Cancer Previously Treated with or Resistant to an Anthracycline and who are Taxane Resistant. Bristol Myers Squibb via Dana Farber, $24,375. S0016, A Phase III Trial Of CHOP + Rituximab Vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) For Treatment Of Newly Diagnosed Follicular Non-Hodgkins Lymphomas. SWOG via Dana Farber/CALGB, $6,000. A Phase III, Randomized Study of Gemcitabine [fixed-dose rate infusion] and Oxaliplatin (NSC2666046) versus Gemcitabine [fixed-dose rate infusion] versus Gemcitabine [30-min infusion] in Pancreatic Carcinoma. Eastern Cooperative Oncology Group- Dana Farber Cancer Institute,$8,000. A Phase III, Open-Label, Extension Study of Eculizumab in Patients with Transfusion Dependent, Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Participated in the TRIUMPH (C04-001), SHEPHERD (C04-002) or X03-001 Studies. Alexion Pharmaceuticals, Inc., $50,988. An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase 2 Study of S-1 as 2nd Line Therapy for Patients with Metastatic Pancreatic Cancer, Protocol Number TPU-S1201. TAIHO Pharma USA, Inc., $84,812. GPC Protocol SAT3-03-01: A Multi-Center, Multi-National, Double-Blind, Randomized Phase III Study Of Satraplatin Plus Prednisone or Placebo Plus Prednisone In Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen. Pharmanet, $66,176. A Phase II Randomized Double-blinded Efficacy and Safety Study of Three Doses of TAS-108, Administered Orally in Postmenopausal Patients with Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Carcinoma Following Standard First or Second Line Endocrine Therapy. Quintiles, Inc., $138,113. Protocol 2055-003 - A Phase 2, Multi-Center, Randomized, OpenLabel Study of Two Dose Levels of IMOxine (TM) (HYB2055 for injection) in Patients with Metastatic or Locally Recurrent Clear Cell Renal Carcinoma. Idera Pharmaceuticals, $70,638. TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, MultiCenter, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients (C04-001). Alexion Pharmaceuticals, Inc., $40,910. A Multicenter, Open-Label, Single-Arm, Two-Stage Phase II Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Subjects with Platinum-, Taxane-, and Erlotinib-Resistant Advanced Non-Small-Cell Lung

Adenocarcinoma. Sanofi Aventis, $246,775. Alexion EXPLORE: EXamination of PNH, by Level Of CD59 on REd and white blood cells, in bone marrow failure syndromes. Alexion Pharmaceuticals, Inc., $27,100. Phase III Double-blinded Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Nonsmall Cell Lung Cancer (ECOG-91025). A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil vs Fludarabine Phosphate + Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia (C9011). A Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-risk, High-grade, Soft Tissue Sarcomas of the Extremities and Body Wall (ECOG R9514). Phase III Trial of CHOP versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkins Lymphoma (CALGB 9793, formerly ECOG E4494). A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women with Node Positive Stage II/IIIA Breast Cancer (ECOG C9741) A Phase III Randomized Double Blinded Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen (CALGB Study #49805)

tamponade: a rare complication of idiopathic hypereosinophilic syndrome. Journal of Cardiovascular Medicine, 10: 188-91, February 2009. Goldstein M, Siegel R. Thymoma developing 30 years after mantle radiation for Hodgkins lymphoma. Connecticut Medicine, 73: 521523. 2009. Kapadia P and Bona R. Acquired deficiency of vitamin K-dependent clotting factors due to brodifacoum ingestion. Connecticut Medicine, 72: 207-09, April 2008. Madom LM, Brown AK, Lui F, Moore RG, Granai CO, Disilvestro PA. Lower uterine segment involvement as a predictor for lymph node spread in endometrial cancer. Gynecologic Oncology, 107:75-78, 2007. Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard JW, Granai CO, Bast Jr., RC, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology, 110: 196-201, 2008. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast Jr. RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology, 108:404-408, 2008. Moore RG, McMeekin SD, Brown AK, DiSilvestro PA, Miller CM,Allard JW, Gajewski W, Kurman RJ, Bast RC, Skates SK. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 112:40-46, 2009. Moore RG, Robison K, Brown AK, DiSilvestro PA, Steinhoff M, Noto R, Brard L, Granai CO. Isolated Sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: A prospective trial. Gynecologic Oncology, 109:65-70, 2008. Nieves L, Currie J, Hoffman J, Sorosky JI. Ototoxicity after intraperitoneal chemotherapy: a case report. International Journal of Gynecological Cancer, 17: 1133-5. September October 2007. Nieves L, Hoffman J, Allen G, Currie J and Sorosky JI. Placental-site trophoblastic tumor with PET scan-detected surgically treated lung metastasis. International Journal of Clinical Oncology, 13: 263-5, June 2008. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz

Stein, Kevin, PhD

National Quality of Life Study (Study of Cancer Survivors). National Quality of Life Study (Study of Cancer Survivors)/ Windham Hospital.

Publications
Alekshun TJ, Rezania D, Ayala E, Cualing H, Sokol L. Skeletal muscle peripheral T-cell lymphoma. Journal of Clinical Oncology, 26: 501503, Jan 20, 2008. Brown AK, Madom L, Moore R, Granai CO, DiSilvestro P. The prognostic significance of lower uterine segment involvement in surgically staged endometrial cancer patients with negative nodes. Gynecologic Oncology, 105:55-58, 2007. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Group Study. Journal of Clinical Oncology, 25: 5165-71., November 20, 2007. Fernandez AB, Ahmed S, Duncan BV, Firshein S and Kluger J. Cardiac

62.

Oncology

HI, Dev I, Nixon AB, Lyerly HK, Clay T, Morse MA The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother, 2008 Aug;57(8):111524. Epub 2008 Jan 10. Schnatz PF, Murphy JL, OSullivan DM, Sorosky JI. Patient choice: comparing criteria for selecting an obstetrician-gynecologist based on image, gender, and professional attributes. American Journal of Obstetrics & Gynecology, 197: 548. November 2007. Servodidio CA. What Makes a Community Clinical Research Program Successful? ONS Connect, 15: December 2008. Servodidio CA. Technology is Illuminating the Full Spectrum. MGND New Media. December 30, 2008. Sharma R, Usmani S, Siegel R. Primary squamous cell carcinoma of breast in background of phyllodes tumor-A case report. Connecticut Medicine, 73: 341-343; 2009. Sorosky JI. Endometrial cancer. Obstetrics & Gynecology, 112: 186, February 2008. Weren J, Schnatz PF, Mandavilli S, Allen G, Murphy JL, Greene JF, Egan JF, Sorosky JI. Prevalence of the human papillomavirus in an inner-city indigent population with previously normal Pap tests. Journal of Lower Genital Tract Disease, 12: 287-92, October 2008.

Abstracts
Grubbs SS, Gonzalez M, Krasna M, Siegel R, Bryant D, Tsechetter L et al. Tracking clinical trial accrual strategies and barriers via a webbased screening tool. Proc ASCO # 6586. 2009. Hawkins RP, Pingree S, Shaw B, Serlin RC, Swoboda C, Han J, Carmack-Taylor C. and Salner A. Mediating processes and effects of two communication interventions for breast cancer patients. Presented at the annual meeting of the International Communication Association, TBA, Montreal, Quebec, Canada, May 21, 2008. Karak S and Ricci A Jr. Prevalence and significance of perineural invasion (PIN) in invasive breast carcinoma. USCAP (United State and Canadian Academy of Pathology), March 2009. Rustagi T, Siegel R. Zollinger-Ellison Syndrome with subsequent association of insulinoma. Presented at the 6th Annual ISGIO Conference, 2009.

Orthopedics
New Projects
Industry
Kime, Charles, MD
A Prospective and Randomized Controlled Trial to Evaluate the Safety and Effectiveness of Total Facet Arthroplasty in the Treatment of Degenerative Spinal Stenosis. Archus Orthopedics, $82,000.

Active Projects
Browner, Bruce, MD
Evaluation of Osteoporosis Outreach and Education Initiative. Merck & Co., Inc, $100,365.

Caputo, Andrew, MD
FDA-HDE (Humanitarian Device Exemption) Approved Ascension PIP Finger Joint.

Krompinger, W. Jay, MD
Evaluation of Outcomes Following Lumbar Spine Fusion Surgery at Hartford Hospital: Phase I. Hartford Hospital Small Grant, $9,725.

Lewis, Courtland, MD
Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS). National Heart, Lung & Blood Institute, University of Medicine & Dentistry of New Jersey, $700. Functional Status, Morbidity and Mortality in Cemented versus Uncemented Hemiarthroplasty: A Prospective Randomized Trial. Zimmer Corporation, $166,492. A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery. Bristol-Myers Squibb, $172,860.

Mastella, Daniel, MD
Does Simultaneous Carpal Tunnel Release Improve Outcomes Following Distal Radius Open Reduction and Internal Fixation: A Retrospective Review.

Sullivan, Raymond, MD
A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of GEM OS1 Compared to Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions. Biomimetic Therapeutics, $168,825.

64.

Pathology
William T. Pastuszak, MD, Chairman, Jaber Aslanzadeh, PhD Margaret Assaad, MD, Fabiola Balarezo, MD, Richard Cartun, PhD Thomas Ciesielski, MD, Joseph DiGiuseppe, MD, Jonathan Earle, MD Mary Fiel-Gan, MD, Lisa Laird, MD, Saverio Ligato, MD Gregory Makowski, PhD, Srinivas Mandavilli, MD, Laila Mnayer, PhD Richard Muller, MD, William Rezuke, MD, Andrew Ricci, MD Peter Shen, MD, Bradford Sherburne, MD, Dean Uphoff, MD Terry Voytek, MD, Rebecca Williams, MD he Department of Pathology and Laboratory Medicine (DPLM) through its biomedical and chemical research initiatives seeks to improve the understanding of the mechanisms of human disease and acquire knowledge that will assist in clinical diagnosis and development of new therapies that will improve cellular, molecular and genetic disease manifestations. Research-based knowledge provides the fundamental basis for translating information into clinically useful diagnostic testing and treatment for patients served at Hartford Hospital. DPLM oversees state-of-the-art equipment and technologies that support complex analysis of biochemical, infectious, molecular, cytogenetic and tissue markers of disease as demonstrated by the Departments current research projects. Several divisions of DPLM conduct independent research and development. The Division of Hematology conducts research in use of immunologic and molecular techniques in the diagnosis and classification of hematologic and lymphoid malignancies. Anatomic Pathology uses immunohistochemistry to investigate a variety of pathologic disorders. Microbiology has investigated the application of molecular diagnostics to infectious diseases. The Department is fortunate to have a staff member with credentials in both Molecular Pathology and Cytogenetics which has opened new opportunities for research and development in both Anatomic and Clinical Pathology within the Department.

Unfunded
Cartun, Richard, PhD
The Role of Lymphangitis in Crohns Disease.

DiGiuseppe, Joseph, MD
Flow Cytometric Evaluation of CD49f in Precursor B-cell Acute Lymphoblastic Leukemia.

Active Projects
Bowers, George, MD
Development of a Reference System for the Measurement of the Activity of Erythrocyte Choline Estrase Eche in Human Blood. Hartford Hospital Research Endowment Funds, $6,500.

Roper, Liz, MS
Use of Laboratory Tests and a Neural Network for the Detection of Myocardial Ischemia in Patients with Acute Coronary Syndromes. Hartford Hospital Research Endowment Funds, $10,000.

Robert McComb recieved support through med staff funds for manuscript preperation during this reporting period.

Publications
Anderson WF, Luo S, Chatterjee N, Rosenberg PS, Matsuno RK, Goodman MT, Hernandez BY, Reichman M, Dolled-Filhart MP, ORegan RM, Garcia-Closas M, Perou CM, Jatoi I, Cartun RW, Sherman ME. Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat. 2009 Jan;113(1):189-96. Aslanzadeh J, Zheng X, IL H, Tetreault J, Ratkiewicz I, Meng S, Hamilton1 P, Tang YW. Prospective evaluation of rapid antigen tests for diagnosis of Respiratory Syncytial Virus and Human Metapneumovirus Infections. J Clin Microbiol 46(5):1682-1685, 2008. Asthana N, Mandich D, Ligato S. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barretts Esophagus. Am J Surg Pathol Vol. 32 (10), pp1581-1585, 2008. Berzolla C, Mandavilli S, Sorosky J. Dysplasia and malignancy in endocervical polyps. J Womens Health. 16(9):1317-1321, 2007.

New Projects
Industry
Mnayer, Laila, PhD
A Multi-Center Blinded Reproducibility Study of the XTAG Cystic Fibrosis Core Panel v2 and XTAG Cystic Fibrosis Expanded Panel v2. Luminex Molecular Diagnostics, $22,750.

Csako G, Makowski GS. Clinical chemistry of neurological and psychiatric diseases and body fluids. In Self Assessment in Clinical Laboratory Sciences II, Wu AHB (ed.), AACC Press, Washington, DC pp 219-234, 2008. DiGiuseppe JA. Acute lymphoblastic leukemia: Diagnosis and detection of minimal residual disease following therapy. Clin Lab Med 27:533-549, 2007. DiGiuseppe JA. Flow cytometric immunophenotyping of plasmacytic neoplasms. Am J Clin Pathol 127:172-174, 2007. DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residual disease detection. Cytometry Part B (Clinical Cytometry). 76B:150-155. Glaser SL, Gulley ML, Clarke CA, Keegan TH, Chang ET, Shema SJ, Craig FE, DiGiuseppe JA, Dorfman RF, Mann RB, Anton-Culver H, Cozen W, Ambinder RF. Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. Int J Cancer 123:1499-1507, 2008. Hurford MT, Altman AJ, DiGiuseppe JA, Sherburne BJ, Rezuke WN. Unique pattern of nuclear TdT immunofluorescence distinguishes normal precursor B cells (hematogones) from lymphoblasts of precursor B-lymphoblastic leukemia. Am J Clin Pathol 129:700-705, 2008. Lee CJ, Park JH, Ciesielski TE, Thomson JG, Persing JA. Retinoids, 585-nm laser, and carbon dioxide laser: A numeric comparison of neocollagen formation in photoaged airless mouse skin. Aesth Plast Surg 32:894-901, 2008. Ligato S, Mandich D, Cartun RW. Utility of Glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: An immunocytochemical study. Mod Pathol Vol. 21, 5, 626-631, 2008. Ligato S. Zhao H. Mandich D, Cartun RW. KOC and S100A4 protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreatobiliary malignancies. Diag Cytopath Vol. 36, No 8, 561567, 2008. Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of automated screening and confirmation of extended-spectrum b-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. J Med Microbiol 57:11471151, 2008. Ogawa F, Mino-Kenudson M, Shimizu M, Ligato S, Lauwers G. Gastroduodenitis associated with yttrium 90-microsphere selective internal radiation. Arch Pathol Lab Med Vol. 132, 1734-1738. November 2008.

Schnatz PF, Mandavilli SR, OSullivan DM. The prevalence of cervical HPV and cytologic abnormalities in association with reproductive factors of rural Nigerian women. J Womens Health (Larchmt). 17(2):279-85, March 2008. Stetler-Stevenson M, Ahmad E, Barnett D, Braylan RC, DiGiuseppe JA, Marti G, Menozzi D, Oldaker TA, Orfao de Matos A, Rabellino E, Stone EC, Walker C. Clinical flow cytometric analysis of neoplastic hematolymphoid cells; Approved Guideline-Second Edition. CLSI document H43-A2, Clinical and Laboratory Standards Institute, 2007. Werden J, Schnatz PF, Mandavilli S, Sorosky JI. Prevalence of the HPV in an inner-city indigent population with previously normal Pap tests. J Low Genit Tract Dis 12(4):287-92, October 2008. Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker T, Shenkin M, Stone E, Wallace P. Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry Part B (Clin Cytometry) 2007; 72B:S14-22, 2006. Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Cartun RW, Mandich D, Sasano H, Evans DB, Sutter TR, Sherman ME. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res. 2007 Nov 1;67(21):10608-17. Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG; Members of the Standardization Ad-Hoc Consensus Committee. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):513-20. Zhao HD, Davydova L, Mandich D, Cartun RW, Ligato S. S100A4 protein and Mesothelin expression in dysplasia and carcinoma of extrahepatic bile duct. Am J Clin Pathol 127, 3:374-384, March 2007. Zhao HD, Mandich D, Cartun RW, Ligato S. Expression of KOC in pancreatic FNA cytology for diagnosing invasive pancreatic adenocarcinoma. Diag Cytopath Vol. 35, 700-704, 2007.

66.

Pathology

Abstracts and Presentations

Aslanzadeh J, Bisaillon C, Pajor J, Meng S, White-Abell J, Gauthier C, Newsom B, Missett C, Ratkiewicz I, Li, Frankin J, Chappell, Tang YW. Detection of Human Meta Pneumovirus in Respiratory Samples from an Adult Patient Population. 25th Annual Clinical Virology Symposium and Annual Meeting of the Pan-American Society for Clinical Virology, 2009. Aslanzadeh J, Hamilton P, Miller J, Maldonada Y, Ratkiewicz I. Evaluation of GenProbe APTIMA COMBO 2 Assay Performed on Tigris DTS System for Detecting Chlamydia trachomatis and Neisseria gonorrhoeae. 108th Annual Meeting of the American Society for Microbiology, 2008. Aslanzadeh JH, Li J, Tetreault J, Ratkiewicz I, Meng S, Hamilton P, Tang YW. Performance of Rapid Tests for Detection of Respiratory Syncytial Virus and Human Meta Pneumovirus. 23rd Annual Clinical Virology Symposium and Annual Meeting of the Pan-American Society for Clinical Virology, 2007. Aslanzadeh J, Zheng X, Li H, Tetreault J, Ratkiewicz I, Meng S, Hamilton P, Tang YW. Prospective Evaluation of Rapid Antigen Tests for Diagnosis of Respiratory Syncytial Virus and Human Meta pneumovirus Infections. 18th Annual Meeting of European Society of Clinical Microbiology and Infectious Diseases, 2008. Cartun RW. Technical Issues in Immunohistochemistry. Invited address at the Third Annual International Retreat on Applied Immunohistochemistry and Molecular Morphology. January 26-30, 2009 - Duck Key, FL. Cartun RW. Advances in Histology and Immunohistochemistry Techniques. Invited address at Leica-Microsystems 2009 Educational Symposia Series. May 13, 2009 - Jersey City, NJ. Invited address at Leica-Microsystems 2009 Educational Symposia Series August 12, 2009 - Dallas, TX. Currie C, Brown A, Sorosky J, Mandavilli S, Joyner A, Currie, J. (Abstract #27) Endometrioid Carcinoma of Fallopian Tube with Metastasis and Extension to the Obturator Space: A Case Report. New England Association of Gynecologic Oncologists, 2009 Meeting. Gorusu M, Menon M, Firshein SI, Dekker PT, DeFusco PA, Rezuke W, Sharma R, Mnayer LO. Philadelphia ChromosomeNegative Chronic Myeloid Leukemia: Tailored Monitoring. Clinical Lymphoma & Myeloma, Vol. 9, No. 2, 171-182, 2009. Gull, Batti, Balarezo. Vascularity in Obstructive vs. Infected Tonsils. Otolaryngology Head & Neck Surgery, Vol. 137, Issue 2, pp. P96, 2007.

He W, Hodges K, Windemuth K, Mnayer LO, Mandavilli S, , UroVysion Tm FISH Assay for Detection of Urothelial Carcinoma: A Tertiary Care Hospital Experience with149 Cases. American Society of Cytopathology, Houston, Texas, 2007. He W, Mandavilli S. Utility of p63 and CK34BE12 Antibodies in Diagnosis of Urothelial Carcinoma in Cytology Specimens. Cancer Cytopathology. Oct 25, 2008. 114 (5), page 363. Ibrahim G, White S, Karak SG, Ricci Jr. A. Histopathologic and Staging Characteristics of ER/PR/HER triple positive Mammary carcinoma. Mod Pathol 22(1) supp 47A. Joyner A, Sorosky J, Currie C, Mandavilli S, Brown A, and Currie J. (Abstract #29) Neuroendocrine Tumor of Uterus and Cervix after Uterine Artery Embolization for Leiomyomas: A Case Report. New England Association of Gynecologic Oncologists, 2009 Meeting. Karak SG and Ricci Jr A. Prevalence of Significance of Perineural Invasion in Invasive Breast Carcinoma. Mod Pathol. 22(1) supp 49A. Ligato S, Mandich D, Cartun RW. Is Immunohistochemical Analysis of DNA Mismatch Repair Proteins (MMR) in Unselected Sebaceous Neoplasms Warranted as a Screening Test for Muir-Torre Syndrome? 98th USCAP Annual Meeting. Section E Dermatopathology Section Proffered paper Denver Colorado, 2008. Mandavilli S. Effusion Cytology with an Emphasis on Ancillary Studies. Invited lecturer at IX Internal CME Meeting on Surgical Pathology and Cytology at NIMHANS, Bangalore, India (January 26-28, 2008). Nataraj, Vellanki, Dada, Balarezo, Ranga. De Novo Foal Segmental Glomerulosclerosis (FSG) Following Renal Transplant in a Patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD). American Journal of Kidney Diseases, Vol. 51, Issue 5, pp. B73, 2008. Parab MS, Ahmad N, Fuller SG, DiGiuseppe JA. Changes in Antigen Density During Remission Induction in Precursor B-cell Acute Lymphoblastic Leukemia Detected by Flow Cytometric Immunophenotyping. Mod Pathol 20:353-4A, 2007. Parab M, Mandich D, Cartun RW, Ligato S. Biliary Brush Cytology Combined with Immunocytochemical Staining for IMP3 Provides Superior Diagnostic Sensitivity for Detection of Pancreatobiliary Malignancies. 22nd European Congress of Pathology. Florence, Italy. Cytopathology Section, 4-9 September 2009.

Platt L., Brown A.K., Mandavilli S., Currie J., Sorosky J. Hartford Hospital, Hartford, CT. Complex Atypical Hyperplasia and the Incidence of Endometrial Cancer at the Time of Hysterectomy. New England Association of Gynecologic Oncologists, 2009 Meeting, June 2009. Rotundo E, Waszczak W, ODonell M, Mandavilli SR. Thyroid FNA Diagnosis of Cellular Follicular Lesion: A Clinico-pathologic Study of 161 Cases. American Society of Cytology, Houston, TX, November 2007. Shinoda-Matsuoka H, DiGiuseppe JA. Overexpression of CD49f in Precursor B-cell Acute Lymphoblastic Leukemia: Efficiency of Minimal Residual Disease (MRD) Detection by Flow Cytometric Immunophenotyping Compared with Commonly Used Markers. Mod Pathol 22:388A, 2009. Sun Y, Waszczak W, Mandavilli S. Significance of Ductal Epithelial Cells in Nipple Discharge Cytology Specimens. Cancer Cytopathology. Oct 25, 2008. 114 (5), page 352. Presented American Society of Cytopathology Meeting, November 20, 2008. Tetreault J, Aslanzadeh J. Measures to Control False Negative and False Positive Blood Cultures in a Large Tertiary Care Hospital. 107th Annual Meeting of the American Society for Microbiology, 2007. Umenyi C, Schnatz P, Waszczak W, Mandavilli SR. Incidence of HR-HPV and Cervical Dysplasia in Nigeria. American Society of Cytology, Houston, TX, November 2007. White S, Ibrahim G, Karak SG, Mnayer L, Ricci Jr. A. Proliferative Activity and HER2-FISH Results on Hormone Receptor Positive/HER2 Positive (Luminal Type B) Breast Cancer. Mod Pathol 22(1) supp 74A.

68.

Psychiatry
Harold I. Schwartz, MD
Psychiatrist-in-Chief; Vice President, Behavioral Health The research enterprise at The Institute of Living is organized in four specialized centers. The Olin Neuropsychiatry Research Center, directed by Godfrey Pearlson, M.D., focuses on studies of the major psychiatric disorders using brain imaging and electrophysiological techniques along with genetic analysis. The Anxiety Disorders Center, directed by David Tolin, Ph.D., researches treatments for Obsessive-Compulsive Disorder (OCD), Panic Disorder, Compulsive Hoarding and other disorders on the anxiety spectrum. The Braceland Center for Mental Health and Aging (Karen Blank, M.D., Director) addresses issues related to memory in normal aging and in individuals with Alzheimers Disease or other dementing processes. Finally, the Burlingame Center for Psychiatric Research and Education, directed by John Goethe, M.D., focuses on outcomes and best practices research as well as pharmacogenetics, metabolic syndrome and treatment resistant mood disorders. The success of our research enterprise can be measured through grants awarded, the dissemination of important findings and the synergy between our research efforts and our training and clinical programs. As for grants, the Olin Neuropsychiatry Research Center alone was awarded $7.2 million in new federal funding in fiscal year 2009. A reflection of the huge dissemination of information from these centers can be seen in the lists of publications from each. The synergy between our research and clinical and training programs is a building block of excellence at the IOL and continues to grow stronger every year.

Godfrey Pearlson, MD: Director Faculty:

Godfrey Pearlson, MD, Center Director and Director of COBBRA Lab (COgnition, Brain, Behavior, Research and Allelic Variation) Michael Stevens, PhD, Director, CND Lab (Clinical Neurosciences and Development) and Director of Child and Adolescent Research at IOL David Glahn, PhD, Director ADAPTING Lab (Affective Disorders and Clinical Trials, Imaging, Neurocognition and Genetics) Michal Assaf, MD, Senior Scientist, Pawel Skudlarski, PhD, Senior Scientist

Post-Doctoral Fellows:
Beth Anderson, PhD, Christopher Hyatt, PhD, Suzanne Witt, PhD, Anderson Winkler, PhD The mission of the Olin Center is to be at the forefront of research in major psychiatric and psychological disorders, in particular schizophrenia, mood disorders and addictions. Techniques employed by Center faculty include functional and structural magnetic resonance imaging (MRI) and electrophysiology (EED, ERPs). Our newly designed Website is at http://www.nrc-io.org. Center faculty have active research interests in many aspects of cognitive function including normal aging, working and long term memory, spatial navigation, salience detection, orienting processes, response inhibition, error monitoring, language emotional processing, theory of mid and attention. We examine these cognitive and emotive processes in schizophrenia, Alzheimers disease, manic-depressive illness, Major Depressive Disorder, disruptive behavior disorders such as ADHD or Conduct Disorder, alcohol & drug abuse, post-traumatic stress disorder and psychopathy. The Center is supported in part by multiple grants from the National Institute of Health, (NIAAA, NIMN, NINDS, NIA and NIDA) totaling several million dollars annually. Center faculty have been exceptionally successful in being awarded NIH grants in the past year. Faculty also provide mentorship and training for IOL residents and undergraduate, graduate, and postdoctoral fellows. With the publication of the Human Genome and the arrival of GENOMAS at Hartford Hospital, genetic testing is becoming an integral

OLIN Neuropsychiatry Research Center

part of research at the Olin Research Center. All research subjects now have samples taken for genetic characterization, and neuroimaging projects are increasingly taking on a genetic component. Notably, a recent collaborative study between ONRC and Genomas identified a series of risk genes for schizophrenia that contribute to abnormal brain activation during an attention task. This finding is the basis of a new grant seeking biological risk markers of schizophrenia. Increasing attention is being paid to Alzheimers disease and joint projects involving both the Olin Research Center and the Memory Disorders Center were recently refunded. Additional collaborations have begun with Child and Adolescent Psychiatry in the areas of ADHD, adolescent depression, and autism and with the addictions program for research on alcohol and drug abuse. These include collaborations with Yale, Trinity College and CCSU. Research scanning on the Olin Centers 3 Tesla scanner continues to grow we have scanned over 7000 research subjects since the Center opened in 2002. We have been able to hire more staff. At a time when federal grant dollars are shrinking, and only about 5% of federal grant submissions are being funded, the Olin Center continues to have large-scale new grants funded.

Arango C, McMahon RP, Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan RW. Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res. 2008 Feb 28;162(2):91-100. Assaf M, Jagannathan K, Calhoun V, Kraut M, Hart J Jr, Pearlson G. Temporal sequence of hemispheric network activation during semantic processing: a functional network connectivity analysis. Brain Cogn. 2009 Jul;70(2):238-46. PMID: 19307050. Astur RS, Shipman SL. Factors affecting the hippocampal BOLD response during spatial memory. Behav Brain Res. 2008 Mar 5;187(2):433-41. Astur RS, Newhouse P, Newhouse C. Sex differences in visual-spatial learning using a virtual water maze in pre-pubertal children. Behav Brain Res. 2007 Oct 1;183(1):1-7. Bearden CE, Cannon TD, Chiang MC, Glahn DC, Lee AD, Reiss AL, Thompson PM, Toga AW, van Erp TG. Neural phenotypes of common and rare genetic variants. Biol Psychol. 2008 Sep;79(1):43-57. Bearden CE, Thompson PM, Dutton RA, Frey BN, Peluso MA, Nicoletti M, Dierschke N, Hayashi KM, Klunder AD, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Soares JC. Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacology. 2008 May;33(6):1229-38. Bearden, C.E., Glahn DC, Thompson, P.M., Dalwani, M., Hayashi, K.M., Lee, A.D., Nicoletti, M., Trakhtenbroit, M., et al., Reply: Lithium and Increased Cortical Gray Matter-More Tissue or More Water? Biol Psychiatr, 2007. Bearden, C.E., Thompson, P.M., Dalwani, M., Glahn DC, Hayashi, K.M., Lee, A.D., Nicoletti, M., Trakhtenbroit, M., et al., Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry, 2007. 62(1): p. 7-16. Bearden, C.E., van Erp, T.G., Glahn DC, Dutton, R.A., Tran, H., Zimmermann, L., Sun, D., Geaga, J.A., et al., Mapping cortical thickness in children with 22q11.2 deletions. Cereb Cortex, 2007. 17(8): p. 1889-98. Bearden, C.E., Thompson, P.M., Glahn DC, Dutton, R.A., Frey, B.N., Peluso, M.A., Nicoletti, M., Dierschke, N., et al., Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacology, 2008. 33(6): p. 1229-38.

OLIN Center Publications

Acheson A, Robinson JL, Glahn DC, Lovallo WR, Fox PT. Differential activation of the anterior cingulate cortex and caudate nucleus during a gambling simulation in persons with a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project. Drug Alcohol Depend. 2009 Feb 1;100(1-2):17-23. Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: a selective review. Schizophr Res. 2009 Apr;109(1-3):24-37. Allen AJ, Meda SA, Skudlarski P, Calhoun VD, Astur R, Ruopp KC, Pearlson GD. Effects of alcohol on performance on a distraction task during simulated driving. Alcohol Clin Exp Res. 2009 Apr;33(4):617-25. Almeida S, Glahn DC, Argyropoulos SV, Frangou S. Acute citalopram administration may disrupt contextual information processing in healthy males. Eur Psychiatry. 2009 Aug 18. PMID: 19695841. Almeida S, Glahn DC, Argyropoulos SV, Frangou S. Acute citalopram administration may disrupt contextual information processing in healthy males. Eur Psychiatry. 2009 Aug 18.

70.

Calhoun VD, Maciejewski PK, Pearlson GD, Kiehl KA. Temporal lobe and default hemodynamic brain modes discriminate between schizophrenia and bipolar disorder. Hum Brain Mapp. 2008 Nov;29(11):1265-75.PMID: 17894392. Calhoun VD, Kiehl KA, Pearlson GD. Modulation of temporally coherent brain networks estimated using ICA at rest and during cognitive tasks. Hum Brain Mapp. 2008 Jul;29(7):828-38. Caprihan A, Pearlson GD, Calhoun VD. Application of principal component analysis to distinguish patients with schizophrenia from healthy controls based on fractional anisotropy measurements. Neuroimage. 2008 Aug 15;42(2):675-82. Cascella NG, Testa SM, Meyer SM, Rao VA, Diaz-Asper CM, Pearlson GD, Schretlen DJ. Neuropsychological impairment in deficit vs. non-deficit schizophrenia. J Psychiatr Res. 2008 Sep;42(11):930-7. Contreras J, Hare L, Camarena B, Glahn D, Dassori A, Medina R, Contreras S, Ramirez M, Armas R, Munoz R, Mendoza R, Raventos H, Ontiveros A, Nicolini H, Palmer R, Escamilla M.The serotonin transporter 5-HTTPR polymorphism is associated with current and lifetime depression in persons with chronic psychotic disorders. Acta Psychiatr Scand. 2009 Feb;119(2):117-27. PMID: 19016667. Cykowski MD, Coulon O, Kochunov PV, Amunts K, Lancaster JL, Laird AR, Glahn DC, Fox PT. The central sulcus: an observer-independent characterization of sulcal landmarks and depth asymmetry. Cereb Cortex. 2008 Sep;18(9):1999-2009. PMID: 18071195. Demirci O, Clark VP, Magnotta VA, Andreasen NC, Lauriello J, Kiehl KA, Pearlson GD, Calhoun VD. A Review of Challenges in the Use of fMRI for Disease Classification / Characterization and A Projection Pursuit Application from Multisite fMRI Schizophrenia Study. Brain Imaging Behav. 2008 Sep 1;2(3):147-226. PMID: 19562043. Demirci O, Stevens MC, Andreasen NC, Michael A, Liu J, White T, Pearlson GD, Clark VP, Calhoun VD. Investigation of relationships between fMRI brain networks in the spectral domain using ICA and Granger causality reveals distinct differences between schizophrenia patients and healthy controls. Neuroimage. 2009 Jun;46(2):419-31. Driesen NR, Leung HC, Calhoun VD, Constable RT, Gueorguieva R, Hoffman R, Skudlarski Impairment of working memory maintenance and response in schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry. 2008 Dec 15;64(12):1026-34. PMID: 18823880. Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation metaanalysis. Am J Psychiatry. 2008 Aug;165(8):1015-23. PMID: 18381902. Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, Lancaster JL, Bullmore E, Fox PT. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol Psychiatry. 2008 Nov 1;64(9):774-81. PMID: 18486104. Glahn D, Reichenberg A, Frangou S, Ormel H. Psychiatric neuroimaging: joining

forces with epidemiology. Eur Psychiatry. 2008 Jun;23(4):315-9. Glahn, D.C., Almasy, L., Blangero, J., Burk, G.M., Estrada, J., Peralta, J.M., Meyenberg, N., Adjudicating neurocognitive endophenotypes for schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 2007. 144B(2): p. 242-9. Glahn, D.C., Lovallo, W.R. and Fox, P.T. Reduced amygdala activation in young adults at high risk of alcoholism: studies from the Oklahoma family health patterns project. Biol Psychiatry, 2007. 61(11): p. 1306-9. Glahn, D.C., Paus, T. and Thompson, P.M. Imaging genomics: mapping the influence of genetics on brain structure and function. Hum Brain Mapp, 2007. 28(6): p. 461-3. Glahn, D.C., Thompson, P.M. and Blangero, J. Neuroimaging endophenotypes: strategies for finding genes influencing brain structure and function. Hum Brain Mapp, 2007. 28(6): p. 488-501. Glahn, D., Reichenberg, A., Frangou, S. and Ormel, H., Psychiatric neuroimaging: Joining forces with epidemiology. Eur Psychiatry. 2008 Jun;23(4):315-9. Goldstein G, Panchalingam K, McClure RJ, Stanley JA, Calhoun VD, Pearlson GD, Pettegrew JW. Molecular neurodevelopment: an in vivo 31P-1H MRSI study. J Int Neuropsychol Soc. 2009 Sep;15(5):671-83. Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol. 2008 Nov;18(11):787-93. Gordon RJ, Seamon JG, Pearlson GD. An fMRI study of neurocognitive functioning in schizophrenia with a mere exposure paradigm. Schizophr Res. 2009 Mar;108(1-3):290-2. PMID: 18835759. Guo Y, Pagnoni G. A unified framework for group independent component analysis for multi-subject fMRI data. Neuroimage. 2008 Sep 1;42(3):1078-93. PMID: 18650105. Hare E, Glahn DC, Dassori A, Raventos H, Nicolini H, Ontiveros A, Medina R, Mendoza R, Jerez A, Muoz R, Almasy L, Escamilla MA. Heritability of age of onset of psychosis in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 6. PMID: 19350535. Holmes M, K., Bearden CE, Barguil M, Fonseca M, Serap Monkul E, Nery FG, Soares JC, Mintz J, Glahn DC. Conceptualizing impulsivity and risk taking in bipolar disorder: importance of history of alcohol abuse. Bipolar Disord. 2009 Feb;11(1):33-40.PMID: 19133964. Hong CC, Harris JC, Pearlson GD, Kim JS, Calhoun VD, Fallon JH, Golay X, Gillen JS, Simmonds DJ, van Zijl PC, Zee DS, Pekar JJ. fMRI evidence for multisensory recruitment associated with rapid eye movements during sleep. Hum Brain Mapp. 2009 May;30(5):1705-22.PMID: 18972392.

Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimers Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain. 2009 May;132(Pt 5):1355-65. PMID: 19339253. Jafri MJ, Pearlson GD, Stevens M, Calhoun VD. A method for functional network connectivity among spatially independent resting-state components in schizophrenia. Neuroimage. 2008 Feb 15;39(4):1666-81. PMID: 18082428. Karlsgodt, K.H., Glahn, D.C., van Erp, T.G., Therman, S., Huttunen, M., Manninen, M., Kaprio, J. The relationship between performance and fMRI signal during working memory in patients with schizophrenia, unaffected co-twins, and control subjects. Schizophr Res, 2007. 89(1-3): p. 191-7. Kiehl KA, Pearlson GD, Stevens MC. An FMRI auditory oddball study of combined-subtype attention deficit hyperactivity disorder. Am J Psychiatry. 2007 Nov;164(11):1737-49.PMID: 17974940. Kim D, Burge J, Lane T, Pearlson GD, Kiehl KA, Calhoun VD. Hybrid ICABayesian network approach reveals distinct effective connectivity differences in schizophrenia. Neuroimage. 2008 Oct 1;42(4):1560-8. PMID: 18602482. Kim D, Pearlson GD, Kiehl KA, Bedrick E, Demirci O, Calhoun VD. A method for multi-group inter-participant correlation: abnormal synchrony in patients with schizophrenia during auditory target detection. Neuroimage. 2008 Feb 1;39(3):1129-41. PMID: 17996465. Liotti M, Pliszka SR, Perez R 3rd, Luus B, Glahn D, Semrud-Clikeman M. Electrophysiological correlates of response inhibition in children and adolescents with ADHD: influence of gender, age, and previous treatment history. Psychophysiology. 2007 Nov;44(6):936-48. PMID: 17666028. Liu J, Kiehl KA, Pearlson G, Perrone-Bizzozero NI, Eichele T, Calhoun VD. Genetic determinants of target and novelty-related event-related potentials in the auditory oddball response. Neuroimage. 2009 Jul 1;46(3):809-16. PMID: 19285141. Liu J, Pearlson G, Windemuth A, Ruano G, Perrone-Bizzozero NI, Calhoun V. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum Brain Mapp. 2009 Jan;30(1):241-55.PMID: 18072279. Matsuo, K., Glahn, D.C., Peluso, M.A., Hatch, J.P., Monkul, E.S., Najt, P., Sanches, M., et al., Prefrontal hyperactivation during working memory task in untreated individuals with major depressive disorder. Mol Psychiatry, 2007. 12(2): p. 158-66. Meda SA, Stevens MC, Potenza MN, Pittman B, Gueorguieva R, Andrews MM, Thomas AD, Muska C, Hylton JL, Pearlson GD. Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol. 2009 Sep;20(5-6):390-9.PMID: 19724194. Meda SA, Gelernter J, Gruen JR, Calhoun VD, Meng H, Cope NA, Pearlson GD. Polymorphism of DCDC2 Reveals Differences in Cortical Morphology of Healthy Individuals-A Preliminary Voxel Based Morphometry Study. Brain Imaging Behav.

2008 Mar;2(1):21-26.PMID: 19096528. Meda SA, Bhattarai M, Morris NA, Astur RS, Calhoun VD, Mathalon DH, Kiehl KA, Pearlson GD. An fMRI study of working memory in first-degree unaffected relatives of schizophrenia patients. Schizophr Res. 2008 Sep;104(13):85-95. Epub 2008 Aug 3.PMID: 18678469. Meda SA, Calhoun VD, Astur RS, Turner BM, Ruopp K, Pearlson GD. Alcohol dose effects on brain circuits during simulated driving: an fMRI study. Hum Brain Mapp. 2009 Apr;30(4):1257-70.PMID: 18571794. Meda SA, Giuliani NR, Calhoun VD, Jagannathan K, Schretlen DJ, Pulver A, Cascella N, Keshavan M, Kates W, Buchanan R, Sharma T, Pearlson GD. A large scale (N=400) investigation of gray matter differences in schizophrenia using optimized voxel-based morphometry. Schizophr Res. 2008 Apr;101(1-3):95105. Epub 2008 Apr 18.PMID: 18378428. Michael AM, Calhoun VD, Pearlson GD, Baum SA, Caprihan A. Correlations of diffusion tensor imaging values and symptom scores in patients with schizophrenia. Conf Proc IEEE Eng Med Biol Soc. ;2008:5494-7.PMID: 19163961. Michael AM, Baum SA, White T, Demirci O, Andreasen NC, Segall JM, Jung RE, Pearlson G, Clark VP, Gollub RL, Schulz SC, Roffman JL, Lim KO, Ho BC, Bockholt HJ, Calhoun VD. Functional brain networks in schizophrenia: a review. Front Hum NeuGlahnci. 2009;3:17. Epub 2009 Aug 17.PMID: 19738925. Michael AM, Baum SA, White T, Demirci O, Andreasen NC, Segall JM, Jung RE, Pearlson G, Clark VP, Gollub RL, Schulz SC, Roffman JL, Lim KO, Ho BC, Bockholt HJ, Calhoun VD. Does function follow form?: Methods to fuse structural and functional brain images show decreased linkage in schizophrenia. Neuroimage. 2009 Sep 3 PMID: 19733247. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009 Aug;66(8):811-22.PMID: 19652121. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ; Alzheimers Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampalmediated beta-amyloid deposition in elderly subjects. Brain. 2009 May;132(Pt 5):1310-23. Epub 2008 Nov 28.PMID: 19042931. Najt, P., Perez, J., Sanches, M., Peluso, M.A., Glahn, D. and Soares, J.C., Impulsivity and bipolar disorder. Eur Neuropsychopharmacol, 2007. 17(5):31320. Nery FG, Hatch JP, Glahn DC, Nicoletti MA, Monkul ES, Najt P, Fonseca M, Bowden CL, Cloninger CR, Soares JC. Temperament and character traits in patients with bipolar disorder and associations with comorbid alcoholism or anxiety disorders. J Psychiatr Res. 2008 Jun;42(7):569-77. Epub 2007 Aug 6.PMID: 17675066.

72.

Pearlson G. Multisite collaborations and large databases in psychiatric neuroimaging: advantages, problems, and challenges. Schizophr Bull. 2009 Jan;35(1):1-2. Epub 2008 Nov 20. PMID: 19023121. Pearlson GD, Folley BS. Endophenotypes, dimensions, risks: is psychosis analogous to common inherited medical illnesses? Clin EEG Neurosci. 2008 Apr;39(2):73-7. Review. PMID: 18450172. Pearlson GD, Folley BS. Schizophrenia, psychiatric genetics, and Darwinian psychiatry: an evolutionary framework. Schizophr Bull. 2008 Jul;34(4):722-33. Epub 2007 Nov 21. Review.PMID: 18033774. Peluso MA, Glahn DC, Matsuo K, Monkul ES, Najt P, Zamarripa F, Li J, Lancaster JL, Fox PT, Gao JH, Soares JC. Amygdala hyperactivation in untreated depressed individuals. Psychiatry Res. 2009 Aug 30;173(2):158-61. Epub 2009 Jun 28.PMID: 19545982. Peluso, M.A., Hatch, J.P., Glahn, D.C., Monkul, E.S., Sanches, M., Najt, P., Bowden, C.L. Trait impulsivity in patients with mood disorders. J Affect Disord, 2007. 100(1-3): p. 227-31. Rabins PV, Pearlson G. Treating dementia: progress and promise. Am J Geriatr Psychiatry. 2009 Sep;17(9):723-5. PMID: 19700945. Ragland JD, Laird AR, Ranganath C, Blumenfeld RS, Gonzales SM, Glahn DC. Prefrontal activation deficits during episodic memory in schizophrenia. Am J Psychiatry. 2009, Aug;166(8):863-74. Epub 2009 May 1. Review. PMID: 19411370. Rapin I, Dunn MA, Allen DA, Stevens MC, Fein D. Subtypes of language disorders in school-age children with autism. Dev Neuropsychol. 2009;34(1):66-84. PMID: 19142767. Robinson JL, Bearden CE, Monkul ES, Tordesillas-Gutirrez D, Velligan DI, Frangou S, Glahn DC. Fronto-temporal dysregulation in remitted bipolar patients: an fMRI delayed-non-match-to-sample (DNMS) study. Bipolar Disord. 2009 Jun;11(4):351-60.PMID: 19500088. Robinson JL, Laird AR, Glahn DC, Lovallo WR, Fox PT. Meta-analytic connectivity modeling: Delineating the functional connectivity of the human amygdala. Hum Brain Mapp. 2009 Jul 14. [Epub ahead of print]PMID: 19603407. Robinson JL, Monkul ES, Tordesillas-Gutirrez D, Franklin C, Bearden CE, Fox PT, Glahn DC. Fronto-limbic circuitry in euthymic bipolar disorder: evidence for prefrontal hyperactivation. Psychiatry Res. 2008 Nov 30;164(2):106-13. Epub 2008 Oct 19.PMID: 18930635. Rogers, J., Kochunov, P., Lancaster, J., Shelledy, W., Glahn, D., Blangero, J. and Fox, P., Heritability of brain volume, surface area and shape: an MRI study in an extended pedigree of baboons. Hum Brain Mapp, 2007. 28(6): p. 576-83. Sabb FW, Bearden CE, Glahn DC, Parker DS, Freimer N, Bilder RM. A collaborative knowledge base for cognitive phenomics. Mol Psychiatry. 2008 Apr;13(4):350-60. Epub 2008 Jan 8.PMID: 18180765.

Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, Pearlson GD, Gordon B, Jinnah HA. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007 Oct 2;69(14):1418-23.PMID: 17909154. Schretlen DJ, Testa SM, Winicki JM, Pearlson GD, Gordon B. Frequency and bases of abnormal performance by healthy adults on neuropsychological testing. J Int Neuropsychol Soc. 2008 May;14(3):436-45.PMID: 18419842. Schretlen DJ, Winicki JM, Meyer SM, Testa SM, Pearlson GD, Gordon B. Development, psychometric properties, and validity of the Hopkins Adult Reading Test (HART). Clin Neuropsychol. 2009 Aug;23(6):926-43.PMID: 19191072. Shane MS, Stevens MC, Harenski CL, Kiehl KA. Double dissociation between perspective-taking and empathic-concern as predictors of hemodynamic response to anothers mistakes. Soc Cogn Affect Neurosci. 2009 Jun;4(2):111-8. Epub 2009 Feb 25.PMID: 19244454. Shipman SL, Baker EK, Pearlson G, Astur RS. Absence of established sex differences in patients with schizophrenia on a two-dimensional object array task. Psychiatry Res. 2009 Apr 30;166(2-3):158-65. Epub 2009 Mar 10.PMID: 19278735. Skelly LR, Calhoun V, Meda SA, Kim J, Mathalon DH, Pearlson GD. Diffusion tensor imaging in schizophrenia: relationship to symptoms. Schizophr Res. 2008 Jan;98(1-3):157-62. Epub 2007 Nov 26.PMID: 18031994. Skudlarski P, Jagannathan K, Calhoun VD, Hampson M, Skudlarska BA, Pearlson G. Measuring brain connectivity: diffusion tensor imaging validates resting state temporal correlations. Neuroimage. 2008 Nov 15;43(3):554-61. Epub 2008 Aug 15.PMID: 18771736. Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, Filippini N, Watkins KE, Toro R, Laird AR, Beckmann CF. Correspondence of the brains functional architecture during activation and rest. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13040-5. Epub 2009 Jul 20.PMID: 19620724. Stevens MC, Skudlarski P, Pearlson GD, Calhoun VD. Age-related cognitive gains are mediated by the effects of white matter development on brain network integration. Neuroimage. 2009 Dec;48(4):738-46. Epub 2009 Jul 3.PMID: 19577651. Stevens MC, Pearlson GD, Calhoun VD. Changes in the interaction of restingstate neural networks from adolescence to adulthood. Hum Brain Mapp. 2009 Aug;30(8):2356-66.PMID: 19172655. Stevens MC, Pearlson GD, Kiehl KA. Brain network dynamics during error commission. Hum Brain Mapp. 2009 Jan;30(1):24-37. Stevens MC. The developmental cognitive neuroscience of functional connectivity. Brain Cogn. 2009 Jun;70(1):1-12. Epub 2009 Jan 29. Review.PMID: 19185406.

Sui J, Adali T, Pearlson GD, Calhoun VD. An ICA-based method for the identification of optimal FMRI features and components using combined groupdiscriminative techniques. Neuroimage. 2009 May 15;46(1):73-86. Epub 2009 Feb 10.PMID: 19457398. Sui J, Adali T, Pearlson GD, Clark VP, Calhoun VD. A method for accurate group difference detection by constraining the mixing coefficients in an ICA framework. Hum Brain Mapp. 2009 Sep;30(9):2953-70.PMID: 19172631. van Erp TG, Therman S, Pirkola T, Tuulio-Henriksson A, Glahn DC, Bachman P, Huttunen MO, Lnnqvist J, Hietanen M, Kaprio J, Koskenvuo M, Cannon TD. Verbal recall and recognition in twins discordant for schizophrenia. Psychiatry Res. 2008 Jun 30;159(3):271-80. Epub 2008 Apr 28.PMID: 18442861. Vannorsdall TD, Waldstein SR, Kraut M, Pearlson GD, Schretlen DJ. White matter abnormalities and cognition in a community sample. Arch Clin Neuropsychol. 2009 May;24(3):209-17. Epub 2009 Jul 18.PMID: 19617597. Velligan DI, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, Miller AL. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res. 2008 Jul;102(13):312-9. Epub 2008 Apr 18.PMID: 18374542. Velligan, D.I., Diamond, P., Glahn, D.C., Ritch, J., Maples, N., Castillo, D. and Miller, A.L., The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). Psychiatry Res, 2007. 151(1-2): p. 55-66 Velligan, D.I., Diamond, P.M., Maples, N.J., Mintz, J., Li, X., Glahn, D.C. and Miller, A.L., Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res. 2008 Jul;102(1-3):312-9. Weiser M, Reichenberg A, Kravitz E, Lubin G, Shmushkevich M, Glahn DC, Gross R, Rabinowitz J, Noy S, Davidson M. Subtle cognitive dysfunction in nonaffected siblings of individuals affected by nonpsychotic disorders. Biol Psychiatry. 2008 Mar 15;63(6):602-8. Epub 2007 Sep 7.PMID: 17825797. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008 Mar;165(3):335-41; quiz 409. Epub 2008 Feb 1.PMID: 18245177. Windemuth A, Calhoun VD, Pearlson GD, Kocherla M, Jagannathan K, Ruao G. Physiogenomic analysis of localized FMRI brain activity in schizophrenia. Ann Biomed Eng. 2008 Jun;36(6):877-88. Epub 2008 Mar 11.PMID: 18330705. Wynn JK, Green MF, Engel S, Korb A, Lee J, Glahn D, Nuechterlein KH, Cohen MS. Increased extent of object-selective cortex in schizophrenia. Psychiatry Res. 2008 Nov 30;164(2):97-105. Epub 2008 Oct 19.PMID: 18938066. Xu L, Pearlson G, Calhoun VD. Joint source based morphometry identifies linked gray and white matter group differences. Neuroimage. 2009 Feb 1;44(3):777-89. Epub 2008 Oct 18.PMID: 18992825.

Xu L, Groth KM, Pearlson G, Schretlen DJ, Calhoun VD. Source-based morphometry: the use of independent component analysis to identify gray matter differences with application to schizophrenia. Hum Brain Mapp. 2009 Mar;30(3):711-24.PMID: 18266214. Zhao, X., Li, G., Glahn, D.C., Fox, P.T. and Gao, J.H., Derivative temporal clustering analysis: detecting prolonged neuronal activity. Magn Reson Imaging, 2007. 25(2): p. 183-7. Zuo L, Luo X, Listman JB, Kranzler HR, Wang S, Anton RF, Blumberg HP, Stein MB, Pearlson GD, Covault J, Charney DS, van Kammen DP, Price LH, Lappalainen J, Cramer J, Krystal JH, Gelernter J. Population admixture modulates risk for alcohol dependence. Hum Genet. 2009 Jun;125(5-6):605-13. Epub 2009 Mar 22.PMID: 19306106.

Olin Center Abstracts

Assaf M, Jagannathan K, Miller L, Sahl R, Schultz R and Pearlson G. Mentalization Network Gray Matter Volume Abnormalities in Autism Spectrum Disorders. International Meeting for Autism Research 2008 Annual Meeting Proceedings. Assaf M, Jagannathan K, Moult M, Lorenzoni R, Kraut K, Hart J and Pearlson G. Semantic Memory Retrieval Brain Abnormalities in Schizophrenia: State vs. Trait? 2009 International Congress on Schizophrenia Research, San Diego, CA. Assaf, M, Jagannathan, K., Miller, L, OBoyle, J., Pearlson, G., Sahl, R., Schultz, R. T. Stevens, M. Default Mode Network in Patients with High Functioning Autism Spectrum Disorders during Resting State fMRI. Presented at the International Meeting for Autism Research, 2009: Chicago, IL. Bellis C, Freed KA, Curran JE, Winkler AM, Carless M, Johnson MP, Gring HH, Dyer TD, Almasy L, Fox PT, Kochunov P, Duggirala R, Glahn DC, Moses EK, Blangero J. Deep sequencing of VPS13A reveals effects on brain function and structure. 59th Annual Meeting of the American Society of Human Genetics, 20-24 October 2009, Honolulu, HI, USA. Book GA, Thomas AD, Johnson MR, Hylton JL, Andrews MM, Assaf M and Pearlson GD. Reward Processing in Social Competitive Task in Subjects with Familial History of Alcoholism. 2008 ICANA conference. Calhoun, V.D, Folley, B.S., Meda, S.A., Pearlson, G.D, Stevens, M.C. Evidence for anomalous network connectivity during working memory in schizophrenia: An ICA based analysis. Poster presented at the annual meeting of the Society for Biological Psychiatry, 2008: Washington, DC.

74.

Cykowski M, Lancaster JL, Ingham RJ, Ingham J, Winkler AM, Kochunov P, Fox PT.An omnibus test for case-control studies utilizing Tract-Based Spatial Statistics (TBSS). 14th Human Brain Mapping, 1519th June 2008, Melbourne, Victoria, Australia. Della-Justina HM, Winkler AM, Manczak T, de Oliveira PH, de Arajo DB, Carvalho Neto A, Zwick A, Gamba HR. Development of a galvanic vestibular stimulator for fMRI exams. 15th Human Brain Mapping, 18-23 June 2009, San Francisco, CA, USA. Jagannathan K, Pearlson G, Calhoun VD, Kraut MA, Hart J Jr and Assaf M. Functional network connectivity in schizophrenia during semantic memory task. Society of Biological Psychiatry 2008 Annual Meeting. Jagannathan K, Assaf M, Calhoun VD, Kraut MA, Hart J Jr and Pearlson G. Functional network connectivity in semantic memory. CNS 2008 Anuual Meeting. Jagannathan K, Assaf M, Calhoun VD, and Pearlson G. Functional network connectivity in semantic object recall task using independent component analysis. ISMRM 2008 Annual meeting. Jagannathan K, Moult M, Pearlson GD and Assaf M. Abnormal Functional Connectivity in the Default Mode Network in Schizophrenia: State vs. Trait? Society of Biological Psychiatry 2009 Annual Meeting, Vancouver, CA. Jagannathan K, Calhoun VD, Gelernter J, Liu J, Bolognani F, Assaf M, Pearlson GD. Genetic associations of brain structural networks in schizophrenia-a preliminary study. American College of Neuropsychopharmacology. ACNP 2009 Annual Meeting, Hollywood, FL. Jagannathan, K, Moult, M, Pearlson, G.D., Sharma, R., Stevens, M.C., von Pechmann, D. Event-Related Spectral Perturbations In Schizophrenia And Healthy Controls During Auditory Oddball Performance. Presented at EPIC XV: The 15th International Congress on Event-Related Potential of the Brain, 2009: Indianapolis, IN. Kochunov P, Glahn DC, Winkler AM, Duggirala R, Olvera RL, Cole S, Dyer TD, Almasy L, Fox PT, Blangero J. Analysis of genetic variability and whole genome linkage of whole-brain, subcortical, and ependymal hyperintense white matter volume. Stroke 2009;40(12):3685-90 Kochunov P, Winkler AM, Blangero J, Lancaster JL, Almasy L, Fox PT, Glahn DC. Genetics of DTI-derived parameters of cerebral white matter. A track-based heritability and linkage study in extended pedigree. 15th Human Brain Mapping, 18-23 June 2009, San Francisco, CA, USA.

Kochunov P, Blangero J, Winkler AM, Cole S, Almasy L, Lancaster JL, Fox PT, Glahn DC. Heritability and linkage analysis of hyperintense (FLAIR) white matter lesion volumes in normal aging. 15th Human Brain Mapping, 18-23 June 2009, San Francisco, CA, USA. Kochunov P, Blangero J, Winkler AM, Lancaster JL, Kochunova V, Mangin JF, Cachia A, Fox PT, Glahn DC. Heritability of gyral surface area and gyral gray matter thickness. 15th Human Brain Mapping, 18-23 June 2009, San Francisco, CA, USA. Kochunov P, Glahn DC, Cole S, Dyer TD, Almasy L, Winkler AM, Lancaster JL, Kochunova V, Fox PT. Genetics of cerebral aging. Heritability and linkage analysis of cerebral health markers in a large multifamily pedigree. 15th Human Brain Mapping, 18-23 June 2009, San Francisco, CA, USA. Miller L, Assaf M, Book G and Pearlson G. Face Building: An fMRI investigation of brain activation of faces versus houses, objects, and patterns in individuals with high functioning autism. 2008 Cognitive Neuroscience Society Annual Meeting, San Francisco, CA. Miller L, Jagannathan K, OBoyle J, Schultz R, Stevens M, Sahl R, Pearlson G and Assaf M. Default Mode Network in Patients with High Functioning Autism Spectrum Disorders During Resting State fMRI. International Meeting for Autism Research 2009 Annual Meeting Proceedings. Chicago, IL. Pearlson G.D., Stevens M.C. Szeles D.M. Age-related Differences in Mental Timekeeping: an fMRI study. Poster presented at the annual meeting of the Society for Biological Psychiatry, 2008: Washington, DC. Skudlarski P, Skudlarska B, Pearlson G. Age Related Changes in the Brain Connectivity Revealed and Characterized by Fusion of Two Neuroimaging Modalities : Diffusion Tensor Imaging and Resting State Functional Connectivity. American Geriatric Society 2009, Chicago, IL. Skudlarski P, Anderson K, Stevens M, Pearlson G. Schizophrenia Disconnection Analyzed by Conjunction of fMRI Resting Connectivity and Diffusion Tensor Imaging. Human Brain Mapping 2009, San Francisco, CA. Skudlarski P, Anderson K, Pearlson G. Functional Connectivity Is More Closely linked to Anatomical Connectivity in Schizophrenia. International Conference Schizophrenia Research 2009, San Diego, CA. Winkler AM, Kochunov P, Dierschke NA, Lancaster JL, Fox PT, Glahn DC. An automatic segmentation tool for white matter hyperintensities using FLAIR and T1-weighted images. 15th Human Brain Mapping, 18-23 June 2009, San Francisco, CA, USA.

Anxiety Disorders Center

Winkler AM, Kochunov P, Fox PT, Duggirala R, Almasy L, Blangero J, Glahn DC. Heritability of volume, surface area and thickness for anatomically defined cortical brain regions estimated in a large extended pedigree. 15th Human Brain Mapping, 18-23 June 2009, San Francisco, CA, USA. Winkler AM, Kochunov P, Dierschke NA, Fox PT, Blangero J, Glahn DC. Heritability of gray matter density estimated in large extended pedigrees. 64th Annual Meeting of the Society of Biological Psychiatry, 14-16 May 2009, Vancouver, BC, Canada. Winkler AM, Nichols TE, Glahn DC. On non-normality, nonparametric tests and pooling permutations over space for Voxel Based Morphometry. 14th Human Brain Mapping, 15-19th June 2008, Melbourne, Victoria, Australia.

David F. Tolin, PhD, Director

Faculty and Staff: David F. Tolin, PhD, ABPP, Director Gretchen J. Diefenbach, PhD, Senior Scientist Scott Hannan, PhD, Staff Psychologist Elizabeth Moore, PhD, Staff Psychologist Christina Gilliam, PhD, Staff Psychologist Samantha Morrison, PhD, Postdoctoral Fellow Anna Villavicencio, PhD, Postdoctoral Fellow Christina Ryan, Research Assistant Dianna Hidalgo, Research Assistant Diana Harrington, Research Assistant he mission of the Anxiety Disorders Center (ADC) at The Institute of Living is to provide evidence-based psychosocial treatment for anxiety-related problems, to conduct meaningful research on the nature and treatment of anxiety, and to provide education for students, staff, and the community. Areas of clinical emphasis include obsessivecompulsive disorder and obsessive-compulsive spectrum disorders, generalized anxiety disorder, panic disorder, social phobia, and posttraumatic stress disorder. Compulsive Hoarding Research: The ADC has developed the nations largest and most comprehensive program of research on compulsive hoarding. In one recently-completed study, Psychopathology of Compulsive Hoarding (sponsor: NIMH), we interviewed large numbers of patients with compulsive hoarding, patients with obsessivecompulsive disorder, and participants without mental disorders in order to define the phenomenon of compulsive hoarding and differentiate it from obsessive-compulsive disorder. An ongoing study, Neural Mechanisms of Compulsive Hoarding (sponsor: NIMH), uses functional magnetic resonance imaging (fMRI) to examine brain activity during a decision-making task in compulsive hoarding patients with and without major depressive disorder, obsessive-compulsive disorder patients, and individuals without mental disorders. In Neuropsychological Functioning in Compulsive Hoarding (sponsor: Hartford Hospital), we are examining brain-behavior relationships by assessing a variety of cognitive functions in individuals with and without compulsive

76.

hoarding. Finally, we recently completed Treatment of Compulsive Hoarding (sponsor: NIMH), the aim of which was to develop and test a cognitive-behavioral intervention for patients with compulsive hoarding. This year, Dr. Tolin submitted three additional NIMH grants related to compulsive hoarding. Two of these propose to augment cognitivebehavioral therapy with the stimulant medication methylphenidate (study 1) or cognitive remediation exercises (study 2). The third grant, a continuation of the fMRI study, proposes to examine changes in neural activity among hoarders receiving cognitive-behavioral therapy. Obsessive-Compulsive Disorder (OCD) and Obsessive-Compulsive Spectrum Research: We recently completed enrollment for the study Stepped Care for Obsessive-Compulsive Disorder (sponsor: NIMH), the aim of which is to develop and test a variant of cognitive-behavioral therapy for OCD in which patients start with a largely self-directed treatment and move to progressively more intensive treatment as needed. We also finished D-Cycloserine Augmentation of Behavior Therapy for Obsessive-Compulsive Disorder (unfunded), a pilot study in which the n-methyl d-aspartate (NMDA) receptor agonist d-cycloserine was added to traditional cognitive-behavioral therapy. Results of that study (published in American Journal of Psychiatry) were promising and led to the development of a multi-site grant proposal to the National Institute of Mental Health. We are currently conducting a follow-up study, D-Cycloserine for OCD Treatment Nonresponders (sponsor: Hartford Hospital), in which cognitive-behavioral therapy plus openlabel d-cycloserine are provided for patients who have failed to respond to cognitive-behavioral monotherapy. We have also partnered with Columbia University and the University of Pennsylvania to collaborate on the study Maximizing Treatment Outcome for OCD (sponsor: NIMH), which compares cognitive-behavioral therapy and the medication risperidone for OCD patients who have not responded fully to antidepressant medications. Older Adult Research: Dr. Gretchen Diefenbach has developed several studies investigating anxiety-related concerns in older adults. In one study, Screening for GAD among Frail Elderly (sponsor: NIMH), we examined optimal ways to assess frail older individuals receiving home care services for generalized anxiety disorder and related concerns. Another study, The Nature and Impact of Anxiety Symptoms upon Psychosocial Functioning of Older Adults with Major Depressive Disorder (sponsor: Hartford Hospital), examined differences between older depressed patients with and without anxiety symptoms who were attending the Geriatric Day Program at the Institute of Living. Finally, the recently-completed study Cognitive Enhancing Effects of D-Cycloserine among Non-Demented Elderly (sponsor: Hartford Hospital) examined whether d-cycloserine can affect cognitive processes such as learning, memory, and attention in older adults with ageappropriate cognitive function.

Panic Disorder Research: We recently completed the study Augmenting Exposure Therapy with an NMDA Agonist: A Pilot Study (sponsor: Hartford Hospital), in which we examined the effect of adding d-cycloserine to brief cognitive-behavioral therapy for adults with panic disorder. Results of that study (currently in preparation for submission) led to the development of our current study, Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder (sponsor: NIMH), in which we are conducting a larger version of the study and examining genetic factors associated with response to cognitivebehavioral therapy and d-cycloserine. A parallel study, A Multi-Center, Double-Blind, Fixed Dose Trial Examining the Safety and Efficacy of Org 25935 vs. Placebo as Augmentation to Cognitive Behavioral Therapy in Subjects with Panic Disorder (sponsor: Organon/Schering-Plough), tests whether an alternative NMDA receptor agonist can augment cognitivebehavioral therapy.

Anxiety Disorders Center Peer Reviewed Publications

Aikins, D.E., Johnson, D.C., Borelli, J.K., Klemanski, D., Morrissey, P.M., Southwick, S., & Tolin, D.F. (2009). Thought suppression failures in combat PTSD: A cognitive load hypothesis. Behaviour Research and Therapy, 47, 744-751. Corcoran, K. M., Woody, S. R., & Tolin, D. F. (2008). Recognition of facial expressions in obsessive-compulsive disorder. Journal of Anxiety Disorders, 22, 56-66. Diefenbach, G.J., Abramowitz, J.S., Norberg, M., & Tolin, D.F. (2007). Changes in quality of life following cognitive-behavior therapy for obsessive-compulsive disorder. Behaviour Research and Therapy, 45, 3060-3068. Diefenbach, G. J., Tolin, D. F., Meunier, S. A., & Gilliam, C. M. (2009). Assessment of anxiety in older home care recipients. The Gerontologist, 49, 141-153. Diefenbach, G. J., Tolin, D. F., Meunier, S., & Worhunsky, P. (2008). Emotion regulation and trichotillomania: a comparison of clinical and nonclinical hair pulling. Journal of Behavior Therapy and Experimental Psychiatry, 39, 32-41. Frost, R. O., Steketee, G., Tolin, D. F., & Renaud, S. (2008). Development and validation of the Clutter Image Rating. Journal of Psychopathology and Behavioral Assessment, 32, 401-417. Frost, R. O., Tolin, D. F., Steketee, G., Fitch, K. E., & Selbo-Bruns, A. (2009). Excessive acquisition in hoarding. Journal of Anxiety Disorders, 23, 632-639. Norberg, M. M., Diefenbach, G. J., & Tolin, D. F. (2008). Quality of life and anxiety and depressive disorder comorbidity. Journal of Anxiety Disorders, 22, 1516-1522. Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008). A meta-analysis of dcycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry, 63, 1118-1126.

Olatunji, B.O., Cisler, J., & Tolin, D.F. (2007). Quality of life in the anxiety disorders: A meta-analytic review. Clinical Psychology Review, 27, 572-581. Olatunji, B. O., Williams, B. J., Haslam, N., Abramowitz, J. S., & Tolin, D. F. (2008). The latent structure of obsessive-compulsive symptoms: A taxometric study. Depression and Anxiety, 25, 956-968. Olatunji, B.O., Williams, N.L., Tolin, D.F., Sawchuk, C.N., Abramowitz, J.S., Lohr, J.M., & Elwood, L. (2007). The Disgust Scale: Item analysis, factor structure, and suggestions for refinement. Psychological Assessment, 19, 281-297. Tolin, D. F., Brady, R. E., & Hannan, S. E. (2008). Obsessional beliefs and symptoms of obsessive-compulsive disorder in a clinical sample. Journal of Psychopathology and Behavioral Assessment, 30, 31-42. Tolin, D.F., Diefenbach, G.J., Flessner, C.A., Franklin, M.E., Keuthen, N.J., Moore, P., Piacentini, J., Stein, D.J., & Woods, D.W. (2008). The Trichotillomania Scale for Children: Development and validation. Child Psychiatry and Human Development, 39, 331-349. Tolin, D.F., Franklin, M.E., Diefenbach, G.J., Anderson, E., & Meunier, S.A. (2007). Pediatric trichotillomania: Descriptive psychopathology and an open trial of cognitive-behavioral therapy. Cognitive Behaviour Therapy, 36, 129-144. Tolin, D.F., Frost, R.O., & Steketee, G. (2007). An open trial of cognitivebehavioral therapy for compulsive hoarding. Behaviour Research and Therapy, 45, 1461-1470. Tolin, D. F., Frost, R. O., Steketee, G., & Fitch, K. E. (2008). Family burden of compulsive hoarding: Results of an internet survey. Behaviour Research and Therapy, 46, 334-344. Tolin, D. F., Frost, R. O., Steketee, G., Gray, K. D., & Fitch, K. E. (2008). The economic and social burden of compulsive hoarding. Psychiatry Research, 160, 200-211. Tolin, D.F., Hannan, S., Maltby, N., Diefenbach, G.J., Worhunsky, P., & Brady, R.E. (2007). A randomized controlled trial of self-directed versus therapistdirected CBT for OCD patients with prior medication trials. Behavior Therapy, 38, 179-191. Tolin, D. F., Kiehl, K. A., Worhunsky, P., Book, G. A., & Maltby, N. (2009). An exploratory study of the neural mechanisms of decision-making in compulsive hoarding. Psychological Medicine, 38, 1-12. Tolin, D.F., Robison, J.T., Gaztambide, S., Horowitz, S., & Blank, K. (2007). Ataques de nervios and psychiatric disorders in older Puerto Rican primary care patients. Journal of Cross-Cultural Psychology, 38, 659-669. Tolin, D. F., Whiting, S., Maltby, N., Diefenbach, G. J., Lothstein, M. A., Hardcastle, S., Catalano, A., & Gray, K. D. (2009). Intensive (daily) behavior therapy for school refusal: A multiple baseline case series. Cognitive and Behavioral Practice, 16, 332-344.

Tolin, D.F., Worhunsky, P., Brady, R.E., & Maltby, N. (2007). The relationship between obsessive beliefs and thought control strategies in a clinical sample. Cognitive Therapy and Research, 31, 307-318. Wilhelm, S., Buhlmann, U., Tolin, D.F., Meunier, S.A., Pearlson, G.D., Reese, H.E., Cannistraro, P., Jenike, M.A., & Rauch, S.L. (2008). Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry, 165, 335-341.

Anxiety Disorders Center Non-Peer Reviewed Articles

Tolin, D. F. (2009). Alphabet soup: ERP, CT, and ACT for OCD. Cognitive and Behavioral Practice, 16, 40-48. Tolin, D.F., & Breslau, N. (2007). Sex differences in risk of PTSD. PTSD Research Quarterly, 18, 1-7. Tolin, D.F., & Lohr, J.M. (2009, Fall). Psychologists, American Psychological Association, and torture. Clinical Science, 4-10.

Books and Book Chapters

Edelberg, M., & Tolin, D. F. (2008). The Posttraumatic Cognitions Inventory. In G. Reyes, J. D. Elhai, & J. Ford (Eds.), Encyclopedia of psychological trauma (pp. 480481). New York: John Wiley & Sons. Franklin, M.E., & Tolin, D.F. (2007). Treating trichotillomania: Cognitive behavior therapy for hair pulling and related problems. New York: Springer. Franklin, M.E., Tolin, D.F., & Diefenbach, G.J. (2007). Trichotillomania. In Abramowitz, D. McKay S., & Taylor, J.S. (Eds.), Obsessive-compulsive disorder: Subtypes and spectrum conditions (pp. 139-159). New York: Elsevier. Frost, R.O., & Tolin, D.F. (2008). Compulsive hoarding. In S. Taylor, J. S. Abramowitz, & D. McKay (Eds.), Clinical handbook of obsessive-compulsive disorder and related problems (pp. 76-94). Baltimore: Johns Hopkins University Press. Meunier, S.A., Maltby, N.A., & Tolin, D.F. (2008). Compulsive hoarding. In M. Hersen (Series & Vol. Ed.) & J. Rosqvist (Vol. Ed.), The handbook of assessment, conceptualization, and treatment: Vol. 1 (pp. 728-752). New York: John Wiley & Sons. Tolin, D.F., Frost, R.O., & Steketee, G. (2007). Buried in treasures: Help for compulsive acquiring, saving and hoarding. New York: Oxford University Press. Tolin, D.F., & Maltby, N. (2008). Motivating treatment-refusing patients with obsessive-compulsive disorder. In H. Arkowitz, H.A. Westra, W.R. Miller, & S. Rollnick (Eds.), Motivational interviewing in the treatment of psychological problems (pp. 85-108). New York: Guilford Press.

78.

Tolin, D.F., & Meunier, S.A. (2007). Contamination and decontamination. In Abramowitz, D. McKay S., & Taylor, J.S. (Eds.), Obsessive-compulsive disorder: Subtypes and spectrum conditions (pp. 3-18). New York: Elsevier. Tolin, D.F., & Steketee, G. (2007). General issues in psychological treatment for OCD. In M.M. Antony, C.L. Purdon, & L.J. Summerfeldt (Eds.), Psychological treatment of OCD: Fundamentals and beyond (pp. 31-59). Washington, DC: American Psychological Association. Treadwell, K. R. H., & Tolin, D. F. (2007). Clinical challenges in the treatment of pediatric OCD. In E. A. Storch, T. K. Murphy, & G. R. Geffken (Eds.), A comprehensive handbook of child and adolescent obsessive-compulsive disorder (pp. 273-294). Mahwah, NJ: Lawrence Erlbaum Associates.

Association of Behavioral and Cognitive Therapies, Philadelphia. Gibson, A., Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (2008, November). Ethical considerations in the treatment of compulsive hoarding. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Gilliam, C.M., Brady, R.E., & Tolin, D.F. (2007, November). Changes in obsessive beliefs following CBT among individuals with OCD. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Gilliam, C.M., Diefenbach, G.J., Catayong, K.D., Pearlson, G.D., Blank, K., & Tolin, D.F. (2008, November). Emotion regulation and anxiety disorders: A lifespan perspective. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Gilliam, C.M., Diefenbach, G.J., Tolin, D.F., & Edelberg, M.L. (2007, November). The role of metacognitive beliefs and experiential avoidance in late-life anxiety. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Gilliam, C.M., Tolin, D.F., Diefenbach, G.J., Carlson, S.E., Whiting, S.E., Norberg, M.M., & Meunier, S.A. (2008, November). Stepped care for obsessivecompulsive disorder: A replication and extension. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Gilliam, C.M., Tolin, D.F., & Pineault, J. (2007, November). Attentional bias in panic disorder: The impact of cognitive behavioral treatment. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Hannan, S.E., Diefenbach, G.J., Meunier, S.A., Norberg, M.M., & Tolin, D.F. (2008, November). Intensive treatment for pediatric OCD: Results from an outpatient treatment setting. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Hannan, S.E., Edelberg, M., & Tolin, D.F. (2007, November). Factors associated with work impairment in individuals with diagnoses of anxiety and depressive disorders. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Hannan, S.E., & Tolin, D.F. (2007, November). Examination of the validity of therapist rated and patient rated Clinical Global Impression scores. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Hannan, S.E., Tolin, D.F., Meunier, S.A., Norberg, M.M., Gilliam, C.M., & Diefenbach, G.J. (2008, November). Intensive treatment for OCD: Results from a psychiatric hospital outpatient treatment setting. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Koby, D. G., Tartar, S., Carlson, S., Meunier, S. A., Lovejoy, D. W., Kurtz, M., & Tolin, D. F. (2008, November). Emerging evidence for frontal lobe dysfunction in compulsive hoarding. Paper presented at the Annual Meeting of the National Academy of Neuropsychology, New York.

Anxiety Disorders Center Abstracts

Chasson, G.S., Buhlmann, U., Tolin, D.F., Rowley, T., Welsh, K.S., & Wilhelm, S. (2009, March). How much quicker? Accelerating OCD recovery using d-cycloserine to enhance exposure and response prevention. Paper presented at the Annual Meeting of the Anxiety Disorders Association of America, Santa Ana Pueblo, NM. Cisler, J., Lohr, J. M., Tolin, D. F., Olatunji, B. O., Willems, J. L., & Brady, R. E. (2008, November). Development and initial validation of the Contamination Aversion Scale. Paper presented at the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Diefenbach, G.J., Tolin, D.F., & Edelberg, M. (2007, November). Predicting quality of life among older adults with major depressive disorder: The potential role of worry severity. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Diefenbach, G.J., Tolin, D.F., Meunier, S.A., Gilliam, C., & Edelberg, M. (2007, November). Psychometric properties of anxiety measures among elderly receiving home health care services. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Fabricant, L., Frost, R.O., Tolin, D.F., & Steketee, G. (2007, November). The role of homework in the treatment of compulsive hoarding. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Fitch, K.E., Ring, K.M., & Tolin, D.F. (2008, November). Long-term effectiveness of cognitive-behavioral therapy for anxiety in an adult outpatient clinic sample. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Fitch, K.E., Tolin, D.F., Frost, R.O., & Steketee, G. (2007, November). Compulsive hoarding: Assessing insight. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Frost, R.O., Steketee, G., Tolin, D.F., Sorrentino, C., Carlson, S., & Brady, R.E. (2007, November). Cognitive-behavioral therapy for compulsive hoarding: Results from a controlled trial. In D.F. Tolin (Chair), The nature and treatment of compulsive hoarding. Symposium presented to the Annual Meeting of the

Loew, B., Talbott, S. N., Khanna, M., Diefenbach, G. J., Tolin, D. F., & Franklin, M. E. (2008, November). Family functioning in pediatric trichotillomania: Results from a randomized, controlled trial. Paper presented at the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Meunier, S.A., Tolin, D.F., Frost, R.O., & Steketee, G. (2007, November). The impact of significant life events on hoarding symptom severity and course. In D.F. Tolin (Chair), The nature and treatment of compulsive hoarding. Symposium presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Muroff, J., Steketee, G., Rasmussen, J., Gibson, A., Frost, R.O., & Tolin, D.F. (2007, November). Group cognitive and behavioral treatment (CBT) for compulsive hoarding. In D.F. Tolin (Chair), The nature and treatment of compulsive hoarding. Symposium presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Oh, M., Frost, R. O., Tolin, D. F., Steketee, G., & Fitch, K. E. (2008, November). Indecisiveness and compulsive hoarding. Paper presented at the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Olatunji, B. O., Ciesielski, B. G., & Tolin, D. F. (2009, March). A meta-analytic review of the specificity of anger in PTSD. Paper presented at the Annual Meeting of the Anxiety Disorders Association of America, Santa Ana Pueblo, NM. Pekareva-Kochergina, A., Frost, R. O., Tolin, D. F., Steketee, G., & Fitch, K. E. (2008, November). OCD symptoms and associated features in early- versus late-onset hoarding. Paper presented at the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Rasmussen, J. L., Muroff, J., Steketee, G., Tolin, D. F., & Frost, R. O. (2008, November). Family psychopathology in an internet study of compulsive hoarding. Paper presented at the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November). Prevalence and associated characteristics of squalor in an internet sample of compulsive hoarders. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November). The Home Environment Index: A measure of squalor in compulsive hoarding. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November). Enhancing motivation in treatment for compulsive hoarding. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Tolin, D.F. (2007, November). The nature and treatment of compulsive hoarding. Symposium presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia.

Tolin, D. F. (2008, July). Enhancing the efficacy of behavior therapy for OCD with d-cycloserine. Presented to the International Congress of Psychology, Berlin. Tolin, D.F., Diefenbach, G.J., Flessner, C.A., Franklin, M.E., Woods, D.W., Keuthen, N.J., Moore, P., Piacentini, J., & Stein, D.J. (2007, November). The Trichotillomania Scale for Children: Development and validation. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Tolin, D. F., Frost, R. O., & Steketee, G. (2008, July). Buried in treasures: Cognitive-behavioral therapy for compulsive hoarding. Presented to the British Association of Behavioural and Cognitive Psychotherapies, Edinburgh. Tolin, D.F., Frost, R.O., Steketee, G., Gray, K.D., & Fitch, K.E. (2007, November). The economic and social burden of compulsive hoarding. In D.F. Tolin (Chair), The nature and treatment of compulsive hoarding. Symposium presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Tolin, D. F., Norberg, M. M., & Krystal, J. H. (2008, August). A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Presented to the Annual Meeting of the Obsessive-Compulsive Foundation, Boston. Tolin, D.F., Steketee, G., Frost, R.O., Monteiro, M., & Fitch, K.E. (2007, November). Compulsive hoarding: Assessing family burden. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Treadway, M., Frost, R.O., Steketee, G., Tolin, D.F., & Fabricant, L. (2007, November). Compulsive hoarding and generalized anxiety disorder: Features and correlates. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia. Whiting, S.E., & Tolin, D.F. (2008, November). Psychosocial impairment in childhood anxiety: Utility and validation of the Sheehan Disability Scale-Child/ Parent Version. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Whiting, S.E., Tolin, D.F., Maltby, N., & Gray, K.D. (2008, November). Intensive (daily) cognitive behavior therapy for school refusal: A multiple baseline case series. Presented to the Annual Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL. Wilhelm, S., Buhlmann, U., Tolin, D.F., Meunier, S.A., Pearlson, G.D., Reese, H., Cannistraro, P., Jenike, M.A., Pitman, R., & Rauch, S. (2008, July). D-cycloserine augmentation of behavior therapy for obsessive-compulsive disorder. Presented to the British Association of Behavioural and Cognitive Psychotherapies, Edinburgh.

80.

Braceland Center for Mental Health and Aging

Director: Karen Blank, MD Assistant Director: Charles Wilber MEd Faculty and Staff: Denise Fogel, PsyD Jackie Cmero, OT Meghan Lawrence, LCSW Gretchen Difenbach, PhD Karen Raigaisis, RN Ilene West, PsyD Kheera Bandari, BS The Braceland Centers research programs address issues related to normal aging, to medical and psychiatric disorders such as Alzheimers disease, and to the physical, emotional and overall well being of the elderly. As one of the four research centers at the Institute of Living, we actively collaborate with the other centers. Our research accomplishments include the following: Memory Disorders Center Electronic research database: The Memory Disorders Center (MDC) has successfully designed a comprehensive intake form for all new patients to the Memory Disorders Center. The form is electronically scanned into a database that supports a vast array of research questions and proposals. To date 103 new intakes have been entered and we have obtained written consent for inclusion in the electronic database for 100% of new MDC patients. Alzheimers Disease Neuroimaging Initiative (ADNI): The Braceland Center, in collaboration with the Olin Center, has been an active site for this NIH-funded multi-site, 80+ million dollar study. We have nearly completed three years of data collection with a total of 14 participants. Through the Alzheimers Disease Neuroimaging Initiative Grand Opportunity (ADNI-GO) Study, our site will participate in the recruitment of additional Early MCI (EMCI) participants and includes follow-up of participants originally enrolled as Cognitively Normal (CN) or Late MCI (LMCI) in the original ADNI. Cognitive training in the elderly: We have been awarded a grant from the Hartford Hospital Research Program to develop a novel approach for cognitive training in the elderly with normal aging and mild cognitive impairments including persons with mild depression. We are currently recruiting our second group of subjects into this manualized training program. Subjects receive group and computerized training sessions,

genetic testing, and a subset will receive functional neuroimaging all with before and after assessment of neuropsychological and functional performance and Quality of life. Anxiety disorders, mild memory disorders and early dementia: We have gained research office approval for a study on anxiety disorders and symptoms among patients with mild memory disorders and early dementia aimed to better delineate those anxiety features that correlate with and possible help identify those at risk for cognitive decline and dementia. D-cycloserine in neuropsychological test performance in older adults: We have collaborated with researchers from the Anxiety Disorders Center on a study examining the effects of D-cycloserine on neuropsychological test performance in older adults. Financial decisional capacity and psychiatric disability: In collaboration with faculty at Yale University School of Medicine, we have received funding on two new NIH intervention grants to assess and improve financial decisional capacity in individuals with serious psychiatric disabilities, Benefits Management for People with Psychiatric Disabilities (R34) and Improving Clinician Ratings of Money Mismanagement: Addictions Impact (R01). fMRI/PET study: We collaborate in the NIMH funded fMRI/PET study designed to advance the early detection of significant cognitive decline and early Alzheimers disease. To date the Memory Disorders Center has identified and recruited 14 subjects for this project. Driving simulation: Two manuscripts are in preparation from our driving study done in collaboration with the Olin Center using their virtual driving simulator. The MDC has contributed to this research by improving the assessment of decisional capacity to continue or terminate driving among normal elderly and those with cognitive decline and early dementia.

Burlingame Center for Psychiatric Research and Education

Services for persons with early onset Alzheimers Disease : We are in the process of submitting two research proposals aimed at improving specialized services for persons with early onset Alzheimers Disease (occurring younger than age 65) and their families entitled When Alzheimers disease strikes the young and middle aged: Improving care, family adjustment, and reducing caregiver depression.

John W. Goethe, MD, Director Faculty and Staff: Stephen Woolley, DSci Charles Wilber, MEd Alex Cardoni, MSPharm. Brenda Woznicki, BA Bonnie Szarek, RN Charles Caley, PharmD Megan Ehret, PharmD he mission of the Burlingame Center for Psychiatric Research and Education is to promote excellence in psychiatric care through applied research. The Center maintains the Institutes research infrastructure (e.g., clinical research database, Outcome Assessment Program) and utilizes this infrastructure for studies of best practices, patient outcomes and comparisons of interventional strategies. Other areas of ongoing research include: Pharmacogenetics the goal of these studies is to utilize genotyping technology to optimize medication. Prediction and management of metabolic syndrome in psychiatric patients the goal of these studies is to identify clinical, treatment and demographic variables that are associated with this syndrome, now widely recognized as a major health risk in psychiatric patients. Treatment resistant mood disorders the goal of these studies is to develop optimal treatments for individuals who have not responded to conventional therapies; this research and clinical initiative includes the development of an extensive infrastructure for comprehensive patient assessment as well as novel treatments for these disorders (e.g., Transcranial Magnetic Stimulation (TMS)).

MDC Publications and Abstracts

Bullock K, Blank K. Factors that influence the completion of advance directives between Black and White older adults: A pilot investigation. Gerontological Society of America, San Francisco. Nov. 2008. Bullock K, Blank K. Diversity in Geriatric Psychiatry, AAGP committee. American Association for Geriatric Psychiatry Annual Meeting, March 2008. Gilliam CM, Diefenbach GJ, Catayong K, Pearlson G, Blank K, Tolin DT. Emotion Regulation and Anxiety Disorders: A Lifespan Perspective. Association for Behavioral and Cognitive Therapies, October 2008. Goethe JW, Szarek BL, Blank, K, Caley CF. Metabolic syndrome in patients with major depressive disorder. Psychiatric Times 26:18-19, 2009. Tolin D, Robinson J, Gaztambide S, Horowitz S, Blank K. Ataques de nervios and psychiatric disorders in older Puerto Rican primary care patients. J of CrossCultural Psychology 2007; 38(6)659-669.

Burlingame Center Publications

Blair EW, Szarek BL. Exploring the relationship of psychotropic medications to fall events in an inpatient geriatric psychiatric population. International Journal of Psychiatric Nursing Research, 14: October 2008.
Diefenbach GJ, Woolley SB, Goethe JW. The association between selfreported anxiety symptoms and suicidality. Journal of Nervous and Mental Disease,197:92-97, 2009.

82.

Goethe JW, Szarek BL, Blank, K, Caley CF. Metabolic syndrome in patients with major depressive disorder. Psychiatric Times 26:18-19, 2009. Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms associated with metabolic syndrome in psychiatric inpatients receiving antipsychotics. Journal of Clinical Psychiatry, 68:22-28, 2007. Goethe JW, Szarek BL, Caley CF. Metabolic syndrome and depression: a review. Depression: Mind and Body 3:138-149, 2008. Goethe JW, Szarek BL, Caley CF. Metabolic syndrome in psychiatric inpatients treated for depression. In Thakore J, Leonard BE (eds). Modern Trends in Pharmacopsychiatry: Metabolic Effects of Psychotropic Drugs 26:90-104, 2009. Goethe JW, Woolley SB, Cardoni AC, Woznicki B, Piez D. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. Journal of Clinical Psychopharmacology, 27:451-58, 2007. Goethe JW. A time of change: challenges and choices. Invited article. Connecticut Medicine 73:367-8, 2009. Goethe JW. Expanding the do no harm mandate. Invited article. Connecticut Medicine, 71:499-500, 2007. Grgas M, Ehret MJ. Psychopharmacology: much the same. Connecticut Medicine 73:281-284, 2009. Ruao G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman Y, Pearlson G, Goethe JW, Schwartz HI. Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies. Connecticut Medicine, 71:197-200, 2007. Ruao G, Goethe JW, Caley C, Woolley S, Holford TR, Kocheria M, Windemuth A, de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Molecular Psychiatry, 12:47482, 2007. Ruao G, Villagra D, Rahim US, Windemuth A, Kocherla M, Bower B, Szarek BL, Goethe JW. Increased carrier prevalence of deficient BYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital. Personalized Medicine 5:579-587, 2008. Sopko MA Jr. Ehret MJ. Grgas M. Desvenlafaxine: another me too drug? Annals of Pharmacotherapy 42:1439-46, 2008. Szarek BL, Goethe JW, Woolley SB: Assessing metabolic syndrome: waist circumference versus BMI. Schizophrenia Research 108:295-296, 2009. Woolley SB, Goethe JW, Lincoln AK, Heeren T. Headache complaints and the risk of suicidal thoughts or behaviors in community-dwelling adults: results from the ECA study. Journal of Nervous and Mental Disease 196:822-828, 2008.

Burlingame Center Abstracts

Bullock K, Szarek BL, Goethe JW. Ethnic differences in length of stay and choice of antipsychotic medication among in-patients diagnosed with schizophrenia. Presented at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 2009. Caley CF. Antipsychotics for anxiety disorders: What is the evidence? Presented at the annual Northeastern Psychiatric Pharmacotherapy Symposium, Mystic, CT, September 2008. Caley CF. Utilizing a psychiatric pharmacy specialist in a college health setting. Presented at the annual meeting of the New England College Health Association, Mystic, CT, October 2008. Caley CF. Optimizing ADHD medication therapy in college health: evaluating the issues. Presented at the annual meeting of the American College Health Association, San Francisco, CA, May 2009. Caley CF. Psychotropic drugdrug interactionsthe most important you should know about. Presented at the annual meeting of the American College Health Association, San Francisco, CA, May 2009. Caley CF, Goethe JW, Woolley SB, Bardack D, Martello T, Azhar N, Ruano G, Windemuth A. Lifestyle, socioeconomics, and health history versus medications as predictors of metabolic syndrome. Presented at the annual meeting of the American Psychiatric Association May, 2009. Caley CF. Staying on your medicationsa perspective from pharmacy. Presented at the 2009 National Alliance of the Mentally Ill (NAMI), San Francisco, CA, July 2009. Christensen A, Ehret M, Szarek B, Goethe J. Treatment of major depressive disorder for elderly inpatients at a psychiatric facility. Presented at the annual meeting of the American Society of Health-System Pharmacists, Orlando, FL, December 2008. Ehret MJ, Goethe JW, Szarek BL. Who receives guideline-based pharmacotherapy for bipolar depression? Presented at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 2009. Goethe JD Blank K, Szarek BL. Metabolic risk factors in geriatric inpatients with major depressive disorder. Presented at the annual meeting of the American Psychiatric Association, San Diego, CA, 2007. Goethe JW, Szarek BL. Is schizoaffective disorder a distinct clinical entity? Presented at the annual meeting of the American Psychiatric Association, San Francisco CA, May 2009. Grgas M, Woolley SB, Goethe JW, Ruao G, Szarek BL, Caley C, Ehret M. An analysis of CYP450 genotype and patients perceived response and tolerance to their antidepressants. Presented at the College of Psychiatric and Neurologic Pharmacists, Jacksonville, FL, April 2009.

Szarek BL, Goethe JW. Diagnostic stability in patients with schizoaffective disorder compared to schizophrenia and bipolar disorder. Presented at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 2009. Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T. Severe headaches and the risk of subsequent suicidal thoughts or behaviors. Presented at the annual meeting of the American Psychiatric Association, San Diego, CA, 2007. Woolley SB, Goethe JW, Fredman L, Lincoln A. Heeren T. Schizophreniaspectrum disorders were associated with cardiovascular disease symptoms, independent of known risk factors for symptoms. Presented at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 2009. Woznicki BA, Woolley SB, Goethe JW, Bardack S, Azhar N. Locus of control, life events, treatment history and longitudinal outcomes of treatment for depression. Presented at the annual meeting of the American Psychiatric Association, May 2009.

Foundation
Assaf, Michal, PhD
Buspirone Efficacy and its Brain Correlates in the Treatment of Anxiety in Autism Spectrum Disorders. Private Donor, $40,000.

Stevens, Michael, PhD

Measuring Differences in Brain Activity in Adolescents with Major Depressive Disorder (MDD) using fMRI. American Foundation for Suicide Prevention, $70,000.

Industry
Goethe, John, MD
A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, PlaceboControlled Efficacy and Safety Study of Adjunctive AzD6765 in Subjects with Major Depressive Disorder (MDD) with at Least Moderate Symptomatology and a History of Poor Response to Antidepressants. AstraZeneca (MultiCenter), $109,850. A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients. AstraZeneca (Multicenter), $19,000.

New Projects
Federal
Glahn, David, MD
Influence of Psychosis on Brain-Behavior Endophenotypes for Bipolar Disorder. NIMH through Yale University, $1,351,780.

Tolin, David, PhD

A 3-Arm, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Pagoclone for the Treatment of Adults with Stuttering. Indevus Pharmaceuticals, $71,688. A Phase 3, Randomized, Double Blind, Parallel Group, 10 Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder. Pfizer, Inc., $148,392. A Multi-Center, Double-Blind, Fixed Dose Trial Examining the Safety and Efficacy of Org 25935 vs. Placebo as Augmentation to Cognitive Behavioral Therapy in Subjects with Panic Disorder. Organon USA Inc. (Investigator Initiated), $214,875.

Pearlson, Godfrey, MD
Bipolar & Schizophrenia Consortium for Parsing Intermediate Phenotypes. NIMH through Yale University, $2,816,321. Multivariate Methods for Identifying Multi-Task Multimodal Brain Imaging Biomarkers. NIBIB through MIND Institute, $10,943. Informed Data-Driven Fusion of Behavior, Brian Function, and Genes. NIMH through MIND Institute, $38,528.

Stevens, Michael, PhD

Language Functioning in Optimal-Outcome Children with ASD: An fMRI Study. NIMH through the University of Connecticut, $203,401. Characterizing Two Distinct ADHD Neurobiologies with fMRI. NIMH, $378,246.

State
Bullock, Karen, PhD
Factors Influencing Breast and Cervical Cancer Screening Among Racially/ Ethnically Diverse Women. UCONN Storrs, $1,500.

Tolin, David, PhD

Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder. NIMH, $1,144,599. Maximizing Treatment Outcome in OCD. NIMH through (University of Columbia) Research Foundation for Mental Hygiene, Inc., $34,372.

Ehret, Megan, PharmD

Feasibility of Administering a Pharmacist Consultation Service Targeting Inpatients with Bipolar Disorder, Most Recent Episode Depressed. ASHP through the University of Connecticut, $5,000.

Wilber, Charles, MEd

Reducing the Adverse Impact of Mental Illness Stigma Among Family Caregivers. Mount Sinai School of Medicine, $264,507.

84.

Departmental Funds
Astur, Robert, PhD
Hippocampal Structure and Function in People with Depression. $8,100.

Niego, Sara, MD
Media Literacy in Eating Disorder Treatment.

Pearlson, Godfrey, MD
An MRI Study of Neurobiological Markers of Trait Dysfunction in Major Depressive Disorder. Sex-Gender Differences in the Effects of Marijuana on Behavioral and Cognitive Tests.

Stevens, Michael, PhD

An fMRI Study of the Effect of Working Memory Training on ADHD Brain Dysfunction. $1,000.

Hartford Hospital Research Endowment Funds

Goethe, John, MD
Research Infrastructure for the Depression and Bipolar Disorders Center. Open Competition, $49,760.

Seltzer, Jim, PhD

Evaluation of BrainDance.

Shagan, Dana, PsyD

A Study of the Effect of Social Cognition and Interaction Training on People with Schizophrenia.

Stevens, Michael, PhD

Linux Cluster Infrastructure Enhancement. Open Competition, $74,513.

Stevens, Michael, PhD

ADHD Medications: Are The Benefits Worth The Risks?

Wilber, Charles, MEd

Cognitive Training in Elderly with Normal Aging and Mild Cognitive Impairments. Open Competition, $82,487.

Tolin, David, PhD

Psychological and Physiological Correlates of Anxiety.

Corbera, Silvia, PhD

Application of Event-Related Potentials (ERPs) to Evaluate the Effects of Coaching on Cognitive Rehabilitation in Schizophrenia. Small Grant, $300

Active Projects
Aikins, Deane, PhD
fMRI Investigation of PTSD-Related Cognitive Deficits and DNA Tissue Banking. National Center for PTSD, $48,293.

Mace, Melanie, PsyD

A Survey of Regional Referring Providers Use of and Perceived Utility of Neuropsychological Services. Small Grant, $750.

Assaf, Michal, MD
Differential Diagnosis of Psychotic Patients. Donaghue Medical Research Foundation, $239,179. FMRI, PET and the Default Mode Network Classify MCI and AD. NIA, $147,600. Implicit Mentalizing in Adults with Autistic Spectrum Disorders. Hartford Hospital Research Endowment Funds, $54,938. Neuronal Correlates of Implicit Social Interaction in Autism Spectrum Disorders: A Functional MRI Study. National Alliance for Autism Research, $118,968. Social Interactions in Developmental Disorders: Functional MRI Study. Departmental, $500. The Neuronal Correlates of Theory of Mind in Schizophrenia. NIMH, $164,000.

Tolin, David, PhD

D-Cycloserine-Augmented CBT for Prior Treatment Nonresponders with OCD. Small Grant, $9,531.

Turner Anderson, Beth, PhD

Simulated Driving: Effects of Road Conditions and Visibility. Small Grant, $9,811.

Unfunded
Diefenbach, Gretchen, PhD
Anxiety Symptoms and Disorders Among Patients with Mild Cognitive Impairment and Early Stage Dementia. Unified Treatment for Geriatric Emotional Disorders.

Astur, Robert, PhD

Amphetamine and Memory in Virtual Reality. Departmental, $3,000. Attention and Memory in Eating Disorder Populations. Cocaine-Induced Place Preference in Virtual Reality Environments R21 DA020013-01. National Institute of Drug Abuse, $290,852.

Jacobs, Barbara, PhD

Staff Nurses as Expert Judges for Content Validity of the Empowerment and Autonomy Measurement Survey. Use of an Ethics Consultation Service Registry to Identify Moral Triggers For Requesting Ethics Consultations.

Fear Conditioning During Functional Magnetic Resonance Imaging. Departmental, $400. fMRI of Virtual Reality Navigation. Departmental, $2,000. Neuroimaging Cognition in Post-Traumatic Stress Disorder. Neuroimaging of Mothers Overcoming and Managing Stress Breaking the Cycle. Office of Juvenile Justice and Delinquency Program/University of Connecticut, $49,500. Prospective Memory in Schizophrenia. Trinity College, $938. Sleep Dependent Consolidation of Spatial Memory. Hartford Hospital Research Endowment Funds, $7,750. Virtual Navigation in Individuals with Alzheimers Disease During fMRI. Hartford Hospital Research Endowment Funds, $49,950.

The Nature and Impact of Anxiety Symptoms upon Psychosocial Functioning of Older Adults with Major Depressive Disorder. Hartford Hospital Research Endowment Funds, $33,371. Treatment of Late-Life Anxiety Among Home Health Care Recipients: A Feasibility Study.

Ferrand, Jennifer, APRN

Long-term Psychological Adjustment in Patients with Implantable Cardioverter Defibrillators. Hartford Hospital Research Endowment Funds, $7,559.

Folley, Bradley, PhD

Modulation of Neuroimaging and Neurocognitive Correlates of Attention and Memory by Nicotine and Nicotinic Alpha-7 Receptor Genotype Polymorphisms in Schizophrenia and Healthy Controls. Philip Morris USA, Inc., $86,400.

Goethe, John, MD Blair, Ellen, APRN

Inpatient Psychiatric Unit Medications and Falls Outcomes. A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine with Olanzapine in Subjects who Completed Protocol A7501014 (Pfizer 1014). Pfizer, $47,693. A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine with Olanzapine in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia (Pfizer 1013). Pfizer, $86,125. A Randomized, Parallel Group, Multiple Dose, 6-week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects with Psychosis. Pfizer, $47,362. A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-on Oral Ziprasidone in Subjects with Acute Mania Treated with Lithium or Divalproex. Pfizer, $57,005. Adjunctive Treatment with Bupropion in Major Depressive Disorder. Glaxo Smith Kline, $60,700. DNA Diagnostics for Minimizing Side-Effects of Antipsychotics. NIH/SBIR, Genomas, $150,000. Enhancing Short-Term Memory in Patients with Schizophrenia. Information Dissemination as a Method of Improving Patient Outcome: A Demonstration Project and Study of the Outcomes of Patients with Major Depressive Disorder. Hartford Hospital Research Endowment Funds, $119,375. Physiogenomic Analysis of Antipsychotic Therapies and their Metabolic Side Effects. Genomas/NIH, $100,000. Psychiatric Treatment Practices and Patient Outcomes. SSRIs in the Treatment of Major Depressive Disorder: Side Effects and Patient Choices of Treatment. Merck, $112,500.

Bullock, Karen, PhD

Dying Experiences Among Racially Diverse Hospitalized Patients: Are There Differences Between Older African Americans and Whites in End-Of-Life Treatment Outcomes? Departmental, $10,593.

Caley, Charles, PharmD

A Controlled, Cross-sectional Comparison of Total Homocysteine concentrations in Schizophrenic Outpatients Treated With Risperidone or Olanzapine. Jannsen Pharmaceutical, $30,000; Hartford Hospital Research Endowment Funds,$11,537. Tenex (guanfacine) Augmentation for the Remediation of Attention and Working Memory Deficits in Patients with Schizophrenia: A Pilot Study. Hartford Hospital Research Endowment Funds, $7,198.

Calhoun, Vincent, PhD

Collaborative Research: Spatiotemporal Fusion of fMRI, EEG, and Genetic Data Using Independent Component Analysis. National Institute of Biomedical Imaging and BioEngineering, $886,292.

Choi, James, PhD

Comparison of Remediation Techniques on the WCST in Schizophrenia. Hartford Hospital Research Endowment Funds, $9,851.

Diefenbach, Gretchen, PhD

Clinical Characteristics of OCD Spectrum Disorders: A Comparison of OCD and Trichotillomania. Hartford Hospital Research Endowment Funds, $9,329. Screening for GAD Among Frail Elderly. NIMH, $147,200. The Cognitive-Enhancing Effects of D-Cycloserine Among Non-Demented Elderly. Hartford Hospital Research Endowment Funds, $74,923.

86.

The Utility of Routine Cytochrome P450 Genotyping in the Selection of Type and Dosage of Antidepressant Medication. Hartford Hospital Research Endowment Funds, $74,797.

Lovejoy, David
Patterns of Verbal List Learning in Mild Traumatic Brain Injury: The Role of Effort and Motivation.

Griss, Melina, PhD

White Matter Changes in Normal Aging: Impact on Everyday Functioning. Hartford Hospital Research Endowment Funds, $16,563.

Meda, Shashwath, MS
Characterizing the Dyslexia Phenotype Using Genetics and MR Morphology. Hartford Hospital Research Endowment Funds, $9,722.

Jaffe, Adam, PhD

Expectancy Therapy and Medication for Smoking Cessation. Hartford Hospital Research Endowment Funds, $54,432.

Meunier, Suzanne, PhD

Group Treatment for Compulsive Hoarding. Understanding Repetitive Behavior and Associated Experiences.

Kiehl, Kent, PhD

Brain Mechanisms of Interpersonal Judgment. Departmental, $2,400. Electrophysiological Assessment of Error Monitoring in Psychotic Illnesses. Hartford Hospital Research Endowment Funds, $50,000. Functional Magnetic Resonance Imaging Correlates of Decision-Making. Yale University, $50,000. Syntactic Development and Learning Processes in Autism Spectrum Disorders. University of Connecticut, $18,250.

Pearlson, Godfrey, MD
A Unified Framework for Flexible Brain Image Analysis. NIH/MIND Institute, $1,000,000. Aberrant Functional Connectivity in Psychosis. NIMH, $1,564,000. Alcohol and Driving: A Functional MRI Study . NIAAA/Yale University, $1,283,384. Alzheimers Disease Neuroimaging Initiative . University of California, San Diego, $292,959. Amphetamine and Reward Mechanisms: fMRI Study. Yale University, $15,000. Brain Structure and Function in Schizophrenia: Neuroanatomical and Neurophysiological Predictors of Clinical Outcome in Prodromal Schizophrenia. NARSAD,$530. Computer-Based Driving Assessment in Early Alzheimers Disease. Hartford Hospital Research Endowment Funds, $47,488. fMRI of Brain Activation During Menstrual Migraine. Departmental, $8,955. fMRI Studies of Healthy Volunteers at 3.0 Tesla. Departmental, $2,000. Human 31 - IH MRI and MRI Brain Studies of Nicotine. NIH, $53,767. Marijuana and Driving: A Functional MRI Study. Molecular Studies of Cognition and Chronic Alcoholism. NIAAA/University of Pittsburgh, $134,843. Neurocognitive Changes Associated with Behavioral Treatment in Cocaine Abusers. NIDA, $2,647,970. Physiogenomic Arrays for Clinical Neuropsychiatry. NIH subcontract through Genomas, $294,576. Quantitative Neuroimaging in Psychosis. NIMH, $2,753,077. Schizophrenia Biomarkers: Memory, Genes and fMRI. NIMH, $1,493,033.

Kurtz, Matthew, PhD

Cognitive Remediation for Schizophrenia: Effects on Distal Outcome Measures and Relationship to Social-Skills Training. NARSAD, $51,130. Facial Affect Recognition, Social Functioning, and Neurocognitive Deficits in Schizophrenia. FMRI Assessment of Treatment Response in the Schizophrenia Rehabilitation Program at the Institute of Living. Hartford Hospital Research Endowment Funds, $46,447. Neurocognitive Predictors of Response to Cognitive Remediation in Patients with Schizophrenia. National Alliance for Research on Schizophrenia and Depression, $60,000. Neurocognitive Remediation for Schizophrenia. NIH, $749,579; Hartford Hospital Research Endowment Funds, $9,362. Predictors of Treatment Response to Rehabilitation in Schizophrenia. NIH, $71,450. Virtual Reality Assessment of Psychosocial Status in Patients with Schizophrenia. Hartford Hospital Research Endowment Funds,$9,690.

Lothstein, Leslie, PhD

Assessment of Thought Disorder in Adults: The Relationship of the Rorschach Perceptual Thinking Index, Other Rorschach Variables, and the Millon Clinical Multiaxial Inventory - III Thought Disorder Index to Diagnoses in a Psychiatric Sample. Intimacy - Sexuality Group Therapy for Impaired and Distressed Professionals.

Sex Differences in Schizophrenia. NIMH, $776,448. The Effects of Tobacco on Brain Structure and Function are Amplified by Genotype. Dept. of Public Health/University of Connecticut, $200,730. Ventral Striatal Functional Deficits and Familial Alcoholism Risk. Yale University, $466,956.

Cognitive Processes in Anxiety Disorders. Cognitive-behavioral Bibliotherapy for the Treatment of Obsessive Compulsive Disorder in Children and Adolescents. Dismantling the Neural Systems of Obsessive-Compulsive Disorder: A Symptom Provocation Study of Compulsive Hoarding. Hartford Hospital Research Endowment Funds, $53,602. Long-Term Follow-Up of Cognitive-Behavioral Therapy Patients with Anxiety Disorders. Neural Mechanisms of Compulsive Hoarding. NIMH, $1,062,000.

Roffer, Wayne, PsyD

Accuracy of a Mental Status Exam for Assessing Cognitive Dysfunction in Patients with Schizophrenia.

Stevens, Michael, PhD

Diffusion Tensor Magnetic Resonance Imaging Correlates of Cognitive and Functional Outcome After Closed-Head Traumatic Brain Injury. Hartford Hospital Research Endowment Funds, $65,000. fMRI of CBT and CM Cocaine Dependence. Yale University, $172,183. Stepped Care for Obsessive-Compulsive Disorder. NIMH, $596,160. Functional Genomics of Behavioral Control. Treatment of Compulsive Hoarding. Boston University, $113,072.00 Functional MRI Activation in Children to Monaural, Binaural and Dichotic Words. University of Connecticut, $14,000. Girls in Recovery from Life Stress (GIRLS) Study. Office of Juvenile Justice and Delinquency Program, University of Connecticut, $49,500. Neural Correlates of Trauma and Stress Treatment Change. Departmental, $6,688. Neuroimaging Cognition in Adolescent Behavior Disorders. NIMH, $798,709. Response Inhibition in Attention-Deficit/Hyperactivity Disorder. Hartford Hospital Research Endowment Funds, $65,000. Reward, Impulsivity and Cocaine Addiction: fMRI Studies. Yale University, $1,303,559. The Effect of Pharmacotherapy on Trauma-Related Sleep Disturbance in Pediatric Populations. Virtual Reality Exposure Treatment for Combat-Related Posttraumatic Stress Disorder in Operation Iraqi Freedom and Operation Enduring Freedom Veterans. Hartford Hospital Research Endowment Funds, $73,894. Neuropsychological Functioning in Compulsive Hoarding. Hartford Hospital Research Endowment Funds, $74,898. Psychopathology of Compulsive Hoarding. Smith College, $365,563.

Woolley, Stephen, DSci

Assessment of a Suicide Screening Program to Improve Detection of PostDischarge Suicide Risk. Hartford Hospital Research Endowment Funds, $27,662. Extension of the Longitudinal Study of SSRIs in the Treatment of Depressive Disorder: Side Effects and Patient Choices of Treatment. Hartford Hospital Research Endowment Funds, $9,494. Prospective Follow-up Study of the Effects of Locus-of-Control and Life Stressors on Long-Term Outcome of Treatment for Major Depressive Disorder. Hartford Hospital Research Endowment Funds, $9,723.

Tolin, David, PhD

A Randomized, Double-Blind, Placebo-Controlled Trial of D-Cycloserine Augmentation of Behavior Therapy for Obsessive-Compulsive Disorder. Departmental, $245. An Internet Survey of Compulsive Hoarding. Anxiety Disorders Outcomes Protocol. Augmenting Exposure Therapy with an NMDA Agonist: A Pilot Study. Hartford Hospital Research Endowment Funds, $64,865. Cognitive Differences Between Generalized Anxiety Disorder and ObsessiveCompulsive Disorder. Hartford Hospital Research Endowment Funds, $10,062.

88.

Radiology
New Projects
Federal
Cronin, Edward, MD
Near Infrared Optical Imaging Guided by Ultrasound: Assessing Neoadjuvant Chemotherapy Response. NIH subcontract through the University of Connecticut, $287,124. Assessment of the GE Vascular Pack Noncontrast MRA Techniques.

Kallen, Joshua, MD
Exploratory Retrospective Review to Determine the Location of Pulmonary Emboli as Defined as within a Limited Scan Range or not within a Limited Scan Range.

OLoughlin, Michael, MD
Evaluation of GE Healthcares MSLAB, MFGRE and Viz Pack.

Industry
Foster, John, MD
Investigational Plan to Evaluate the Use of the Endologix 34mm Powerlink Cuff for Continued Access, IDE: G990139, Protocol Number: 03-023CA - Revision A. Endologix, Inc., $50,875. The SIR-Spheres(R) Registry. Sirtex Medical, $30,000.

Spiegel, Gary, MD
CORDIS Enterprise Vascular Reconstruction Device and Delivery System.

Stein, Barry, MD
AW Enterprise Application Server Prototype Evaluation.

Active Projects
Hallisey, Michael, MD
(VALOR) Evaluation of the Medtronic AVE Thoracic Stent Graft System for the Treatment of Thoracic Aortic Aneurysms. Medtronic AVE, $52,000. Treatment IDE for use of the GORE TAG Thoracic Endoprosthesis in Subjects with Descending Thoracic Aortic Aneurysms Requiring Surgical Repair. W.L. Gore & Associates, $10,220. Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy - SAPPHIRE WW - Protocol Number P06-3603. Cordis Corporation, a Johnson and Johnson Company, $47,200. TAG) A Clinical Study Comparing Use of the Thoracic EXCLUDER Endoprosthesis to Open Surgical Repair in the Primary Treatment of Descending Thoracic Aortic Aneurysms. W.L. Gore & Associates, Inc., $78,750. An Investigation of the Talent Endoluminal Spring Stent-Graft System for the Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are Candidates for Standard Surgical Intervention. Medtronic AVE / Talent, $72,000. An Investigation of the Talent Endoluminal Spring Stent-Graft System for the Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are Not Candidates for Standard Surgical Intervention. Medtronic AVE / Talent, $50,000. An Investigation of the TALENT LPS A Low Profile Endoluminal Stent-Graft System for the Treatment of Sub-renal Abdominal Aortic Aneurysms in Patients

Hallisey, Michael, MD
CRUX Biomedical Evaluation of the Crux Inferior Vena Cava Filter System (Retrieve) Study. Crux Biomedical, Inc., $38,792. Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft System in the Treatment of Descending Thoracic Aneurysms of Degenerative Etiology in Subjects Who are Candidates for Endovascular Repair. Medtronic Vascular, Inc. $54,315.

Unfunded
Kallen, Joshua, MD
Retrospective Validation of Limited Scan Range CTA for Suspected Pulmonary Embolism for Diagnostic Accuracy and Prevalence and Clinical Significance of Alternative and Secondary Diagnoses. Statistical analysis generously supported by Medical Staff funds.

Coughlin, Bret, MD
Gadolinium-Enhanced Tissue Visualization: A Feasibility Study.

Hallisey, Michael, MD
Evaluation of Prototype Inferior Vena Cava Filtration Device in Ovine. Screening Abdominal Aortic Aneurysms Based on the Stability of the Aneurysm. Evaluation of BW2R Paperwork for Patient Prescriptions.

Jacunski, Joanna, MD

who are Candidates for Standard Surgical Intervention (LOW RISK). Medtronic Vascular, $10,000. An Investigation of the TALENT Endoluminal Spring Stent-Graft System for the Treatment of the Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are Candidates for Standard Surgical Intervention (Low Risk Stock Device Study). Medtronic AVE, $20,000. An Investigation of the Talent Endoluminal Spring Stent-Graft System for the Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who are Not Candidates for Standard Surgical Intervention - Emergency Protocol. Medtronic AVE, $40,000. Emergency Use of the Talent Endoluminal Spring Stent-Graft System in High Surgical Risk Patients with Thoracic Aortic Aneurysms. Medtronic AVE, $80,000. Evaluation of the Enhanced TALENT LPS Stent Graft System for the Treatment of Abdominal Aortic Aneurysm. Medtronic AVE, $50,000. The EXACT Study - Emboshield(R) and Xact(R) Post Approval Carotid Stent Trial. Abbott Vascular Devices, $22,000.

Tubbs, Daniel, MD
Contrast Enhanced Multi-Detector Computed Tomography (MDCT) as a Noninvasive Modality for the Evaluation of Active Lower Gastrointestinal Bleeding: Initial Prospective Assessment of Contrast Enhanced MDCT Verses Technetium 99m Tagged Red Blood Cell Scanning at a Large Community Hospital. Berlex Laboratories, Inc., $99,769.

Zink, Stephen, MD
Incidental Non-cardiac Findings Seen Prospectively on Cardiac CT Angiogram (CTA).

Publications and Abstracts

Kallen J, Coughlin B, OLoughlin MT, Stein B, Chhabra J. Reduced Z-axis coverage CTA versus standard Z-axis coverage CTA for pulmonary embolism. Abstract LL-CH4342-R08. Radiological Society of North America, posted online May, 2009. Available at http:// rsna2009.rsna.org Kallen JA, Coughlin BF, OLoughlin MT, Stein B. Reduced Z-axis coverage multidetector CT angiography for suspected acute pulmonary embolism could decrease dose and maintain diagnostic accuracy. Emergency Radiology 2009;17:31-35. Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB, Postoak DW, Rajan DK, Sacks D, Schwartzberg MS, Zuckerman DA, Cardella JF, Standards of Practice Committee with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. Journal of Vascular & Interventional Radiology, 20 (7): S240-S249, 2009. Malloy PC. Management of pelvic hemorrhage in trauma. In Mauro MA, Murphy K, Thomson K, Venbrux A, Zollikofer CL. (Eds.) Image Guided Intervention. Saunders, pp. 907-913, 2008. OLoughlin M, McLaughlin T, Staff I, Cronin E. Prospective outcome of BIRADS category 3 Probably Benign breast MRI lesions. Abstract SSA01-01. Radiological Society of North America, posted online May, 2009. Available at http://rsna2009.rsna.org Richard HM, Widlus DM, Malloy PC. Percutaneous fluoroscopically guided jejunostomy placement. J Trauma, 65(5):1072-7, 2008.

Hauser, Stephen, MD
Compassionate Use Protocol DMS: A Prospective Study of Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors.

Jacunski, Joanna, MD
Retrospective Analysis of the Utility of MRI for Evaluation of Acute Abdominal Pain in Pregnant Patients. Use of 18F-FDG PET/CT for Diagnosis of Osteomyelitis of the Foot.

Norton, Timothy, MD
Trends in the Utilization of Radiologic Studies at Hartford Hospital.

OLoughlin, Michael, MD
MRI Evaluation of the Contralateral Breast in Women with a Recent Diagnosis of Breast Cancer/ACRIN 6667. American College of Radiology Imaging Network, $170,000. Prospective Analysis of Breast MRI Outcomes in a Large Hospital Population. CT Breast Health Initiative, $49,939.

Silk, Portia, MD
Analysis of CT Perfusion and Salvageable Penumbra as a Function of Time in Acute Stroke. Small Grant, $10,000.

Spiegel, Gary, MD
Humanitarian Use Device: Neuroform Microdelivery Stent. Wingspan Stent System with Gateway PTA Balloon Catheter, a Humanitarian Use Device.

Stein, Barry, MD
MRI Image and Clinical Application Development Protocol.

90.

Surgery
Orlando C. Kirton, MD, FACS, FCCM, FCCP, Ludwig J. Pyrtek MD Chair in Surgery, Director of Surgery, Chief, Division of General Surgery
The Department of Surgery continues to participate in clinical and scientific research and has contributed significantly to the surgical body of knowledge. Members of the department have presented their findings at several prestigious forums and have published in a variety of refereed journals. The Department continues to encourage its members to be involved in academic as well as clinical endeavors. It seeks to engage its staff in a variety of experiences that contribute to the growth of the department, the reputation of the institution as well as the enhancement of the individuals themselves. The faculty of the department continues to be actively involved in the education process within the institution and the community and continues to encourage the residents and fellows to pursue research activities. The Department of Surgery currently supports two surgical residents as they participate in research fellowships at the University of Connecticut. Both have been involved in conducting clinical research and basic science research and have published and presented their findings. Dr. Pavlos Papasavas, the Director of Research for the Department of Surgery has provided presentations to residents and medical students to encourage participation in research projects. In addition, he selected and trained residents for the Skills competition of the CT-Chapter of the ACS and the selected group won first prize. The Department of Surgery and the Section of Bariatric Surgery are working on establishing a Bariatric Database to provide valid data to conduct meaningful research. The Department continues to identify ways to access data for the purpose of trending and quality improvement. The Departments own database (ORBIT) has been redesigned to facilitate the input and download of specific data from other databases (i.e. SIS). The Division of Colo-Rectal Surgery has created an on-going database for ileoanal pouch procedures and is collaborating with UConn (Storrs) on a project entitled Psychosocial Needs Assessment of Patients with Colorectal Cancer and Partners with the goal of addressing the area of patient and family support systems.

New Projects
Industry
Cheema, Mohiuddin, MD
PRICELESS: PRessure and Imaging - using the CardioMEMS EndoSure Sensor for Long-term follow-up after EVAR with Standard Surveillance (PRICELESS PROSPECTIVE REGISTRY). CardioMEMS, Inc., $12,250.

Hull, David, MD
Deceased Donor Vessel Storage: A Study of Tissue Viability for Organ Transplantation. Essential Pharmaceuticals, $3,000. A Double-Blind, Randomized, Placebo Controlled, Multi-Center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients. F. Hoffman-La Roche LTD, $62,000.

Mah, John, MD
Assessment of the Economic Impact on Fecal Containment in Bedridden Patients Comparing Zassi Bowel Management System (BMS) with Flexi-Seal Fecal Management System (FMS). Hollister, Inc., $17,000.

McKay, Raymond, MD
A Pilot Study to Assess the Histological Effects and Biomechanical Strength of a Novel, Knotless Suturing Technique in the Repair of Rotator Cuff Injury. Cordis Corporation (Investigator Initiated), $13,306.

Papasavas, Pavlos, MD
A Multi-Center Open-Label Clinical Evaluation of the LAP-Band AP System in Severely Obese Patients. Allergan (Multicenter), $27,850.

Unfunded
Allen, Brian, MD
A Successful Wound Care Algorithm to Heal Venous Stasis Ulcers.

Butler, Karyn, MD
Is Delayed DVT Prophylaxis in the Neurocritical Care Unit Effective?

Cohen, Jeffrey, MD
Recurrent Diverticulitis After Laparoscopic Colectomy.

Divinagracia, Thomas, MD
The Natural History of Moderate Stenosis of the Carotid Artery.

Feeney, James, MD
The Use of a Simulator to Improve Technique and Procedural Confidence In Emergency Cricothyroidotomy. Statistical analysis supported through Hartford Hospital Small Grant.

Active Projects
Alberghini, Tod, BS
Clinical Significance of Solid-Phase Assay (Flow Cytometric and Luminex) Detection of Pre-Transplant HLA Antibody as Measured by Graft Survival in Renal Transplant Recipients: A Retrospective Analysis. Hartford Hospital Small Grant, $9,954. Histocompatability Determination for Highly Sensitized Patients.

Gallagher, Robert, MD
Aortic Valve Replacement - Is Age an Independent Predictor of Risk? Statistical analysis supported through Hartford Hospital Small Grant. Incidence and Risk Factors Associated with Post Procedure Hypotension Following Carotid Artery Endarterectomy and Carotid Artery Angioplasty.

Bass, David, MD
McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical Study.

Hammond, Jonathan, MD
Benefit of Prophylactic Donor Tricuspid Annuloplasty in Bicaval Orthotopic Heart Transplantation. Data support provided through Hartford Hospital small grant.

Brown, Matthew, MD
A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy. Wyeth Pharmaceuticals, $213,147.

Hull, David, MD
Retrospective Study of Liver Transplant Pre-Procedure MELD Scores and PostSurgical Outcomes. Statistical analysis supported through Hartford Hospital Small Grant.

Orlando, Rocco, MD
A Prospective Study of Early Outcomes After Stapled Versus Unstapled Preformed Mesh in Laparoscopic Extraperitoneal Inguinal Herniorrhaphy.

Cohen, Jeffrey, MD
Safety, Feasibility and Long-term Outcomes of Laparoscopic Ileal-Pouch-Anal Anastomosis: A Single Institution Case-Matched Experience.

Papasavas, Pavlos, MD
Bariatric Outcomes Longitudinal Database (BOLD). Hartford Hospital Bariatric Registry. Hiatal Hernia Repair at the Initial Laparoscopic Adjustable Gastric Band Operation. Massive Hernia Repair with Separation of Components Technique: A General and Plastic Surgery Combined Approach. Weight Loss Surgery and Diabetes Mellitus in Patients Undergoing Weight Loss Surgery.

DeLucia, Orlando, MD
Allergan Corporation Style 410 Silicone-Filled Breast Implant Continued Access Reconstruction/Revision Expansion (CARE) Clinical Study. Inamed, $8,300. McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical Study.

Drezner, David, MD
A Comparison of CT Venography to Duplex Ultrasonography in the Diagnosis of DVT. Outcomes of Patients Undergoing Lower Limb Amputations.

Paquette, Anthony, MPH

Reliability of a Donation after Cardiac Death (DCD) Assessment Tool in Predicting Time to Cardiac Death after Withdrawal of Support.

Gallagher, Robert, MD
Oxygen Mapping of the Peri-sternal Chest Wall in Post-Operative Open Heart Surgery Patients.

Ranga, Kasturi, MD
Depression, Anxiety, and Quality of Life in Living Kidney Donors. Statistical analysis supported through Hartford Hospital Small Grant. Does Beta 2 Microglobulin Correlate with Creatinine as a Marker of Renal Function in Renal Transplant Recipients at Points of Transition, and During Stable Renal Function? Statistical analysis supported through Hartford Hospital Small Grant.

Graydon, James, MD
Post-Prostatectomy Erectile Dysfunction and Urinary Incontinence: Effect of Hyperbaric Oxygen Therapy.

Hull, David, MD

92.

Intimal Hyperplasia in Arteriovenous Fistulas. Roche, $18,162. Oral Infection and Inflammation in Transplant Patients. NIH/University of Connecticut, $25,000. An open label randomized, multicenter study to evaluate the efficacy and safety of early calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on mycophenolate mofetil; MMF (CellCept) and sirolimus (Rapamune). Roche Hoffman - La Roche, $430,709. Transplant Clinical Outcomes Blanket Protocol.

Enterra Therapy Humanitarian Device Exemption.

Pepe, Judith, MD
Training Organ Procurement Organization Coordinators to Use an Esophageal Doppler Monitor for Donor Management to Improve Organs Transplanted per Donor. HRSA, $94,253.

Poultsides, George, MD
Hand Assisted Laparoscopic Transduodenal Resection: Initial Experience. Laparoscopic Gastric Resection: Technique and Outcomes in 25 Patients. Safety and Long-term Efficacy of Angiographic Embolization for Upper Gastrointestinal Hemorrhage: A Single Institution Experience.

Ivy, Michael, MD
Intraoperative and Preoperative Parameters That Predict Abdominal Compartment Syndrome After Repair of Ruptured Abdominal Aortic Aneurysm.

Reed, Michael, MD Keating, Kevin, MD

A Randomized, Double-Blind, Placebo-Controlled, Phase-2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation. Artisan Pharma Inc., $96,000. McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical Study.

Tamim, Patrick, MD
An Analysis of Subclavian Stenosis by Duplex Ultrasonography as Evaluated in Tandem with Arterial Angiography.

Kirton, Orlando, MD
Advanced Laparoscopic Training Course. Departmental, $17,500.

Tishler, Darren, MD
Evaluation of Sublingual Capnometry in Critically Ill Surgical Patients Subjected to a Resuscitation Protocol (SLT). Tyco Healthcare/Nelcor, $66,250. Surgery Clinical Outcomes Blanket Protocol. A Randomized, Prospective Study Comparing Needle Stick Injuries with Hand versus SuturTek Device Closure of Abdominal Fascia. SutruTek Inc., $27,000.

Underhill, David, MD
Study 98-1 Carpentier-Edwards PERIMOUNT Plus Pericardial Bioprosthesis, Model 6900P. Edwards LifeSciences, LLC, $110,250.

Mah, John, MD
Application of a Web-Based Teaching Module for Instruction and Standardization of Post-Pyloric Feeding Tube Insertion.

Publications and Abstracts

Allen B, Cuzzone D, Rowin C, Perdrizet G, Babigian A. Fluoroscopic radiation burn following embolization of a spinal arteriovenous malformation. Journal of Burn Care and Research, 2009; 30(2): 349-351. Allen B, Rader C, Babigian A. Giant lipomas of the upper extremity. Canadian Journal of Plastic Surgery 2007;15(3):141-144. Antonetti M, Kirton OC, Bui D, Ademi A, Staff I, Hudson-Civetta J, Lilly R: The effects of pre- operative rofecoxib, metoclopramide, dexamethasone, and ondansetron on postoperative pain and nausea in patients undergoing elective laparoscopic cholecystectomy. Surg Endosc 2007; 21:1855-1861. Banever, T, Brautigam, RT, Pressure Ulcer Assessment Work Group. Pressure Ulcer Assessment for Physicians and Licensed Independent Practitioners Education Program. Hartford Hospital Intranet, 2008. Barnes SL, Richards T, Pritts TA, Robinson BR, Tsuei BJ, Butler KL, Muskat PC, Davis K, Johannigman JA. Devil is in the details: maximizing revenue for daily trauma care. Surgery 2008; 144(4): 670-676. Bokhari F, Phelan H, Holevar M, Brautigam R, Collier B, Como J, Clancy K,

Mavanur, Arun, MD
Differences Between Male and Females in the Operative Findings and Outcome of Laparoscopic Cholecystectomy. Indeterminate for Dysplasia, What Next?

McIsaac, Joseph, MD
Surgical Cooling Garment Phase III. Hartford Hospital Research Endowment Funds, $65,625.

Miranda, Michael, MD
Humanitarian Use Device: OP-1 Implant.

NasirKhan, Mohammad, MD
Role of Intravenous Chromium in Reducing Insulin Requirements in Critically Ill Patients.

Norton, Timothy, MD
Cryoablation of Irresectable Lung Tumors.

Papasavas, Pavlos, MD

Cumming J, Cullinane D, and Smith L. Diagnosis and management of pancreatic trauma. Posted on EAST.org, 2009. Brautigam RT, Schott E, and Burns K. A simulation education course for the initial management of blunt trauma. Connecticut Medicine, May 2009; 73(5): 267-271. Brautigam RT, Sheppard R, Robinson K and Jacobs LM. Evaluation and treatment of the multiple-trauma patient. In: Browner BD, Jupiter JB, Levine AM and Trafton PG. Skeletal Trauma: Basic Science, Management and Reconstruction, 4th ed., 2009. Cheema M, Lukose B, Kirton OC, Gallagher J: Ligation of the subclavian artery after blunt trauma presenting as massive hemothorax.. J Trauma 2008; 64(4):1126-1130. Clarke CN, Tsuei B, Butler KL. Equine-related injury: a retrospective analysis of outcomes over a 10 year period. Am. J. Surg. 2008;195:702-704. Crisanti, Koutzaki, Mondrinos, Lelkes, Finck. Novel methods for delivery of cellbased therapies. Journal of Surgical Research May 2008;146(1):3-10. Cuzzone D, Allen B, Rowin C, Tulikangas P, Babigian A. Development of vaginal erosion and vesico-cutaneous fistula following midurethral transvaginal tape with Pelvilace for treatment of stress urinary incontinence. International Wound Journal, 2009; 6:55-58. Feeney JM, Burns K, Staff I, Bai J, Rodrigues N, Fortier, Jacobs LM. Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Am Coll Surg. 2009. Finck, Moront, Newton, Timmapuri, Lyons, Rozans, DeChadarevian, Halligan. Pediatric granular cell tumor of the tracheobronchial tree. Journal of Pediatric Surgery, 2008;43(3):568-70. Folcik MA, Kirton OC, Ivy ME: A two-tiered quality management program : morbidity and mortality conference data applied to resident education. Connecticut Medicine, 2007; 71(8):417-424. Fortuna GR, Mueller EW, James L, Shutter LA, Butler KL. The impact of preinjury anti-platelet or anticoagulant pharmacotherapy and outcomes following hemorrhagic brain injury. Surgery 2008; 144(4): 598-605. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating risk: a role for jak-stat signaling in post-conditioning? Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1649-56. Goodman MD, Koch SE, Reid MD, Caldwell CC, Butler KL. Thermal injury activates myocardial JAK-STAT signaling. J Surg. Res. 2008;144(2):342. Gross RI, Jacobs LM. Initial Assessment and Resuscitation. Airway Management: What Every Trauma Surgeon Should Know, From Intubation to Cricothyroidotomy. In Current Therapy of Trauma and Surgical Critical Care. Eds. Juan A. Asensio and Donald D. Trunkey. 2008. Huffman LC, Koch SE, Butler KL. Coronary effluent from a preconditioned heart

activates the JAK-STAT pathway and induces cardioprotection in a donor heart. Am J Physiol Heart Circ Physiol. 2008;294:H257-H262. Hyman NH, Kozol RA, Kirton OC, Berger DL. Attending surgeon work hours restriction. Archives of Surgery. 2008; 143(5): 443. Jackson S, Mueller EW, Ernst NE, Butler KL. Utility of bilateral bronchoalveolar lavage for the diagnosis of ventilator-associated pneumonia in critically ill surgical patients. Am J Surg. 2008; 195:159-163. Jacobs LM, Abbensetts JMK. Acute care surgery. In A Guide for General Surgeons. Emergency Management of the Oropharynx and Neck. (Eds) Vicente H. Gracias, Patrick Reilly, Mark G. McKenney George C. Velmahos. Publisher: McGraw Hill. 2009. Jacobs LM, Burns K, Jacobs BB. Trauma death: Views of the public and trauma professionals on death and dying from injuries. Archives of Surgery. 2008;143(8):730- 735. Jacobs LM, Luk SS, Sproviero J. TRAUMA Sociedad Panamericana De Trauma 2nd Edition. Trauma Hepatico. Editors. Ricardo Ferrada, MD, Aurelio Rodriguez, MD. Pp 369-278. Published by Distribuna Editorial. Pittsburgh, PA 2009. Kirton OC, Folcik M, Calabrese E, Ivy M, Keating K, Mah, J, Pepe, J, Dobkin et al: Mid Level Practitioner (MLP) work force analysis at a university affiliated teaching hospital. Arch Surg. 2007; 142:336-341. Kowal-Vern A, Poulakidas S, Barnett B, Conway D, Culver D, Ferrari M, Potenza B, KoenigM, Mah J, Majewski M, Morris L, Powers J, Stokes E, Tan M, Salstrom SJ, Zaletel C, Ambutas S, Casey K, Stein J, DeSane M, Berry K, Konz EC, Riemer MR, Cullum ME. Fecal containment in bedridden patients: economic impact of 2 commercial bowel catheters systems. Am J Crit Care. 2009. 18(Suppl 3):S2-14. Mah J, Kirton O. Pharmacologic support of cardiac failure. In Asenio J, Trunkey D, editors: Current Therapy of Trauma and Surgical Critical Care. 1st ed. Philadelphia, Mosby, 2008 pp 598-602. Mah J, Kirton O. Splanchnic flow and resuscitation. In Gabrielli, Layon AJ, and Yu M, editors: Civetta, Taylor, and Kirbys Critical Care. 4th ed. Philadelphia, Lippincott Williams & Wilkins,2009, pp 941-948. Mah JW, Bingham K, Dobkin ED, Malchiodi L, Russell A, Donahue S, Staff I, Ivy ME, Kirton OC. Mannequin simulation identifies common surgical ICU teamwork errors long after introduction of sepsis guidelines. Simul Healthc 2009 Vol.4, No. 4 Mami, Moront, Pascasio, Schlichting, Finck. Ruptured abdominal aortic aneurysm in an 11-year-old boy. Journal of Pediatric Surgery 2008;43(4):762-4. Master D, Piorkowski J, Zani S, Babigian A. Snowblower injuries to the hand:

Epidemiology, patterns of injury, and strategies for prevention. Annals of Plastic Surgery, 2008; 61(6):613- 617. Mondrinos, Koutzaki, Poblete, Crisanti, Lelkes, Finck. In vivo pulmonary tissue engineering: contribution of donor-derived endothelial cells to construct vascularization. Tissue Engineering Part A 2008 Mar; 14(3):361-8. Orenstein S, Kreutzer D, Novitsky Y. Human monocyte activation by biologic and biodegradable meshes in vitro. Surgical Endoscopy. Vol. 23; Supp 1; April 2009. Orenstein S, Kaur M, Qiao Y, Klueh U, Kreutzer D, Novitsky Y. Activation of human monocytes by human biologic meshes in vitro. Journal of Surgical Research. Vol. 151; Issue 2; pg 290. Orenstein SB, Qiao Y, Klueh U, Kreutzer DL, Novitsky YW. Role of mast cells in the biocompatibility of synthetic mesh in mice. Hernia. Vol. 13; Supp. 1; Sept. 2009. Rader C, Piorkowski J, Bass D, Babigian A. Epulis garavidarum manum: Pyogenic granuloma of the hand occurring in pregnant women. Journal of Hand Surgery 2008;33A:263-265. Rangel EL, Butler KL, Johannigman JA, Tsuei BJ, Solomkin JS. Risk factors for relapse of ventilator-associated pneumonia in trauma patients. J Trauma. 2009 Jul;67(1):91-5. Roszell BR, Mondrinos MJ, Seaton A, Simons DM, Koutzaki SH, Fong GH, Lelkes PI, Finck CM. Efficient derivation of alveolar type II cells from embryonic stem cells for in vivo application. Tissue Eng Part A. 2009 Apr 23 epub ahead of print. Roszell, Seaton, Fong, Finck. Cell-based therapy improves cell viability and increases airway diameter in an explant model of pulmonary hypoplasia, Experimental Lung Research 1521- 0499, Volume 35, Issue 6, 2009, Pages 501 - 513 Sobieraj DM, Wang F, Kirton OC. Warfarin resistance after total gastrectomy and Roux-en-Y Esophagojejunostomy. Pharmocotherapy 2008; 28(12):1537- 1541 Tandon, M., Poi, M., Shapiro, D. Chapter 4: Surgical nutrition. In: Kozol R.A., Novitsky, Y.W. (Eds.) Surgery Mentor - Your Clerkship & Shelf Exam Companion, 2nd edition. Philadelphia, PA. F.A. Davis Company. 2009; 31-37. Tisherman SA, Kirton OC, Ivy M, Frangos S: Acute care surgery (ACS): Are surgeons ready for a new training paradigm? Crit Care Med 2007;35/12:A122. Vignati, P. Anastomotic leaks: What is the best imaging study? DCR 2007;50:97-203 Vignati, P. The efficacy and durability of super selective embolization in the treatment of lower gastrointestinal bleeding. DCR 2008 51(3);301-5 Zani S, Babigian A. Necrotizing fasciitis of the shoulder following routine rotator cuff repair. Journal of Bone and Joint Surgery 2008; 90:1117-1120.

Allen B, Babigian A. Breast Reconstruction in a 19 Year Old Female with Anhydrotic Ectodermal Dysplasia. Presented at the CTACS Scientific and Annual Meeting, Meriden, CT, 11/07. Allen B, Caputo AE, Babigian A. Pediatric Revascularization and Replantation in the Hand: Our Experience at Hartford Hospital and Connecticut Childrens Medical Center. Presented at the New England Hand Society Thirty-Sixth Annual Meeting and Scientific Program, Sturbridge, MA 12/08. Allen B, Perdrizet G, Babigian A. Hyperbaric Oxygen Therapy for Treatment of Delayed Radiation Tissue Injury. Presented at the New England Society of Plastic and Reconstructive Surgery 2008 Annual Meeting, Manchester, VT 6/08. Babigian, A. Moderator, Scientific Session. New England Society of Plastic and Reconstructive Surgery 2008 Annual Meeting, Manchester, VT 6/08. Babigian, A. Moderator, Scientific Session. New England Society of Plastic and Reconstructive Surgery 2009 Annual Meeting, Boston, MA 6/09. Babigian, A. Panel Member. University of Massachusetts Plastic Surgery Practice Management Strategies Panel, Worcester, MA 12/07. Babigian, A. Soft Tissue Coverage of the Upper Extremity. Presented at the University of Massachusetts Plastic Surgery Educational Conference, 6/09. Barnes SL, Richards T, Pritts TA, Robinson BR, Tsuei BJ, Butler KL, Muskat PC, Davis K, Johannigman JA. Devil is in the Details: Maximizing Revenue for Daily Trauma Care. Proceedings of the Central Surgical Association, March 2008. Butler KL, Goodman MD, Koch SE, Friend L, Afzal MR. STAT Subtype Switch in Pressure-overload Hypertrophy Improves Ischemic Tolerance in STAT-3 KO Mice. Presented at the American College of Surgeons, Papers Session, October 2008. Butler, K. Academic Surgery: The Road Less Traveled. Keynote Speaker SNMA Banquet Cincinnati, OH February 4, 2008. Butler, K. Cardiac Specific STAT-3 Deletion Prevents Myocardial Decompensation Following Pressure Overload. Society of Black Academic Surgeons Cleveland, OH April 2008. Butler, K. Critical Illness Related Corticosteroid Insufficiency: The Heart of the Matter. Cardiology Grand Rounds Hartford Hospital, August 18, 2009. Butler, K. Gender, Science and Serendipity. Annual William Matory MD Lecture, National Medical Association July 27, 2009. Butler, K. Heparin-induced Thrombocytopenia: Who Gets HIT? Society of Black Academic Surgeons Cleveland, OH April 2008. Butler, K. Procalcitonin: A Novel Biomarker for Infection in the Critically Ill

Presentations

Patient. Division of Critical Care Research Forum, Hartford Hospital, March 11, 2009. Butler, K. STAT Subtype Switch in Pressure-overload Hypertrophy Improves Ischemic Tolerance in STAT-3 KO Mice. American College of Surgeons, San Francisco, CA, October 2008. Butler, K. Thermal Injury Activates Myocardial JAK-STAT Signaling. Academic Surgical Congress Huntington Beach, CA February 6, 2008. Butler, K. Intimate Partner Violence. University of Cincinnati Brown Bag Lunch Series, May 2008. Butler, K. The Impact of Pre-injury Anti-platelet and Anticoagulant Pharmacotherapy on Outcomes Following Hemorrhagic Brain Injury. Central Surgical Association Cincinnati, OH March 4, 2008. Butler, K. Women in Medicine. Howard University Hospital Department of Surgery Grand Rounds November 17, 2008. Clarke CN, Keegan SP, Mueller EW, Ernst NE, Butler KL. Heparin-induced Thrombocytopenia: Who Gets HIT? Proceedings of the Society of Black Academic Surgeons, April 2008. Finck, C. Pulmonary Tissue Engineering. Invited Speaker, Stem Cells and Cellular Therapies in Lung Biology and Lung Diseases Conference University of Vermont, Burlington, VT 7/28/09. Finck, C. Stem Cells and Pulmonary Hypoplasia. Invited Speaker, American Thoracic Society International Conference San Diego, CA 5/19/09. Finck, C. Stem Cells and Treatment of Pulmonary Hypoplasia. Invited speaker, New England Surgical Society 2008 Boston, MA 9/08. Fortuna GR, Mueller EW, James LE, Shutter LA, Butler KL. The Impact of Preinjury Anti-platelet and Anticoagulant Pharmacotherapy on Outcomes Following Hemorrhagic Brain Injury. Proceedings of the Central Surgical Association, March 2008. Goodman MD, Koch SE, Afzal MR, Butler KL. Compensatory STAT Subtype Activation Does Not Limit Ischemia-reperfusion Injury in Mice with Cardiac Restricted STAT-3 Deletion. Presented at the Society of University Surgeons, February 2009. Goodman MD, Koch SE, Butler KL. JAK-STAT Activation in Postconditioning is not Without RISK. Presented at the American College of Surgeons, Surgical Forum, October 2008. Goodman MD, Koch SE, Butler KL. Regulating Risk: A Role for Jak-stat Signaling in Postconditioning. University of Cincinnati Dept of Surgery Resident Research Competition, First Place. June 2008. Goodman MD, Koch SE, Lou Ann Friend, Butler KL. Cardiac Performance is Preserved Following Pressure-overload Stress in STAT-3 KO Mice. Presented at the

Ohio Chapter, American College of Surgeons, May, 2008. Goodman MD, Koch SE, Lou Ann Friend, Butler KL. Cardiac Specific STAT-3 Deletion Prevents Myocardial Decompensation Following Pressure Overload. Proceedings of the Society of Black Academic Surgeons, April 2008. Jackson L, Drezner D, Freund J, Palter M, Butler KL. Is Delayed DVT Prophylaxis in the Neurocritically Ill Patient Effective? Presented at the Society of Black Academic Surgeons, April 2009. Jacobs LM, Burns KJ, Luk S, Hull D. Advanced Trauma Operative Management (ATOM) Course: Participant Survey. Poster presentation. New England Surgical Society, Newport, RI. September 12, 2009. Jacobs, L. Acute Care Surgeon: Should Critical Care Management Be An Essential Component? American College of Surgeons Point/Counterpoint Trauma Conference. National Harbor, Maryland. June 9, 2009. Jacobs, L. The Advanced Trauma Operative Management Course: An Innovative Response to the technical Challenges of Trauma Surgery. Visiting Professor. Cedars-Sinai Medical Center. Los Angeles, CA. November 12, 2008. Jacobs, L. An Innovation in Surgical Education in Trauma, Grand Rounds. University of Iowa. February 25, 2009. Jacobs, L. Invasive Procedures Performed by Prehospital Personnel: The Indications Should be Broad. American College of Surgeons Point/Counterpoint Trauma Conference. National Harbor, Maryland. June 8, 2009. Jacobs, L. Necrotizing Soft Tissue Infections: Is Hyperbaric Oxygen Therapy Even An Essential Adjunct? American College of Surgeons Point/Counterpoint Trauma Conference. National Harbor, Maryland. June 8, 2009. Jacobs, L. Pediatric Trauma Moderator. CT Trauma Conference. Foxwoods Resort. Ledyard, CT. April 2, 2009. Jacobs, L. Simulated Education in Trauma. Grand Rounds Speaker. Rush University, Chicago, IL. October 28, 2008. Kirton O, Jacobs L, Brautigam R, Hyman N, Kaplan L and Ferguson C. Rationalization of Acute Care Surgery. Panel Discussion, New England Surgical Society Annual Meeting. Newport, RI. September 12, 2009. Kowal-Vern A, Barnett B, Ferrari M, Koenig M, Mah J, Morris L, Powers J, Stokes E, Tan M, Zaletel C, Cullum M. Comparison of Economic Value of Two Indwelling Bowel Catheters in the Acute and Critical Care Setting. (Abstract 396). Society of Critical Care Medicine, Gaylord Conference Center, Nashville, TN, Jan 29-Feb 2, 2009. Orenstein S, Kaur M, Qiao Y, Klueh U, Kreutzer D, Novitsky Y. Activation of

96.

Surgery

Human Monocytes By Human Biologic Meshes In Vitro. Association for Academic Surgery-2009 Academic Surgical Congress (February 2009) Fort Myers, FL. Orenstein S, Kreutzer D, Novitsky Y. Human Monocyte Activation by Biologic and Biodegradable Meshes In Vitro. Society of American Gastrointestinal and Endoscopic Surgeons - 2009 Annual Meeting (April 2009) Phoenix, AZ. Orenstein SB, Qiao Y, Klueh U, Kreutzer DL, Novitsky YW. Role of Mast Cells in the Biocompatibility of Synthetic Mesh in Mice. Fourth International Hernia Congress -Joint Meeting of the American and European Hernia Societies (September 2009) Berlin, Germany. Park B, Madej O, McPhelimy C, Piccirillo B, Dahn M, Burleson JA and Menzoian JO. Predictors of Clinically Significant Post-Procedure Hypotension Following Carotid Endarterectomy and Carotid Angioplasty with Stenting. The Society for Clinical Vascular Surgery Podium Presentation, Ft. Lauderdale, FL, March 8, 2008. Perdrizet G, Rader C, Allen B, Bass D, Cech A, Castiglione C, Babigian A. Coverage of Complex Scalp Wounds. Presented at the Northeast Chapter of the Undersea and Hyperbaric Medical Society Conference/Chapter Meeting, Newport RI, 11/07. Poi MJ, Novitsky Y. Laparoscopic Ventral Hernia Repair with Closure of the Defect: The Shoelace Technique. Presented at the 4th Joint Meeting of the American Hernia Society (AHS) and The European Hernia Society (EHS); Berlin, Germany. September 2009. Poi, MJ, Liang Y, Senatus P, Onyiuke H, Novitsky YW. Laparoscopic-assisted Ventriculoperitoneal Shunt Placement. Presented at the American College of Surgeons 95th Annual Clinical Congress; Chicago, IL. October 2009 (Mead/ Pyrtek Fund). Poi, MJ, Novitsky, Y. Abdominal Wall Reconstruction for Multiple Recurrent Incisional Hernia with Marked Loss Of Domain. Presented at: The Hernia Repair 2008; Scottsdale, AZ. March 2008 (Mead fund). Raad W, Onayemi A, Nelson S, Babigian A. Traumatic Forearm Arterio-Venous Malformation. Presented at the CTACS Scientific and Annual Meeting, Waterbury, CT, 10/08. Rowin C, Luu X, Nelson M, Babigian A. Squamous Cell Carcinoma of the Hand Presenting as a Painless Volar Mass. Presented at the New England Hand Society Thirty-Sixth Annual Meeting and Scientific Program, Sturbridge, MA, 12/08. Vignati P. Instructor, Laparoscopic Colon Course. American Society of Colon and

Rectal Surgeons, Hollywood, Fl, 2009. Vignati P. Instructor, Laparoscopic Colon Course. American College of Surgeons, New Orleans, LA 2008. Vignati P. Instructor, Laparoscopic Hartmann Closure Penn Lap Colon Course. Philadelphia, PA 2007. Vignati P. Recurrent Diverticulitis Following Laparoscopic Colectomy. American Society of Colon and Rectal Surgery, Hollywood Fl 2009. Zani S, Allen B, Babigian A. Black Belt Fracture: A Characteristic Injury in Trained Martial Artists. Presented at the New England Hand Society Thirty-Fifth Annual Meeting and Scientific Program, Sturbridge, MA 12/07. Zani S, Nelson S, Finck C, Babigian A. Congenital/ Infantile Fibrosarcoma of the Hand: A Multimodality Therapeutic Approach Aimed At Limb Salvage. Presented at the New England Hand Society Thirty-Sixth Annual Meeting and Scientific Program, Sturbridge, MA, 12/08.

Traumatology
and Emergency Medicine
Lincoln Abbott, MD Lauri Bolton, MD Kevin Borrup, JD, MPA Karyl Burns, PhD Brendan Campbell, MD, MPH Joo Delgado, MD Michael Drescher, MD Susan Dufel, MD James Feeney, MD Catherine Glazer, MD Ronald Gross, MD Jennifer Hiscoe, RN Lenworth Jacobs, MD, MPH Kelly Johnson-Arbor, MD Richard Kamin, MD Joanne Kuntz, MD Garry Lapidus, PA-C, MPH Stephen Luk, MD Charles McKay, MD Jacqueline McQuay, RN, MS Tahira Mirza, MD Thomas Nowicki, MD George Perdrizet, MD, PhD Kenneth Robinson, MD, MHCM Hassan Saleheen, MBBS, MPH Alan Jon Smally, MD esearch is integral to the activities of the Department of Traumatology and Emergency Medicine at Hartford Hospital. Our mission includes the conduct of research to improve the clinical, operational, and educational endeavors across all divisions in the department. The divisions include the LIFE STAR Critical Care Helicopter Service, the Emergency Department, the Trauma Program, the Center for Wound Healing and Hyperbaric Medicine, Toxicology, and the Center for Emergency Medical Preparedness. versus direct laryngoscopy by paramedics in the simulated airway was also completed by our emergency physicians. A current project is a study of intimate partner violence in patients with acute overdose. Research regarding emergency department operations included a study of over crowding and another about patients who left without being seen. On the international scene a study was conducted in Israel by our Associate Chief. It was a randomized, placebo controlled trial of etoricoxib taken prophylactically to prevent Yom Kippur headache. The study was funded by Merck, Sharp, Dohme.

Trauma Program
A highlight of projects by the Trauma Program is the TELOS (Trauma end-of-life optimum support) best practice model supported by the Aetna Foundation. The model was developed and implemented at Hartford Hospital and will soon be disseminated nationally. Data continue to be collected to assess the Advanced Trauma Operative Management (ATOM) course that is now offered in 26 sites in the United States, Canada, Ghana, Qatar, Saudi Arabia, and Japan. A survey of over 1,000 participants in the ATOM Course was recently completed. Other projects have included examinations of the relationships of the prehospital use of HMG-Co-A Reductase Inhibitor and mortality due to hemorrhagic shock associated with ruptured abdominal aneurysm and hemorrhagic shock due to trauma. A current study is investigating the relationship of pre-hospital HMG-Co-A Reductase Inhibitor use in traumatic brain injury. Another ongoing study is examining the use of a simulator to improve technique and procedure confidence of surgical residents for emergency cricothyroidotomy. A study that was recently completed was a retrospective review of the utilization and costs of routine pelvic x rays in trauma.

Life Star
The LIFE STAR Critical Care Helicopter Service has a long history of quality research. Recent projects have included studies regarding the documentation of medications administered by critical care transport teams, the use of bispectral analysis to assess sedation in patients requiring sedation and transported by helicopter, and reasons why LIFE STAR is cancelled. A recently completed study was a comparison of intra-osseous and central venous access in helicopter transport.

Emergency Medicine
The Division of Emergency Medicine has had numerous projects relating to the diagnosis and treatment of medical emergencies. For instance, one study is examining the interventional management of stroke in a phase III, randomized, multi-center clinical trial. This study seeks to determine if a combined IV and IA approach to recanalization is superior to standard IV rt-PA (Activase) alone. A recently completed study investigated the relationship of family history and appendicitis. Another study looked at thrombocytopenia and antiheparin antibodies in adult patients in the emergency department. A comparison of the Airtraq airway device

Toxicology and the Center for Emergency Medical Preparedness

In collaboration with the Center for Emergency Medical Preparedness at Hartford Hospital the Toxicology Division has been working on a project to identify normative distributions of plasma and erythrocyte cholinesterase activity based on demographic and clinical data for use as a rule-out screen for significant nerve agent toxicity. Other projects by the Toxicology Division include a study that investigated

98.

cyanmethemoglobin as an alternate laboratory test for the diagnosis of cyanide toxicity and cyanide and cyanmethemoglobin determinations in cyanide-exposed individuals. Another study was a retrospective comparison of safety and efficacy between the oral and the intravenous form of N-acetylcysteine. Other studies by members of the Toxicology Division include a comparative pharmacokinetic study of intranasal Naloxone versus intravenous Naloxone and a poison center surveillance project regarding the prescription of opioid and amphetamine-related medication mis-use and abuse. A recently approved study is an examination of the contribution of lactate, lactate dehydrogenase, and hemoglobin concentration to alterations in the plasma enzymatic/whole blood gas chromatography-flame ionization detector ratio for ethanol determinations.

Hartford Hospital Research Endowment Funds

Gross, Ronald, MD (Spinella, Philip, MD)
Relationship Between Age of RBCs Transfused and Mortality in Critically Ill Trauma Patients. Small Grant, $9,861.

Departmental Funds
McKay, Charles M.D.
Contribution of Lactate, Lactate Dehydrogenase, and Hemoglobin Concentration to Alterations in the Plasma Enzymatic/Whole Blood Gas Chromatography-flame Ionization Detector Ratio for Ethanol Determinations. $1,500.

Unfunded
Abbott, Lincoln M.D.
Validation of Core Measure Pneumonia Keyword Filter.

Center for Wound Healing and Hyperbaric Medicine

Research in the Center for Wound Healing and Hyperbaric Medicine includes a collaboration with the Center for Anti-Infective Research and Development to examine the effect of hyperbaric oxygen therapy on the penetration of linezolid into subcutaneous tissue of diabetic patients with lower extremity wounds. Another project is a collaboration with the Division of Urology to study the effect of hyperbaric oxygen therapy postprostatectomy erectile dysfunction and urinary incontinence. As a community of clinicians and researchers, members of the Department of Traumatology and Emergency Medicine strive to answer research questions that will ultimately improve patient care. To achieve this goal, the department has a strong focus on scientific inquiry, scholarship, and mentoring of young professionals. Our research agenda for the future is to participate in practice-oriented translational research to promote effective dissemination and use of evidence-based guidelines, new technologies, and new ways to educate health care professionals.

Bolton, Lauri, MD
Comparison of IO and Central Venous Access in Helicopter Transport. Statistical analysis supported through Hartford Hospital Small Grant.

Burns, Karyl, PhD

Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in Hemorrhagic Shock Due to Trauma. Statistical analysis supported through Hartford Hospital Small Grant.

Dufel, Susan, MD
A Survey of Current Emergency Medicine Residents and Graduates of 20022007 Classes Regarding the ABEM Oral Board Certification Examination. Statistical analysis supported through Hartford Hospital Small Grant.

Feeney, James, MD
Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in Traumatic Brain Injury. Statistical analysis supported through Hartford Hospital Small Grant. Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in Hemorrhagic Shock Due to Ruptured Abdominal Aortic Aneurysm (AAA): An Exploratory Study. Statistical analysis supported through Hartford Hospital Small Grant. Retrospective Review of the Utilization and Costs of Routine Pelvic X rays in Trauma. Statistical analysis supported through Hartford Hospital Small Grant.

New Projects
Industry
Montminy, John, DO
An Investigation of Topical Application of Gaseous Nitric Oxide on Safety and Efficacy in Venous Stasis Ulcers of the Lower Extremities. Nitric BioTherapeutics, $63,516.

Jacobs, Lenworth, MD
Nonoperative Management of Grade IV and V Splenic Injuries: A RECONECT (Research Consortium of New England Center for Trauma) Study. Development of Best Clinical Practice Guidelines for the Mature Trauma Patient with Rib Fractures.

Drescher, Michael, MD
Randomized, Placebo Controlled Trial of Etoricoxib Taken Prophylactically to Prevent Yom Kippur Headache. Merck, Sharp & Dohme (Israel-1996) Ltd. (Investigator Initiated), $18,500. Statistical analysis supported through Hartford Hospital Small Grant.

Kuntz, Joanne, MD
Delivering Bad News: Perceptions of Residency Directors Regarding Current Practice and Resident Education.

Effectiveness of a Read-and-Respond Checklist in Assuring Safety Behavior Compliance at a Rotor Wing Air Medical Program. Evaluation of a Modified Sign-Out Procedure on Hospital Documentation of Medications Administered by Critical Care Transport Teams. Evaluation of Helicopter Air Medical Transport Utilization by Prospective Application of Consensus Criteria.

Luk, Stephen, MD
Calciphylaxis and Chronic Dialysis Therapy. Retrospective Review of Post-Hospital Complications in Victims of Blunt Abdominal Trauma (BAT).

Glazer, Catherine, MD
Is the Use of D Dimers in A Low Risk Population Cost Effective and Safe in Ruling Out PE? Statistical analysis supported through Hartford Hospital small grant

McKay, Charles, MD
Digoxin Toxicity in Renal Failure with Hyperkalemia.

Mirza, Tahira, MD
CT Chest or CTA Chest for the Diagnosis of Blunt Aortic Injury.

Gross, Ronald, MD
Evaluation of Outcomes After Pancreato-Duodenal Injuries In New England Hospitals. Role of Ultrasound in Pre-Hospital Aeromedical Evacuation and Triage. Hartford Hospital Research Endowment Funds, $10,128.

Thibeault, Susan, APRN

Reasons for Cancellation of LIFE STAR Transport by Requester.

Active Projects
Abbott, Lincoln, MD
Interventional Management of Stroke: A Phase III, Randomized, Multi-Center Clinical Trial to Examine Whether a Combined IV and IA Approach to Recanalization is Superior to Standard IV rt-PA (Activase) Alone. NIH subcontract through University of Cincinati, $33,221.

Jacobs, Lenworth, MD
Advanced Trauma Operative Management (ATOM) Course. American College of Surgeons Advance Trauma Life Support Course (ATLS). Bioterrorism Surveillance and Response Preparedness and Training. University of Connecticut, $50,000. Development, Implementation, and Testing of a Best Practice Model for End-ofLife Care in Trauma. Aetna Foundation, $295,000. Evaluation of the Advanced Trauma Operative Management (ATOM) Course. Multi-Center Trial of the Advanced Trauma Operative Management (ATOM) Course. QuikClot versus Packing For Hemostasis After Grade V Liver Injury in Swine. Z-Medica, $224,000.

Brautigam, Robert, MD
Evaluation of the Trauma Simulation Education Course. The Development of Lower Extremity Compartment Syndrome Following Fractures of the Tibia and Fibula.

Corson, Thomas, DO
Reliability of Emergency Department Patients Contact Information.

Kuntz, Joanne, MD
Thrombocytopenia and antiheparin antibodies in adult ED patients. Glaxo Smith Kline, $9,800.

Delgado, Joo, MD
Bispectral Analysis of Air Transport Patients. Prevalence of Intimate Partner Violence in Acute Overdose Patients Retrospective Comparison of Safety and Efficacy Between the Oral and the Intravenous Form of N-acetylcysteine. Rocky Mountain Poison and Drug Center, $2,200.

Lewis, Myra, DO
History Taking in Emergency Department Patients Presenting with Acute Chest Pain.

Drescher, Michael, MD
Can Family History be used as a Predictor for Appendicitis? Statistical analysis supported through Hartford Hospital Small Grant. Overcrowding in the Emergency Department.

Luk, Stephen, MD
Crush Injuries and Hyperbaric Oxygen Therapy: Inital Experience at a Level 1 Trauma Center with a Multiplace Hyperbaric Chamber. Radionecrosis Research Registry. The Role of Hyperbaric Oxygen Therapy in the Treatment of Severe Soft-Tissue Infections.

Frakes, Michael, APRN

A Comparison of Pre-hospital Trauma Analgesia By Air and Ground EMS Providers. Effect of Line Oriented Flight Training On Team Behaviors and Beliefs at a Helicopter Air Medical Program.

Lynch, John, MD
Emergency Procedures for Emergency Medicine Residents.

100.

McKay, Charles, MD
Comparative Pharmacokinetic Study of Intranasal Naloxone Versus Intravenous Naloxone. Hartford Hospital Research Endowment Funds, $6,981 Cyanmethemoglobin: An Alternative Laboratory Test for the Diagnosis of Cyanide Toxicity. Departmental, $2,460. Normative Distributions of Plasma and Erythrocyte Cholinesterase Activity in a Tertiary Care Emergency Department, Based on Demographic and Clinical Data, for Use as a Rule-Out Screen for Significant Nerve Agent Toxicity. HRSA c/o State of Connecticut, $60,250. Relationship between CPK and Aminotransferase Elevations in Rhabdomyolysis Patients. Statistical analysis supported through Hartford Hospital small grant

Brautigam RT, Schott E, Burns KJ. A simulation education course for the initial management of blunt trauma. Conn Med. 2009;73:267-271. Campbell BT, Saleheen H, Borrup K, McQuay J, Luk S, Hiscoe J, Lapidus G. Epidemiology of trauma at a level 1 trauma center. Conn Med. 2009;73:389-394. Cronin D, Dufel S. Plague. E-Medicine chapter July, 2009. Available at:http:// emedicine.medscape.com. Dada MR, Hirst JA, Kiernan FJ, Smally AJ, Lundbye JB, Thompson PD, McKay RG. Use of prehospital electrocardiograms for the treatment of patients with ST-segment elevation myocardial infarction. Conn Med. 2009;73(2):69-72. Drescher M J, Aharonson L, Peleg J, Liebman J. A study of the workforce in emergency medicine in Israel 2003. J of Emerg Med. 2007;33(4):433-437. Drescher M. Guest editorial: Patient satisfaction in the ED: nicety or necessity? Israeli J Emerg Med. 2009;9(1):3-4. Feeney J M, Burns K J, Staff I, Bai J, Rodrigues N, Fortier J, Jacobs LM. Prehospital HMG Co-A Reductase Inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Amer Coll Surg. 2009;209:41-46. Goldstein RA, DesLauriers, Burda A, Johnson-Arbor K. Cocaine: history, social implications, and toxicity: a review. SEMIN DIAGN PATHOL. 2009;26:10-17. Gross RI, Jacobs LM. Initial assessment and resuscitation, airway management: what every trauma surgeon should know, from intubation to cricothyroidotomy. In: Asensio JA, Trunkey DD, editors. Current Therapy of Trauma and Surgical Critical Care. Philadelphia: WB Saunders/Elsevier; 2008. Hoffman RS, Kirrane BM, Marcus SM, and the Clenbuterol Study Investigators (McKay C). A descriptive study of an outbreak of clenbuterol-containing heroin. Ann Emerg Med. 2008;52:548-553. Jacobs LM, Burns KJ, Bennett Jacobs B. Trauma death: views of the public and trauma professionals on death and dying from injuries. Arch Surg. 2008;143:730-735. Lefberg J, Delgado J. Hyper- and Hypo-natremia. In ToxED Online Reference based on Haddad & Winchester Clinical Management of Poisoning and Drug Overdose. Elsevier and Gold Standard. V2, 2008. Available at: http://www. toxed.com. Matz, T, Abbott, L. Review article: bilateral acute angle closure glaucoma. Resident and Staff Physician. 2008;(54)3:10-14. McKay CA. Chlorine. In ToxED Online Reference based on Haddad & Winchester Clinical Management of Poisoning and Drug Overdose. Elsevier and Gold Standard. V2, 2008. Available at: http://www.toxed.com. McLaughlin S, Fitch M, Deepi G, Hayden E, Kauh C, Laack T, Nowicki T et al. Simulation in graduate medical education 2008: a review for emergency medicine. Acad Emerg Med. 2008;15 (11):1117-1129.

Nowicki, Thomas, MD
Airtraq Airway Device in Emergency Airway Management. Statistical analysis supported through Hartford Hospital Small Grant. Management of the Difficult Airway (CME - Educational Course).

Perdrizet, George, MD
Chart review of the treatment of delayed radiation tissue injury of soft tissue and bone with hyperbaric oxygen therapy. Development of a Stress-Sensitive Assay Using Discarded Human Red Blood Cells. Geriatric Trauma: A Comparison of Bone Fracture Healing Rates. Hartford Hospital Research Endowment Funds, $43,164. Minimally Invasive Treatment of the Abdominal Compartment Syndrome: Initial Experience. Outcomes of Patients with Diabetic Foot Ulcers Treated with Hyperbaric Oxygen Therapy. Prevention of Complicated Alcohol Withdrawal Syndrome in the Hospitalized Trauma Patient: A Comparison of Intravenous Benzodiazepine vs. Ethyl Alcohol Therapies. Hartford Hospital Research Endowment Funds, $65,650.

Regan, Thomas, MD
Variations in Usage of Emergency Medicine.

Robinson, Kenneth, MD
Flight Nurse Training of Surgical Skills. Patients who leave without being seen at the Hartford Hospital Emergency Department. Statistical analysis supported through Hartford Hospital Small Grant.

Schott, Eric, PA
Evaluation Of Trauma Orientation.

Publications
Brautigam RT, Sheppard R, Robinson K, Jacobs LM. Evaluation and treatment of the multiple-trauma patient. In: Browner BD, Jupiter JB, Levine AM, Trafton PG. Skeletal Trauma: Basic Science, Management and Reconstruction, 4th ed. 2009.

Nowicki TA, Suozzi JC, Dziedzic M, Kamin R, Donahue S, Robinson K. Comparison of the use of the Airtraq with direct laryngoscopy by paramedics in the simulated airway. Prehosp Emerg Care. 2009;13:75-80. OToole K, Delgado J. Methemoglobinemia. In ToxED Online Reference based on Haddad & Winchester Clinical Management of Poisoning and Drug Overdose. Elsevier and Gold Standard. V2, 2008. Available at: http://www.toxed.com. OToole K, Delgado J. Glucose Disturbances. In ToxED Online Reference based on Haddad & Winchester Clinical Management of Poisoning and Drug Overdose. Elsevier and Gold Standard. V2, 2008. Available at: http://www.toxed.com. Phelan HA, Velmahos GC, Jurkovich GJ, et al. (Feeney J.). An evaluation of multidetector computed tomography in detecting pancreatic injury: results of a multicenter AAST study. J Trauma. 2009;66:641-647. Scalora MA, Gross RI, Burns KJ. Management of blunt hepatic trauma at a Connecticut level I trauma center. Conn Med. 2007;71:529-532. Smally, AJ. Aging in america, in your own words emergency physicians discuss end-of-life care. Emergency Physicians Monthly. 2009;16(6). Vorih DC, Bolton LD, Marcelynas J, Nowick TA, Jacobs LM, Robinson KJ. Comparison of Nitrile gloves and Nitrile over Nomex gloves. Air Med J. 2009;28:250-253. Wu AHB, Smith A, McComb R, Bowers GN, Makowski GS, McKay CA, Vena J, McDonagh J, Hopfer S, Sena SF, Malkus H, Forte E, Kelly K. Statewide hospital clinical laboratory plan for measuring cholinesterase activity for individuals suspected of exposure to nerve agent chemical weapons. Clin Toxicol. 2008;46(2):110-116.

Chartoff S. Hartford Hospital Emergency Department mass casualty incident, a table top disaster drill. Grand Rounds, Department of Traumatology and Emergency Medicine Hartford Hospital, Hartford, CT, January 15, 2009. Chartoff S. Critical care in the air en route care system during recent military operations. Nursing Critical Care Day, Hartford Hospital, Hartford, CT, March 27, 2009. Drescher MJ, Spence A, Rockwell D, Smally AJ. Point of care testing for coagulation studies in an emergency department stroke protocol: a time saving innovation. Scientific Assembly, American College of Emergency Physicians, Seattle WA. October, 2007. Ann Emerg Med. 2007; 50(3):S25. Drescher MJ, Spence A, Rockwell D, Smally AJ. Point of care testing for coagulation studies in an emergency department stroke protocol: a time saving innovation. Scientific Assembly, Connecticut College of Emergency Physicians, Rocky Hill, CT, October 10, 2007. Drescher MJ. Altered standards of medical care in disasters. Annual meeting, Israeli Association of Emergency Medicine, Tel Aviv, Israel, March 11, 2008. Drescher MJ, Spence A, Rockwell D, Staff I, Smally AJ. Point of care testing for coagulation studies in an emergency department stroke protocol: a time saving innovation. Poster presentation. New England Regional Society of Academic Emergency Medicine, Shrewsbury, MA, April 30, 2008. Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis in adults presenting to the emergency department. Scientific Assembly, Connecticut College of Emergency Physicians, Rocky Hill, CT, October 22, 2008. Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis in adults presenting to the emergency department. Scientific Assembly, American Academy of Emergency Medicine, Phoenix, AZ, March 2-4, 2009. Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis in adults presenting to the emergency department. New England Regional Society of Academic Emergency Medicine, Shrewsbury, MA, March 18, 2009. Drescher MJ. An evidence based approach to urolithiasis in the emergency department. Fifth Mediterranean Emergency Medicine Congress, Valencia, Spain, September 14, 2009. Drescher MJ. A placebo controlled double blind and randomized trial of prophylactic etoricoxib given to prevent Yom Kippur headache. Fifth Mediterranean Emergency Medicine Congress, Valencia, Spain, September 15, 2009. Drescher MJ. Family history is a predictor of appendicitis in the adult emergency department patient. Fifth Mediterranean Emergency Medicine Congress, Valencia, Spain, September 16, 2009. Dziedzic M, Suozzi J, Nowicki T. Comparison of the Airtraq optical laryngoscope to direct laryngoscopy in a manikin model for easy and difficult

Abstracts and Presentations

Alhelail MA, Hoppe JA, Rhyee SH, Heard KJ, Toxicology Investigator Network (J. Delgado, et al.) Clinical course of repeated supratherapeutic ingestion of acetaminophen. Platform presentation. 2008 North American Congress of Clinical Toxicology, Toronto, Canada, September 13-16, 2008. Brayton A, Delgado D, Flowers D, Delgado J. Prevalence of intimate partner violence in an urban ED population. New England Regional Society of Academic Emergency Medicine, Shrewsbury, MA, March 18, 2009. Buchanan JA, Phua DH, Mlynarchek SL, Heard K, Toxicology Investigator Network (J. Delgado, et al.) Serum acetaminophen levels, intravenous N-acetylcysteine infusion rate and risk of anaphylactoid reactions. Platform presentation. 2008 North American Congress of Clinical Toxicology, Toronto, Canada, September 13-16, 2008. Chartoff S. Critical care in the air - en route care system during recent military operations. Grand Rounds, Department of Traumatology and Emergency Medicine, Hartford Hospital, Hartford, CT, July 17, 2008.

102.

intubations. Poster presentation. Scientific Assembly, American College of Emergency Physicians, Seattle, WA, October, 2007. Frakes M, Delgado J. Bispectral analysis of air transport patients. Poster presentation. Hartford Hospital Research Day, Hartford, CT, November, 2008. Frakes M, Thibeault S, Robinson K, McQuay J. Evaluation of a modified sign-out procedure on hospital documentation of medications administered by critical care transport teams. Poster presentation. Hartford Hospital Research Day, Hartford, CT, November, 2008. Frakes M, Thibeault S, Robinson K, McQuay J. Evaluation of a modified sign-out procedure on hospital documentation of medications administered by critical care transport teams. Poster presentation. Society of Academic Emergency Medicine, New Orleans, LA, May 14-17, 2009. Jacobs LM. Case Presentations Moderator. UT Southwestern Medical Center. Dallas, TX, October 17, 2007. Jacobs LM. Advanced Trauma Operative Management: A new and innovative method of surgical education. Distinguished Lecturer. Royce Laycock, MD, Lectureship in Surgery. UT Southwestern Medical Center, Dallas, TX, October 17, 2007. Jacobs LM. New ways to education physicians in a changing time. Trends in Medicine and Surgery, Beaver Creek, CO, February 5, 2008. Jacobs LM. The trauma system in Connecticut and its clinical importance. Stable spine fractures: when should we be concerned? Multidisciplinary Conference, Hartford Hospital. Hartford, CT, March 20, 2008. Jacobs LM. Thoracic trauma: have we made any progress? Moderator. Looking back moving forward. Connecticut Trauma Conference, Foxwoods Resort and Conference Center, Ledyard, CT, April 3, 2008. Jacobs LM. New ways to educate practitioners in a changing time. Keynote address. Jacobi Medical Center Trauma/Emergency Medicine Symposium, Bronx, NY, May 14, 2008. Jacobs LM. Splenic injuries: should the preference be angiography/embolization over operative intervention? Point/Counterpoint, American College of Surgeons, Baltimore, MD, June 10, 2008. Jacobs LM. Closed head injuries and insertion of intracranial pressure monitors: should this procedure be strictly done by neurosurgeons only? Point/Counterpoint, American College of Surgeons, Baltimore, MD, June 10, 2008. Jacobs LM. New topical hemostatic agents: are they cost effective? Point/ Counterpoint, American College of Surgeons, Baltimore, MD, June 10, 2008. Jacobs LM. Simulated education in trauma. Grand Rounds. Rush University, Chicago, IL, October 28, 2008. Jacobs LM. The Advanced Trauma Operative Management Course: an innovative

response to the technical challenges of trauma surgery. Visiting Professor, Cedars-Sinai Medical Center, Los Angeles, CA, November 12, 2008. Jacobs LM. An innovation in surgical education in trauma. Grand Rounds. University of Iowa, Iowa City, IA, February 25, 2009. Jacobs LM, Burns KJ. Advanced Trauma Operative Management (ATOM) Course: an exemplar of simulation education scenario development. Poster presentation. American College of Surgeons Consortium of Accredited Education Institutes, Chicago, IL, March, 2009. Jacobs LM. Pediatric trauma. Moderator. Connecticut Trauma Conference, Foxwoods Resort, Ledyard, CT, April 2, 2009. Jacobs LM. Necrotizing soft tissue infections: is hyperbaric oxygen therapy even an essential adjunct? Point/Counterpoint, American College of Surgeons, National Harbor, MD, June 8, 2009. Jacobs LM. Invasive procedures performed by prehospital personnel: the indications should be broad. Point/Counterpoint, American College of Surgeons, National Harbor, MD, June 8, 2009. Jacobs LM. Acute care surgeon: should critical care management be an essential component? Point/Counterpoint, American College of Surgeons, National Harbor, MD, June 9, 2009. Jacobs L M, Burns K J, Luk S, Hull S. Advanced Trauma Operative Management (ATOM) Course: participant survey. Poster presentation. New England Surgical Society, Newport, RI, September 12, 2009. Johnson-Arbor K. Drugs of abuse for EMS providers. LIFE STAR EMS Conference, Hartford, CT, October 29, 2007. Johnson-Arbor K. Toxicologic emergencies. LIFE STAR EMS Conference, Hartford, CT, October 29, 2007. Johnson-Arbor K. Hyperbaric oxygen therapy: intracranial abscess, osteomyelitis, acute blood loss anemia, carbon monoxide poisoning. University of Hartford, Hartford, CT, CT, November 26, 2007. Johnson-Arbor K. Pressure ulcers: overview and medicolegal issues. PA/NP Grand Rounds, Hartford Hospital, Hartford, CT, March 4, 2008. Johnson-Arbor K. Toxins and envenomations for the intensivist. Surgical ICU Conference, Yale New-Haven Hospital, New Haven, CT , March 18, 2008. Johnson K. Chemical contamination of food, water, and medication. Toxic Industrial Chemicals and Materials Conference, American College of Medical toxicology, Knoxville, TN, May 29, 2008. Johnson-Arbor K. Pressure ulcers and wounds for ED physicians. Integrated Residency in Emergency Medicine, University of Connecticut, Hartford, CT, September 23, 2008.

Judson B, Tilden F, Delgado J, Dean A. Availability of emergency ultrasound: a statewide survey. Poster presentation. New England Regional Society of Academic Emergency Medicine, Shrewsbury, MA, April 30, 2008. Judson B, Tilden F, Delgado J, Dean A. Availability of emergency ultrasound: a statewide survey. Poster presentation. Scientific Assembly, Connecticut College of Emergency Physicians, Rocky Hill, CT, October 22, 2008. Kirton O, Jacobs L, Brautigam R, Hyman N, Kaplan L, Ferguson C. Rationalization of acute care surgery, Panel Discussion. New England Surgical Society. Newport, RI, September 12, 2009. Luk S. Presentation, diagnosis & treatment of major bleeding pelvic vs. other sources. Orthopedic Multidisciplinary Conference, Hartford Hospital, Hartford, CT, August 1, 2008. Luk S. Advanced Trauma Operative Management (ATOM) Course. University of Alberta, Edmonton, Alberta, Canada, November 9, 2007. Luk S. Advanced Trauma Operative Management (ATOM) Course. University of Iowa Hospitals and Clinics, Iowa City, IA, November 19, 2007. Luk S. Advanced Trauma Operative Management (ATOM) Course. University of Texas Medical Branch, Galveston, TX, May 20, 2008. Luk S. Advanced Trauma Operative Management (ATOM) Course. Massachusetts General Hospital, Boston, MA, June 1, 2008. Luk S. Pelvic fracture management. Grand Rounds. University of Iowa Hospitals & Clinics, Iowa City, IA, September 30, 2008. Luk S. Advanced Trauma Operative Management (ATOM) Course, Course faculty and site evaluator. King Abdulaziz Medical City & Hamad Medical Corp., Doha, Qatar, November 27, 2008. Luk S. Advanced Trauma Operative Management (ATOM) Course, Course faculty and site evaluator. Jichi Medical University, Jichi, Japan, December 18, 2008. Luk S. Whats new in the diagnosis and management of pelvic trauma? William Backus Hospital, Norwich, CT, January, 2009. Martinelli CJ, Barko IR, OToole K, Bayer MJ. Vitamin B17 toxicity treated with hydroxocobalamin. Clin Toxicol. 2008;46: 631. McKay CA. Interpreting biomonitoring results. Environmental Health Research Foundation web video, October 2007. McKay CA. The role of the medical toxicologist in the assessment of moldrelated complaints. American College of Medical Toxicology Practice Symposium (moderator), North American Congress of Clinical Toxicology, New Orleans, LA, October 22, 2007. McKay CA. Arsenic. Clinical/Analytical Toxicology Case Conference, Connecticut Department of Public Health Laboratory, Hartford, CT, October 25, 2007.

McKay CA. Introduction/clinical neurotoxicology of chemical terrorism/ delayed toxic syndromes - chemical Agents of Opportunity: Toxic Industrial Chemicals and Materials Conference, HazMat EXPO 2007, Las Vegas, NV, November 6, 2007. McKay CA. Carbon monoxide poisoning in Connecticut: an analysis of three databases using capture-recapture statistics. Undersea and Hyperbaric Medical Society Northeast Chapter Annual Scientific Meeting, Newport, RI, November 10, 2007. McKay CA. Decompression theory and illness. Hyperbaric Medicine Course (HS490). University of Hartford, Hartford, CT, November 19, 2007. McKay CA. Cotinine. Clinical/Analytical Toxicology Case Conference, Connecticut Department of Public Health Laboratory, Hartford, CT, November 29, 2007. McKay CA. Environmental instrumentation/post-incident medical surveillance - chemical agents of opportunity. Toxic Industrial Chemicals and Materials Conference, American College of Medical Toxicology, Oakland, CA, December 18, 2007. McKay CA. Introduction/post-incident medical surveillance - chemical agents of opportunity. International Emergency Management Conference. Emergency Medicine Learning Resource Center, Orlando, FL, January 31, 2008. McKay CA. Legal (forensic) ethanol. Clinical/Analytical Toxicology Case Conference, Connecticut Department of Public Health Laboratory, Hartford, CT, February 28, 2008. McKay CA. Munchausen by proxy. Clinical/Analytical Toxicology Case Conference, Connecticut Department of Public Health Laboratory, Hartford, CT, March 27, 2008. McKay CA. Introduction and tabletop exercise. Toxic Industrial Chemicals and Materials Conference, American College of Medical Toxicology, Knoxville, TN, May 29, 2008. McKay CA. Cellular toxins. American Association of Poison Control Centers Webcast, June 13, 2008. McKay CA. Adulterated heroin. Clinical/Analytical Toxicology Case Conference, Connecticut Department of Public Health Laboratory, Hartford, CT, June 19, 2008. McKay CA. Food, water and medication as vehicles for terrorism and radiation - chemical agents of opportunity. Toxic Industrial Chemicals and Materials Conference. 94th Civil Support Team/National Guard, Guam, July 16, 2008. McKay CA. Chemical terrorism. Connecticut Laboratory Preparedness Meeting, Connecticut Department of Public Health Laboratory, Hartford, CT, August 4, 2008.

104.

McKay CA. Toxic warfare: looking beyond conventional chemical weapons. Force Health Protection Conference, United States Army Center for Health Promotion and Preventive Medicine (USACHPPM), Louisville, KY, August 5, 2008. McKay CA. The psychological impact of mass chemical exposures. Force Health Protection Conference, United States Army Center for Health Promotion and Preventive Medicine (USACHPPM), Louisville, KY, August 5, 2008. McKay CA. Introduction. Toxic Industrial Chemicals and Materials Conference, Force Health Protection Conference, United States Army Center for Health Promotion and Preventive Medicine; Albuquerque, NM, August 10, 2008. McKay CA. Melamine-contaminated Chinese food products. Clinical/Analytical Toxicology Case Conference, Connecticut Agricultural Experiment Station, New Haven, CT, October 23, 2008 (with MaryJane Mattina PhD). McKay CA. Introduction/clinical psychological responses to mass exposures. Chemical agents of opportunity. Toxic Industrial Chemicals & Materials Conference, Hazmat Expo 2008, Las Vegas, NV, November 5, 2008. McKay CA. History & epidemiology/table top exercise. Health Consequences of Clandestine Methamphetamine Laboratories Conference, Hazmat Expo 2008, Las Vegas, NV, November 5, 2008. McKay CA. Medical aspects of crucifixion, symposium and banquet. FaithCare, Bloomfield, CT, November 8, 2008. McKay CA. Homicidal poisoning. Clinical/Analytical Toxicology Case Conference. Connecticut Department of Public Health Laboratory, Hartford, CT, November 20, 2008. McKay CA. Lethal poisoning. Caribbean Emergency Medicine Congress, University of the West Indies and the American Academy of Emergency Medicine, Barbados, West Indies, January 5, 2009. McKay CA. Chemical terrorism. Caribbean Emergency Medicine Congress, University of the West Indies and the American Academy of Emergency Medicine, Barbados, West Indies, January 7, 2009. McKay CA. Risk communication, neurotoxicology update: advances, challenges, & future directions. 7th Annual ACMT Spring Conference, American College of Medical Toxicology, San Juan, Puerto Rico, March 27, 2009. McKay CA. Mercury exposure & neurotoxicology update: advances, challenges, & future directions. 7th Annual ACMT Spring Conference, American College of Medical Toxicology, San Juan, Puerto Rico, March 28, 2009. McKay CA. Fellows-in-training: roundtable luncheon: assessment of job offers. 7th Annual ACMT Spring Conference, American College of Medical Toxicology, San Juan, Puerto Rico, March 28, 2009. McKay CA. Physiologic effects of chemical terrorism. Responding to a chemical terrorism attack: training for the first responder. Connecticut Department of Public Health (with FBI, CT State Police, 14th CST, US DHS), Berlin, CT, April 14, 2009.

McKay CA. Use of drug testing in child protection cases. 10th Annual Child and Youth Law Forum, Cromwell, CT, June 24, 2009 (presentation and panel discussion w/Attnys. Michael Besso, Scott Sandler, and Carolyn Signorelli). Mckinney C, Bolton L, Robinson K, Burns K. Characterization of patients who leave an emergency department without being seen. Scientific Assembly, American College of Emergency Physicians, Seattle, WA, October 1, 2007. Mlynarchek SL, Bogdan GM, Heard K, Dart RC, Toxicology Investigator Network (J. Delgado, et al.). Safety profile of oral versus intravenous N-acetylcysteine for acute ingestion of acetaminophen. Poster Presentation. 2008 North American Congress of Clinical Toxicology, Toronto, Canada, September 13-16, 2008. Nowicki TA. Triage of NBC Casualties. Estonian National Medical Conference, Tartu, Estonia, December, 2007. Nowicki T. Nuclear and Radiation Emergencies. Estonian Military Physician Group, Tartu, Estonia, December, 2007. Nowicki T. Management of the difficult airway, skills laboratory faculty instructor. 37th Critical Care Congress, Society of Critical Care Medicine, Honolulu, HI, February 2-6, 2008. Nowicki T, Dziedzic M, Suazzi J. Comparison of the Airtraq optical laryngoscope to direct laryngoscopy in a manikin model for easy and difficult intubations. New England Regional Society of Academic Emergency Medicine, Shrewsbury, MA, April 30, 2008 Palla K, Jacobs L, Burns K, Luk S, Hull S. Survey of participants attending the Advanced Trauma Operative Management (ATOM) Course at all sites worldwide since its inception. Scientific and Annual Meeting, Connecticut Chapter American College of Surgeons, Waterbury, CT, October 24, 2008. Robinson K. Developing a three-year marketing plan. Medical Director Forum, Air Medical Physician Association, Minneapolis, MN, October 1, 2008. Roche KM, Hart K, Sangalli B, Lefberg J, Bayer M. Kratom: A case of a legal high. Clin Toxicol. 2008;46:598. Schnatz PF, Vaidyanathan G, Surette A, Tower M, Price C, Delgado J, Sundaram K. The medical needs and demographic makeup of menopausal women in a rural Nigerian village. Poster presentation. 2008 North American Menopause Society Annual Meeting, Orlando, FL, September 24-27, 2008. Smally AJ. Management of the difficult airway. Caribbean Emergency Medicine Congress, University of the West Indies and the American Academy of Emergency Medicine, Barbados, West Indies, January 7, 2009. Zosel AE, Varney SM, Heard K, Toxicology Investigator Network (J. Delgado, et al.). Outcomes of acetaminophen ingestion patients unable to be classified as acute or repeated supratherapeutic ingestions. Poster Presentation. 2008 North American Congress of Clinical Toxicology, Toronto, Canada, September 13-16, 2008. UROLOGY

Urology
he Department of Urology continues to expand its research capacity. Recently the Department welcomed Anoop Meraney, MD. Dr. Meraney, who completed fellowships at the Cleveland Clinic and at Memorial Sloane Kettering, will be spending a portion of his time in the department reviewing its current research efforts and programs and directing the development of a comprehensive urology database which will be supported by the hospital. The Departments current research includes important work by Drs. Joseph Wagner and Stuart Kesler comparing the results and complications of robotic prostatectomy vs traditional prostatectomy. Hartford Hospital performs more robotic procedures (urologic, gynecologic, and cardiac) than any hospital in New England. The data obtained through the robotic prostatectomy studies performed at Hartford Hospital compare favorably with other high volume centers nationally and verify the excellent clinical outcomes being obtained at this institution.

SS, Wagner JR and Laudone VP. Does Prior Abdominal Surgery Influence Outcomes or Complications of Robotic Assisted Laparoscopic Radical Prostatectomy? American Urological Association New England Section Annual Meeting, Rio Grande, Puerto Rico, 2008. Abstract #5, page 59. Ginzburg S, Staff I, Tortora J, Champagne A, Shichman S, Kesler S, Laudone VP, Wagner JR. Prostate Cancer Biochemical Recurrence Rates After Robot Assisted Laparoscopic Radical Prostatectomy. American Urological Association New England Section Annual Meeting, Washington, DC, 2009. Abstract #13, pages 83-84. Ginzburg S, Staff I, Tortora J, Champagne A, Shichman S, Kesler S, Laudone VP, Wagner JR. Functional Outcomes After Robot Assisted Laparoscopic Radical Prostatectomy. American Urological Association New England Section Annual Meeting, Washington, DC, 2009. Abstract #14, pages 85-86. Irwin BH and Wagner JR. Complications of robotic surgery. In Complications of Urologic Surgery: Prevention and Diagnosis. Taneja (Ed.). 4th Edition. Elsevier, 2009. Myer EG and Wagner JR. Robotic-assisted laparoscopic bladder diverticulectomy. J. Urol., 178 (6): 2406-2410, 2007. Schimpf M, Gottenger E, and Wagner J. Universal ureteral stent placement at hysterectomy to identify ureteral injury: A decision analysis. BJOG, 115 (9): 1151 -1158, 2008. Schimpf MO and Wagner JR. Robotic-assisted laparoscopic boari flap ureteral reimplantion. J. Endourol., 22(12): 2691-4, 2008. Schimpf MO and Wagner JR. Robotic-assisted laparoscopic distal ureteral surgery. JSLS 13(1):44-9, 2009. Schimpf MO and Wagner JR. Robotic-assisted laparoscopic ureterocalicostomy with long-term follow-up. J. Endourol. 23(2): 293-5, 2009. Wagner JR and Schimpf MO. Robot assisted laparoscopic boari flap and ureteral reimplantation. J. Urol. 181(4): V1547, 553, 2009. Wagner JR, Schimpf MO, and Cohen JL. Robot-assisted laparoscopic ileal ureter. JSLS 12 (3): 306-9, 2008.

New Projects
Unfunded
Wagner, Joseph, MD
Use of Robotic Assistance in Laparoscopic Ureteral Surgery.

Active Projects
Shichman, Steven, MD
Trends in Renal Cancer Surgery: The Hartford Hospital Experience. Analysis supported by Hartford Hospital Small Grant. Hartford Hospital Nephrectomy Research Database. Database supported by Hartford Hospital Small Grant.

Publications and Presentations

Ercole B, Staff I, Champagne A, Tortora J, Kesler SS, Laudone VP, and Wagner JR. Complications of Robotic Assisted Laparoscopic Prostatectomy: Review and Assessment of Risk Factors. American Urological Association New England Section Annual Meeting, Rio Grande, Puerto Rico, 2008. Abstract #28, page 143. Ginzburg S, Hu F, Staff I, Tortora, J, Champagne A, Salner A, Shichman S, Kesler

106.

Womens Health Services Collaborative Management Team

Joel Sorosky, MD, Janice Cousino RNC, MSN, CNS and John Greene, MD

Womens Health
New Projects
Industry
Steinberg, Adam, DO
A Phase 2, 16 Week, Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Proof of Concept Study Evaluating the Efficacy and Safety of PF04383119 for the Treatment of Pain Associated with Interstitial Cystitis. Pfizer, Inc.(MultiCenter), $44,163.

Brown, Amy, MD
The Impact of a Structured Training Program on Gynecology Residents Attitudes Towards Robotic Assisted Surgery.

Collins, Sarah, MD
Patient Characteristics Associated PISQ-12 Completion. Statistical Analysis supported through Hartford Hospital Small Grant. The Impact of Flatal Incontinence on Quality of Life and Sexual Function. Statistical Analysis supported through Hartford Hospital Small Grant.

Hartford Hospital Research Endowment Funds

Collins, Sarah, MD
Perioperative Exercise Tolerance and Pain Control in Women Undergoing Robotic vs Traditional Abdominal Sacral Colpopexy. Small Grant, $8,428.

Delude, Cassandra
Floor Disorders in Women Under the Age of 65: Quality of Life and Care-Seeking Behavior.

Patel, Minita, MD
The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery: A Randomized Double Blinded Placebo Controlled Trial. Small Grant, $9,758.

Feldman, Deborah, MD
Indications for Full-term NICU Admission in a Large Urban Community Hospital. Risk Factors and Clinical Implications of Cesarean Hysterectomy.

Unfunded
Borgida, Adam, MD
Determining the Significance of Nuchal Translucency and Pregnancy Associated Plasma Protein-A in Relation to Adverse Outcomes in the Euploid Fetus. Outcomes of Fetal Cystic Hygroma Detected at First Trimester Ultrasound. Predictors of Neonatal Morbidity and Mortality in the Extremely Low Birth Weight Infant. Trends in Near-Term Preterm Births at Hartford Hospital.

Greene, John, MD
An Institutional Ethnography of the Practice of Male Neonatal Circumcision.

Ingardia, Charles, MD
Effect of Placental Lakes on First Trimester Serum Screening Results.

Johnson, Amy, MD
Is Adenomyosis Associated with Preterm Delivery?

LaSala, Christine, MD
Causes of Overactive Bladder in Women from a Urogynecology Practice. Statistical Analysis supported through Hartford Hospital Small Grant. Does Short Interval Pregnancy Increase Risk of Pelvic Floor Disorders?

Patel, Minita, MD
A Cost Minimization Analysis of Three Surgical Procedures for Sacral Colpopexy. Statistical Analysis supported through Hartford Hospital Small Grant. Bother Symptoms and Quality of Life as Related to Prolapse. Statistical Analysis supported through Hartford Hospital Small Grant. The Utility of the Beef Tongue Model for Teaching Residents Anatomy and Repair of a Fourth Degree Laceration. Statistical Analysis supported through Hartford Hospital Small Grant. Urinary Incontinence Outcomes After Sacral Colpopexy. Statistical Analysis supported through Hartford Hospital Small Grant. Written Survey of How Vaginal Pessaries Affect Body Image in Pelvic Organ Prolapse. Statistical Analysis supported through Hartford Hospital Small Grant.

Currie, John, MD
ChemoFx Registry: An Observational, Longitudinal, Multi-center Study Examining Outcomes Associated with the Use of the ChemoFx Assay in Solid Tumor Malignancies. Precision Therapeutics, $30,031.

Feldman, Deborah, MD
A Comparison of Antenatal Betamethasone vs Dexamethasone in Reducing Neonatal Complications of Prematurity. Short-term Outcomes of Neonatal Congenital Heart Disease.

Gonci, Mary-Ellen, APRN

Oral Health and its Implications During Pregnancy.

Greene, John, MD
Cigarette Smoking and Effects on Infant/Child Health. UCHC, $37,025. Resident Education Research Blanket Protocol. Statistical Analysis supported through Hartford Hospital Small Grant. Transcatheter Arterial Embolization of Uterine Fibroids.

Pope, Kisti, MD
Ultrasonographic Evaluation of Post-Partum Endometrial Stripe.

Spencer, Jeffrey, MD
Levels of Cell-Free Fetal DNA in Maternal Plasma in Pregnant Patients with Euploid and Aneuploid Fetuses. Natural History of Isolated Fetal Intracardiac Focus and its Relationship to Down Syndrome.

Johnson, Amy, MD
A Prospective Cohort Study Comparing the Discontinuation Rates Between Levonorgestrel-Releasing Intrauterine Systems and Etonogestrel Subdermal Single-Rod Contraceptive Implants in a Residency Clinic Population. An Institutional Review of Management Outcomes for High Grade Cervical Dysplasia in Adolescent Women. Incidence of HPV in an Inner City Population without Dysplasia. Statistical Analysis supported through Hartford Hospital Small Grant. Is Breast Arterial Calcification (BAC) Found on Routine Mammography Associated with an Increased Risk of Cardiovascular Disease? Statistical Analysis supported through Hartford Hospital Small Grant. Is Menopause the Same Cross-Culturally? Wyeth Pharmaceuticals, $4,000. The Role Of The Provider In Racial And Ethnic Disparities In Prenatal Care. CT Health Foundation, $5,000.

Active Projects
Beck, Cheryl, DNSc
Docosahexaenoic Acid in Pregnancy: Postpartum Depression.

Borgida, Adam, MD
Effect of Mode of Delivery of 23-28 Week Infants on Infant Morbidity and Mortality. Infant Neuronal Maturity and Tobacco Use in Pregnancy: Is There An Association? Pregnancy Outcomes After Prenatal Exposure to Antidepressants. Pregnancy Outcomes of Women Who Report Antepartum Depression. Trends in Down Syndrome Screening. Trends in Mode of Delivery for Clinic Versus Private Patients From 1988-2005.

LaSala, Christine, MD
Is Isolated Rectocele Repair Associated with Post-Operative Voiding Dysfunction? Statistical Analysis supported through Hartford Hospital Small Grant. Outcomes of Vaginal Prolapse Surgery on Urinary Continence. Porcine-Derived Small Intestine Submucosa Graft-Augmented Rectocele Repair A Randomized Trial.

Brown, Susanne, RN
Does Simulation Training Improve Nursing and Residents Clinical Performance?

Collins, Sarah, MD
Sexual Activity and Function in Women with Pelvic Floor Disorders.

Patel, Minita, MD
Anal Incontinence and Impact on Sexual Function. Statistical Analysis supported through Hartford Hospital Small Grant.

108.

Satherlie-Deasy, Lynn, RN
Food Insecurity, Meal Skipping, Nutrient Intakes and Pregnancy Outcomes Among Low-Income Latinas.

Prolifts Effect on Post-Operative Hematocrit. Statistical Analysis supported through Hartford Hospital Small Grant.

Stepnowski, Roxanne, PsyD Schimpf, Megan, MD

Are Mondays and Fridays the Busiest Days for Nursing Phone Triage in a Urogynecology Office Practice? Is There a Relationship Between Glomerular Filtration Rate and Detrusor Overactivity in Women? Statistical Analysis supported through Hartford Hospital Small Grant. Using Color, Clarity and Smell to Predict Urinary Tract Infections in Community-Dwelling Women. Antepartum Depression Inventory: A Comparative Analysis of Performance With The Beck Depression Inventory. Hartford Hospital Research Endowment Funds, $9,966.

Taylor, Linda, MD
Patient-Centered Techniques to Enhance Outcomes for Abdominal Hysterectomy. Hartford Hospital Research Endowment Funds, $10,000.

Tulikangas, Paul, MD
A Comparison of Connective Tissue Remodeling in the Pelvic Floor of Pre and Postmenopausal Women. NIH / University of Pittsburgh, $4,820. Late-Pregnancy Fears of Labor and Delivery in Nulliparous Pregnant Women: A Survey. Hartford Hospital Research Endowment Funds, $8,840.

Schnatz, Peter, DO
Comparison of Hormonal Therapy Tapering Regimens for Mediating Hot Flashes. Hartford Hospital Research Endowment Funds, $56,623. A Comparison of Skin Closure Techniques after Primary Cesarean Delivery. Ethicon, Inc., $3,000. A Retrospective Analysis of Cervical Polyps. Statistical Analysis supported through Hartford Hospital Small Grant. Association of Adolescent and Early Adult Pregnancy with Future Development of Postmenopausal Osteoporosis. Statistical Analysis supported through Hartford Hospital Small Grant. Factors Influencing a Third-Year Medical Students Decision to Choose Obstetrics and Gynecology Versus Another Specialty Prior to Beginning Clinical Rotations. Departmental, $400. Statistical Analysis supported through Hartford Hospital Small Grant. Relative Importance of Gender in Patients Selection of Obstetrics and Gynecology Provider. Statistical Analysis supported through Hartford Hospital Small Grant.

Watson, James, MD
Recent Trends in VBAC at Hartford Hospital.

Young, Sara, MSN

Breastfeeding Education and Support Trial for Obese Women (BESTOW). Donaghue Medical Research Foundation/University of Connecticut, $20,590. Breastfeeding Education and Support Trial for Obese Women: Early Dyad Dynamics (BESTOW:EDD). University of Connecticut, $16,796.

Publications and Abstracts

Allen GL, Klobocista MM, Sugarman S, Gravel K, Feldman DM, Schnatz PF. Prevalence of high-risk human papillomavirus in an inner-city population with atypical squamous cells of undetermined significance. Journal of Lower Genital Tract Disease, 13(2): 63-65, April 2009. Batal I, Domsic RT, Shafer A, Medsger TA Jr, Kiss LP, Randhawa P, Bastacky S. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009 Mar;40(3):332-40. Berzolla CE, Schnatz PF, OSullivan DM, Bansal R, Mandavilli S, Sorosky JI. Dysplasia and malignancy in endocervical polyps. Journal of Womens Health. 16(9):1317-21, 2007 Nov. Boggess JF, Gehrig PA, Cantrell L, Shafer A, Mendivil A, Rossi E, Hanna R.Perioperative outcomes of robotically assisted hysterectomy for benign cases with complex pathology. Obstet Gynecol. 2009 Sep;114(3):585-93.

Shaneyfelt, Kristin, DO
Is an ECC Always Necessary During the Colposcopic Evaluation of an Abnormal Pap Smear?

Sorosky, Joel, MD
GOG 220: Pelvic Mass Study to Develop Serum Proteomic Profiles (Signatures) for Epithelial Ovarian Cancer Diagnosis and Prognosis. GOG, $8,712. Womens Health Clinical Outcomes Protocol. Statistical Analysis supported through Hartford Hospital Small Grant.

Spencer, Jeffrey, MD
Outcomes of Triplet Gestations Based on Chorionicity. Screening for Fetal Aneuploidy: A Patient Survey.

Steinberg, Adam, MD

Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of

bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 25(33):5165-71, 2007. Cuzzone D, Allen B, Rowin C, Tulikangas PK, Babigian A. Development of vaginal erosion and vesicocutaneous fistula following midurethral transvaginal tape with Pelvilace. International Wound Journal. 2009;6(1):55-8. Egan J, Fang YMV, Kaminski L, Smith K, Turner G, Benn P. Changes in antenatal Down Syndrome risk assessment in the US from 2001 to 2007. Am J Obstet Gynecol 2007;197: 589 (suppl). Egan J, Fang YMV, Kaminski L, Campbell W, Spencer J, Benn P. Changes in Down Syndrome screening practices in the US from 2001 to 2007. Am J Obstet Gynecol 2007;197: 149 (suppl) Fang YM, Benn P, Campbell W, Bolnick J, Prabulos AM, Egan JF. Down syndrome screening in the United States in 2001 and 2007: a survey of maternal-fetal medicine specialists. Am J Obstet Gynecol. 2009 Jul; 201(1):97.e1-5. Fang YMV, Benn P, Egan JF. Use of the genetic sonogram in the United States in 2001 and 2007. J Ultrasound Med. 2008 Nov;27(11):1543-8. Fang YMV, Benn P, Tribulato K, Fitzpatrick C, Bolnick J , Egan J. Down Syndrome screening strategies utilized by United States Maternal-Fetal Medicine specialists in 2007. Am J Obstet Gynecol; 197: 588 (suppl). Fang YMV, Egan J, Benn P, Magidina I, Prabulos AM, Sanders M. Placental pathologic findings associated with intrauterine growth restriction, preeclampsia and normal pregnancies. Am J Obstet Gynecol. 2008; 199: S97. Fang YMV, Egan JFX, Kaminsky L, Bolnick J, Prabulos A, Benn P. The growing acceptance of second trimester ultrasound to identify aneuploid fetuses: Markers used in the genetic sonogram by United States practitioners in 2001 and 2007. J Ultrasound Med 2008;27: S46 (suppl). Fang YMV, Egan J, Sanders M, Magidina I, Bolnick J, Benn P. Placental pathologic findings seen in preterm deliveries, intrauterine fetal demises, and uncomplicated full term deliveries. Am J Obstet Gynecol. 2008; 199: S106. Fang YMV, Egan J, Sanders M, Magidina I, Bolnick J, Mackeen D, Benn P. Prediction of adverse pregnancy outcome using the results of the second trimester quadruple maternal serum screening test. Am J Obstet Gynecol. 2008; 199: S193. Fang YMV, Mackeen D, Dileo C, Egan J, Zelop C. Insulin glargine

(Lantus) compared with neutral protamine hagedorn insulin in the treatment of pregnant diabetics. Obstet Gynecol. 2008;111:108S. Fang YM, MacKeen D, Egan JF, Zelop CM. Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med. 2009 Mar;22(3):249-53. Fang YM, Egan JF, Rombro T, Morris B, Zelop CM. A comparison of reasons for choosing obstetrician/gynecologist subspecialty training. Conn Med. 2009 Mar; 73(3):165-70. Johnson AM, Schnatz PF. Gender preferences in ObGyn clinic vs private patients. Connecticut Medicine. 73(4):205-9, 2009 Apr. Madom LM, Brown AK, Lui F, Moore RG, Granai CO, DiSilvestro PA. Lower uterine segment involvement as a predictor for lymph node spread in endometrial cancer Gynecologic Oncology, 107:75-78, 2007. Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard JW, Granai CO, Bast RC, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology, 110: 196-201, 2008. Moore RG, Brown AK, Miller CM, Skates S, Allard J, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology, 108:404-408, 2008. Moore RG, McMeekin SD, Brown AK, DiSilvestro PA, Miller CM, Allard JW, Gajewski W, Kurman RJ, Bast RC, Skates SK. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 112:40-46, 2009. Moore RG, Robison K, Brown AK, DiSilvestro PA, Steinhoff M, Noto R, Brard L, Granai, CO. Isolated Sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: A Prospective Trial. Gynecologic Oncology, 109:65-70, 2008. Nieves L, Currie J, Hoffman J Sorosky JI. Ototoxicity after intraperitoneal chemotherapy: a case report. International Journal of Gynecological Cancer. 17(5):1133-1135, September/October 2007. [Letter.][Correspondence and Brief Report] Nieves L, Hoffman J, Allen G, Currie J, Sorosky JI. Placental-site trophoblastic tumor with PET scan-detected surgically treated lung metastasis. International Journal of Clinical Oncology. 13(3):263-5, 2008 Jun. Patel M, OSullivan DM, Steinberg AC. The impact of anal

110.

incontinence on sexual function. Journal of Reproductive Medicine. 2009;54(8):493-499 Patel M, OSullivan DM, Tulikangas PK. A comparison of costs for open, laparoscopic and robot assisted sacral colpopexy. Int J Urogynecol J Pelvic Floor Dysfunct. 2009(20):223-8. Rotter MA, Schnatz PF, Currier AA Jr., OSullivan DM. Breast arterial calcifications (BACs) found on screening mammography and their association with cardiovascular disease. Menopause. 15(2):27681, 2008 Mar-Apr. Saks E, Vakili B, Steinberg AC. Primary Amenorrhea with a periumbilical abdominal mass. J of Pediatric and Adolescent Gynecology. 2009: 22 (1): E1-3 Schimpf MO, OSullivan DM, Steinberg AC, LaSala CA, Tulikangas PK. Patterns of phone calls to a nursing triage line in a urogynecology practice. Urologic Nursing 2008; 28(3):213-216. Schimpf MO, OSullivan DM, Steinberg AC, LaSala CA, Tulikangas PK. Is there a relationship between glomerular filtration rate and detrusor overactivity in women? Neurourol. Urodyn. 2009; 28(3): 202-204 Schimpf MO, Patel M, OSullivan DM, Tulikangas PK. Differences in quality of life in women with urge urinary incontinence compared to women with stress urinary incontinence. Int J Urogynecol J Pelvic Floor Dysfunct. 2009; 20: 781-786. Sharpless KE, OSullivan DM, Schnatz PF. The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. Journal of Lower Genital Tract Disease. 13(2):72-8, 2009 Apr. Schnatz PF. A unique faith-based medical organization: the Christian Medical Fellowship. Connecticut Medicine. 72(6):345-50, 2008 Jun-Jul. Schnatz PF, Guile MW, OSullivan DM. Relative importance of gender in patients selection of an obstetrics and gynecology provider. Connecticut Medicine. 71(9):563, 2007 Oct. Schnatz PF, Humphrey K. Reasons and principles for starting an obstetrics and gynecology scholars group. Obstetrics & Gynecology. 111(4):953-8, 2008 Apr. Schnatz PF, Marakovits K. The next generation of menopause providers: are medical students being properly prepared? Menopause. 15(5):871-4, 2008 Sep-Oct. Schnatz PF, Markelova NV, Holmes D, Mandavilli SR, OSullivan DM. The prevalence of cervical HPV and cytological abnormalities in association with reproductive factors of rural Nigerian women.

Journal of Womens Health. 17(2):279-85, 2008 Mar. Schnatz PF, Murphy JL, OSullivan DM, Sorosky JI. Patient choice: comparing criteria for selecting an obstetrician-gynecologist based on image, gender, and professional attributes. American Journal of Obstetrics & Gynecology. 197(5):548.e1-7, 2007 Nov. Schnatz PF, Ricci S, OSullivan DM. Cervical polyps in postmenopausal women: is there a difference in risk? Menopause. 16(3):524-8, 2009 May-Jun. Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham D, OSullivan DM. The North American Menopause Society: from abstract to publication. Menopause. 15(5):996-1001, 2008 Sep-Oct. Schnatz PF, Sharpless KE, OSullivan DM. Use of human papillomavirus testing in the management of atypical glandular cells. Journal of Lower Genital Tract Disease. 13(2):94-101, 2009 Apr. Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer. 2009 Aug 17. Sorosky JI. Endometrial cancer. Obstetrics & Gynecology. 111(2, Part 1):436-447, February 2008. Sorosky JI. Endometrial cancer. Obstetrics & Gynecology. 112(1):186-187, July 2008. [Letter.][Departments: Letters to the Editor] Spencer J, Fang YMV, Borgida A, Benn P, Egan J. Patients understanding of first trimester aneupliody screening based on counseling time. Obstet Gynecol. 2008;111:38S. Spencer JV, Ingardia CJ, Nold CJ, Borgida AF, Herson VC, Egan JFX. Perinatal and neonatal outcomes of triplet gestations based on placental chorionicity. American Journal of Perinatology. 2009;26:587-90. Steinberg AC, Collins SA, OSullivan, DM. The impact of flatal incontinence on quality of life. American Journal of Obstetrics and Gynecology. 2009;201. Werden J, Schnatz PF, Mandavilli S, Allen G, Murphy J, Greene JF; Egan JF, Sorosky JI. Prevalence of the human papillomavirus in an inner-city indigent population with previously normal pap tests. Journal of Lower Genital Tract Disease. 12(4):287-292, October 2008.

Presentations

Allen GL, Klobocista M, Sugarman S, Gravel K, Schnatz PF. Prevalence of High Risk Human Papilloma Virus in an Inner City Population with Atypical Squamous Cells of Undetermined Significance. Presented March 17th, 2008 at the biennial ASCCP meeting in Lake Buena Vista, FL. Borgida AF, Hopkins S, St- Aubin C, Feldman DM, Fang YM, Ingardia CJ. Trends in near-term preterm birth. Presented at the Society for Maternal Fetal Medicine, San Diego, February 2009. Brown AK, Clements A, Robison K, Allard JW, Somers E, Theil R, Granai CO, Moore R. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. Presented at the 7th Biennial Ovarian Cancer Research Symposium of the Marcia Rivkin Center, September 2008. Brown AK, Currie J, Sorosky, JI. A retrospective comparison of clinical outcomes between laparotomy and robotic hysterectomy for endometrial cancer. Presented at the International Gynecologic Oncology Robotics Symposium, November, 2008. Brown AK, Raughley M, Robison K, Miller C, Allard JW, Kurman R, Granai CO, Moore R. Comparison of a novel multiple biomarker assay to the risk of malignancy index in the prediction of epithelial ovarian cancer in patients with a pelvic mass. Presented at the 7th Biennial Ovarian Cancer Research Symposium of the Marcia Rivkin Center, September, 2008. Carbone J, Feldman DM, Lazarus S, Borgida AF. Clinical implications of prenatally diagnosed marginal placental cord insertion. Society for Maternal Fetal Medicine, San Diego, February 2009. Carbone J, Feldman DM, Lazarus S, Borgida AF. Clinical implications of prenatally diagnosed marginal placental cord insertion. American Institute of Ultrasound in Medicine, New York, April 2009. Carbone J, Schnatz PF, Werden J. Stump the Professor: Post Partum Patient with Acute Chest Pain. Presented September 29th, at the 2007 annual ACOG District I meeting in Newport, Rhode Island. Clements A, Brown AK, Miller C, Robison K, Allard JW, Granai CO, Moore R. Utility of a Novel Serum Tumor Marker HE4 to Predict Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of the Uterus. Presented at the 2008 NEAGO Annual Meeting, June 2008. Clements A, Brown AK, Robison K, Allard JW, Somers E, Theil R, Granai CO, Moore R. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. Presented at the 2008 NEAGO Annual Meeting, June 2008. Collins SA, OSullivan DM, LaSala CA. Factors which correlate with PISQ-12 completion in an academic urogynecology population.

Poster Presentation at the American Urogynecological Society Meeting, September, 2009. Currie C, Brown AK, Sorosky JI, Mandavilli S, Joyner A, Currie J. Endometrial Carcinoma of Fallopian Tube with Metastasis and Extension to the Obturator Space: A Case Report. Presented at the 2009 NEAGO meeting, June 2009. Cushman N, Currie J, Romak J, Sorsoky JI, Brown AK. Vulvar Polyps Secondary to Crohns Disease. Presented at the 2008 NEAGO Annual Meeting, June 2008. Greene, JF. Uterine Fibroid Embolization: Who, Why, Where and When. American College of Obstetricians and Gynecologists Annual Clinical Meeting, New Orleans, LA 2008. Greene, JF. Uterine Fibroid Embolization: Who, Why, Where and When. American College of Obstetricians and Gynecologists Annual Clinical Meeting, Chicago, IL, May 5, 2009. Greene, JF. A comparison of ACGME Resident Statistics with Institutional Totals. Association of Professors in Gynecology and Obstetrics/Coundil on Residency Education in Obstetrics and Gynecology Annual Meeting, March, 2009, San Diego, CA. Awarded third best oral presentation. Joyner A, Sorosky JI, Mandavilli S, Brown AK, Currie, J . Neuroendocrine Tumor of Uterus and Cervix after Uterine Artery Embolization for Leiomyomas: A Case Report. Presented at the 2009 NEAGO meeting, June 2009. Maclaughlan S, Brown AK, Miller C, Robison K, Allard JW, Granai CO, Bast R, Moore R. Differential expression of CA125 and a novel serum tumor marker HES in epithelial ovarian cancer. Presented at the 2008 NEAGO Annual Meeting, June 2008. McNamara J, Smith K, Feldman DM, Fang YM, Ingardia CJ, Borgida AF. Predicting survival among neonates born at 24 weeks gestation. Society for Maternal Fetal Medicine, San Diego, February 2009. Moore R, McMeekin S, Brown AK, DiSilvestro P, Miller C, Allard J, Gajewski W, Kurman R, Bast R, Skates S. A Novel Multiple Marker Bioassay Utilizing HE4 and CA125II for the Prediction of Ovarian Cancer in Patients with a Pelvic Mass. Presented at the 2008 SGO Annual Meeting, March 2008. Nwana C, Johnson A, Egan J, Dumont T. Racial and Ethnic Disparities in Prenatal Care. Poster presented at the 2009 ACOG. Patel M, LaSala CA, Tulikangas P, Steinberg AC. Beef tongue model versus instructional video for teaching residents fourth degree laceration repair. Poster presentation at 30th annual American Urogynecologic Society meeting, September 24-26, 2009, Hollywood, Florida.

112.

Womens Health

Patel M, Mellen C, OSullivan DM, LaSala, CA. Impact of pessary use on prolapse symptoms, quality of life and body image. Oral presentation at the American Urogynecological Society Meeting, September, 24-26, 2009, Hollywood, Florida. Patel M, OSullivan D, LaSala C. Do bowel symptoms change after pelvic organ prolapse surgery? Poster presentation at 30th annual American Urogynecologic Society meeting, September 24-26, 2009, Hollywood, Florida. Patel M, Schimpf, MO, OSullivan DM, LaSala, CA. The use of SennaS for post-operative constipation after pelvic reconstructive surgery: a randomized, double blinded, placebo-controlled trial. Oral presentation at the 30th annual American Urogynecologic Society Meeting, September 24-26, 2009, Hollywood, Florida. Best scientific presentation award. Patel M, Tulikangas P. Does size matter? A comparison of bother and quality of life in women with prolapse. Poster presentation at the 35th annual Society of Gynecologic Surgeons Meeting, March 30-April 1, 2009, New Orleans, Louisiana. Patel M, Tulikangas P. Evaluation of prolapse type and pelvic floor symptoms: is every prolapse the same? Poster presentation at 30th annual American Urogynecologic Society meeting, September 24-26, 2009, Hollywood, Florida. Platt L, Brown AK, Mandavilli S, Currie J, Sorosky, JI. Complex Atypical Hyperplasia and the Incidence of Endometrial Cancer at the Time of Hysterectomy. Presented at the 2009 NEAGO meeting, June 2009. Platt L, Currie J, Hoffman J, Sorosky JI, Brown AK. Managing Patients with Pseudomyxoma Peritonei. Presented at the 2008 NEAGO Annual Meeting, June 2008. Platt L, Sorosky JI, Currie J, Brown AK. An unusual presentation of metastatic papillary serous ovarian cancer. Presented at the 2008 NEAGO Annual Meeting, June 2008. Raughley M, Brown AK, Robison K, Miller C, Allard JW, Kurman R, Granai CO, Moore R. Comparison of a novel multiple biomarker

assay to the risk of malignancy index in the prediction of epithelial ovarian cancer in patients with a pelvic mass. Presented at the 2008 NEAGO Annual Meeting, June 2008. Schnatz PF. Medical Missions Provide Education, Experience, and an Example of Professionalism for Students and Residents. Presented at the annual APGO Faculty Development Seminar; Womens Health Education, Think Globally, Teach Locally, January 13th, 2009. Schnatz PF. ObGyn Scholars: Developing a Student Interest Group and Learning from Past Experiences. Presented at the annual APGO Faculty Development Seminar; The Ob-Gyn Curriculum: The Ideal, The Practical, The Hidden. Kapalua, Maui, Hawaii. January 22nd, 2008. Schnatz PF. Preparing the Next Generation of Menopause Providers. Presented October 4th, 2007 at the NAMS 18th Annual Meeting in Dallas, Texas. Schnatz PF, Johnson AM, Hemphill M, Tortora J. Sexual Dysfunction in Patients of an Inner City Menopause Clinic. Presented September 26th, 2008 at the NAMS 19th Annual Meeting in Orlando, Florida. Schnatz PF, Kubica L, Murphy J, and OSullivan DM. The Risk of Cardiovascular Disease in Women with a History of Low Birth Weight. Presented October 5th, 2007 at the NAMS 18th Annual Meeting in Dallas, Texas. Schnatz PF, Pattison K, and OSullivan DM. The Association of Breast Disease and Atypical Glandular Cells. Presented at the NAMS 20th Annual Meeting in San Diego, California, October, 2009. Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham D, OSullivan DM. The North American Menopause Society: From Abstract to Publication. Presented September 26th, 2008 at the NAMS 19th Annual Meeting in Orlando, Florida. Schnatz PF, Sharpless KE, Bansal R. Use of Human Papillomavirus Testing in the Management of Atypical Glandular Cells. Presented March 19th and 20th, 2008 at the biennial ASCCP meeting in Lake Buena Vista, FL. Schnatz PF, Vaidyanathan G, Surette A, Tower M, Price C, Delgado J, Sundaram K. The Medical Needs and Demographic Makeup

of Menopausal Women in a Rural Nigerian Village. Presented September 26th, 2008 at the NAMS 19th Annual Meeting in Orlando, Florida. Sharpless KE, Bansal R, OSullivan DM, Schnatz PF. The Utility of Human Papillomavirus Testing in the Management of Atypical Glandular Cells on Cytology. Presented March 17th, 2008 at the biennial ASCCP meeting in Lake Buena Vista, FL and winner of the best overall resident presentation. Sorosky JI. Abnormal Cervical Cytology Complicating Pregnancy. American College of Obstetricians and Gynecologists Annual Clinical Meeting, New Orleans, LA 2008. Sorosky JI. Endometrial Hyperplasia. American College of Obstetricians and Gynecologists Annual Clinical Meeting, Chicago, IL, May 4, 2009. Sorosky JI. Management of Atypical Glandular Cells (AGC) on Pap Smear Screen Screening. American College of Obstetricians and Gynecologists Annual Clinical Meeting, New Orleans, LA 2008. Sorosky JI. Management of Atypical Glandular Cells, (AGC), the Consensus Guidelines. American College of Obstetricians and Gynecologists Annual Clinical Meeting, Chicago, IL, May 5, 2009. Sorosky JI. Techniques in Abdominal Wound Closure. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Chicago, IL, May 4, 2009. Sorosky JI. Techniques in Abdominal Wound Closure. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, New Orleans, LA 2008. Steinberg AC, Collins SA, OSullivan DM. The Impact of Flatal Incontinence on Quality of Life. Poster Presentation at the Society for Gynecological Surgeons, New Orleans, LA April, 2009. St- Aubin C, Hopkins S, Feldman DM, Fang YM, Ingardia CJ, Borgida AF. Mode of delivery and neonatal respiratory morbidity in near-term preterm births. Society for Maternal Fetal Medicine, San Diego, February, 2009. Surette AM, Schnatz PF, OSullivan DM, Sharpless KE. Delayed Diagnosis Following Atypical Glandular Cells on Cervical Cytology.

Presented March 20th, 2008 at the biennial ASCCP meeting in Lake Buena Vista, FL. Umenyi C, Waszczak W, Schnatz PF, and Mandavilli S. Incidence of high risk HPV (HR-HPV) and cervical dysplasia in Nigeria. Presented at the American Society of Cytopathologys 55th Annual Scientific Meeting; November 2-6, 2007 in Houston, Texas. Werden J, Schnatz PF, Mandavilli S, Allen G, Greene JF, Sorosky JI. Prevalence of the Human Papillomavirus in an Inner City Indigent Population with Previously Normal Pap Tests. Presented at the 2007 annual ACOG District I meeting in Newport, Rhode Island, September, 2007.

Other Departments &

Collaborations
New Projects
Hartford Hospital Research Endowment Funds
Kureshi, Inam, MD, Neurosurgery
Craniotomy for Intraventricular Lesions. Small Grant for Statistics Database Support.

Lehmann, William, MD, Otolaryngology

Methods of Education for Patients Undergoing Tonsillectomy.

McLaughlin, Tara, PhD, Research Administration

Utilizing Focus Groups to Support Community Health Collaborations.

Nailor, Michael, PharmD, Pharmacy

Approach to Enhance the Likelihood of Initial Effective Antibacterial Therapy: Examining Cross-Resistance.

OSullivan, David, PhD, Research Administration

Blanket Protocol for Endocrinology/Diabetes Mellitus Outcomes.

Wang, Fei, PharmD, Pharmacy

Health Literacy and Prescription Medication Adherence in Urban Latino Patients

Mort,Thomas, MD, Anesthesiology

Comparison of Standard Laryngoscopy vs. Video/Optical Laryngoscopy in Exchanging an ETT in the High Risk Difficult Airway Patient. Supported through Hartford Hospital Small Grant.

New Collaborations
Herson, Victor, MD, CCMC
Epigenetic Modifications of Human Umbilical Cord Vessel Endothelium. Clinical Factors Determining the Care Needs For 35 Week Infants.

Federal
Baker, William, PharmD, Pharmacy
Epilepsy Medication CERs. AHRQ, $342,651. Human Growth Hormone in Patients With Cystic Fibrosis. AHRQ, $342,710.

Kurtz, Matthew, PhD, Wesleyan University

Neurological Soft Signs, Neurocognitive Measures, and Everyday Life Skills. Wesleyan University, $700.

Kureshi, Inam, MD, Neurosurgery

A Randomized Multicenter Clinical Trial of Unruptured Brain Arteriovenous Malformations (ARUBA). National Institute of Neurological Disorders through Columbia University, $56,700.

Lapidus, Garry, PA-C, CCMC

Safe Transportation of Normal Newborns at Hospital Discharge. The Epidemiology of Trauma Presenting to a Level One Trauma Center.

Foundation
Colby, Jennifer, PharmD, Pharmacy
Predictors of Medication Non-Adherence Among Urban Latinos: A CrossSectional Analysis of Patients Enrolled in the Diabetes Among Latinos Best Practices (DIALBEST) Trial. American Society HealthSystems Pharmacists, $5,184.

Nichols, Mary, Wesleyan University

Narrative Coherence and Neurocognition in Schizophrenia: The Effects of Illness Duration. Wesleyan University, $600.

Oncken, Cheryl, MD, University of Connecticut Health Center

Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy. UCHC, $1,500.

Industry
Baker, William, PharmD, Pharmacy
Biologic and Non-Biologic Systemic Treatments for Moderate to Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. Pfizer, $100,000.

Wang, Fei, PharmD, University of Connecticut

Establishing Benchmarks for the Medical Office Survey On Patient Safety (SOPS). The Oregon Health and Science University, $200.

Active Projects
Chhabra, Jyoti, PhD, Research Administration
Examining Behavioral Risk Factors, Chronic Disease and Health Related Polysyndromes in Hartford CT. DPH subcontract through the City of Hartford, $80,000.

Kureshi, Inam, MD, Neurosurgery

S.T.I.C.H. II - Surgical Trial in Lobar Intracerebral Hemorrhage. Newcastle upon Tyne Hospital NHS Trust, $6,410.

Unfunded
Delgado, Danica, MSW, Social Work
The Domestic Violence Learning Needs of Health Care Social Workers.

Gaudio, Paul, MD, Ophthalmology

Detection of Triamcinolone Acetonide in Human Intraocular Fluids. Small Grant, $9,900.

McIsaac, Joseph, MD, Anesthesiology

Power Quality in the Operating Room Pilot Study. Dental Pressure During Intubation Pilot Study. The Brain Temperature Tunnel During General Anesthesia. Minimum Training for Successful Cricothyroidotomy: The Effect of an Adverse Environment. High Fidelity Simulation: Assessment of its Role in Resident Education. A Multi-Center Survey of Anesthesiologists Attitudes and Abilities in Difficult Airway Management Using Simulation-Based Performance Evaluation.

Horan, Mary, MA
Ethical Force Programs Organizational Toolkit for Patient-Centered Communication (Windham).

Jones, Beth. PhD

Glutathione-S-Transferase Polymorphisms, Race, and Survival from Cancer.

Kenny, Anne, MD
Testosterone Effects on Bone Frailty in Men with Osteoporosis.

McLaughlin, Tara, PhD, Research Administration

An Assessment of the Homeless of Hartford, 2002. Hartford Health Dept, $33,750. Evaluating the Hartford Continuum of Cares Increased Demands for Shelter Care Project. Hartford Foundation for Public Giving & City of Hartford, $18,500. A Brief Assessment of the Homeless of Hartford, 2004. City of Hartford, $1,200. Hartford Resident Survey of Environmental Issues. 2005 Census of the Homeless of Hartford. Community Renewal Team, $1,700. 2006 Census of the Homeless of Hartford. Community Renewal Team, $1,500.

Lammi-Keefe, Carol, PhD

Can DHA-functional Food in Pregnancy Enhance Infant Neurobehavioral Development?

Park, Crystal, PhD

Feasibility Study of Gender Differences in Psychosocial Determinants of Recovery Following MI. UCHC Center for Interdisciplinary Research on Womens Health, $2,400. Predicting and Understanding Positive Life Changes in Young Adult Cancer Survivors: Types, Trajectories, Predictors, and Relations with Adjustment. Lance Armstrong Foundation, $500.

Active Collaborations
Anderson, Elizabeth, PhD
Exploration of the Effect of Nausea, Self-efficacy, and Health Care Relationships on Medication Adherence in AIDS Patients. Donaghue Medical Research Foundation, $4300.

Price, Thomas, PhD

Magnetic Resonance Spectroscopy Studies of Statin-Induced Myopathy. Hartford Hospital Research Endowment Funds, $11,824.

Risch, Harvey, MD
Case Control Study of Ovarian Cancer Hormonal Etiology. Hartford Hospital Case Control Study of Pancreas Cancer Etiology Factors. Windham Hospital Case Control Study of Pancreas Cancer Etiology Factors.

Claus, Elizabeth, MD
Genetic Epidemiology of Breast Carcinoma In Situ.

Epperson, Neill, MD
The Role of GABA and Neurosteroids in Postpartum Depression. The Impact of Fluoxetine Treatment on GABA and Neurosteroid Levels in Women with Premenstrual Dysphoric Disorder.

Swede, Helen, PhD

Prognostic Value of Intra-Chromosomal Genomic Instability in Colon Cancer.

Wagner, Joseph, MD
Influence of Patient Size and Prostate Weight on Operative and Peri-Operative Outcomes for Robot-assisted Radical Prostatectomy.

Fisher, Jeffrey, PhD

Changing Antiretroviral Therapy (ART) Adherence Behavior. NIH subcontract through the University of Connecticut (Storrs), $326,482.

Woods, Scott, MD
Atypical Antipsychotic Medications: Outcomes and Costs. Yale University, $8,960. Longitudinal Follow-Up of Patients Undergoing Evaluation for the Schizophrenia Prodrome. NIMH, Yale University Subcontract, $11,382.

Ferris, Ann, PhD

Assessment of the Prevalence of Anemia, and its Correlates and Predictors, Among Low Income Two Year Olds in Hartford, CT.

Hadler, James, MD
Surveillance of Connecticut for Organisms Causing Neonatal Sepsis.

Yu, Herbert, MD
Hartford Hospital Epidemiologic Study of Uterus Cancer. Windham Hospital Epidemiologic Study of Uterus Cancer.

Heimer, Robert, PhD

Unexplained Deaths Related to Bioterrorism.

Zheng, Tongzhang, MD
The Role of Epstein-Barr Virus in the Etiology of Hodgkins Disease.

116.

Hartford Hospital Research Program 80 Seymour St. Hartford, CT

Staff photos by: Kevin Hagan Design by: Anthony Tropea